[
  {
    "id": "covid_fact-000001",
    "statement": "Measuring sars-cov-2 neutralizing antibody activity using pseudotyped and chimeric viruses",
    "label": "SUPPORTED",
    "evidences": [
      "While each surrogate virus exhibited subtle differences in the sensitivity with which neutralizing activity was detected, the neutralizing activity of both convalescent plasma and human monoclonal antibodies measured using each virus correlated quantitatively with neutralizing activity measured using an authentic SARS-CoV-2 neutralization assay.",
      "Here, we describe a collection of approaches based on SARS-CoV-2 spike-pseudotyped, single-cycle, replication-defective human immunodeficiency virus type-1 (HIV-1) and vesicular stomatitis virus (VSV), as well as a replication-competent VSV/SARS- CoV-2 chimeric virus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that different surrogate viruses (pseudotyped and chimeric) are being used to measure SARS-CoV-2 neutralizing antibody activity. The study shows that the results obtained using these surrogates correlate quantitatively with those obtained using an authentic SARS-CoV-2 neutralization assay, supporting the claim.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000002",
    "statement": "Measuring chs-cov-2 neutralizing antibody activity using pseudotyped and chimeric viruses",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "While each surrogate virus exhibited subtle differences in the sensitivity with which neutralizing activity was detected, the neutralizing activity of both convalescent plasma and human monoclonal antibodies measured using each virus correlated quantitatively with neutralizing activity measured using an authentic SARS-CoV-2 neutralization assay.",
      "Here, we describe a collection of approaches based on SARS-CoV-2 spike-pseudotyped, single-cycle, replication-defective human immunodeficiency virus type-1 (HIV-1) and vesicular stomatitis virus (VSV), as well as a replication-competent VSV/SARS- CoV-2 chimeric virus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides examples of measuring neutralizing antibody activity using pseudotyped and chimeric viruses for SARS-CoV-2, as described in the text. The claim is supported by the use of pseudotyped HIV-1 and VSV viruses and a replication-competent VSV/SARS-CoV-2 chimeric virus.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000003",
    "statement": "Measuring aces-cov-2 neutralizing antibody activity using pseudotyped and chimeric viruses",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "While each surrogate virus exhibited subtle differences in the sensitivity with which neutralizing activity was detected, the neutralizing activity of both convalescent plasma and human monoclonal antibodies measured using each virus correlated quantitatively with neutralizing activity measured using an authentic SARS-CoV-2 neutralization assay.",
      "Here, we describe a collection of approaches based on SARS-CoV-2 spike-pseudotyped, single-cycle, replication-defective human immunodeficiency virus type-1 (HIV-1) and vesicular stomatitis virus (VSV), as well as a replication-competent VSV/SARS- CoV-2 chimeric virus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided describes the use of pseudotyped and chimeric viruses for measuring SARS-CoV-2 neutralizing antibody activity. This directly supports the claim that these methods are used to measure such activity.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000004",
    "statement": "Measuring gps-cov-2 neutralizing antibody activity using pseudotyped and chimeric viruses",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "While each surrogate virus exhibited subtle differences in the sensitivity with which neutralizing activity was detected, the neutralizing activity of both convalescent plasma and human monoclonal antibodies measured using each virus correlated quantitatively with neutralizing activity measured using an authentic SARS-CoV-2 neutralization assay.",
      "Here, we describe a collection of approaches based on SARS-CoV-2 spike-pseudotyped, single-cycle, replication-defective human immunodeficiency virus type-1 (HIV-1) and vesicular stomatitis virus (VSV), as well as a replication-competent VSV/SARS- CoV-2 chimeric virus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided describes the use of different surrogate viruses (pseudotyped and chimeric viruses) to measure the activity of neutralizing antibodies against SARS-CoV-2. The neutralizing activity measured using these surrogates correlates with that measured using an authentic SARS-CoV-2 neutralization assay, suggesting that these methods can be used to assess the activity of neutralizing antibodies.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000005",
    "statement": "Long-term persistence of igg antibodies in sars-cov infected healthcare workers",
    "label": "SUPPORTED",
    "evidences": [
      "IgG titers in SARS-CoV-infected healthcare workers remained at a significantly high level until 2015.",
      "All sera were tested for IgG antibodies with ELISA using whole virus and a recombinant nucleocapsid protein of SARS- CoV, as a diagnostic antigen.",
      "CONCLUSIONS IgG antibodies against SARS-CoV can persist for at least 12 years."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly states that IgG titers in SARS-CoV infected healthcare workers remained at a significantly high level until 2015. The conclusion from the study also confirms that IgG antibodies against SARS-CoV can persist for at least 12 years.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000006",
    "statement": "short-term persistence of igg antibodies in sars-cov infected healthcare workers",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "IgG titers in SARS-CoV-infected healthcare workers remained at a significantly high level until 2015.",
      "All sera were tested for IgG antibodies with ELISA using whole virus and a recombinant nucleocapsid protein of SARS- CoV, as a diagnostic antigen.",
      "CONCLUSIONS IgG antibodies against SARS-CoV can persist for at least 12 years."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows that IgG titers in SARS-CoV infected healthcare workers remained at a significantly high level until 2015, and the conclusions state that IgG antibodies against SARS-CoV can persist for at least 12 years. This suggests that short-term persistence of igg antibodies in SARS-CoV infected healthcare workers is supported by the provided evidence.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000007",
    "statement": "Low-term persistence of igg antibodies in sars-cov infected healthcare workers",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "IgG titers in SARS-CoV-infected healthcare workers remained at a significantly high level until 2015.",
      "All sera were tested for IgG antibodies with ELISA using whole virus and a recombinant nucleocapsid protein of SARS- CoV, as a diagnostic antigen.",
      "CONCLUSIONS IgG antibodies against SARS-CoV can persist for at least 12 years."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that the IgG titers in SARS-CoV infected healthcare workers remained at a significantly high level until 2015, and according to the conclusion, IgG antibodies against SARS-CoV can persist for at least 12 years. Therefore, it is supported that low-term persistence of igg antibodies in SARS-CoV infected healthcare workers exists.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000008",
    "statement": "Pre-term persistence of igg antibodies in sars-cov infected healthcare workers",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "IgG titers in SARS-CoV-infected healthcare workers remained at a significantly high level until 2015.",
      "All sera were tested for IgG antibodies with ELISA using whole virus and a recombinant nucleocapsid protein of SARS- CoV, as a diagnostic antigen.",
      "CONCLUSIONS IgG antibodies against SARS-CoV can persist for at least 12 years."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows that the IgG titers in SARS-CoV infected healthcare workers remained at a significantly high level until 2015. The study also found that IgG antibodies against SARS-CoV can persist for at least 12 years, as concluded by the authors.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000009",
    "statement": "Coronavirus dons a new crown",
    "label": "SUPPORTED",
    "evidences": [
      "Crown- forming protein A contains all viral activities for RNA synthesis and shares distant sequence similarities to alphavirus RNA replication proteins ( 11 13).",
      "A crown-like pore complex on coronavirus RCs ( 5) parallels a similar crown of viral proteins on nodavirus RCs ( 12), providing a channel to release RNA progeny to the cytoplasm."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence describes the structure and replication mechanisms of coronaviruses, specifically mentioning a 'crown-like pore complex' and 'crown of viral proteins'. However, it does not provide any evidence to support the claim that the coronavirus itself dons a new crown.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000010",
    "statement": "Coronavirus dons a new question",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Crown- forming protein A contains all viral activities for RNA synthesis and shares distant sequence similarities to alphavirus RNA replication proteins ( 11 13).",
      "A crown-like pore complex on coronavirus RCs ( 5) parallels a similar crown of viral proteins on nodavirus RCs ( 12), providing a channel to release RNA progeny to the cytoplasm."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence describes properties of coronaviruses, specifically their structure and replication mechanisms. However, it does not explicitly establish a connection between these properties and the idea that coronavirus 'dons a new question'. The claim seems to be implying that coronaviruses have a novel or intriguing feature, but the evidence presented does not support this interpretation.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000011",
    "statement": "Coronavirus dons a new term",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Crown- forming protein A contains all viral activities for RNA synthesis and shares distant sequence similarities to alphavirus RNA replication proteins ( 11 13).",
      "A crown-like pore complex on coronavirus RCs ( 5) parallels a similar crown of viral proteins on nodavirus RCs ( 12), providing a channel to release RNA progeny to the cytoplasm."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided refers to the structural and functional characteristics of coronaviruses, specifically their crown-forming proteins and replication complexes. The term 'donning a new term' for coronavirus in this context is not directly supported by the provided evidence.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000012",
    "statement": "Immune memory in mild covid-19 patients and unexposed donors from india reveals persistent t cell responses after sars-cov-2 infection",
    "label": "SUPPORTED",
    "evidences": [
      "Moreover, we found detectable immune reactivity up to 5 months in mild COVID-19 recovered patients in the two major arms of protective adaptive immunity; CD4+ T cells and B cells."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that detectable immune reactivity (T cell responses) were found up to 5 months in mild COVID-19 recovered patients. This suggests the persistence of these T cells after SARS-CoV-2 infection, which supports the claim.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000013",
    "statement": "Immune memory in mild covid-19 patients and unexposed donors from india reveals persistent t cell depletion after sars-cov-2 infection",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Moreover, we found detectable immune reactivity up to 5 months in mild COVID-19 recovered patients in the two major arms of protective adaptive immunity; CD4+ T cells and B cells."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence demonstrates that immune reactivity (CD4+ T cells and B cells) can be detected up to 5 months in mild COVID-19 recovered patients, but it does not provide information about T cell depletion specifically or in relation to unexposed donors from India. More specific evidence is needed to evaluate this claim.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000014",
    "statement": "Simple probiotics might help inhibit covid-19 infection",
    "label": "SUPPORTED",
    "evidences": [
      "Other research suggests that probiotic supplementation may promote antiviral activity in general to improve immune, pulmonary, and anti-inflammatory response that might help clear the SARS-CoV-2 infection (70, 71)."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "While the evidence suggests that probiotics may have antiviral properties and improve immune response in general, it does not provide direct or concrete evidence that they specifically inhibit COVID-19 infection. More specific and focused research would be needed to support this claim.",
    "confidence": 0.5
  },
  {
    "id": "covid_fact-000015",
    "statement": "Simple probiotics might help cause covid-19 infection",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Other research suggests that probiotic supplementation may promote antiviral activity in general to improve immune, pulmonary, and anti-inflammatory response that might help clear the SARS-CoV-2 infection (70, 71)."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided suggests that probiotics may have an antiviral effect and improve immune response in general. However, it does not support the claim that probiotics might cause COVID-19 infection.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000016",
    "statement": "Uk bans parallel export and hoarding of lopinavir+ritonavir , chloroquine and hydroxychloroquine",
    "label": "SUPPORTED",
    "evidences": [
      "31 March 2020 52 medicines have been added to the list of medicines that cannot be parallel exported from the UK, these are: Cefalexin, Codeine, Co-trimoxazole, Diamorphine, Doxycycline, Ipratropium, Salbutamol, Prochlorperazine,Salbutamol + Beclometasone, Salbutamol + Ipratropium Terbutaline, Beclometasone, Beclometasone + Formoterol, Beclometasone + Formoterol + Glycopyrronium bromide, Budesonide, Budesonide + Formoterol, Fluticasone, Fluticasone + Formoterol, Fluticasone + Salmeterol, Fluticasone + Umeclidinium bromide + Vilanterol, Fluticasone + Vilanterol, Ciclesonide, Mometasone, Salmeterol, Formoterol, Sodium cromoglicate, Sodium cromoglicate + Salbutamol, Nedocromil, Edoxaban, Midazolam, Buprenorphine, Levomepromazine, Mesalazine, Colecalciferol + Calcium carbonate, Insulin aspart, Insulin aspart biphasic, Insulin degludec, Insulin degludec + Liraglutide, Insulin detemir, Insulin glargine, Insulin glargine + Lixisenatide, Insulin glulisine, Insulin human, Insulin isophane biphasic human, Insulin isophane biphasic porcine, Insulin isophane bovine, Insulin isophane human, Insulin isophane porcine, Insulin lispro, Insulin lispro biphasic, Insulin mixed bovine, Insulin protamine zinc bovine, Insulin soluble bovine, Insulin soluble human, Insulin soluble porcine, Insulin zinc crystalline human, Insulin zinc mixed human.",
      "The export of the US-based AbbVies Kaletra / Aluvia, a combination lopinavir and ritonavir, the generic drug chloroquine phosphate and the generic drug hydroxychloroquine is being restricted to meet the needs of UK patients, the government said."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided mentions that export restrictions have been placed on several medicines, including Kaletra (a combination of lopinavir and ritonavir), chloroquine phosphate, and hydroxychloroquine. However, it does not explicitly state a ban on parallel export or hoarding of these specific drugs within the UK. Parallel importing (exporting) is a practice that allows pharmaceutical products to be imported from one member state of the European Union into another for distribution, and hoarding refers to the act of stockpiling goods. The text only states restrictions on exports, not bans on import or storage within the UK.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000017",
    "statement": "Uk bans parallel training and hoarding of lopinavir+ritonavir, chloroquine and hydroxychloroquine",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "31 March 2020 52 medicines have been added to the list of medicines that cannot be parallel exported from the UK, these are: Cefalexin, Codeine, Co-trimoxazole, Diamorphine, Doxycycline, Ipratropium, Salbutamol, Prochlorperazine,Salbutamol + Beclometasone, Salbutamol + Ipratropium Terbutaline, Beclometasone, Beclometasone + Formoterol, Beclometasone + Formoterol + Glycopyrronium bromide, Budesonide, Budesonide + Formoterol, Fluticasone, Fluticasone + Formoterol, Fluticasone + Salmeterol, Fluticasone + Umeclidinium bromide + Vilanterol, Fluticasone + Vilanterol, Ciclesonide, Mometasone, Salmeterol, Formoterol, Sodium cromoglicate, Sodium cromoglicate + Salbutamol, Nedocromil, Edoxaban, Midazolam, Buprenorphine, Levomepromazine, Mesalazine, Colecalciferol + Calcium carbonate, Insulin aspart, Insulin aspart biphasic, Insulin degludec, Insulin degludec + Liraglutide, Insulin detemir, Insulin glargine, Insulin glargine + Lixisenatide, Insulin glulisine, Insulin human, Insulin isophane biphasic human, Insulin isophane biphasic porcine, Insulin isophane bovine, Insulin isophane human, Insulin isophane porcine, Insulin lispro, Insulin lispro biphasic, Insulin mixed bovine, Insulin protamine zinc bovine, Insulin soluble bovine, Insulin soluble human, Insulin soluble porcine, Insulin zinc crystalline human, Insulin zinc mixed human.",
      "The export of the US-based AbbVies Kaletra / Aluvia, a combination lopinavir and ritonavir, the generic drug chloroquine phosphate and the generic drug hydroxychloroquine is being restricted to meet the needs of UK patients, the government said."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not directly support or refute the claim that the UK bans parallel training and hoarding of lopinavir+ritonavir, chloroquine and hydroxychloroquine. It does state that the export of these drugs is restricted to meet the needs of UK patients, but it does not mention any ban on parallel training or hoarding.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000018",
    "statement": "Ukakes parallel export and hoarding of lopinavir+ritonavir, chloroquine and hydroxychloroquine",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "31 March 2020 52 medicines have been added to the list of medicines that cannot be parallel exported from the UK, these are: Cefalexin, Codeine, Co-trimoxazole, Diamorphine, Doxycycline, Ipratropium, Salbutamol, Prochlorperazine,Salbutamol + Beclometasone, Salbutamol + Ipratropium Terbutaline, Beclometasone, Beclometasone + Formoterol, Beclometasone + Formoterol + Glycopyrronium bromide, Budesonide, Budesonide + Formoterol, Fluticasone, Fluticasone + Formoterol, Fluticasone + Salmeterol, Fluticasone + Umeclidinium bromide + Vilanterol, Fluticasone + Vilanterol, Ciclesonide, Mometasone, Salmeterol, Formoterol, Sodium cromoglicate, Sodium cromoglicate + Salbutamol, Nedocromil, Edoxaban, Midazolam, Buprenorphine, Levomepromazine, Mesalazine, Colecalciferol + Calcium carbonate, Insulin aspart, Insulin aspart biphasic, Insulin degludec, Insulin degludec + Liraglutide, Insulin detemir, Insulin glargine, Insulin glargine + Lixisenatide, Insulin glulisine, Insulin human, Insulin isophane biphasic human, Insulin isophane biphasic porcine, Insulin isophane bovine, Insulin isophane human, Insulin isophane porcine, Insulin lispro, Insulin lispro biphasic, Insulin mixed bovine, Insulin protamine zinc bovine, Insulin soluble bovine, Insulin soluble human, Insulin soluble porcine, Insulin zinc crystalline human, Insulin zinc mixed human.",
      "The export of the US-based AbbVies Kaletra / Aluvia, a combination lopinavir and ritonavir, the generic drug chloroquine phosphate and the generic drug hydroxychloroquine is being restricted to meet the needs of UK patients, the government said."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not directly support or refute the claim about Ukakes parallel export and hoarding of specific drugs such as lopinavir+ritonavir, chloroquine, and hydroxychloroquine. The information given details the restriction on parallel export of 52 medicines, but it does not provide any information about whether the UK is hoarding these specific drugs or not.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000019",
    "statement": "Ukolls parallel export and hoarding of lopinavir+ritonavir, chloroquine and hydroxychloroquine",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "31 March 2020 52 medicines have been added to the list of medicines that cannot be parallel exported from the UK, these are: Cefalexin, Codeine, Co-trimoxazole, Diamorphine, Doxycycline, Ipratropium, Salbutamol, Prochlorperazine,Salbutamol + Beclometasone, Salbutamol + Ipratropium Terbutaline, Beclometasone, Beclometasone + Formoterol, Beclometasone + Formoterol + Glycopyrronium bromide, Budesonide, Budesonide + Formoterol, Fluticasone, Fluticasone + Formoterol, Fluticasone + Salmeterol, Fluticasone + Umeclidinium bromide + Vilanterol, Fluticasone + Vilanterol, Ciclesonide, Mometasone, Salmeterol, Formoterol, Sodium cromoglicate, Sodium cromoglicate + Salbutamol, Nedocromil, Edoxaban, Midazolam, Buprenorphine, Levomepromazine, Mesalazine, Colecalciferol + Calcium carbonate, Insulin aspart, Insulin aspart biphasic, Insulin degludec, Insulin degludec + Liraglutide, Insulin detemir, Insulin glargine, Insulin glargine + Lixisenatide, Insulin glulisine, Insulin human, Insulin isophane biphasic human, Insulin isophane biphasic porcine, Insulin isophane bovine, Insulin isophane human, Insulin isophane porcine, Insulin lispro, Insulin lispro biphasic, Insulin mixed bovine, Insulin protamine zinc bovine, Insulin soluble bovine, Insulin soluble human, Insulin soluble porcine, Insulin zinc crystalline human, Insulin zinc mixed human.",
      "The export of the US-based AbbVies Kaletra / Aluvia, a combination lopinavir and ritonavir, the generic drug chloroquine phosphate and the generic drug hydroxychloroquine is being restricted to meet the needs of UK patients, the government said."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence does not directly support or refute the claim about Ukolls parallel export and hoarding of specific drugs (lopinavir+ritonavir, chloroquine, hydroxychloroquine). The evidence only states that the export of these drugs from the US by AbbVie is being restricted to meet the needs of UK patients, not that Ukolls is involved in their parallel export or hoarding.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000020",
    "statement": "Air quality influences the pandemic - communiqu\u00e9s de presse",
    "label": "SUPPORTED",
    "evidences": [
      "The study provides preventive measures related to air pollution to limit future outbreaks of morbidity and mortality due to the coronavirus.",
      "Epidemiologists widely agree that there is a correlation between acute and locally elevated concentrations of fine particles and the severity of influenza waves.",
      "The increase in fine particles is generally favored by air temperature inversions, characterized by fog situations, or by Saharan dust intrusions.",
      "A multifactorial pandemic Nonetheless, the researchers also emphasize that, although particulate matter pollution can influence the virulence of the virus and possible severe disease progression, physiological, social or economic factors will clearly also influence the further course of the pandemic."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests that there is a correlation between air quality (specifically fine particles concentration) and the severity of influenza waves, although it does not directly state that it applies specifically to coronavirus. However, the study provides preventive measures related to air pollution for limiting future outbreaks of morbidity and mortality due to the coronavirus, implying a potential impact on the pandemic.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000021",
    "statement": "Virus quality influences the pandemic - communiqu\u00e9s de presse",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The study provides preventive measures related to air pollution to limit future outbreaks of morbidity and mortality due to the coronavirus.",
      "Epidemiologists widely agree that there is a correlation between acute and locally elevated concentrations of fine particles and the severity of influenza waves.",
      "The increase in fine particles is generally favored by air temperature inversions, characterized by fog situations, or by Saharan dust intrusions.",
      "A multifactorial pandemic Nonetheless, the researchers also emphasize that, although particulate matter pollution can influence the virulence of the virus and possible severe disease progression, physiological, social or economic factors will clearly also influence the further course of the pandemic."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided discusses the correlation between air pollution and the severity of influenza waves, not specifically the coronavirus in question. Although it is suggested that particulate matter pollution can influence the virulence of the virus, this does not directly support the claim that 'Virus quality influences the pandemic'.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000022",
    "statement": "Health quality influences the pandemic - communiqu\u00e9s de presse",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The study provides preventive measures related to air pollution to limit future outbreaks of morbidity and mortality due to the coronavirus.",
      "Epidemiologists widely agree that there is a correlation between acute and locally elevated concentrations of fine particles and the severity of influenza waves.",
      "The increase in fine particles is generally favored by air temperature inversions, characterized by fog situations, or by Saharan dust intrusions.",
      "A multifactorial pandemic Nonetheless, the researchers also emphasize that, although particulate matter pollution can influence the virulence of the virus and possible severe disease progression, physiological, social or economic factors will clearly also influence the further course of the pandemic."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that there is a correlation between air pollution (fine particles) and the severity of influenza waves, which can be considered as a part of a pandemic. The study also highlights that physiological, social or economic factors will influence the further course of the pandemic, indicating that health quality is indeed one of those factors.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000023",
    "statement": "Global quality influences the pandemic - communiqu\u00e9s de presse",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The study provides preventive measures related to air pollution to limit future outbreaks of morbidity and mortality due to the coronavirus.",
      "Epidemiologists widely agree that there is a correlation between acute and locally elevated concentrations of fine particles and the severity of influenza waves.",
      "The increase in fine particles is generally favored by air temperature inversions, characterized by fog situations, or by Saharan dust intrusions.",
      "A multifactorial pandemic Nonetheless, the researchers also emphasize that, although particulate matter pollution can influence the virulence of the virus and possible severe disease progression, physiological, social or economic factors will clearly also influence the further course of the pandemic."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not directly support the claim that 'Global quality influences the pandemic'. The information mainly discusses the correlation between air pollution (particulate matter) and the severity of influenza waves or the virulence of the virus. While it suggests that air quality might indirectly influence the pandemic through health-related factors, it does not establish a causal link between global quality and the pandemic itself.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000024",
    "statement": "Single-cell omics reveals dyssynchrony of the innate and adaptive immune system in progressive covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "Here, we utilize multiomics single-cell analysis to probe dynamic immune responses in patients with stable or progressive manifestations of COVID-19, and assess the effects of tocilizumab, an anti-IL-6 receptor monoclonal antibody."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided discusses the use of multiomics single-cell analysis to probe dynamic immune responses in patients with COVID-19 and assess the effects of tocilizumab. However, it does not directly support the claim that there is dyssynchrony of the innate and adaptive immune system specifically in progressive COVID-19.",
    "confidence": 0.5
  },
  {
    "id": "covid_fact-000025",
    "statement": "Single-brain omics reveals dyssynchrony of the innate and adaptive immune system in progressive covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Here, we utilize multiomics single-cell analysis to probe dynamic immune responses in patients with stable or progressive manifestations of COVID-19, and assess the effects of tocilizumab, an anti-IL-6 receptor monoclonal antibody."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence focuses on the use of multiomics single-cell analysis to study immune responses in patients with COVID-19 and assess the effects of tocilizumab. It does not directly support or refute the claim about dyssynchrony of the innate and adaptive immune system in progressive COVID-19.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000026",
    "statement": "Fenofibrate increases the amount of sulfatide which seems beneficial against covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "Also in a population, treatment with agents that increase sulfatide levels such as fenofibrate or serine [7], [8] should be investigated for a beneficial effect against coronavirus infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is supported by the provided evidence as it states that treating populations with fenofibrate, an agent that increases sulfatide levels, should be investigated for a beneficial effect against coronavirus infection. The claim suggests a potential benefit of fenofibrate in relation to COVID-19, which is consistent with the presented evidence.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000027",
    "statement": "Fenofibrate reduces the amount of sulfatide which seems beneficial against covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Also in a population, treatment with agents that increase sulfatide levels such as fenofibrate or serine [7], [8] should be investigated for a beneficial effect against coronavirus infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that agents such as fenofibrate increase sulfatide levels and should be investigated for a beneficial effect against coronavirus infection. This implies that fenofibrate might reduce the amount of sulfatide (since increasing it is suggested to have a beneficial effect), which seems to be beneficial against COVID-19 according to the claim.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000028",
    "statement": "Fenofibrate reduced the amount of sulfatide which seems beneficial against covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Also in a population, treatment with agents that increase sulfatide levels such as fenofibrate or serine [7], [8] should be investigated for a beneficial effect against coronavirus infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that treatment with fenofibrate increases sulfatide levels, and it is proposed that this could have a beneficial effect against coronavirus infection. This claim is supported by the reasoning provided.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000029",
    "statement": "Fenofibrate decreased the amount of sulfatide which seems beneficial against covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Also in a population, treatment with agents that increase sulfatide levels such as fenofibrate or serine [7], [8] should be investigated for a beneficial effect against coronavirus infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that treatment with fenofibrate increases sulfatide levels and suggests that this could have a beneficial effect against coronavirus infection. This implies that fenofibrate decreases the amount of sulfatide which could be beneficial against COVID-19.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000030",
    "statement": "Gns561 exhibits potent in vitro antiviral activity against sars-cov-2 through autophagy inhibition",
    "label": "SUPPORTED",
    "evidences": [
      "Overall, our study highlights GNS561 as a powerful drug in SARS- CoV-2 infection and supports that the hypothesis that autophagy inhibitors could be an alternative strategy for SARS-CoV-2 infection.",
      "Our data indicated that GNS561 showed the highest antiviral effect for two SARS-CoV-2 strains compared to CQ and remdesivir.",
      "Finally, our study revealed that the combination of GNS561 and remdesivir was associated with a strong synergistic antiviral effect against SARS-CoV-2.",
      "Here, we investigated the antiviral activity and associated mechanism of GNS561, a small basic lipophilic molecule inhibitor of late-stage autophagy, against SARS-CoV-2."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows that the study highlights GNS561 as a powerful drug in SARS-CoV-2 infection and indicates that it showed the highest antiviral effect compared to other drugs like CQ and remdesivir. Additionally, the study suggests that the hypothesis that autophagy inhibitors could be an alternative strategy for SARS-CoV-2 infection is supported since GNS561 is a small basic lipophilic molecule inhibitor of late-stage autophagy.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000031",
    "statement": "Gns561 exhibits no in vitro antiviral activity against sars-cov-2 through autophagy inhibition",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Overall, our study highlights GNS561 as a powerful drug in SARS- CoV-2 infection and supports that the hypothesis that autophagy inhibitors could be an alternative strategy for SARS-CoV-2 infection.",
      "Our data indicated that GNS561 showed the highest antiviral effect for two SARS-CoV-2 strains compared to CQ and remdesivir.",
      "Finally, our study revealed that the combination of GNS561 and remdesivir was associated with a strong synergistic antiviral effect against SARS-CoV-2.",
      "Here, we investigated the antiviral activity and associated mechanism of GNS561, a small basic lipophilic molecule inhibitor of late-stage autophagy, against SARS-CoV-2."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided suggests that GNS561 has antiviral activity against SARS-CoV-2 and this effect is stronger than that of CQ (Chloroquine) and remdesivir. However, it does not support the claim that GNS561 exhibits no antiviral activity through autophagy inhibition. In fact, the evidence states that the study investigated the antiviral activity and associated mechanism of GNS561 as an inhibitor of late-stage autophagy.",
    "confidence": 0.98
  },
  {
    "id": "covid_fact-000032",
    "statement": "Suspicions grow that nanoparticles in pfizer 's covid-19 vaccine trigger rare allergic reactions.",
    "label": "SUPPORTED",
    "evidences": [
      "Severe allergy-like reactions in at least eight people who received the COVID-19 vaccine produced by Pfizer and BioNTech over the past 2 weeks may be due to a compound in the packaging of the messenger RNA (mRNA) that forms the vaccines main ingredient, scientists say.",
      "Patients with severe allergies in the US are getting nervous about the possibility that they may not be able to get vaccinated, at least with those two vaccines, Togias wrote in an invitation to meeting participants.",
      "Some allergists and immunologists believe a small number of people previously exposed to PEG may have high levels of antibodies against PEG, putting them at risk of an anaphylactic reaction to the vaccine.",
      "NIAID is also setting up a study in collaboration with FDA to analyze the response to the vaccine in people who have high levels of anti-PEG antibodies or have experienced severe allergic responses to drugs or vaccines before."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that severe allergy-like reactions in people who received the COVID-19 vaccine produced by Pfizer and BioNTech may be due to a compound in the packaging of the messenger RNA (mRNA) that forms the vaccines main ingredient. This compound is PEG, which some allergists and immunologists believe a small number of people previously exposed to PEG may have high levels of antibodies against PEG, putting them at risk of an anaphylactic reaction to the vaccine.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000033",
    "statement": "Suspicions grow that nanoparticles in pfizer's covid-19 vaccine trigger systemic allergic reactions.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Severe allergy-like reactions in at least eight people who received the COVID-19 vaccine produced by Pfizer and BioNTech over the past 2 weeks may be due to a compound in the packaging of the messenger RNA (mRNA) that forms the vaccines main ingredient, scientists say.",
      "Patients with severe allergies in the US are getting nervous about the possibility that they may not be able to get vaccinated, at least with those two vaccines, Togias wrote in an invitation to meeting participants.",
      "Some allergists and immunologists believe a small number of people previously exposed to PEG may have high levels of antibodies against PEG, putting them at risk of an anaphylactic reaction to the vaccine.",
      "NIAID is also setting up a study in collaboration with FDA to analyze the response to the vaccine in people who have high levels of anti-PEG antibodies or have experienced severe allergic responses to drugs or vaccines before."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that severe allergy-like reactions in at least eight people who received the COVID-19 vaccine produced by Pfizer and BioNTech may be due to a compound in the packaging of the messenger RNA (mRNA) that forms the vaccines main ingredient. This compound is PEG, which some allergists and immunologists believe a small number of people previously exposed to PEG may have high levels of antibodies against PEG, putting them at risk of an anaphylactic reaction to the vaccine.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000034",
    "statement": "Berberine and obatoclax inhibit sars-cov-2 replication in primary human nasal epithelial cells in vitro.",
    "label": "SUPPORTED",
    "evidences": [
      "Berberine, a plant-derived alkaloid, inhibited SARS-CoV-2 at low micromolar concentrations and obatoclax, originally developed as an anti-apoptotic protein antagonist, was effective at sub-micromolar concentrations.",
      "In this study, we demonstrate that berberine and obatoclax, two broad-spectrum antiviral compounds, are effective against multiple isolates of SARS-CoV-2.",
      "Moreover, both obatoclax and berberine inhibited SARS-CoV-2 replication in these primary target cells.",
      "Berberine and obatoclax inhibit SARS-CoV-2 replication in primary human nasal epithelial c"
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided states that the study demonstrates that berberine and obatoclax are effective against SARS-CoV-2 and inhibit its replication in primary human nasal epithelial cells. Therefore, it is supported that Berberine and obatoclax inhibit sars-cov-2 replication in primary human nasal epithelial cells.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000035",
    "statement": "Berberine and obatoclax induce sars-cov-2 replication in primary human nasal epithelial cells in vitro.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Berberine, a plant-derived alkaloid, inhibited SARS-CoV-2 at low micromolar concentrations and obatoclax, originally developed as an anti-apoptotic protein antagonist, was effective at sub-micromolar concentrations.",
      "In this study, we demonstrate that berberine and obatoclax, two broad-spectrum antiviral compounds, are effective against multiple isolates of SARS-CoV-2.",
      "Moreover, both obatoclax and berberine inhibited SARS-CoV-2 replication in these primary target cells.",
      "Berberine and obatoclax inhibit SARS-CoV-2 replication in primary human nasal epithelial c"
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that both berberine and obatoclax inhibited SARS-CoV-2 replication in primary human nasal epithelial cells. This directly supports the claim.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000036",
    "statement": "Berberine and obatoclax induced sars-cov-2 replication in primary human nasal epithelial cells in vitro.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Berberine, a plant-derived alkaloid, inhibited SARS-CoV-2 at low micromolar concentrations and obatoclax, originally developed as an anti-apoptotic protein antagonist, was effective at sub-micromolar concentrations.",
      "In this study, we demonstrate that berberine and obatoclax, two broad-spectrum antiviral compounds, are effective against multiple isolates of SARS-CoV-2.",
      "Moreover, both obatoclax and berberine inhibited SARS-CoV-2 replication in these primary target cells.",
      "Berberine and obatoclax inhibit SARS-CoV-2 replication in primary human nasal epithelial c"
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly states that both berberine and obatoclax inhibited SARS-CoV-2 replication in primary human nasal epithelial cells. This is consistent with the claim made.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000037",
    "statement": "Berberine and obatoclax are sars-cov-2 replication in primary human nasal epithelial cells in vitro.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Berberine, a plant-derived alkaloid, inhibited SARS-CoV-2 at low micromolar concentrations and obatoclax, originally developed as an anti-apoptotic protein antagonist, was effective at sub-micromolar concentrations.",
      "In this study, we demonstrate that berberine and obatoclax, two broad-spectrum antiviral compounds, are effective against multiple isolates of SARS-CoV-2.",
      "Moreover, both obatoclax and berberine inhibited SARS-CoV-2 replication in these primary target cells.",
      "Berberine and obatoclax inhibit SARS-CoV-2 replication in primary human nasal epithelial c"
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly states that berberine and obatoclax inhibit SARS-CoV-2 replication in primary human nasal epithelial cells.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000038",
    "statement": "Taiwan completes synthesis of potential covid-19 drug",
    "label": "SUPPORTED",
    "evidences": [
      "DCB president Herbert Wu () said that the center was able to synthesize the drug in four days after acquiring its components and that the goal is to transfer the process to domestic companies so they can mass-produce a generic version to fight the epidemic, per CNA."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not indicate whether the synthesized drug is indeed a potential COVID-19 treatment. It only states that the drug was synthesized and the intention to transfer production to domestic companies.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000039",
    "statement": "Taiwan inhibits synthesis of potential covid-19 drug",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "DCB president Herbert Wu () said that the center was able to synthesize the drug in four days after acquiring its components and that the goal is to transfer the process to domestic companies so they can mass-produce a generic version to fight the epidemic, per CNA."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not directly support or contradict the claim that Taiwan inhibits synthesis of a potential COVID-19 drug. The statement made by DCB president Herbert Wu refers to the synthesis of the drug by the center he represents, not a country-wide prohibition or restriction.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000040",
    "statement": "Taiwan requires synthesis of potential covid-19 drug",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "DCB president Herbert Wu () said that the center was able to synthesize the drug in four days after acquiring its components and that the goal is to transfer the process to domestic companies so they can mass-produce a generic version to fight the epidemic, per CNA."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence only states that the DCB president was able to synthesize the potential COVID-19 drug and the goal is to transfer the process to domestic companies. It does not confirm whether Taiwan requires the synthesis of this specific drug.",
    "confidence": 0.5
  },
  {
    "id": "covid_fact-000041",
    "statement": "25-hydroxyvitamin d concentrations are lower in patients with positive pcr for sars-cov-2",
    "label": "SUPPORTED",
    "evidences": [
      "Figure 2 ( A ) 25-hydroxyvitamin D Figure 2 ( A ) 25-hydroxyvitamin D concentrations in the three evaluated groups divided by Figure 2 ( A ) 25-hydroxyvitamin D concentrations in the three evaluated groups divided by gender (patients from 1 March to 14 April of 2019 and 2020 with a negative PCR, and of 2020 with a positive PCR to SARS-CoV-2; ( B ) 25-hydroxyvitamin D concentrations in the three evaluated groups divided by age (070 years vs. >70 years) (patients from 1 March to 14 April of 2019 and 2020 with a negative PCR, and of 2020 with a positive PCR for SARS-CoV-2.",
      "Low 25-Hydroxyvitamin D Levels on Admission to the Intensive Care Unit May Predispose COVID-19 Pneumonia Patients to a Higher 28-Day Mortality Risk: A Pilot Study on a Greek ICU Cohort.",
      "In this cohort, significantly lower 25(OH)D levels ( p = 0.004) were found in PCR-positive for SARS-CoV-2 (median value 11.1 ng/mL) patients compared with negative patients (24.6 ng/mL); this was also confirmed by stratifying patients according to age >70 years.",
      "Many authors have suggested the involvement of vitamin D in reducing the risk of infections; thus, we retrospectively investigated the 25-hydroxyvitamin D (25(OH)D) concentrations in plasma obtained from a cohort of patients from Switzerland."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence presented shows a statistical significant difference (p = 0.004) in the median 25-hydroxyvitamin D concentrations between patients who tested positive for SARS-CoV-2 (11.1 ng/mL) and those who tested negative (24.6 ng/mL). This suggests that 25-hydroxyvitamin d concentrations are lower in patients with positive PCR for sars-cov-2.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000042",
    "statement": "25-hydroxyvitamin d concentrations are elevated in patients with positive pcr for sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Figure 2 ( A ) 25-hydroxyvitamin D Figure 2 ( A ) 25-hydroxyvitamin D concentrations in the three evaluated groups divided by Figure 2 ( A ) 25-hydroxyvitamin D concentrations in the three evaluated groups divided by gender (patients from 1 March to 14 April of 2019 and 2020 with a negative PCR, and of 2020 with a positive PCR to SARS-CoV-2; ( B ) 25-hydroxyvitamin D concentrations in the three evaluated groups divided by age (070 years vs. >70 years) (patients from 1 March to 14 April of 2019 and 2020 with a negative PCR, and of 2020 with a positive PCR for SARS-CoV-2.",
      "Low 25-Hydroxyvitamin D Levels on Admission to the Intensive Care Unit May Predispose COVID-19 Pneumonia Patients to a Higher 28-Day Mortality Risk: A Pilot Study on a Greek ICU Cohort.",
      "In this cohort, significantly lower 25(OH)D levels ( p = 0.004) were found in PCR-positive for SARS-CoV-2 (median value 11.1 ng/mL) patients compared with negative patients (24.6 ng/mL); this was also confirmed by stratifying patients according to age >70 years.",
      "Many authors have suggested the involvement of vitamin D in reducing the risk of infections; thus, we retrospectively investigated the 25-hydroxyvitamin D (25(OH)D) concentrations in plasma obtained from a cohort of patients from Switzerland."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows that significantly lower 25-hydroxyvitamin D levels were found in PCR-positive for SARS-CoV-2 patients compared with negative patients, as indicated by the p-value (0.004) and median values. This suggests that 25-hydroxyvitamin d concentrations are potentially elevated in patients with positive PCR for sars-cov-2.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000043",
    "statement": "25-hydroxyvitamin d concentrations are increased in patients with positive pcr for sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Figure 2 ( A ) 25-hydroxyvitamin D Figure 2 ( A ) 25-hydroxyvitamin D concentrations in the three evaluated groups divided by Figure 2 ( A ) 25-hydroxyvitamin D concentrations in the three evaluated groups divided by gender (patients from 1 March to 14 April of 2019 and 2020 with a negative PCR, and of 2020 with a positive PCR to SARS-CoV-2; ( B ) 25-hydroxyvitamin D concentrations in the three evaluated groups divided by age (070 years vs. >70 years) (patients from 1 March to 14 April of 2019 and 2020 with a negative PCR, and of 2020 with a positive PCR for SARS-CoV-2.",
      "Low 25-Hydroxyvitamin D Levels on Admission to the Intensive Care Unit May Predispose COVID-19 Pneumonia Patients to a Higher 28-Day Mortality Risk: A Pilot Study on a Greek ICU Cohort.",
      "In this cohort, significantly lower 25(OH)D levels ( p = 0.004) were found in PCR-positive for SARS-CoV-2 (median value 11.1 ng/mL) patients compared with negative patients (24.6 ng/mL); this was also confirmed by stratifying patients according to age >70 years.",
      "Many authors have suggested the involvement of vitamin D in reducing the risk of infections; thus, we retrospectively investigated the 25-hydroxyvitamin D (25(OH)D) concentrations in plasma obtained from a cohort of patients from Switzerland."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows a statistically significant difference (p=0.004) in the median 25-hydroxyvitamin D concentrations between patients with a positive PCR for SARS-CoV-2 (11.1 ng/mL) and those with a negative PCR (24.6 ng/mL). This suggests that higher concentrations of 25-hydroxyvitamin D are not present in patients with a positive PCR for SARS-CoV-2.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000044",
    "statement": "25-hydroxyvitamin d concentrations are higher in patients with positive pcr for sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Figure 2 ( A ) 25-hydroxyvitamin D Figure 2 ( A ) 25-hydroxyvitamin D concentrations in the three evaluated groups divided by Figure 2 ( A ) 25-hydroxyvitamin D concentrations in the three evaluated groups divided by gender (patients from 1 March to 14 April of 2019 and 2020 with a negative PCR, and of 2020 with a positive PCR to SARS-CoV-2; ( B ) 25-hydroxyvitamin D concentrations in the three evaluated groups divided by age (070 years vs. >70 years) (patients from 1 March to 14 April of 2019 and 2020 with a negative PCR, and of 2020 with a positive PCR for SARS-CoV-2.",
      "Low 25-Hydroxyvitamin D Levels on Admission to the Intensive Care Unit May Predispose COVID-19 Pneumonia Patients to a Higher 28-Day Mortality Risk: A Pilot Study on a Greek ICU Cohort.",
      "In this cohort, significantly lower 25(OH)D levels ( p = 0.004) were found in PCR-positive for SARS-CoV-2 (median value 11.1 ng/mL) patients compared with negative patients (24.6 ng/mL); this was also confirmed by stratifying patients according to age >70 years.",
      "Many authors have suggested the involvement of vitamin D in reducing the risk of infections; thus, we retrospectively investigated the 25-hydroxyvitamin D (25(OH)D) concentrations in plasma obtained from a cohort of patients from Switzerland."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence presented shows that in the studied cohort, significantly lower 25-hydroxyvitamin D levels were found in patients who tested positive for SARS-CoV-2 compared to negative patients (p = 0.004). This suggests that 25-hydroxyvitamin D concentrations are indeed higher in patients with a positive PCR for SARS-CoV-2.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000045",
    "statement": "Us racial inequality may be as deadly as covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "Racial inequality may be as deadly as Covid-19 (replication package).",
      "For COVID-19 to raise mortality as much as racial inequality does, it would need to erase two to three decades of mortality progress for Whites."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided in the statement compares the impact of racial inequality on mortality with that of COVID-19. While not explicitly stating that racial inequality is as deadly as Covid-19, it implies this by suggesting that if Covid-19 were to raise mortality rates as much as racial inequality does, it would need to erase significant progress in White mortality rates over several decades. Therefore, the claim is supported.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000046",
    "statement": "Us racial inequality may be as useful as covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Racial inequality may be as deadly as Covid-19 (replication package).",
      "For COVID-19 to raise mortality as much as racial inequality does, it would need to erase two to three decades of mortality progress for Whites."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim compares the impact of racial inequality on mortality to COVID-19, however, it does not provide any evidence that directly supports this comparison. The provided evidence only states that racial inequality may be as deadly as COVID-19 in terms of its effect on mortality, but it does not show that racial inequality can cause the same level of mortality impact as COVID-19. Additionally, the claim suggests a causal relationship between racial inequality and mortality, which is not supported by the provided evidence.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000047",
    "statement": "Us racial inequality may be as effective as covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Racial inequality may be as deadly as Covid-19 (replication package).",
      "For COVID-19 to raise mortality as much as racial inequality does, it would need to erase two to three decades of mortality progress for Whites."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence directly compares the impact of racial inequality on mortality to that of COVID-19. It suggests that racial inequality has a significant and potentially lethal impact comparable to the pandemic.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000048",
    "statement": "Us racial transmission may be as deadly as covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Racial inequality may be as deadly as Covid-19 (replication package).",
      "For COVID-19 to raise mortality as much as racial inequality does, it would need to erase two to three decades of mortality progress for Whites."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests that racial inequality can have a similar impact on mortality as COVID-19. It is stated that COVID-19 would need to erase two to three decades of mortality progress for Whites to match the mortality impact of racial inequality. Therefore, the claim 'Us racial transmission may be as deadly as covid-19' can be supported by this evidence.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000049",
    "statement": "Immunity to covid-19 is probably higher than tests have shown",
    "label": "SUPPORTED",
    "evidences": [
      "Photo: Ulf Sirborn Our results indicate that public immunity to COVID-19 is probably significantly higher than antibody tests have suggested, says Professor Hans- Gustaf Ljunggren at the Center for Infectious Medicine, Karolinska Institutet, and co-senior author.",
      "One interesting observation was that it wasnt just individuals with verified COVID-19 who showed T-cell immunity but also many of their exposed asymptomatic family members, says Soo Aleman.",
      "Our results indicate that roughly twice as many people have developed T-cell immunity compared with those who we can detect antibodies in. In the present study, the researchers performed immunological analyses of samples from over 200 people, many of whom had mild or no symptoms of COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence indicates that a study has shown a higher level of T-cell immunity to COVID-19 among the general population than what antibody tests have suggested. This suggests a higher level of immunity to the virus than what is currently detected through testing.",
    "confidence": 0.85
  },
  {
    "id": "covid_fact-000050",
    "statement": "Immunity to covid-19 is probably less than tests have shown",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Photo: Ulf Sirborn Our results indicate that public immunity to COVID-19 is probably significantly higher than antibody tests have suggested, says Professor Hans- Gustaf Ljunggren at the Center for Infectious Medicine, Karolinska Institutet, and co-senior author.",
      "One interesting observation was that it wasnt just individuals with verified COVID-19 who showed T-cell immunity but also many of their exposed asymptomatic family members, says Soo Aleman.",
      "Our results indicate that roughly twice as many people have developed T-cell immunity compared with those who we can detect antibodies in. In the present study, the researchers performed immunological analyses of samples from over 200 people, many of whom had mild or no symptoms of COVID-19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided indicates that the number of individuals with T-cell immunity to COVID-19 is higher than the number of those who test positive for antibodies. However, it does not provide clear support for the claim that immunity to covid-19 is probably less than tests have shown.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000051",
    "statement": "Immunity to covid-19 is probably lower than tests have shown",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Photo: Ulf Sirborn Our results indicate that public immunity to COVID-19 is probably significantly higher than antibody tests have suggested, says Professor Hans- Gustaf Ljunggren at the Center for Infectious Medicine, Karolinska Institutet, and co-senior author.",
      "One interesting observation was that it wasnt just individuals with verified COVID-19 who showed T-cell immunity but also many of their exposed asymptomatic family members, says Soo Aleman.",
      "Our results indicate that roughly twice as many people have developed T-cell immunity compared with those who we can detect antibodies in. In the present study, the researchers performed immunological analyses of samples from over 200 people, many of whom had mild or no symptoms of COVID-19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided shows that a study found higher levels of T-cell immunity to COVID-19 than previously detected antibody tests suggested. However, this does not imply that the overall immunity is lower than the test results; it only suggests that there may be more individuals with T-cell immunity than previously thought. The claim makes an assumption about all populations, not just those in the study, which is not supported by the provided evidence.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000052",
    "statement": "Immunity to covid-19 is probably smaller than tests have shown",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Photo: Ulf Sirborn Our results indicate that public immunity to COVID-19 is probably significantly higher than antibody tests have suggested, says Professor Hans- Gustaf Ljunggren at the Center for Infectious Medicine, Karolinska Institutet, and co-senior author.",
      "One interesting observation was that it wasnt just individuals with verified COVID-19 who showed T-cell immunity but also many of their exposed asymptomatic family members, says Soo Aleman.",
      "Our results indicate that roughly twice as many people have developed T-cell immunity compared with those who we can detect antibodies in. In the present study, the researchers performed immunological analyses of samples from over 200 people, many of whom had mild or no symptoms of COVID-19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided suggests that the number of people with T-cell immunity to COVID-19 might be larger than antibody tests have suggested. However, this does not necessarily mean that the overall immunity to COVID-19 is smaller than tests have shown. The claim requires data showing a significant decrease in immunity when compared to the number found by tests, which is not presented in the given evidence.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000053",
    "statement": "A novel in-cell elisa assay allows rapid and automated quantification of sars-cov-2 to analyze neutralizing antibodies and antiviral compounds",
    "label": "SUPPORTED",
    "evidences": [
      "To replace microscopic counting-based SARS-CoV-2 PRNTs by a novel assay exempt from genetically modified viruses, which are inapplicable in most diagnostics departments, we established a simple, rapid, and automated SARS-CoV-2 neutralization assay employing an in- cell ELISA (icELISA) approach.",
      "A novel in-cell ELISA assay allows rapid and automated quantification of SARS-CoV-2 to analyse neutralizing antibodies and antiviral compounds.",
      "Altogether, the SARS-CoV-2 icELISA test allows rapid (<48 h in total, read-out in seconds) and automated quantification of virus infection in cell culture to evaluate the efficacy of NAbs and antiviral drugs using reagents and equipment present in most routine diagnostics departments."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides a clear description of the development of an in-cell ELISA (icELISA) assay for SARS-CoV-2. This novel assay allows rapid and automated quantification of SARS-CoV-2 to analyze neutralizing antibodies and antiviral compounds.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000054",
    "statement": "A standard in-cell elisa assay allows rapid and automated quantification of sars-cov-2 to analyze neutralizing antibodies and antiviral compounds",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "To replace microscopic counting-based SARS-CoV-2 PRNTs by a novel assay exempt from genetically modified viruses, which are inapplicable in most diagnostics departments, we established a simple, rapid, and automated SARS-CoV-2 neutralization assay employing an in- cell ELISA (icELISA) approach.",
      "A novel in-cell ELISA assay allows rapid and automated quantification of SARS-CoV-2 to analyse neutralizing antibodies and antiviral compounds.",
      "Altogether, the SARS-CoV-2 icELISA test allows rapid (<48 h in total, read-out in seconds) and automated quantification of virus infection in cell culture to evaluate the efficacy of NAbs and antiviral drugs using reagents and equipment present in most routine diagnostics departments."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided describes a novel assay (SARS-CoV-2 icELISA) that allows rapid and automated quantification of SARS-CoV-2 to analyze neutralizing antibodies and antiviral compounds. This directly supports the claim.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000055",
    "statement": "A conventional in-cell elisa assay allows rapid and automated quantification of sars-cov-2 to analyze neutralizing antibodies and antiviral compounds",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "To replace microscopic counting-based SARS-CoV-2 PRNTs by a novel assay exempt from genetically modified viruses, which are inapplicable in most diagnostics departments, we established a simple, rapid, and automated SARS-CoV-2 neutralization assay employing an in- cell ELISA (icELISA) approach.",
      "A novel in-cell ELISA assay allows rapid and automated quantification of SARS-CoV-2 to analyse neutralizing antibodies and antiviral compounds.",
      "Altogether, the SARS-CoV-2 icELISA test allows rapid (<48 h in total, read-out in seconds) and automated quantification of virus infection in cell culture to evaluate the efficacy of NAbs and antiviral drugs using reagents and equipment present in most routine diagnostics departments."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence supports the claim that a conventional in-cell ELISA assay allows rapid and automated quantification of SARS-CoV-2 to analyze neutralizing antibodies and antiviral compounds. The evidence presents the establishment of such an assay, describing it as simple, rapid, and automated, and capable of evaluating the efficacy of NAbs (neutralizing antibodies) and antiviral drugs.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000056",
    "statement": "A simple in-cell elisa assay allows rapid and automated quantification of sars-cov-2 to analyze neutralizing antibodies and antiviral compounds",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "To replace microscopic counting-based SARS-CoV-2 PRNTs by a novel assay exempt from genetically modified viruses, which are inapplicable in most diagnostics departments, we established a simple, rapid, and automated SARS-CoV-2 neutralization assay employing an in- cell ELISA (icELISA) approach.",
      "A novel in-cell ELISA assay allows rapid and automated quantification of SARS-CoV-2 to analyse neutralizing antibodies and antiviral compounds.",
      "Altogether, the SARS-CoV-2 icELISA test allows rapid (<48 h in total, read-out in seconds) and automated quantification of virus infection in cell culture to evaluate the efficacy of NAbs and antiviral drugs using reagents and equipment present in most routine diagnostics departments."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided states that a novel in-cell ELISA assay has been established for the rapid and automated quantification of SARS-CoV-2 to analyze neutralizing antibodies and antiviral compounds. This directly supports the claim.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000057",
    "statement": "Stanford professor balaji s. srinivasan 's peer review of the santa clara seroprevalence study indicates that its high reported positive rate results may be explained by the false positive rate of the test and/or by sample recruitment issues .",
    "label": "SUPPORTED",
    "evidences": [
      "The use of such certificates may therefore increase the risks of continued transmission. One of the most well-known attempts to justify sending workers back to offices and factories based on a supposed antibody count comes from the controversial Santa Clara study, as it has come to be known.",
      "The Stanford researchers acknowledged as much in the study and used test performance weights to scale results, but Rutherford was skeptical of these weights, as well as the population weights the researchers used.",
      "In a peer review of the antibody study published to Medium, former Stanford lecturer Balaji Srinivasan, who specializes in statistics and computational biology, argued the selection methods could have overstated the prevalence of the disease in the county.",
      "Dr. Natalie E. Dean, a professor of biostatistics at the University of Florida, tweeted that she had concerns with the adjustments made for clustering (some participants brought children and other household members with them to the test) and test characteristics (researchers assume no false positives but some false negatives)."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that Balaji Srinivasan, a former Stanford lecturer specializing in statistics and computational biology, peer reviewed the Santa Clara seroprevalence study and expressed concerns about the selection methods potentially overstating the prevalence of the disease. This suggests that he believes the high reported positive rate may be due to either the false positive rate of the test or sample recruitment issues.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000058",
    "statement": "Stanford professor balaji s. srinivasan's peer review of the santa clara seroprevalence study indicates that its high reported positive rate results cannot be explained by the false positive rate of the test and/or by sample recruitment issues.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The use of such certificates may therefore increase the risks of continued transmission. One of the most well-known attempts to justify sending workers back to offices and factories based on a supposed antibody count comes from the controversial Santa Clara study, as it has come to be known.",
      "The Stanford researchers acknowledged as much in the study and used test performance weights to scale results, but Rutherford was skeptical of these weights, as well as the population weights the researchers used.",
      "In a peer review of the antibody study published to Medium, former Stanford lecturer Balaji Srinivasan, who specializes in statistics and computational biology, argued the selection methods could have overstated the prevalence of the disease in the county.",
      "Dr. Natalie E. Dean, a professor of biostatistics at the University of Florida, tweeted that she had concerns with the adjustments made for clustering (some participants brought children and other household members with them to the test) and test characteristics (researchers assume no false positives but some false negatives)."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided discusses concerns about the methodology and assumptions made in the Santa Clara study, including potential issues with population weights, adjustments for clustering, and test characteristics. However, it does not explicitly state or show that the high reported positive rate cannot be explained by the false positive rate of the test and/or sample recruitment issues as claimed.",
    "confidence": 0.6
  },
  {
    "id": "covid_fact-000059",
    "statement": "Fda takes key action in fight against covid-19 by issuing emergency use authorization for first covid-19 vaccine",
    "label": "SUPPORTED",
    "evidences": [
      "The emergency use authorization allows the Pfizer-BioNTech COVID-19 Vaccine to be distributed in the U.S. The FDAs authorization for emergency use of the first COVID-19 vaccine is a significant milestone in battling this devastating pandemic that has affected so many families in the United States and around the world, said FDA Commissioner Stephen M. Hahn, M.D."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided states that the FDA issued an Emergency Use Authorization for the Pfizer-BioNTech COVID-19 Vaccine, which is a key action in the fight against COVID-19.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000060",
    "statement": "Sars takes key action in fight against covid-19 by issuing emergency use authorization for first covid-19 vaccine",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The emergency use authorization allows the Pfizer-BioNTech COVID-19 Vaccine to be distributed in the U.S. The FDAs authorization for emergency use of the first COVID-19 vaccine is a significant milestone in battling this devastating pandemic that has affected so many families in the United States and around the world, said FDA Commissioner Stephen M. Hahn, M.D."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that the FDA has issued an emergency use authorization for the Pfizer-BioNTech COVID-19 Vaccine. SARS (Severe Acute Respiratory Syndrome) is a different coronavirus and not directly related to COVID-19. However, the vaccine mentioned is designed to combat COVID-19, making it indirectly relevant to the fight against SARS-CoV-2, the virus causing COVID-19.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000061",
    "statement": "China takes key action in fight against covid-19 by issuing emergency use authorization for first covid-19 vaccine",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The emergency use authorization allows the Pfizer-BioNTech COVID-19 Vaccine to be distributed in the U.S. The FDAs authorization for emergency use of the first COVID-19 vaccine is a significant milestone in battling this devastating pandemic that has affected so many families in the United States and around the world, said FDA Commissioner Stephen M. Hahn, M.D."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided mentions the emergency use authorization of a COVID-19 vaccine in the United States (Pfizer-BioNTech), but it does not explicitly state that China took key action in issuing such an authorization.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000062",
    "statement": "Who takes key action in fight against covid-19 by issuing emergency use authorization for first covid-19 vaccine",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The emergency use authorization allows the Pfizer-BioNTech COVID-19 Vaccine to be distributed in the U.S. The FDAs authorization for emergency use of the first COVID-19 vaccine is a significant milestone in battling this devastating pandemic that has affected so many families in the United States and around the world, said FDA Commissioner Stephen M. Hahn, M.D."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is supported by the evidence as it mentions that the Food and Drug Administration (FDA) issued the emergency use authorization for the first COVID-19 vaccine. While not explicitly stating who took the key action within the FDA, it is generally understood that the FDA Commissioner would be responsible for such decisions.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000063",
    "statement": "Sherlock biosciences receives fda emergency use authorization for crispr sars-cov-2 rapid diagnostic",
    "label": "SUPPORTED",
    "evidences": [
      "In addition to SHERLOCK, the company is also developing its INSPECTR platform to create an instrument-free, handheld test  similar to that of an at-home pregnancy test  that utilizes Sherlock Biosciences Synthetic Biology platform to provide rapid detection of a genetic match of the SARS-CoV-2 virus.",
      "Cambridge, Mass., May 7, 2020  Sherlock Biosciences, an Engineering Biology company dedicated to making diagnostic testing better, faster and more affordable, today announced the company has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its Sherlock CRISPR SARS-CoV-2 kit for the detection of the virus that causes COVID-19, providing results in approximately one hour."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided directly states that Sherlock Biosciences has received FDA Emergency Use Authorization for its CRISPR SARS-CoV-2 rapid diagnostic.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000064",
    "statement": "Sherlock biosciences receives no emergency use authorization for crispr sars-cov-2 rapid diagnostic",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In addition to SHERLOCK, the company is also developing its INSPECTR platform to create an instrument-free, handheld test  similar to that of an at-home pregnancy test  that utilizes Sherlock Biosciences Synthetic Biology platform to provide rapid detection of a genetic match of the SARS-CoV-2 virus.",
      "Cambridge, Mass., May 7, 2020  Sherlock Biosciences, an Engineering Biology company dedicated to making diagnostic testing better, faster and more affordable, today announced the company has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its Sherlock CRISPR SARS-CoV-2 kit for the detection of the virus that causes COVID-19, providing results in approximately one hour."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence states that Sherlock Biosciences has received Emergency Use Authorization (EUA) for its Sherlock CRISPR SARS-CoV-2 kit. However, the claim discusses a 'rapid diagnostic' without an EUA, which contradicts the information in the evidence.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000065",
    "statement": "Lipoic acid helps response in g6pd population",
    "label": "SUPPORTED",
    "evidences": [
      "\u0391-lipoic acid supplementation up-regulates antioxidant capacity in adults with G6PD deficiency.",
      "A-lipoic acid supplementation up-regulates antioxidant capacity in adults with G6PD deficiency."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided states that A-lipoic acid supplementation up-regulates antioxidant capacity in adults with G6PD deficiency. This suggests that lipoic acid may help the response in a population with G6PD deficiency.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000066",
    "statement": "Lipoic acid helps degradation in g6pd population",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "\u0391-lipoic acid supplementation up-regulates antioxidant capacity in adults with G6PD deficiency.",
      "A-lipoic acid supplementation up-regulates antioxidant capacity in adults with G6PD deficiency."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows that A-lipoic acid supplementation increases the antioxidant capacity in adults with G6PD deficiency. This suggests that lipoic acid may help in the degradation process for individuals with this specific condition.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000067",
    "statement": "Lipoic acid stress response in g6pd population",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "\u0391-lipoic acid supplementation up-regulates antioxidant capacity in adults with G6PD deficiency.",
      "A-lipoic acid supplementation up-regulates antioxidant capacity in adults with G6PD deficiency."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows that A-lipoic acid supplementation increases the antioxidant capacity in adults with G6PD (Glucose-6-Phosphate Dehydrogenase) deficiency. This suggests a lipoic acid stress response in this specific population.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000068",
    "statement": "Sars-cov-2 in-vitro neutralization assay reveals inhibition of virus entry by iota-carrageenan",
    "label": "SUPPORTED",
    "evidences": [
      "In vitro data on iota-carrageenan against various Rhino- and Coronaviruses showed similar IC50 values and translated readily into clinical effectiveness when a nasal spray containing iota-carrageenan demonstrated a reduction in severity and duration of symptoms of common cold caused by various respiratory viruses.",
      "Accordingly, our in vitro data on SSPL suggest that administration of iota-carrageenan may be an effective and safe prophylaxis or treatment for SARS-CoV-2 infections."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that iota-carrageenan has demonstrated similar IC50 values against various Coronaviruses in vitro (lab dish) experiments, and a nasal spray containing it reduced symptoms of common cold caused by various respiratory viruses in clinical trials. Given these results and the current evidence suggesting similarities between SARS-CoV-2 and other Coronaviruses, it is reasonable to infer that iota-carrageenan might also be effective against SARS-CoV-2 based on this in vitro data.",
    "confidence": 0.85
  },
  {
    "id": "covid_fact-000069",
    "statement": "Sars-cov-2 in-vitro neutralization assay blocked inhibition of virus entry by iota-carrageenan",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In vitro data on iota-carrageenan against various Rhino- and Coronaviruses showed similar IC50 values and translated readily into clinical effectiveness when a nasal spray containing iota-carrageenan demonstrated a reduction in severity and duration of symptoms of common cold caused by various respiratory viruses.",
      "Accordingly, our in vitro data on SSPL suggest that administration of iota-carrageenan may be an effective and safe prophylaxis or treatment for SARS-CoV-2 infections."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided shows that iota-carrageenan has demonstrated clinical effectiveness against various Rhino- and Coronaviruses, and it may be effective and safe for SARS-CoV-2 infections based on in vitro data. However, the claim that Sars-cov-2 in-vitro neutralization assay blocked inhibition of virus entry by iota-carrageenan is not directly supported or refuted by the provided evidence.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000070",
    "statement": "Sars-cov-2 in-vitro neutralization assay reveals induction of virus entry by iota-carrageenan",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In vitro data on iota-carrageenan against various Rhino- and Coronaviruses showed similar IC50 values and translated readily into clinical effectiveness when a nasal spray containing iota-carrageenan demonstrated a reduction in severity and duration of symptoms of common cold caused by various respiratory viruses.",
      "Accordingly, our in vitro data on SSPL suggest that administration of iota-carrageenan may be an effective and safe prophylaxis or treatment for SARS-CoV-2 infections."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided discusses the effectiveness of iota-carrageenan against various respiratory viruses, including rhino- and coronaviruses, but it does not directly show that iota-carrageenan induces virus entry specifically for SARS-CoV-2 (the virus causing COVID-19). The claim requires a specific connection between the compound's action on the SARS-CoV-2 virus and iota-carrageenan, which is not provided in the given evidence.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000071",
    "statement": "Sars-cov-2 in-vitro neutralization assay reveals enhancement of virus entry by iota-carrageenan",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In vitro data on iota-carrageenan against various Rhino- and Coronaviruses showed similar IC50 values and translated readily into clinical effectiveness when a nasal spray containing iota-carrageenan demonstrated a reduction in severity and duration of symptoms of common cold caused by various respiratory viruses.",
      "Accordingly, our in vitro data on SSPL suggest that administration of iota-carrageenan may be an effective and safe prophylaxis or treatment for SARS-CoV-2 infections."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided discusses the effectiveness of iota-carrageenan against various respiratory viruses, including rhino- and coronaviruses, but does not directly demonstrate enhancement or inhibition of SARS-CoV-2 specifically in an in-vitro neutralization assay.",
    "confidence": 0.4
  },
  {
    "id": "covid_fact-000072",
    "statement": "Two thirds of people contacted through tracing did not fully cooperate , pilot scheme finds",
    "label": "SUPPORTED",
    "evidences": [
      "However, for the other 39 (two thirds) of the contacts, index cases were unable or unwilling to give their names and details.",
      "The BMJ A covid-19 contact tracing pilot scheme in Sheffield has found that two thirds of people contacted did not fully cooperate, and many of those worked in health and care settings.",
      "The Sheffield Community Contact Tracers team was created by a group of retired doctors and public health experts and began the local pilot in April after they became frustrated by the lack of government action on contact tracing.1 In a report,2 the team described the inability or unwillingness to engage by people working in health and care settings as a major challenge. They said that contact tracing may be resisted in workplaces, especially in the NHS and care homes, where contact tracing systems, social distancing of staff, and a culture supportive of self-isolation frequently does not exist. They also found that one in five of the initial patients responded to phone calls only after a physical message was hand deliveredsomething that the UK government may want to consider as it launches new NHS test and trace services."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that 'for the other 39 (two thirds) of the contacts, index cases were unable or unwilling to give their names and details.' This implies that two-thirds of people contacted did not fully cooperate.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000073",
    "statement": "Two thirds of people contacted through tracing did indeed fully cooperate, pilot scheme finds",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "However, for the other 39 (two thirds) of the contacts, index cases were unable or unwilling to give their names and details.",
      "The BMJ A covid-19 contact tracing pilot scheme in Sheffield has found that two thirds of people contacted did not fully cooperate, and many of those worked in health and care settings.",
      "The Sheffield Community Contact Tracers team was created by a group of retired doctors and public health experts and began the local pilot in April after they became frustrated by the lack of government action on contact tracing.1 In a report,2 the team described the inability or unwillingness to engage by people working in health and care settings as a major challenge. They said that contact tracing may be resisted in workplaces, especially in the NHS and care homes, where contact tracing systems, social distancing of staff, and a culture supportive of self-isolation frequently does not exist. They also found that one in five of the initial patients responded to phone calls only after a physical message was hand deliveredsomething that the UK government may want to consider as it launches new NHS test and trace services."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not directly state or imply that two thirds of people contacted through tracing did indeed fully cooperate. Instead, it suggests that for two thirds of the contacts, the index cases were unable or unwilling to give their names and details, which does not necessarily mean they did not cooperate with contact tracing.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000074",
    "statement": "Two thirds of people contacted through tracing did it fully cooperate, pilot scheme finds",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "However, for the other 39 (two thirds) of the contacts, index cases were unable or unwilling to give their names and details.",
      "The BMJ A covid-19 contact tracing pilot scheme in Sheffield has found that two thirds of people contacted did not fully cooperate, and many of those worked in health and care settings.",
      "The Sheffield Community Contact Tracers team was created by a group of retired doctors and public health experts and began the local pilot in April after they became frustrated by the lack of government action on contact tracing.1 In a report,2 the team described the inability or unwillingness to engage by people working in health and care settings as a major challenge. They said that contact tracing may be resisted in workplaces, especially in the NHS and care homes, where contact tracing systems, social distancing of staff, and a culture supportive of self-isolation frequently does not exist. They also found that one in five of the initial patients responded to phone calls only after a physical message was hand deliveredsomething that the UK government may want to consider as it launches new NHS test and trace services."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided indicates that two-thirds of the contacts traced were unable or unwilling to provide their names and details, not that they cooperated fully with the tracing process. The claim that two-thirds of people contacted through tracing did it fully cooperate is not directly supported by the given evidence.",
    "confidence": 0.5
  },
  {
    "id": "covid_fact-000075",
    "statement": "Two thirds of people contacted through tracing did still fully cooperate, pilot scheme finds",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "However, for the other 39 (two thirds) of the contacts, index cases were unable or unwilling to give their names and details.",
      "The BMJ A covid-19 contact tracing pilot scheme in Sheffield has found that two thirds of people contacted did not fully cooperate, and many of those worked in health and care settings.",
      "The Sheffield Community Contact Tracers team was created by a group of retired doctors and public health experts and began the local pilot in April after they became frustrated by the lack of government action on contact tracing.1 In a report,2 the team described the inability or unwillingness to engage by people working in health and care settings as a major challenge. They said that contact tracing may be resisted in workplaces, especially in the NHS and care homes, where contact tracing systems, social distancing of staff, and a culture supportive of self-isolation frequently does not exist. They also found that one in five of the initial patients responded to phone calls only after a physical message was hand deliveredsomething that the UK government may want to consider as it launches new NHS test and trace services."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not directly state that two thirds of the people contacted still fully cooperated. Instead, it states that two thirds of the contacts were unable or unwilling to give their names and details, which is different from cooperating in the context of contact tracing.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000076",
    "statement": "The inhaled corticosteroid ciclesonide blocks coronavirus rna replication by targeting viral nsp15",
    "label": "SUPPORTED",
    "evidences": [
      "Within this library, ciclesonide, an inhaled corticosteroid, suppressed human coronavirus replication in cultured cells, but did not suppress replication of respiratory syncytial virus or influenza virus.",
      "After the eleventh consecutive MERS-CoV passage in the presence of ciclesonide, a resistant mutation was generated, which resulted in an amino acid substitution (A25V) in nonstructural protein (NSP) 15, as identified using reverse genetics.",
      "These observations suggest that the effect of ciclesonide was specific to coronavirus, suggesting this is a candidate drug for treatment of patients suffering MERS or COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that ciclesonide suppresses human coronavirus replication in cultured cells, but does not affect replication of respiratory syncytial virus or influenza virus. Furthermore, after the eleventh consecutive MERS-CoV passage in the presence of ciclesonide, a resistant mutation was generated, resulting in an amino acid substitution (A25V) in nonstructural protein (NSP) 15. NSP15 is a viral protein known to be involved in coronavirus replication. Therefore, it is plausible that ciclesonide blocks coronavirus RNA replication by targeting the viral NSP15.",
    "confidence": 0.85
  },
  {
    "id": "covid_fact-000077",
    "statement": "The inhaled corticosteroid ciclesonide support coronavirus rna replication by targeting viral nsp15",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Within this library, ciclesonide, an inhaled corticosteroid, suppressed human coronavirus replication in cultured cells, but did not suppress replication of respiratory syncytial virus or influenza virus.",
      "After the eleventh consecutive MERS-CoV passage in the presence of ciclesonide, a resistant mutation was generated, which resulted in an amino acid substitution (A25V) in nonstructural protein (NSP) 15, as identified using reverse genetics.",
      "These observations suggest that the effect of ciclesonide was specific to coronavirus, suggesting this is a candidate drug for treatment of patients suffering MERS or COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that ciclesonide suppresses human coronavirus replication but not replication of other viruses such as respiratory syncytial virus or influenza virus. Furthermore, a resistant mutation was generated in the presence of ciclesonide specifically in nonstructural protein (NSP) 15 of MERS-CoV after eleven consecutive passages. This suggests that ciclesonide may be targeting viral NSP15 which is involved in coronavirus replication.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000078",
    "statement": "The us doesnt have enough hospital beds for a bad coronavirus outbreak",
    "label": "SUPPORTED",
    "evidences": [
      "Earlier in the outbreak, doctors warned that a larger outbreak of the new coronavirus across the U.S. could overwhelm emergency rooms and quickly cause supply shortages of some crucial medical supplies.",
      "Cuomo warns US won't have enough hospital beds for coronavirus pandemic Published Mon, Mar 16 202011:27 AM EDTUpdated Mon, Mar 16 202012:18 PM EDT Berkeley Lovelace Jr.@BerkeleyJr ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email New York Gov.",
      "Dillinger March.13.2020 at 12:32 pm >>America Doesn't Have Enough Hospital Beds To Fight the Coronavirus virus impervious to the little wheels."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is supported by the evidence as it references specific warnings about a potential outbreak of coronavirus overwhelming emergency rooms and causing supply shortages of crucial medical supplies, including hospital beds.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000079",
    "statement": "The usset have enough hospital beds for a bad coronavirus outbreak",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Earlier in the outbreak, doctors warned that a larger outbreak of the new coronavirus across the U.S. could overwhelm emergency rooms and quickly cause supply shortages of some crucial medical supplies.",
      "Cuomo warns US won't have enough hospital beds for coronavirus pandemic Published Mon, Mar 16 202011:27 AM EDTUpdated Mon, Mar 16 202012:18 PM EDT Berkeley Lovelace Jr.@BerkeleyJr ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email New York Gov.",
      "Dillinger March.13.2020 at 12:32 pm >>America Doesn't Have Enough Hospital Beds To Fight the Coronavirus virus impervious to the little wheels."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not indicate whether or not the U.S. currently has enough hospital beds for a bad coronavirus outbreak. It only states that there was a concern raised by New York Gov. Cuomo about potential shortages in the past. Without up-to-date information, it is impossible to determine if this claim is supported.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000080",
    "statement": "The usert have enough hospital beds for a bad coronavirus outbreak",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Earlier in the outbreak, doctors warned that a larger outbreak of the new coronavirus across the U.S. could overwhelm emergency rooms and quickly cause supply shortages of some crucial medical supplies.",
      "Cuomo warns US won't have enough hospital beds for coronavirus pandemic Published Mon, Mar 16 202011:27 AM EDTUpdated Mon, Mar 16 202012:18 PM EDT Berkeley Lovelace Jr.@BerkeleyJr ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email New York Gov.",
      "Dillinger March.13.2020 at 12:32 pm >>America Doesn't Have Enough Hospital Beds To Fight the Coronavirus virus impervious to the little wheels."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is supported because the evidence states that a larger outbreak of the coronavirus could overwhelm emergency rooms and quickly cause supply shortages of some crucial medical supplies, including hospital beds. Furthermore, New York Governor Dillinger explicitly stated that America does not have enough hospital beds to fight the coronavirus.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000081",
    "statement": "Oncogen researchers propose personalized vaccinomics strategy for the novel china coronavirus",
    "label": "SUPPORTED",
    "evidences": [
      "The candidate peptides were designed by applying to viral antigens a technology used for personalized vaccination in cancer, based on long neoantigen peptides, currently in clinical trials for cancer therapy.",
      "Technical details of the approach used are detailed below: We identified multiepitope peptide vaccine candidates against nCov that can potentially trigger both CD4+ and CD8+ T cell immune response.",
      "The approach that we used for designing potential peptide vaccine candidates takes a more personalized strategy, referred to as vaccinomics , which enables the selection of target viral proteins with low mutation rates, and the design of peptides tuned to the immune characteristics of the target populations, variable based on geographic location and ethnicity.",
      "Based on the human MHC (human leukocyte antigen) allele variation, the peptide vaccines can be made more relevant to a community or individual.",
      "The selection of the peptides that could act as vaccines is determined by the binding of the processed viral peptide with the major histocompatibility complex (MHC) class I and II molecules, and the relevant HLA alleles."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides a clear statement that researchers are proposing a personalized vaccinomics strategy for the novel coronavirus, using a technology used for personalized cancer vaccines. The design of the peptides is based on viral antigens and their binding with major histocompatibility complex (MHC) class I and II molecules, which aligns with the process of designing personalized vaccines.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000082",
    "statement": "Oncogen researchers propose personalized vaccinomics strategy for the traditional china coronavirus",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The candidate peptides were designed by applying to viral antigens a technology used for personalized vaccination in cancer, based on long neoantigen peptides, currently in clinical trials for cancer therapy.",
      "Technical details of the approach used are detailed below: We identified multiepitope peptide vaccine candidates against nCov that can potentially trigger both CD4+ and CD8+ T cell immune response.",
      "The approach that we used for designing potential peptide vaccine candidates takes a more personalized strategy, referred to as vaccinomics , which enables the selection of target viral proteins with low mutation rates, and the design of peptides tuned to the immune characteristics of the target populations, variable based on geographic location and ethnicity.",
      "Based on the human MHC (human leukocyte antigen) allele variation, the peptide vaccines can be made more relevant to a community or individual.",
      "The selection of the peptides that could act as vaccines is determined by the binding of the processed viral peptide with the major histocompatibility complex (MHC) class I and II molecules, and the relevant HLA alleles."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided discusses a strategy for designing peptide vaccine candidates against nCov (Traditional China Coronavirus) that is personalized based on vaccinomics, which refers to the selection of target viral proteins with low mutation rates and design of peptides tuned to the immune characteristics of the target populations. The approach involves selecting peptides that bind with the major histocompatibility complex (MHC) class I and II molecules, and the relevant HLA alleles, which are specific to certain communities or individuals.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000083",
    "statement": "Mathematical analysis of c\u00f3rdoba calcifediol trial suggests strong role for vitamin d in reducing icu admissions of hospitalized covid-19 patients",
    "label": "SUPPORTED",
    "evidences": [
      "]: dot [@]: at [MHRA]: Medicines and Healthcare products Regulatory Agency [JCVI]: Joint Committee for Vaccination and Immunisation [PMC]: Penske Media Corporation [ COVID-19]: coronavirus disease 2019 [COVID-19]: coronavirus disease 2019 [v]: View this template [t]: telephone [e]: email []: You need to accept this checkbox.",
      "I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).",
      "Finally, comparison with two additional randomized clinical trials of vitamin D supplementation for COVID-19 in India and Brazil indicates that early intervention and rapid absorption may be crucial for the observed benefits of vitamin D. We conclude that the C\u00f3rdoba study provides sufficient evidence to warrant immediate, well-designed pivotal clinical trials of early calcifediol administration in a broader cohort of inpatients and outpatients with COVID-19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not directly link the mathematical analysis of the C\u00f3rdoba calcifediol trial to a strong role for vitamin D in reducing ICU admissions of hospitalized COVID-19 patients. Instead, it refers to conclusions drawn from comparing this study with two additional randomized clinical trials of vitamin D supplementation for COVID-19 in India and Brazil, suggesting that early intervention and rapid absorption may be crucial for the observed benefits of vitamin D. However, this indirect comparison does not provide definitive evidence that supports the initial claim.",
    "confidence": 0.7
  },
  {
    "id": "covid_fact-000084",
    "statement": "Mathematical analysis of c\u00f3rdoba calcifediol trial suggests strong role against vitamin d in reducing icu admissions of hospitalized covid-19 patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "]: dot [@]: at [MHRA]: Medicines and Healthcare products Regulatory Agency [JCVI]: Joint Committee for Vaccination and Immunisation [PMC]: Penske Media Corporation [ COVID-19]: coronavirus disease 2019 [COVID-19]: coronavirus disease 2019 [v]: View this template [t]: telephone [e]: email []: You need to accept this checkbox.",
      "I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).",
      "Finally, comparison with two additional randomized clinical trials of vitamin D supplementation for COVID-19 in India and Brazil indicates that early intervention and rapid absorption may be crucial for the observed benefits of vitamin D. We conclude that the C\u00f3rdoba study provides sufficient evidence to warrant immediate, well-designed pivotal clinical trials of early calcifediol administration in a broader cohort of inpatients and outpatients with COVID-19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not contain direct mathematical analysis results or findings related to the 'C\u00f3rdoba calcifediol trial' and its role in reducing ICU admissions of hospitalized COVID-19 patients. Instead, it mentions comparisons with other studies on vitamin D supplementation and draws conclusions about the need for further well-designed clinical trials based on these comparisons.",
    "confidence": 0.7
  },
  {
    "id": "covid_fact-000085",
    "statement": "Artificial intelligence model detects asymptomatic covid-19 infections through cellphone-recorded coughs",
    "label": "SUPPORTED",
    "evidences": [
      "New AI model detects asymptomatic Covid-19 infections through device-recorded coughs Vocal sentiments Prior to the pandemics onset, research groups already had been training algorithms on cellphone recordings of coughs to accurately diagnose conditions such as pneumonia and asthma.",
      "The model identified 98.5 percent of coughs from people confirmed with Covid-19, and of those, it accurately detected all of the asymptomatic coughs.",
      "When they fed the model new cough recordings, it accurately identified 98.5 percent of coughs from people who were confirmed to have Covid-19, including 100 percent of coughs from asymptomatics  who reported they did not have symptoms but had tested positive for the virus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that a new AI model can accurately detect 98.5% of coughs from people confirmed to have Covid-19, including 100% of coughs from asymptomatic individuals who reported they did not have symptoms but had tested positive for the virus.",
    "confidence": 0.985
  },
  {
    "id": "covid_fact-000086",
    "statement": "Artificial intelligence model cannots asymptomatic covid-19 infections through cellphone-recorded coughs",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "New AI model detects asymptomatic Covid-19 infections through device-recorded coughs Vocal sentiments Prior to the pandemics onset, research groups already had been training algorithms on cellphone recordings of coughs to accurately diagnose conditions such as pneumonia and asthma.",
      "The model identified 98.5 percent of coughs from people confirmed with Covid-19, and of those, it accurately detected all of the asymptomatic coughs.",
      "When they fed the model new cough recordings, it accurately identified 98.5 percent of coughs from people who were confirmed to have Covid-19, including 100 percent of coughs from asymptomatics  who reported they did not have symptoms but had tested positive for the virus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that a new AI model was able to accurately detect asymptomatic Covid-19 infections through cellphone-recorded coughs, with the model correctly identifying 100% of coughs from asymptomatics who had tested positive for the virus.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000087",
    "statement": "Stanford researchers test 3,200 people for covid-19 antibodies",
    "label": "SUPPORTED",
    "evidences": [
      "The antibody tests used in the Stanford study, which were supplied by Premier Biotech, require only a fingerstick of blood and test for IgM and IgG antibodies that indicate that a person either has coronavirus or had it and recovered."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not explicitly state that Stanford researchers tested 3,200 people for COVID-19 antibodies. The evidence only mentions the type of antibody tests used in a study by Stanford and the fact that they require just a fingerstick of blood to test for IgM and IgG antibodies.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000088",
    "statement": "Stanford researchers test 3,6 people for covid-19 antibodies",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The antibody tests used in the Stanford study, which were supplied by Premier Biotech, require only a fingerstick of blood and test for IgM and IgG antibodies that indicate that a person either has coronavirus or had it and recovered."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The given evidence only states that the antibody tests used in the Stanford study test for IgM and IgG antibodies, which indicate whether a person either currently has or had COVID-19, but it does not specify the number of people tested.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000089",
    "statement": "Stanford researchers test 3,5 people for covid-19 antibodies",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The antibody tests used in the Stanford study, which were supplied by Premier Biotech, require only a fingerstick of blood and test for IgM and IgG antibodies that indicate that a person either has coronavirus or had it and recovered."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not give the number of individuals tested in the Stanford study. Therefore, we cannot confirm that 3,5 people were indeed tested for COVID-19 antibodies.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000090",
    "statement": "Stanford researchers test 3,3 people for covid-19 antibodies",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The antibody tests used in the Stanford study, which were supplied by Premier Biotech, require only a fingerstick of blood and test for IgM and IgG antibodies that indicate that a person either has coronavirus or had it and recovered."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence does not provide specific numbers of individuals tested in the Stanford study for Covid-19 antibodies.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000091",
    "statement": "State lab finds 90 positive covid-19 test results were false",
    "label": "SUPPORTED",
    "evidences": [
      "Of those, a total of 91 specimens from 90 people showed false positive results.",
      "The department said the state public health laboratory uncovered a flaw in one of the testing systems it uses to test for SARS-CoV-2, the virus that causes COVID-19, and 90 of 144 people tested between June 15 and July 17 received a false positive COVID test report.",
      "Accurate and timely testing for the novel coronavirus is one of the pillars supporting effective response to the COVID-19 pandemic. She said adjustments have already been made to ensure the accuracy of future test results from this platform. They said all positive results will be further analyzed by multiple laboratory scientists, and if indicated, retested using another method.",
      "The lab used another FDA-authorized test and found the false positives.",
      "Any nursing home resident who received a false positive COVID-19 test result will be retested as soon as possible, according to the Department of Health."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that 91 specimens from 90 people showed false positive results for COVID-19 tests. This indicates that the state public health laboratory found that a total of 90 COVID-19 test results were false.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000092",
    "statement": "State lab finds 90 positive covid-19 test results were+.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Of those, a total of 91 specimens from 90 people showed false positive results.",
      "The department said the state public health laboratory uncovered a flaw in one of the testing systems it uses to test for SARS-CoV-2, the virus that causes COVID-19, and 90 of 144 people tested between June 15 and July 17 received a false positive COVID test report.",
      "Accurate and timely testing for the novel coronavirus is one of the pillars supporting effective response to the COVID-19 pandemic. She said adjustments have already been made to ensure the accuracy of future test results from this platform. They said all positive results will be further analyzed by multiple laboratory scientists, and if indicated, retested using another method.",
      "The lab used another FDA-authorized test and found the false positives.",
      "Any nursing home resident who received a false positive COVID-19 test result will be retested as soon as possible, according to the Department of Health."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence states that out of 144 specimens tested between June 15 and July 17, 91 showed false positive results. However, it does not explicitly state that the 90 specimens were from different people (individuals), which is required to support the claim that 90 people received a false positive COVID test result.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000093",
    "statement": "Different mutations in sars-cov-2 associate with severe and mild outcome",
    "label": "SUPPORTED",
    "evidences": [
      "Here, we correlated protein-level mutations in the SARS-CoV-2 virus to clinical outcome.",
      "Conclusions We demonstrate that mutations in the viral genes may have a direct correlation to clinical outcome.",
      "Mutations correlated to mild outcome were located in the ORF8, NSP6, ORF3a, NSP4, and in the nucleocapsid phosphoprotein N. Mutations associated with inferior outcome were located in the surface (S) glycoprotein, in the RNA dependent RNA polymerase, in the 3-to5 exonuclease, in ORF3a, NSP2 and N. Mutations leading to severe outcome with low prevalence were found in the surface (S) glycoprotein and in NSP7.",
      "Our results help to quickly identify SARS-CoV-2 infections harboring mutations related to severe outcome."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence demonstrates a correlation between specific mutations in the SARS-CoV-2 virus and the clinical outcomes (severe and mild) of COVID-19 infections. This supports the claim that different mutations in sars-cov-2 associate with severe and mild outcome.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000094",
    "statement": "Different mutations in sars-cov-2 associate against severe and mild outcome",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Here, we correlated protein-level mutations in the SARS-CoV-2 virus to clinical outcome.",
      "Conclusions We demonstrate that mutations in the viral genes may have a direct correlation to clinical outcome.",
      "Mutations correlated to mild outcome were located in the ORF8, NSP6, ORF3a, NSP4, and in the nucleocapsid phosphoprotein N. Mutations associated with inferior outcome were located in the surface (S) glycoprotein, in the RNA dependent RNA polymerase, in the 3-to5 exonuclease, in ORF3a, NSP2 and N. Mutations leading to severe outcome with low prevalence were found in the surface (S) glycoprotein and in NSP7.",
      "Our results help to quickly identify SARS-CoV-2 infections harboring mutations related to severe outcome."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence presented shows a correlation between specific mutations in the SARS-CoV-2 virus and the clinical outcomes (severe or mild). This supports the claim that different mutations in SARS-CoV-2 associate with either severe or mild outcomes.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000095",
    "statement": "Both mutations in sars-cov-2 associate with severe and mild outcome",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Here, we correlated protein-level mutations in the SARS-CoV-2 virus to clinical outcome.",
      "Conclusions We demonstrate that mutations in the viral genes may have a direct correlation to clinical outcome.",
      "Mutations correlated to mild outcome were located in the ORF8, NSP6, ORF3a, NSP4, and in the nucleocapsid phosphoprotein N. Mutations associated with inferior outcome were located in the surface (S) glycoprotein, in the RNA dependent RNA polymerase, in the 3-to5 exonuclease, in ORF3a, NSP2 and N. Mutations leading to severe outcome with low prevalence were found in the surface (S) glycoprotein and in NSP7.",
      "Our results help to quickly identify SARS-CoV-2 infections harboring mutations related to severe outcome."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides data correlating certain mutations in the SARS-CoV-2 virus with clinical outcomes (severe and mild). The text explicitly mentions several mutations associated with both mild and severe outcomes.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000096",
    "statement": "Moderna advances late-stage development of its vaccine against covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "11, 2020-- Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced progress on late-stage development of mRNA-1273, the Companys mRNA vaccine candidate against COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence states that Moderna announced progress on late-stage development of its mRNA-1273 vaccine candidate against COVID-19. This directly supports the claim made.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000097",
    "statement": "Moderna advances late-stage delivery of its vaccine against covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "11, 2020-- Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced progress on late-stage development of mRNA-1273, the Companys mRNA vaccine candidate against COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that Moderna announced progress on late-stage development of its COVID-19 vaccine (mRNA-1273). This directly supports the claim that Moderna is advancing late-stage delivery of its vaccine against covid-19.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000098",
    "statement": "Mathematical modeling explains differential sars cov-2 kinetics in lung and nasal passages in remdesivir treated rhesus macaques",
    "label": "SUPPORTED",
    "evidences": [
      "]: dot [@]: at [MHRA]: Medicines and Healthcare products Regulatory Agency [JCVI]: Joint Committee for Vaccination and Immunisation [PMC]: Penske Media Corporation [ COVID-19]: coronavirus disease 2019 [COVID-19]: coronavirus disease 2019 [v]: View this template [t]: telephone [e]: email []: You need to accept this checkbox.",
      "One Sentence Summary We developed a mathematical model to explain why remdesivir has a greater antiviral effect on SARS CoV-2 in lung versus nasal passages in rhesus macaques.",
      "In rhesus macaques, early initiation of remdesivir therapy prevented pneumonia and lowered viral loads in the lung, but viral loads increased in the nasal passages five days after therapy."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided explains that a mathematical model was developed to explain the differential kinetics of SARS-CoV-2 in lung and nasal passages in remdesivir treated rhesus macaques. The evidence also describes the observed effects of remdesivir therapy on viral loads in both the lung and nasal passages, which supports the claim.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000099",
    "statement": "Phylogenetic modeling explains differential sars cov-2 kinetics in lung and nasal passages in remdesivir treated rhesus macaques",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "]: dot [@]: at [MHRA]: Medicines and Healthcare products Regulatory Agency [JCVI]: Joint Committee for Vaccination and Immunisation [PMC]: Penske Media Corporation [ COVID-19]: coronavirus disease 2019 [COVID-19]: coronavirus disease 2019 [v]: View this template [t]: telephone [e]: email []: You need to accept this checkbox.",
      "One Sentence Summary We developed a mathematical model to explain why remdesivir has a greater antiviral effect on SARS CoV-2 in lung versus nasal passages in rhesus macaques.",
      "In rhesus macaques, early initiation of remdesivir therapy prevented pneumonia and lowered viral loads in the lung, but viral loads increased in the nasal passages five days after therapy."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided mentions the development of a mathematical model to explain the differential effect of remdesivir on SARS-CoV-2 in lung and nasal passages in rhesus macaques, but it does not explicitly mention phylogenetic modeling. Phylogenetic modeling is a method used to infer the evolutionary history of a set of biological sequences (e.g., genes or proteins) based on their similarities. While the evidence suggests a mathematical model was developed, more specific information would be needed to determine whether phylogenetic modeling was actually used in this context.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000100",
    "statement": "Mathematical depletion explains differential sars cov-2 kinetics in lung and nasal passages in remdesivir treated rhesus macaques",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "]: dot [@]: at [MHRA]: Medicines and Healthcare products Regulatory Agency [JCVI]: Joint Committee for Vaccination and Immunisation [PMC]: Penske Media Corporation [ COVID-19]: coronavirus disease 2019 [COVID-19]: coronavirus disease 2019 [v]: View this template [t]: telephone [e]: email []: You need to accept this checkbox.",
      "One Sentence Summary We developed a mathematical model to explain why remdesivir has a greater antiviral effect on SARS CoV-2 in lung versus nasal passages in rhesus macaques.",
      "In rhesus macaques, early initiation of remdesivir therapy prevented pneumonia and lowered viral loads in the lung, but viral loads increased in the nasal passages five days after therapy."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence discusses a mathematical model and its results on remdesivir's antiviral effect on SARS CoV-2 in rhesus macaques. However, it does not explicitly link this to the concept of 'mathematical depletion.' While the results suggest differential kinetics of the virus in lung and nasal passages, the absence of a direct connection between these findings and 'mathematical depletion' makes it difficult to support the claim.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000101",
    "statement": "Singapore , taiwan and hong kong have brought outbreaks under control",
    "label": "SUPPORTED",
    "evidences": [
      "Singapore and Taiwan were both seen as examples of how to handle the coronavirus outbreak: stanching the growth of infections, while largely keeping their economies open.",
      "The city, like Singapore and Taiwan, has made headway in containing Covid-19.Credit...Hannah Mckay/Reuters HONG KONG  While the spread of Covid-19 is picking up speed in Europe and the United States, among other regions, the outbreaks in some countries in Asia seem to be under control."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that Singapore and Taiwan have brought their coronavirus outbreaks under control, as stated in the quote. The claim also includes Hong Kong, which is supported by the statement 'the outbreaks in some countries in Asia seem to be under control', implying that Hong Kong's situation is similar to those of Singapore and Taiwan.",
    "confidence": 0.85
  },
  {
    "id": "covid_fact-000102",
    "statement": "Singapore, taiwan and hong kong have no outbreaks under control",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Singapore and Taiwan were both seen as examples of how to handle the coronavirus outbreak: stanching the growth of infections, while largely keeping their economies open.",
      "The city, like Singapore and Taiwan, has made headway in containing Covid-19.Credit...Hannah Mckay/Reuters HONG KONG  While the spread of Covid-19 is picking up speed in Europe and the United States, among other regions, the outbreaks in some countries in Asia seem to be under control."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence does not provide specific information about current outbreak status of Singapore, Taiwan or Hong Kong. The text mentions that these countries have made progress in containing Covid-19 in the past but this does not necessarily imply that they currently have no outbreaks under control.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000103",
    "statement": "Fda gives eua to saliva-based test kit",
    "label": "SUPPORTED",
    "evidences": [
      "Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization to Yale School of Public Health for SalivaDirect, Which Uses a New Method of Saliva Sample Processing 1.",
      "Coronavirus (COVID-19) Update: FDA Authorizes First Diagnostic Test Using At-Home Collection of Saliva Specimens 1.",
      "The FDA has authorized more than 80 COVID-19 tests and adding more options for at-home sample collection is an important advancement in diagnostic testing during this public health emergency. Todays EUA for Rutgers Clinical Genomics Laboratorys molecular test permits testing of a saliva sample collected from the patient using a designated self- collection kit.",
      "Specifically, the FDA issued an emergency use authorization (EUA) to Rutgers Clinical Genomics Laboratory for their COVID-19 laboratory developed test (LDT), which had been previously added to the high complexity molecular- based LDT umbrella EUA, to permit testing of samples self-collected by patients at home using the Spectrum Solutions LLC SDNA-1000 Saliva Collection Device.",
      "While FDA has seen variable performance in tests using saliva, Yale School of Public Health submitted data with its EUA request from which the FDA determined that Yales test meets the criteria for emergency authorization when used to test saliva samples for SARS-CoV-2, the virus that causes COVID-19 infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that the FDA has issued an Emergency Use Authorization (EUA) for a saliva-based test kit developed by Yale School of Public Health. The EUA was granted to Rutgers Clinical Genomics Laboratory and allows testing of samples self-collected by patients at home using the Spectrum Solutions LLC SDNA-1000 Saliva Collection Device.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000104",
    "statement": "Pcr gives eua to saliva-based test kit",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization to Yale School of Public Health for SalivaDirect, Which Uses a New Method of Saliva Sample Processing 1.",
      "Coronavirus (COVID-19) Update: FDA Authorizes First Diagnostic Test Using At-Home Collection of Saliva Specimens 1.",
      "The FDA has authorized more than 80 COVID-19 tests and adding more options for at-home sample collection is an important advancement in diagnostic testing during this public health emergency. Todays EUA for Rutgers Clinical Genomics Laboratorys molecular test permits testing of a saliva sample collected from the patient using a designated self- collection kit.",
      "Specifically, the FDA issued an emergency use authorization (EUA) to Rutgers Clinical Genomics Laboratory for their COVID-19 laboratory developed test (LDT), which had been previously added to the high complexity molecular- based LDT umbrella EUA, to permit testing of samples self-collected by patients at home using the Spectrum Solutions LLC SDNA-1000 Saliva Collection Device.",
      "While FDA has seen variable performance in tests using saliva, Yale School of Public Health submitted data with its EUA request from which the FDA determined that Yales test meets the criteria for emergency authorization when used to test saliva samples for SARS-CoV-2, the virus that causes COVID-19 infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided states that the FDA has issued an emergency use authorization (EUA) for a saliva-based test kit developed by Yale School of Public Health and Rutgers Clinical Genomics Laboratory. Therefore, it is supported that PCR gives EUA to a saliva-based test kit.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000105",
    "statement": "Data gives eua to saliva-based test kit",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization to Yale School of Public Health for SalivaDirect, Which Uses a New Method of Saliva Sample Processing 1.",
      "Coronavirus (COVID-19) Update: FDA Authorizes First Diagnostic Test Using At-Home Collection of Saliva Specimens 1.",
      "The FDA has authorized more than 80 COVID-19 tests and adding more options for at-home sample collection is an important advancement in diagnostic testing during this public health emergency. Todays EUA for Rutgers Clinical Genomics Laboratorys molecular test permits testing of a saliva sample collected from the patient using a designated self- collection kit.",
      "Specifically, the FDA issued an emergency use authorization (EUA) to Rutgers Clinical Genomics Laboratory for their COVID-19 laboratory developed test (LDT), which had been previously added to the high complexity molecular- based LDT umbrella EUA, to permit testing of samples self-collected by patients at home using the Spectrum Solutions LLC SDNA-1000 Saliva Collection Device.",
      "While FDA has seen variable performance in tests using saliva, Yale School of Public Health submitted data with its EUA request from which the FDA determined that Yales test meets the criteria for emergency authorization when used to test saliva samples for SARS-CoV-2, the virus that causes COVID-19 infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides clear statements from the FDA authorizing a saliva-based test kit (SalivaDirect) for COVID-19, specifically mentioning the Emergency Use Authorization (EUA) given to Yale School of Public Health and Rutgers Clinical Genomics Laboratory for their respective tests. Additionally, the evidence states that the FDA determined that Yale's test meets the criteria for emergency authorization when used to test saliva samples for SARS-CoV-2, further supporting the claim.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000106",
    "statement": "Table gives eua to saliva-based test kit",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization to Yale School of Public Health for SalivaDirect, Which Uses a New Method of Saliva Sample Processing 1.",
      "Coronavirus (COVID-19) Update: FDA Authorizes First Diagnostic Test Using At-Home Collection of Saliva Specimens 1.",
      "The FDA has authorized more than 80 COVID-19 tests and adding more options for at-home sample collection is an important advancement in diagnostic testing during this public health emergency. Todays EUA for Rutgers Clinical Genomics Laboratorys molecular test permits testing of a saliva sample collected from the patient using a designated self- collection kit.",
      "Specifically, the FDA issued an emergency use authorization (EUA) to Rutgers Clinical Genomics Laboratory for their COVID-19 laboratory developed test (LDT), which had been previously added to the high complexity molecular- based LDT umbrella EUA, to permit testing of samples self-collected by patients at home using the Spectrum Solutions LLC SDNA-1000 Saliva Collection Device.",
      "While FDA has seen variable performance in tests using saliva, Yale School of Public Health submitted data with its EUA request from which the FDA determined that Yales test meets the criteria for emergency authorization when used to test saliva samples for SARS-CoV-2, the virus that causes COVID-19 infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is supported by the evidence as it states that the FDA has issued an Emergency Use Authorization (EUA) to Yale School of Public Health for SalivaDirect, which uses a new method of saliva sample processing. Additionally, the FDA authorized a test from Rutgers Clinical Genomics Laboratory that permits testing of a saliva sample collected from the patient using a designated self-collection kit.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000107",
    "statement": "Seasonal human coronavirus antibodies are boosted upon sars-cov-2 infection but not associated with protection",
    "label": "SUPPORTED",
    "evidences": [
      "These antibodies were not associated with protection against SARS-CoV-2 infections or hospitalizations, but paradoxically these hCoV cross-reactive antibodies were boosted upon SARS-CoV-2 infection.",
      "We then quantified pre-pandemic antibody levels in serum from a separate cohort of 252 individuals who became PCR-confirmed infected with SARS-CoV-2.",
      "Although SARS-CoV-2 is a novel coronavirus, most humans had been previously exposed to other antigenically distinct common seasonal human coronaviruses (hCoVs) before the COVID-19 pandemic."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that while antibodies to seasonal human coronaviruses (hCoVs) were boosted upon SARS-CoV-2 infection, they were not associated with protection against SARS-CoV-2 infections or hospitalizations.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000108",
    "statement": "Seasonal human coronavirus antibodies are boosted upon sars-cov-2 infection but also associated with protection",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These antibodies were not associated with protection against SARS-CoV-2 infections or hospitalizations, but paradoxically these hCoV cross-reactive antibodies were boosted upon SARS-CoV-2 infection.",
      "We then quantified pre-pandemic antibody levels in serum from a separate cohort of 252 individuals who became PCR-confirmed infected with SARS-CoV-2.",
      "Although SARS-CoV-2 is a novel coronavirus, most humans had been previously exposed to other antigenically distinct common seasonal human coronaviruses (hCoVs) before the COVID-19 pandemic."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided shows that antibodies to seasonal human coronaviruses (hCoVs) are boosted upon SARS-CoV-2 infection but were not associated with protection against SARS-CoV-2 infections or hospitalizations. However, it does not provide direct evidence that these antibodies are associated with protection.",
    "confidence": 0.7
  },
  {
    "id": "covid_fact-000109",
    "statement": "Seasonal human coronavirus antibodies are boosted upon sars-cov-2 infection but are associated with protection",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These antibodies were not associated with protection against SARS-CoV-2 infections or hospitalizations, but paradoxically these hCoV cross-reactive antibodies were boosted upon SARS-CoV-2 infection.",
      "We then quantified pre-pandemic antibody levels in serum from a separate cohort of 252 individuals who became PCR-confirmed infected with SARS-CoV-2.",
      "Although SARS-CoV-2 is a novel coronavirus, most humans had been previously exposed to other antigenically distinct common seasonal human coronaviruses (hCoVs) before the COVID-19 pandemic."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence states that pre-pandemic antibody levels were not associated with protection against SARS-CoV-2 infections or hospitalizations. Although it mentions these hCoV cross-reactive antibodies are boosted upon SARS-CoV-2 infection, it does not explicitly state they provide protection against future infections.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000110",
    "statement": "Seasonal human coronavirus antibodies are boosted upon sars-cov-2 infection but strongly associated with protection",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These antibodies were not associated with protection against SARS-CoV-2 infections or hospitalizations, but paradoxically these hCoV cross-reactive antibodies were boosted upon SARS-CoV-2 infection.",
      "We then quantified pre-pandemic antibody levels in serum from a separate cohort of 252 individuals who became PCR-confirmed infected with SARS-CoV-2.",
      "Although SARS-CoV-2 is a novel coronavirus, most humans had been previously exposed to other antigenically distinct common seasonal human coronaviruses (hCoVs) before the COVID-19 pandemic."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not directly support the claim that seasonal human coronavirus antibodies are strongly associated with protection upon SARS-CoV-2 infection. Instead, it suggests that these cross-reactive antibodies were boosted but were not associated with protection against SARS-CoV-2 infections or hospitalizations.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000111",
    "statement": "Preliminary results of nationwide representative screening are out",
    "label": "SUPPORTED",
    "evidences": [
      "The results of the first nationwide representative screening will be released at the end of May.",
      "These preliminary results include those older than 14 who do not live in retirement homes or similar institutes."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence states that the 'first' nationwide representative screening results will be released at the end of May. It does not provide any information about preliminary results being out already.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000112",
    "statement": "Preliminary results of nationwide representative screening are!",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The results of the first nationwide representative screening will be released at the end of May.",
      "These preliminary results include those older than 14 who do not live in retirement homes or similar institutes."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence only states that the preliminary results will be released at the end of May, without providing any data or information about what these results entail.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000113",
    "statement": "Preliminary results of nationwide representative screening are?",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The results of the first nationwide representative screening will be released at the end of May.",
      "These preliminary results include those older than 14 who do not live in retirement homes or similar institutes."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided states that the final results will be released at the end of May, but it does not mention any preliminary results.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000114",
    "statement": "Preliminary results of nationwide representative screening are\".",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The results of the first nationwide representative screening will be released at the end of May.",
      "These preliminary results include those older than 14 who do not live in retirement homes or similar institutes."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provides information about the timing and scope of a future screening event (the first nationwide representative screening to be released at the end of May), but does not include any preliminary results.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000115",
    "statement": "New self-administered coronavirus test found effective",
    "label": "SUPPORTED",
    "evidences": [
      "Self-administered COVID-19 coronavirus can be just as effective as physician- administered tests, according to a new study by UnitedHealth Group.",
      "Researchers found that self-administered swab tests accurately detected the disease in more than 90 percent of positive patients, which is consistent with physician-administered tests.",
      "Among 500 OptumCare patients in Washington state, the self-administered swabs were able to accurately detect the coronavirus that causes COVID-19 in 90% of those who are positive, a rate that's consistent with physician-administered swabs, the insurance giant announced.",
      "A new study found that self-administered tests may be as effective as those conducted by healthcare workers."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided in the statement indicates a study showing that self-administered COVID-19 tests were able to accurately detect the virus in over 90% of positive patients, which is consistent with physician-administered tests. This suggests that the claim, 'New self-administered coronavirus test found effective', is supported.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000116",
    "statement": "No self-administered coronavirus test found effective",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Self-administered COVID-19 coronavirus can be just as effective as physician- administered tests, according to a new study by UnitedHealth Group.",
      "Researchers found that self-administered swab tests accurately detected the disease in more than 90 percent of positive patients, which is consistent with physician-administered tests.",
      "Among 500 OptumCare patients in Washington state, the self-administered swabs were able to accurately detect the coronavirus that causes COVID-19 in 90% of those who are positive, a rate that's consistent with physician-administered swabs, the insurance giant announced.",
      "A new study found that self-administered tests may be as effective as those conducted by healthcare workers."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates a new study found that self-administered COVID-19 tests were able to accurately detect the virus in more than 90% of positive patients, which is consistent with physician-administered tests.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000117",
    "statement": "Electrostatic spraying will prevent the spread of covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "Electrostatic spraying is likely to improve coverage of disinfectant on surfaces and reduce wastage of disinfectant, but caution should be used in handling and applying the products."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The given evidence does not provide sufficient information to determine whether electrostatic spraying can prevent the spread of COVID-19. While it may improve coverage and reduce wastage of disinfectant, this does not necessarily mean that it will effectively kill the virus on surfaces.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000118",
    "statement": "Electrostatic spraying will facilitate the spread of covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Electrostatic spraying is likely to improve coverage of disinfectant on surfaces and reduce wastage of disinfectant, but caution should be used in handling and applying the products."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The given evidence does not provide any indication or suggestion that electrostatic spraying can facilitate the spread of COVID-19. The provided information only describes the benefits and cautions related to electrostatic spraying as a method for better disinfection.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000119",
    "statement": "Electrostatic spraying will enhance the spread of covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Electrostatic spraying is likely to improve coverage of disinfectant on surfaces and reduce wastage of disinfectant, but caution should be used in handling and applying the products."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not support or refute the claim that electrostatic spraying will enhance the spread of COVID-19. The information provided is about the effectiveness of electrostatic spraying in improving coverage of disinfectant on surfaces and reducing wastage, but it does not directly address the claim about the potential enhancement of virus transmission.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000120",
    "statement": "Electrostatic spraying will promote the spread of covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Electrostatic spraying is likely to improve coverage of disinfectant on surfaces and reduce wastage of disinfectant, but caution should be used in handling and applying the products."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided discusses the benefits of electrostatic spraying for improving coverage of disinfectant on surfaces. However, it does not provide any information suggesting that this method promotes the spread of COVID-19. In fact, using an effective disinfectant and following proper application guidelines should help reduce the risk of spreading COVID-19.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000121",
    "statement": "Scientists trace severe covid-19 to faulty genes and autoimmune condition",
    "label": "SUPPORTED",
    "evidences": [
      "These findings provide compelling evidence that the disruption of type I interferon is often the cause of life-threatening COVID-19, says Jean-Laurent Casanova, head of the St. Giles Laboratory of Human Genetics of Infectious Diseases at The Rockefeller University and a Howard Hughes Medical Institute investigator.",
      "COVID-19 may now be the best understood acute infectious disease in terms of having a molecular and genetic explanation for nearly 15 percent of critical cases across diverse ancestries, Casanova says.",
      "Genetics of COVID-19 outliers The way SARS-CoV-2 affects people differently has been puzzling.",
      "Science Inborn errors of type I IFN immunity in patients with life-threatening COVID-19 Zhang Q. et al.",
      "Whether the proteins have been neutralized by so-called auto- antibodies, or were not produced in sufficient amounts in the first place due to a faulty gene, their missing-in-action appears to be a common theme among a subgroup of COVID-19 sufferers whose disease has thus far been a mystery."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that a faulty gene and autoimmune condition are associated with severe cases of COVID-19. The statement 'Scientists trace severe covid-19 to faulty genes and autoimmune condition' is supported by the quote: 'Whether the proteins have been neutralized by so-called auto- antibodies, or were not produced in sufficient amounts in the first place due to a faulty gene, their missing-in-action appears to be a common theme among a subgroup of COVID-19 sufferers whose disease has thus far been a mystery.' The confidence is high because the statement aligns directly with information from the evidence.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000122",
    "statement": "Mice trace severe covid-19 to faulty genes and autoimmune condition",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These findings provide compelling evidence that the disruption of type I interferon is often the cause of life-threatening COVID-19, says Jean-Laurent Casanova, head of the St. Giles Laboratory of Human Genetics of Infectious Diseases at The Rockefeller University and a Howard Hughes Medical Institute investigator.",
      "COVID-19 may now be the best understood acute infectious disease in terms of having a molecular and genetic explanation for nearly 15 percent of critical cases across diverse ancestries, Casanova says.",
      "Genetics of COVID-19 outliers The way SARS-CoV-2 affects people differently has been puzzling.",
      "Science Inborn errors of type I IFN immunity in patients with life-threatening COVID-19 Zhang Q. et al.",
      "Whether the proteins have been neutralized by so-called auto- antibodies, or were not produced in sufficient amounts in the first place due to a faulty gene, their missing-in-action appears to be a common theme among a subgroup of COVID-19 sufferers whose disease has thus far been a mystery."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not directly support the claim that mice trace severe COVID-19 to faulty genes and autoimmune condition. While it does suggest that genetic factors play a role in some cases of severe COVID-19, it does not specify whether these are specific to mice or humans, nor does it mention an autoimmune condition.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000123",
    "statement": "Uv-emitting led lights found to kill coronavirus efficiently and cheaply.",
    "label": "SUPPORTED",
    "evidences": [
      "In a recent study, researchers found that UV light-emitting diodes (LEDs) can quickly and effectively kill the human coronavirus HCoV-OC43.",
      "A new study suggests the novel coronavirus can be killed cheaply and efficiently by ultraviolet light-emitting diodes (UV-LEDs).",
      "LED lights found to kill coronavirus efficiently, quickly, and cheaply ",
      "\"We discovered that it is quite simple to kill the coronavirus using LED bulbs that radiate ultraviolet light.",
      "In the study, the researchers found a range of wavelengths at which UV-LEDs effectively kill coronaviruses."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided in this claim directly states that a study suggests UV-emitting LED lights can efficiently and cheaply kill the novel coronavirus. The researchers found a range of wavelengths at which UV-LEDs effectively kill coronaviruses.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000124",
    "statement": "Uv-emitting bat lights found to kill coronavirus efficiently and cheaply.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In a recent study, researchers found that UV light-emitting diodes (LEDs) can quickly and effectively kill the human coronavirus HCoV-OC43.",
      "A new study suggests the novel coronavirus can be killed cheaply and efficiently by ultraviolet light-emitting diodes (UV-LEDs).",
      "LED lights found to kill coronavirus efficiently, quickly, and cheaply ",
      "\"We discovered that it is quite simple to kill the coronavirus using LED bulbs that radiate ultraviolet light.",
      "In the study, the researchers found a range of wavelengths at which UV-LEDs effectively kill coronaviruses."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided in the statement mentions that a study found that UV-LEDs can quickly and effectively kill the human coronavirus HCoV-OC43, which is similar to SARS-CoV-2 (the novel coronavirus). The statement also aligns with the information given in the study about LED lights killing coronaviruses efficiently, quickly, and cheaply.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000125",
    "statement": "Hydroxychloroquine safety outcome within approved therapeutic protocol for covid-19 outpatients in saudi arabia",
    "label": "SUPPORTED",
    "evidences": [
      "Conclusion: In our study, results show that the use of hydroxychloroquine for COVID-19 patients in mild to moderate cases in an outpatient setting, within the protocol recommendation and inclusion/exclusion criteria, is safe, highly tolerable, and with minimum side effects."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided states that hydroxychloroquine was found to be safe, highly tolerable, and with minimal side effects for COVID-19 patients in mild to moderate cases in an outpatient setting within Saudi Arabia, according to the study.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000126",
    "statement": "Hydroxychloroquine safety outcome within approved therapeutic protocol of covid-19 outpatients in saudi arabia",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusion: In our study, results show that the use of hydroxychloroquine for COVID-19 patients in mild to moderate cases in an outpatient setting, within the protocol recommendation and inclusion/exclusion criteria, is safe, highly tolerable, and with minimum side effects."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The given evidence only shows that the use of hydroxychloroquine in COVID-19 patients in mild to moderate cases in Saudi Arabia within the specific study protocol was safe and tolerable with minimum side effects. However, it does not provide information about whether this outcome is consistent across different therapeutic protocols or regions.",
    "confidence": 0.6
  },
  {
    "id": "covid_fact-000127",
    "statement": "Hydroxychloroquine safety outcome within approved therapeutic protocol included covid-19 outpatients in saudi arabia",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusion: In our study, results show that the use of hydroxychloroquine for COVID-19 patients in mild to moderate cases in an outpatient setting, within the protocol recommendation and inclusion/exclusion criteria, is safe, highly tolerable, and with minimum side effects."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence clearly states that the use of hydroxychloroquine for COVID-19 patients in mild to moderate cases in an outpatient setting is safe and well-tolerated according to the study results.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000128",
    "statement": "Hydroxychloroquine safety outcome within approved therapeutic protocol is covid-19 outpatients in saudi arabia",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusion: In our study, results show that the use of hydroxychloroquine for COVID-19 patients in mild to moderate cases in an outpatient setting, within the protocol recommendation and inclusion/exclusion criteria, is safe, highly tolerable, and with minimum side effects."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided in this study concludes that the use of hydroxychloroquine for COVID-19 patients in mild to moderate cases within an outpatient setting is safe and well tolerated with minimal side effects.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000129",
    "statement": "Covid-19 coronavirus spike holds infectivity details",
    "label": "SUPPORTED",
    "evidences": [
      "As a whole, details contained in the results reported in this weeks paper may help to explain the efficiency of the new coronavirus in delivering its viral code into human cells, and its rapid transmission among people.",
      "This finding might help account for the efficient spread of the new coronavirus between people.",
      "The spikes crowning the new coronavirus that causes COVID-19 atypical pneumonia are divulging how they attach, fuse and gain entry to cells."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided describes a study that investigates the mechanism by which the Covid-19 coronavirus binds and enters human cells. The rapid transmission of the virus is suggested in the claim, which aligns with the reported efficiency of the virus in delivering its viral code into human cells.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000130",
    "statement": "Covid-19 coronavirus genomes holds infectivity details",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "As a whole, details contained in the results reported in this weeks paper may help to explain the efficiency of the new coronavirus in delivering its viral code into human cells, and its rapid transmission among people.",
      "This finding might help account for the efficient spread of the new coronavirus between people.",
      "The spikes crowning the new coronavirus that causes COVID-19 atypical pneumonia are divulging how they attach, fuse and gain entry to cells."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence describes the findings about the structure and function of the spikes on the Covid-19 coronavirus, which is crucial for understanding its infectivity details. The statement 'details contained in the results reported in this weeks paper may help to explain the efficiency of the new coronavirus in delivering its viral code into human cells, and its rapid transmission among people' supports this claim.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000131",
    "statement": "We had the covid-19 vaccine the whole time",
    "label": "SUPPORTED",
    "evidences": [
      "And then we formulate that into a vaccine using essentially the same technology platform that all the other influenza vaccines are based on. The whole process takes a few months, and utilizes a platform that we already know is basically safe.",
      "More precisely, they thought it would be possible to do all the research, development, preclinical testing, and Phase I trials for new viral pandemics before those new viruses had even emerged  to have those vaccines sitting on the shelf and ready to go when they did.",
      "The whole time, we also knew that the Moderna vaccine was essentially safe."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not directly support or disprove the claim about having the COVID-19 vaccine 'the whole time.' While it mentions that a vaccine could be formulated using existing technology platforms in a few months, this is not the same as having the specific COVID-19 vaccine ready before the pandemic. Also, the safety of the Moderna vaccine does not necessarily mean that a COVID-19 vaccine was always available.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000132",
    "statement": "We had the covid-19 vaccine the next time",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "And then we formulate that into a vaccine using essentially the same technology platform that all the other influenza vaccines are based on. The whole process takes a few months, and utilizes a platform that we already know is basically safe.",
      "More precisely, they thought it would be possible to do all the research, development, preclinical testing, and Phase I trials for new viral pandemics before those new viruses had even emerged  to have those vaccines sitting on the shelf and ready to go when they did.",
      "The whole time, we also knew that the Moderna vaccine was essentially safe."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "While the evidence discusses the process and technology platform for developing a vaccine, it does not provide direct information or evidence that a specific covid-19 vaccine was already formulated at the time mentioned in the claim.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000133",
    "statement": "We had the covid-19 vaccine the following time",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "And then we formulate that into a vaccine using essentially the same technology platform that all the other influenza vaccines are based on. The whole process takes a few months, and utilizes a platform that we already know is basically safe.",
      "More precisely, they thought it would be possible to do all the research, development, preclinical testing, and Phase I trials for new viral pandemics before those new viruses had even emerged  to have those vaccines sitting on the shelf and ready to go when they did.",
      "The whole time, we also knew that the Moderna vaccine was essentially safe."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "While the evidence suggests that a covid-19 vaccine could potentially be developed using similar technology to influenza vaccines, it does not provide specific evidence for when such a vaccine was available or administered. Additionally, the statement about having vaccines sitting on the shelf before pandemics emerge is speculative and not supported by this evidence.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000134",
    "statement": "We had the covid-19 vaccine the second time",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "And then we formulate that into a vaccine using essentially the same technology platform that all the other influenza vaccines are based on. The whole process takes a few months, and utilizes a platform that we already know is basically safe.",
      "More precisely, they thought it would be possible to do all the research, development, preclinical testing, and Phase I trials for new viral pandemics before those new viruses had even emerged  to have those vaccines sitting on the shelf and ready to go when they did.",
      "The whole time, we also knew that the Moderna vaccine was essentially safe."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "While the claim discusses a covid-19 vaccine and mentions it was based on a technology platform used in influenza vaccines, there is no direct evidence provided that the subject had received or was eligible for a second covid-19 vaccine dose. The text primarily focuses on the process of creating a new vaccine, not necessarily applying it to an individual.",
    "confidence": 0.75
  },
  {
    "id": "covid_fact-000135",
    "statement": "Quantitative assays reveal cell fusion at minimal levels of sars-cov-2 spike protein and fusion-from-without",
    "label": "SUPPORTED",
    "evidences": [
      "Cell-cell fusion, in contrast, was only moderately inhibited despite requiring much lower levels of S protein, which were below the detection limit of flow cytometry and Western blot."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The given evidence describes that cell-cell fusion was only moderately inhibited by levels of SARS-CoV-2 spike protein below the detection limit of flow cytometry and Western blot. This does not necessarily mean that there is no fusion at all or that it occurs at minimal levels as claimed in the statement.",
    "confidence": 0.6
  },
  {
    "id": "covid_fact-000136",
    "statement": "Quantitative assays reveal no fusion at minimal levels of sars-cov-2 spike protein and fusion-from-without",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Cell-cell fusion, in contrast, was only moderately inhibited despite requiring much lower levels of S protein, which were below the detection limit of flow cytometry and Western blot."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided states that cell-cell fusion was moderately inhibited despite requiring lower levels of S protein than the assays could detect. This does not provide any information about quantitative assays revealing no fusion at minimal levels of sars-cov-2 spike protein and fusion-from-without.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000137",
    "statement": "Weekly national flu and covid-19 surveillance reports published",
    "label": "SUPPORTED",
    "evidences": [
      "By NHS regions, the highest hospital admission rates for COVID-19 were observed in the North West.",
      "COVID-19 hospital and critical care admission rates continued to increase."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates an increase in COVID-19 hospital and critical care admission rates, which is consistent with the publication of weekly national surveillance reports that monitor such data.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000138",
    "statement": "Weekly national flu and covid-19 pandemic reports published",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "By NHS regions, the highest hospital admission rates for COVID-19 were observed in the North West.",
      "COVID-19 hospital and critical care admission rates continued to increase."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows an increase in COVID-19 hospital and critical care admissions, which implies the publication of weekly national flu and COVID-19 pandemic reports as such events would be regularly reported.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000139",
    "statement": "Weekly national flu and covid-19 epidemic reports published",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "By NHS regions, the highest hospital admission rates for COVID-19 were observed in the North West.",
      "COVID-19 hospital and critical care admission rates continued to increase."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows an increase in COVID-19 hospital and critical care admission rates by NHS regions, specifically the North West region having the highest admission rate. This indicates that there are weekly epidemic reports being published on national flu and COVID-19 data.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000140",
    "statement": "Weekly national flu and covid-19 infection reports published",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "By NHS regions, the highest hospital admission rates for COVID-19 were observed in the North West.",
      "COVID-19 hospital and critical care admission rates continued to increase."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence shows a COVID-19 hospital admission rate in a specific region (North West), but it does not directly prove that weekly national flu and covid-19 infection reports are published.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000141",
    "statement": "Coronavirus endoribonuclease targets viral polyuridine sequences to evade activating host sensors",
    "label": "SUPPORTED",
    "evidences": [
      "Furthermore, the HCV replication complexes may hide the viral RNA from recognition by host sensors (43)."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence does not directly support the claim about Coronavirus endoribonuclease targeting viral polyuridine sequences to evade activating host sensors. The evidence mentions that HCV replication complexes may hide the viral RNA from recognition by host sensors, but this is a general mechanism and does not specify if it involves a particular sequence like polyuridines or any specific enzyme like Coronavirus endoribonuclease.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000142",
    "statement": "Coronavirus endoribonuclease targets viral polyuridine sequences to evade activating host defense",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Furthermore, the HCV replication complexes may hide the viral RNA from recognition by host sensors (43)."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that the Coronavirus replication complex hides the viral RNA from host sensors, which could imply a strategy to evade host defense mechanisms, such as those activated by polyuridine sequences (43). However, it does not explicitly state that the endoribonuclease targets viral polyuridine sequences, but the implication is supported.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000143",
    "statement": "The spike glycoprotein of the new coronavirus 2019-ncov contains a furin-like cleavage site absent in cov of the same clade .",
    "label": "SUPPORTED",
    "evidences": [
      "Despite a high similarity with the genome sequence of SARS-CoV and SARS-like CoVs, we identified a peculiar furin-like cleavage site in the Spike protein of the 2019-nCoV, lacking in the other SARS-like CoVs.",
      "It has been speculated that RRAR, a unique furin-like cleavage site (FCS) in the spike protein (S), which is absent in other lineage B \u03b2CoVs, such as SARS-CoV, is responsible for its high infectivity and transmissibility.2 A coronavirus (CoV) infects the target cell by either cytoplasmic or endosomal membrane fusion."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided states that the spike protein of the new coronavirus 2019-nCoV contains a furin-like cleavage site (FCS), which is absent in other lineage B betaCoVs such as SARS-CoV. This directly supports the claim.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000144",
    "statement": "The spike glycoprotein of the new coronavirus a-ncov contains a furin-like cleavage site absent in cov of the same clade.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Despite a high similarity with the genome sequence of SARS-CoV and SARS-like CoVs, we identified a peculiar furin-like cleavage site in the Spike protein of the 2019-nCoV, lacking in the other SARS-like CoVs.",
      "It has been speculated that RRAR, a unique furin-like cleavage site (FCS) in the spike protein (S), which is absent in other lineage B \u03b2CoVs, such as SARS-CoV, is responsible for its high infectivity and transmissibility.2 A coronavirus (CoV) infects the target cell by either cytoplasmic or endosomal membrane fusion."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that a unique furin-like cleavage site (FCS) is present in the spike protein of the new coronavirus a-ncov, which is absent in other lineage B \u03b2CoVs such as SARS-CoV. This difference could contribute to the high infectivity and transmissibility of the new virus.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000145",
    "statement": "The spike glycoprotein of the new coronavirus s-ncov contains a furin-like cleavage site absent in cov of the same clade.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Despite a high similarity with the genome sequence of SARS-CoV and SARS-like CoVs, we identified a peculiar furin-like cleavage site in the Spike protein of the 2019-nCoV, lacking in the other SARS-like CoVs.",
      "It has been speculated that RRAR, a unique furin-like cleavage site (FCS) in the spike protein (S), which is absent in other lineage B \u03b2CoVs, such as SARS-CoV, is responsible for its high infectivity and transmissibility.2 A coronavirus (CoV) infects the target cell by either cytoplasmic or endosomal membrane fusion."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided states that the spike protein of the new coronavirus s-ncov has a furin-like cleavage site, which is absent in other SARS-like CoVs such as SARS-CoV. This matches the claim.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000146",
    "statement": "The spike glycoprotein of the new coronavirus e-ncov contains a furin-like cleavage site absent in cov of the same clade.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Despite a high similarity with the genome sequence of SARS-CoV and SARS-like CoVs, we identified a peculiar furin-like cleavage site in the Spike protein of the 2019-nCoV, lacking in the other SARS-like CoVs.",
      "It has been speculated that RRAR, a unique furin-like cleavage site (FCS) in the spike protein (S), which is absent in other lineage B \u03b2CoVs, such as SARS-CoV, is responsible for its high infectivity and transmissibility.2 A coronavirus (CoV) infects the target cell by either cytoplasmic or endosomal membrane fusion."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly states that the spike protein of the new coronavirus e-ncov has a furin-like cleavage site which is absent in SARS-CoV and other lineage B \u03b2CoVs. This finding explains why it might be responsible for its high infectivity and transmissibility.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000147",
    "statement": "Breakthrough covid-19 antibody test with nearly 100 % accuracy can help reopen economy",
    "label": "SUPPORTED",
    "evidences": [
      "Scientists said Friday they found the test can determine if someone had COVID-19 with nearly 100% accuracy."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided states that scientists found a breakthrough covid-19 antibody test can determine if someone had COVID-19 with nearly 100% accuracy. If the test can accurately detect past infections, it could potentially contribute to reopening economies by identifying individuals who have immunity.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000148",
    "statement": "Breakthrough covid-19 antibody test with nearly 100 % accuracy cannot help reopen economy",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Scientists said Friday they found the test can determine if someone had COVID-19 with nearly 100% accuracy."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided indicates that a breakthrough covid-19 antibody test has high accuracy in detecting if someone had COVID-19. However, it does not inherently imply that this test cannot help reopen the economy. The relationship between testing and economic reopening is complex and depends on various factors such as the scale of testing, contact tracing, isolation measures, vaccination efforts, etc. Therefore, the claim is not directly supported by the given evidence.",
    "confidence": 0.7
  },
  {
    "id": "covid_fact-000149",
    "statement": "Pyridoxal 5'-phosphate to mitigate immune dysregulation and coagulopathy in covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "Pharmacological PLP supplementation may therefore mitigate COVID-19 symptoms by alleviating both the immune suppression underlying viral spread and the pathological hypersecretion of inflammatory cytokines, as well as directly bolstering endothelial integrity and preventing hypercoagulability.",
      "In inflammatory disease, pharmacological doses of PLP decrease circulating TNF\u03b1, IL-6 and D-dimer, and animal studies demonstrate that supplemental PLP shortens the duration and severity of viral pneumonia."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that pharmacological doses of Pyridoxal 5'-phosphate (PLP) may alleviate immune suppression and inflammation associated with COVID-19, as well as prevent hypercoagulability. The evidence includes studies showing a decrease in circulating TNF\u03b1, IL-6, and D-dimer, which are markers of inflammation and coagulation, and the fact that supplemental PLP has been shown to shorten the duration and severity of viral pneumonia in animal studies.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000150",
    "statement": "Pyridoxal 5'- inability to mitigate immune dysregulation and coagulopathy in covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Pharmacological PLP supplementation may therefore mitigate COVID-19 symptoms by alleviating both the immune suppression underlying viral spread and the pathological hypersecretion of inflammatory cytokines, as well as directly bolstering endothelial integrity and preventing hypercoagulability.",
      "In inflammatory disease, pharmacological doses of PLP decrease circulating TNF\u03b1, IL-6 and D-dimer, and animal studies demonstrate that supplemental PLP shortens the duration and severity of viral pneumonia."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests that Pyridoxal 5'- (PLP) supplementation may mitigate immune dysregulation and coagulopathy in COVID-19 by alleviating inflammatory cytokine pathological hypersecretion, bolstering endothelial integrity, and preventing hypercoagulability. The evidence also indicates that pharmacological doses of PLP can decrease circulating TNF\u03b1, IL-6 and D-dimer, and shorten the duration and severity of viral pneumonia in inflammatory disease.",
    "confidence": 0.85
  },
  {
    "id": "covid_fact-000151",
    "statement": "Pyridoxal 5'-phosphate to mitigate cardiac dysregulation and coagulopathy in covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Pharmacological PLP supplementation may therefore mitigate COVID-19 symptoms by alleviating both the immune suppression underlying viral spread and the pathological hypersecretion of inflammatory cytokines, as well as directly bolstering endothelial integrity and preventing hypercoagulability.",
      "In inflammatory disease, pharmacological doses of PLP decrease circulating TNF\u03b1, IL-6 and D-dimer, and animal studies demonstrate that supplemental PLP shortens the duration and severity of viral pneumonia."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests that pharmacological doses of Pyridoxal 5'-phosphate (PLP) may help mitigate symptoms of COVID-19 by alleviating immune suppression and inflammation, as well as preventing hypercoagulability. The evidence cites decreased levels of TNF\u03b1, IL-6, and D-dimer in inflammatory disease with PLP supplementation and animal studies demonstrating that supplemental PLP shortens the duration and severity of viral pneumonia.",
    "confidence": 0.85
  },
  {
    "id": "covid_fact-000152",
    "statement": "Pyridoxal 5'-c to mitigate immune dysregulation and coagulopathy in covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Pharmacological PLP supplementation may therefore mitigate COVID-19 symptoms by alleviating both the immune suppression underlying viral spread and the pathological hypersecretion of inflammatory cytokines, as well as directly bolstering endothelial integrity and preventing hypercoagulability.",
      "In inflammatory disease, pharmacological doses of PLP decrease circulating TNF\u03b1, IL-6 and D-dimer, and animal studies demonstrate that supplemental PLP shortens the duration and severity of viral pneumonia."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that pharmacological doses of Pyridoxal 5'-c (PLP) may alleviate immune suppression and inflammatory cytokine secretion, improve endothelial integrity, and prevent hypercoagulability. These effects could potentially mitigate immune dysregulation and coagulopathy in COVID-19. The evidence also indicates that supplemental PLP has been shown to shorten the duration and severity of viral pneumonia in animal studies.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000153",
    "statement": "Antibodies in infants born to mothers with covid-19 pneumonia",
    "label": "SUPPORTED",
    "evidences": [
      "Assessment of Maternal and Neonatal SARS-CoV-2 Viral Load, Transplacental Antibody Transfer, and Placental Pathology in Pregnancies During the COVID-19 Pandemic."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence is about the assessment of maternal and neonatal SARS-CoV-2 viral load, transplacental antibody transfer, and placental pathology during pregnancies in the COVID-19 pandemic. However, it does not directly address whether infants born to mothers with COVID-19 pneumonia have antibodies or not.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000154",
    "statement": "Antibodies in women born to mothers with covid-19 pneumonia",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Assessment of Maternal and Neonatal SARS-CoV-2 Viral Load, Transplacental Antibody Transfer, and Placental Pathology in Pregnancies During the COVID-19 Pandemic."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence is a research article discussing SARS-CoV-2 viral load, transplacental antibody transfer, and placental pathology in pregnancies during the COVID-19 pandemic. However, it does not directly prove that antibodies in women born to mothers with COVID-19 pneumonia exist. It only establishes that there is a possibility of antibody transfer from mother to fetus, but more specific studies focusing on this aspect would be required for confirmation.",
    "confidence": 0.7
  },
  {
    "id": "covid_fact-000155",
    "statement": "Mortality in infants born to mothers with covid-19 pneumonia",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Assessment of Maternal and Neonatal SARS-CoV-2 Viral Load, Transplacental Antibody Transfer, and Placental Pathology in Pregnancies During the COVID-19 Pandemic."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence is a research article that focuses on maternal and neonatal SARS-CoV-2 viral load, transplacental antibody transfer, and placental pathology in pregnancies during the COVID-19 pandemic. It does not directly provide data about the mortality rate of infants born to mothers with COVID-19 pneumonia.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000156",
    "statement": "Aggregated mobility data could help fight covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "When aggregated, these data can help refine interventions by providing near real-time information about changes in patterns of human movement."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that aggregated mobility data can help provide near real-time information about changes in patterns of human movement. Such insights could be useful in understanding the spread of COVID-19, refining public health interventions, and making informed decisions to combat the pandemic.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000157",
    "statement": "Aggregated mobility data could not fight covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "When aggregated, these data can help refine interventions by providing near real-time information about changes in patterns of human movement."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "While the evidence provided shows that aggregated mobility data can provide useful insights for refining interventions related to COVID-19 (such as identifying areas with increased population density that may require additional resources), it does not demonstrate that such data alone could fight COVID-19. More direct and specific evidence, like the effectiveness of using aggregated mobility data in fighting COVID-19, would be required for a definitive conclusion.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000158",
    "statement": "Aggregated mobility data could help generate covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "When aggregated, these data can help refine interventions by providing near real-time information about changes in patterns of human movement."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "While the claim states that aggregated mobility data could help generate Covid-19, the provided evidence only shows that it can refine interventions by providing near real-time information about changes in patterns of human movement, which indirectly impacts the spread of the virus.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000159",
    "statement": "Aggregated mobility data could help study covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "When aggregated, these data can help refine interventions by providing near real-time information about changes in patterns of human movement."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that aggregated mobility data can provide near real-time information about changes in patterns of human movement. These changes in movement patterns are important indicators during a pandemic like Covid-19, as they may help refine interventions and responses.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000160",
    "statement": "Preliminary evidence that higher temperatures are associated with lower incidence of covid-19 , for cases reported globally up to 29th february 2020",
    "label": "SUPPORTED",
    "evidences": [
      "Using global line-list data on COVID-19 cases reported until 29th February 2020 and global gridded temperature data, and after adjusting for surveillance capacity and time since first imported case, higher average temperature was strongly associated with lower COVID-19 incidence for temperatures of 1\u00b0C and higher.",
      "However, temperature explained a relatively modest amount of the total variation in COVID-19 incidence."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that a positive correlation exists between higher temperatures and lower incidence of COVID-19 cases, based on the data analyzed up to February 29, 2020. The study controlled for surveillance capacity and time since the first imported case. However, it's important to note that temperature only explained a relatively modest amount of the total variation in COVID-19 incidence.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000161",
    "statement": "Preliminary evidence that lower temperatures are associated with lower incidence of covid-19, for cases reported globally up to 29th february 2020",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Using global line-list data on COVID-19 cases reported until 29th February 2020 and global gridded temperature data, and after adjusting for surveillance capacity and time since first imported case, higher average temperature was strongly associated with lower COVID-19 incidence for temperatures of 1\u00b0C and higher.",
      "However, temperature explained a relatively modest amount of the total variation in COVID-19 incidence."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that after adjusting for surveillance capacity and time since first imported case, higher average temperature was associated with lower COVID-19 incidence. However, it's important to note that this correlation does not necessarily mean causation and other factors may contribute significantly as well.",
    "confidence": 0.85
  },
  {
    "id": "covid_fact-000162",
    "statement": "Preliminary evidence that low temperatures are associated with lower incidence of covid-19, for cases reported globally up to 29th february 2020",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Using global line-list data on COVID-19 cases reported until 29th February 2020 and global gridded temperature data, and after adjusting for surveillance capacity and time since first imported case, higher average temperature was strongly associated with lower COVID-19 incidence for temperatures of 1\u00b0C and higher.",
      "However, temperature explained a relatively modest amount of the total variation in COVID-19 incidence."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows an association between higher average temperatures and lower COVID-19 incidence for temperatures of 1\u00b0C and higher, after adjusting for surveillance capacity and time since first imported case. While temperature only explained a relatively modest amount of the total variation in COVID-19 incidence, the correlation still suggests that low temperatures may be associated with lower incidence of COVID-19.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000163",
    "statement": "The fda weighs its first coronavirus vaccine",
    "label": "SUPPORTED",
    "evidences": [
      "https://www.nbcnews.com/health/health-news/moderna-vaccine-appears-protect- against-coronavirus-infection-n1251237 Reply 1.",
      "So it looks like the vaccine has a very strong protective effect, and that's the first thing you'd want to know.",
      "I expect the FDA to grant that, and very soon."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence states that the Moderna vaccine appears to protect against coronavirus infection, and mentions the expectation of FDA granting it soon. However, there is no explicit statement confirming that the FDA has weighed the vaccine.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000164",
    "statement": "The fda weighs its new coronavirus vaccine",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "https://www.nbcnews.com/health/health-news/moderna-vaccine-appears-protect- against-coronavirus-infection-n1251237 Reply 1.",
      "So it looks like the vaccine has a very strong protective effect, and that's the first thing you'd want to know.",
      "I expect the FDA to grant that, and very soon."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence does not directly mention or imply that the FDA weighs the new coronavirus vaccine. The information in the link is about the results of a study on the Moderna vaccine's protective effect against the coronavirus infection.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000165",
    "statement": "The fda weighs its sars coronavirus vaccine",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "https://www.nbcnews.com/health/health-news/moderna-vaccine-appears-protect- against-coronavirus-infection-n1251237 Reply 1.",
      "So it looks like the vaccine has a very strong protective effect, and that's the first thing you'd want to know.",
      "I expect the FDA to grant that, and very soon."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The given evidence does not directly show or confirm that the FDA weighs its SARS Coronavirus vaccine. The article only states that the Moderna vaccine appears to protect against coronavirus infection and mentions an expectation for FDA granting approval, but it doesn't detail the process or method of how the FDA evaluates or weighs vaccines.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000166",
    "statement": "High incidence of venous thromboembolic events in anticoagulated severe covid-19 patients",
    "label": "SUPPORTED",
    "evidences": [
      "Rate of venous thromboembolism in a prospective all-comers cohort with COVID-19.",
      "Venous Thromboembolism in Hospitalized COVID-19 Patients.",
      "Incidence of thrombotic complications in critically ill ICU patients with COVID19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided discusses the incidence of venous thromboembolism (VTE) in hospitalized COVID-19 patients and critically ill ICU patients with COVID-19. The high incidence of VTE is a known complication in anticoagulated severe COVID-19 patients due to hypercoagulability associated with the disease.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000167",
    "statement": "Low incidence of venous thromboembolic events in anticoagulated severe covid-19 patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Rate of venous thromboembolism in a prospective all-comers cohort with COVID-19.",
      "Venous Thromboembolism in Hospitalized COVID-19 Patients.",
      "Incidence of thrombotic complications in critically ill ICU patients with COVID19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not explicitly state or imply the low incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. While it mentions the incidence of venous thromboembolism in hospitalized COVID-19 patients and critically ill ICU patients, there is no information about whether these patients were anticoagulated or not.",
    "confidence": 0.6
  },
  {
    "id": "covid_fact-000168",
    "statement": "Median incidence of venous thromboembolic events in anticoagulated severe covid-19 patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Rate of venous thromboembolism in a prospective all-comers cohort with COVID-19.",
      "Venous Thromboembolism in Hospitalized COVID-19 Patients.",
      "Incidence of thrombotic complications in critically ill ICU patients with COVID19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The given evidence discusses the incidence of venous thromboembolism in a cohort of all COVID-19 patients and in critically ill ICU patients with COVID-19. However, it does not provide information about the median incidence specifically for anticoagulated severe COVID-19 patients.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000169",
    "statement": "Average incidence of venous thromboembolic events in anticoagulated severe covid-19 patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Rate of venous thromboembolism in a prospective all-comers cohort with COVID-19.",
      "Venous Thromboembolism in Hospitalized COVID-19 Patients.",
      "Incidence of thrombotic complications in critically ill ICU patients with COVID19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not directly mention the average incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. Instead, it talks about the incidence of venous thromboembolism in a prospective cohort with COVID-19 and thrombotic complications in critically ill ICU patients with COVID-19. To determine the average incidence in anticoagulated severe COVID-19 patients, more specific data or studies focusing on this particular group would be required.",
    "confidence": 0.4
  },
  {
    "id": "covid_fact-000170",
    "statement": "Epa proposes broad science restrictions in midst of coronavirus pandemic",
    "label": "SUPPORTED",
    "evidences": [
      "The EPAs Science Advisory Board initially called it a license to politicize science and said that it would compromise the agencys decision-making process.",
      "According to EPA, it would apply not only to studies behind EPA decisions about vehicle emissions, clean air standards, and clean water protections, but also EPAs own state-of-science reports, technology assessments, weight-of-evidence analyses, meta-analyses, risk assessments, toxicological profiles of substances, integrated assessment models, hazard determinations, exposure assessments, or health, ecological, or safety assessments. The EPA has not articulated a problem it wants to solve."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence does not directly indicate that the EPA is proposing broad science restrictions during the coronavirus pandemic. The statement refers to actions of the EPA in general, but there is no mention or implication of any actions taken specifically during the pandemic.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000171",
    "statement": "Epa proposes broad science support in midst of coronavirus pandemic",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The EPAs Science Advisory Board initially called it a license to politicize science and said that it would compromise the agencys decision-making process.",
      "According to EPA, it would apply not only to studies behind EPA decisions about vehicle emissions, clean air standards, and clean water protections, but also EPAs own state-of-science reports, technology assessments, weight-of-evidence analyses, meta-analyses, risk assessments, toxicological profiles of substances, integrated assessment models, hazard determinations, exposure assessments, or health, ecological, or safety assessments. The EPA has not articulated a problem it wants to solve."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not directly support the claim that EPA proposes broad science support in midst of coronavirus pandemic. Instead, it provides information about the EPA's Science Advisory Board calling its new policy a license to politicize science and details about what types of studies the new policy would apply to. There is no mention or indication of the EPA proposing broad science support specifically for managing the COVID-19 pandemic.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000172",
    "statement": "Cdc proposes broad science restrictions in midst of coronavirus pandemic",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The EPAs Science Advisory Board initially called it a license to politicize science and said that it would compromise the agencys decision-making process.",
      "According to EPA, it would apply not only to studies behind EPA decisions about vehicle emissions, clean air standards, and clean water protections, but also EPAs own state-of-science reports, technology assessments, weight-of-evidence analyses, meta-analyses, risk assessments, toxicological profiles of substances, integrated assessment models, hazard determinations, exposure assessments, or health, ecological, or safety assessments. The EPA has not articulated a problem it wants to solve."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not directly support the claim that the CDC (Centers for Disease Control and Prevention) proposes broad science restrictions in the midst of the coronavirus pandemic. The statement only mentions the EPA's (Environmental Protection Agency) proposed changes, not the CDC.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000173",
    "statement": "Who proposes broad science restrictions in midst of coronavirus pandemic",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The EPAs Science Advisory Board initially called it a license to politicize science and said that it would compromise the agencys decision-making process.",
      "According to EPA, it would apply not only to studies behind EPA decisions about vehicle emissions, clean air standards, and clean water protections, but also EPAs own state-of-science reports, technology assessments, weight-of-evidence analyses, meta-analyses, risk assessments, toxicological profiles of substances, integrated assessment models, hazard determinations, exposure assessments, or health, ecological, or safety assessments. The EPA has not articulated a problem it wants to solve."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not directly state who is proposing broad science restrictions in the midst of the coronavirus pandemic. It discusses a potential policy change by the EPA (Environmental Protection Agency), but it does not explicitly link this to the ongoing pandemic.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000174",
    "statement": "Moderna provides covid-19 vaccine supply update.",
    "label": "SUPPORTED",
    "evidences": [
      "About the Moderna COVID-19 Vaccine The Moderna COVID-19 Vaccine is an mRNA vaccine against COVID-19 encoding for a prefusion stabilized form of the Spike (S) protein, which was co-developed by Moderna and investigators from National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center.",
      "Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including regarding: the Companys development of a vaccine against the novel coronavirus, and the timeline and scale for manufacturing and distribution of the Moderna COVID-19 Vaccine."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence discusses the Moderna COVID-19 Vaccine and mentions its development by Moderna. This implies that Moderna is involved in providing updates related to the covid-19 vaccine.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000175",
    "statement": "Cdca provides covid-19 vaccine supply update.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "About the Moderna COVID-19 Vaccine The Moderna COVID-19 Vaccine is an mRNA vaccine against COVID-19 encoding for a prefusion stabilized form of the Spike (S) protein, which was co-developed by Moderna and investigators from National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center.",
      "Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including regarding: the Companys development of a vaccine against the novel coronavirus, and the timeline and scale for manufacturing and distribution of the Moderna COVID-19 Vaccine."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not directly mention 'Cdca' or any connection to providing covid-19 vaccine supply updates.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000176",
    "statement": "Wa provides covid-19 vaccine supply update.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "About the Moderna COVID-19 Vaccine The Moderna COVID-19 Vaccine is an mRNA vaccine against COVID-19 encoding for a prefusion stabilized form of the Spike (S) protein, which was co-developed by Moderna and investigators from National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center.",
      "Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including regarding: the Companys development of a vaccine against the novel coronavirus, and the timeline and scale for manufacturing and distribution of the Moderna COVID-19 Vaccine."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not directly state that WA provides the Covid-19 vaccine supply update. Instead, it discusses the development and production of the Moderna COVID-19 Vaccine by the company Moderna.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000177",
    "statement": "Engineered ace2 receptor traps potently neutralize sars-cov-2",
    "label": "SUPPORTED",
    "evidences": [
      ", Mutations from bat ACE2 orthologs markedly enhance ACE2-Fc neutralization of SARS-CoV-2.",
      "The optimized ACE2 receptor traps neutralize authentic SARS-CoV-2 infections as effectively as high-affinity antibodies isolated from convalescent patients and also bind viral spike proteins from other coronaviruses known to cause respiratory diseases.",
      "Engineered ACE2 receptor traps present key advantages in treating SARS-CoV-2 infections.",
      ", Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided describes that engineered ACE2 receptor traps have been shown to neutralize authentic SARS-CoV-2 infections as effectively as high-affinity antibodies isolated from convalescent patients. This indicates that the claim is supported.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000178",
    "statement": "Engineered ace2 receptor cannot potently neutralize sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      ", Mutations from bat ACE2 orthologs markedly enhance ACE2-Fc neutralization of SARS-CoV-2.",
      "The optimized ACE2 receptor traps neutralize authentic SARS-CoV-2 infections as effectively as high-affinity antibodies isolated from convalescent patients and also bind viral spike proteins from other coronaviruses known to cause respiratory diseases.",
      "Engineered ACE2 receptor traps present key advantages in treating SARS-CoV-2 infections.",
      ", Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided describes how an engineered ace2 receptor can potently neutralize sars-cov-2 infections, which contradicts the claim that it cannot do so.",
    "confidence": 0.7
  },
  {
    "id": "covid_fact-000179",
    "statement": "Recombinant ace2 receptor traps potently neutralize sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      ", Mutations from bat ACE2 orthologs markedly enhance ACE2-Fc neutralization of SARS-CoV-2.",
      "The optimized ACE2 receptor traps neutralize authentic SARS-CoV-2 infections as effectively as high-affinity antibodies isolated from convalescent patients and also bind viral spike proteins from other coronaviruses known to cause respiratory diseases.",
      "Engineered ACE2 receptor traps present key advantages in treating SARS-CoV-2 infections.",
      ", Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided states that the optimized ACE2 receptor traps neutralize authentic SARS-CoV-2 infections effectively, which is comparable to high-affinity antibodies isolated from convalescent patients. The structures of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor are also mentioned, further supporting the claim.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000180",
    "statement": "Professional and home-made face masks reduce exposure to respiratory infections among the general population",
    "label": "SUPPORTED",
    "evidences": [
      "Face- masks worn by the general population could be an accessible and affordable intervention, if effective when worn under routine circumstances.",
      "Conclusions/significance: Any type of general mask use is likely to decrease viral exposure and infection risk on a population level, in spite of imperfect fit and imperfect adherence, personal respirators providing most protection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that wearing face masks reduces exposure to respiratory infections among the general population, even though it might not provide as much protection as personal respirators. It also implies that this reduction occurs on a population level despite potential issues with fit and adherence.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000181",
    "statement": "Genomic epidemiology of a densely sampled covid19 outbreak in china",
    "label": "SUPPORTED",
    "evidences": [
      "With few exceptions, genomic epidemiological analysis has focused on geographically distributed data sets with few isolates in any given location.",
      "Here we report an analysis of 20 whole SARS-CoV 2 genomes from a single relatively small and geographically constrained outbreak in Weifang, People's Republic of China."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides a detailed analysis of 20 whole SARS-CoV-2 genomes from a single outbreak in Weifang, China, which aligns with the claim that this is an example of genomic epidemiology of a densely sampled COVID-19 outbreak.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000182",
    "statement": "Genomic epidemiology of a randomly sampled covid19 outbreak in china",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "With few exceptions, genomic epidemiological analysis has focused on geographically distributed data sets with few isolates in any given location.",
      "Here we report an analysis of 20 whole SARS-CoV 2 genomes from a single relatively small and geographically constrained outbreak in Weifang, People's Republic of China."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides genomic epidemiology data for a randomly sampled COVID-19 outbreak in China, specifically in Weifang.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000183",
    "statement": "Large sars-cov-2 outbreak caused by asymptomatic traveler , china",
    "label": "SUPPORTED",
    "evidences": [
      "Timeline of exposure and connections between cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among persons in Heilongjiang Province, China."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence only shows a timeline of exposure and connections between cases of SARS-CoV-2 in Heilongjiang Province, China, but it does not specifically state or imply that the outbreak was caused by an asymptomatic traveler.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000184",
    "statement": "One sars-cov-2 outbreak caused by asymptomatic traveler, china",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Timeline of exposure and connections between cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among persons in Heilongjiang Province, China."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence describes a timeline of cases of SARS-CoV-2 in Heilongjiang Province, China, but it does not directly support or refute the claim that one specific outbreak was caused by an asymptomatic traveler.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000185",
    "statement": "More than 80 clinical trials launch to test coronavirus treatments",
    "label": "SUPPORTED",
    "evidences": [
      "The Chinese Clinical Trial Registry, a database of biomedical studies in China, lists these investigations among dozens of other controlled trials on existing therapies, experimental procedures and traditional medicines."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided lists 'dozens of other controlled trials' in addition to the coronavirus treatments being tested. As a result, it is reasonable to conclude that more than 80 clinical trials may be launched.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000186",
    "statement": "less than 80 clinical trials launch to test coronavirus treatments",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The Chinese Clinical Trial Registry, a database of biomedical studies in China, lists these investigations among dozens of other controlled trials on existing therapies, experimental procedures and traditional medicines."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence only states that there are 'dozens' of clinical trials registered in the Chinese Clinical Trial Registry related to coronavirus treatments, but it does not provide specific numbers or a definitive number less than 80.",
    "confidence": 0.6
  },
  {
    "id": "covid_fact-000187",
    "statement": "fewer than 80 clinical trials launch to test coronavirus treatments",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The Chinese Clinical Trial Registry, a database of biomedical studies in China, lists these investigations among dozens of other controlled trials on existing therapies, experimental procedures and traditional medicines."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided only states that there are 'dozens' of clinical trials for coronavirus treatments on the Chinese Clinical Trial Registry, but it does not specify an exact number or guarantee they are fewer than 80.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000188",
    "statement": "younger than 80 clinical trials launch to test coronavirus treatments",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The Chinese Clinical Trial Registry, a database of biomedical studies in China, lists these investigations among dozens of other controlled trials on existing therapies, experimental procedures and traditional medicines."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that there are ongoing clinical trials testing potential treatments for coronavirus in China. The specific age of these trials (whether they are younger than 80) is not explicitly stated but the fact that new trials are being launched implies that some trials could be relatively recent.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000189",
    "statement": "Ferritin nanoparticle based sars-cov-2 rbd vaccine induces persistent antibody response and long-term memory in mice.",
    "label": "SUPPORTED",
    "evidences": [
      "Thus, we believe our current study provide the first information about the long-term antibody persistence and memory response of a COVID-19 vaccine.",
      "Here, we report that a ferritin nanoparticle based SARS-CoV-2 RBD vaccine induced in mice an efficient antibody response which lasts for at least 7 months post immunization.",
      "Significantly higher number of memory B cells were maintained and a significantly higher level of recall response was induced upon antigen challenge."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided describes an experiment where mice were immunized with a ferritin nanoparticle based SARS-CoV-2 RBD vaccine and the antibody response was monitored for at least 7 months post-immunization. The results showed that the vaccine induced a persistent antibody response and significant maintenance of memory B cells, as well as a higher level of recall response upon antigen challenge. These findings suggest that the vaccine induces long-term memory in mice.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000190",
    "statement": "Ferritin nanoparticle based sars-cov-2 rbd vaccine induces persistent antibody response and long-term memory in humans.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Thus, we believe our current study provide the first information about the long-term antibody persistence and memory response of a COVID-19 vaccine.",
      "Here, we report that a ferritin nanoparticle based SARS-CoV-2 RBD vaccine induced in mice an efficient antibody response which lasts for at least 7 months post immunization.",
      "Significantly higher number of memory B cells were maintained and a significantly higher level of recall response was induced upon antigen challenge."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided in the form of the study results demonstrates that the ferritin nanoparticle-based SARS-CoV-2 RBD vaccine induces a persistent antibody response lasting at least 7 months post immunization in mice. Additionally, the evidence shows an increased number of memory B cells and a higher level of recall response upon antigen challenge.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000191",
    "statement": "Ferritin nanoparticle based sars-cov-2 rbd vaccine induces persistent antibody response and long-term memory in rabbits.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Thus, we believe our current study provide the first information about the long-term antibody persistence and memory response of a COVID-19 vaccine.",
      "Here, we report that a ferritin nanoparticle based SARS-CoV-2 RBD vaccine induced in mice an efficient antibody response which lasts for at least 7 months post immunization.",
      "Significantly higher number of memory B cells were maintained and a significantly higher level of recall response was induced upon antigen challenge."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided in the form of a scientific study describes the development of a ferritin nanoparticle based SARS-CoV-2 RBD vaccine and reports that it induced an efficient antibody response lasting for at least 7 months post immunization in mice. Additionally, it mentions that significantly higher numbers of memory B cells were maintained and a significantly higher level of recall response was observed upon antigen challenge. While the study was conducted on mice, the findings suggest a potential for long-term antibody persistence and memory response in the context of COVID-19 vaccines.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000192",
    "statement": "Ferritin nanoparticle based sars-cov-2 rbd vaccine cans persistent antibody response and long-term memory in mice.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Thus, we believe our current study provide the first information about the long-term antibody persistence and memory response of a COVID-19 vaccine.",
      "Here, we report that a ferritin nanoparticle based SARS-CoV-2 RBD vaccine induced in mice an efficient antibody response which lasts for at least 7 months post immunization.",
      "Significantly higher number of memory B cells were maintained and a significantly higher level of recall response was induced upon antigen challenge."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided in the statement directly supports that the ferritin nanoparticle based SARS-CoV-2 RBD vaccine can induce a persistent antibody response and long-term memory in mice as reported by the study.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000193",
    "statement": "Hydroxychloroquine fails to prevent covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "The additional data we have today provides strong evidence that hydroxychloroquine offers no benefit in preventing people developing COVID-19 with a 14-day treatment course. The results were first presented at IDWeek 2020, the Infectious Disease Society of America's annual scientific meeting, Saturday, Oct. 24.",
      "People who have had close contact with people with confirmed COVID-19 infections who took hydroxychloroquine were just as likely to get COVID-19 as were those who received a placebo, according to a preliminary data analysis from a large randomized, controlled trial.",
      "Media Contact: Susan Gregg - sghanson@uw.edu, 206.390.3226 Getty Images A careful look at hydroxychloroquine finds it ineffective in protecting exposed people from contracting COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence presented states that a large randomized, controlled trial found no benefit of hydroxychloroquine in preventing COVID-19 when taken for a 14-day treatment course. The participants who took hydroxychloroquine were just as likely to get COVID-19 as those who received a placebo.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000194",
    "statement": "Hydroxychloroquine remains to prevent covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The additional data we have today provides strong evidence that hydroxychloroquine offers no benefit in preventing people developing COVID-19 with a 14-day treatment course. The results were first presented at IDWeek 2020, the Infectious Disease Society of America's annual scientific meeting, Saturday, Oct. 24.",
      "People who have had close contact with people with confirmed COVID-19 infections who took hydroxychloroquine were just as likely to get COVID-19 as were those who received a placebo, according to a preliminary data analysis from a large randomized, controlled trial.",
      "Media Contact: Susan Gregg - sghanson@uw.edu, 206.390.3226 Getty Images A careful look at hydroxychloroquine finds it ineffective in protecting exposed people from contracting COVID-19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence presented suggests that hydroxychloroquine does not offer any benefit in preventing COVID-19 based on a 14-day treatment course from the results of a large randomized, controlled trial.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000195",
    "statement": "Hydroxychloroquine appears to prevent covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The additional data we have today provides strong evidence that hydroxychloroquine offers no benefit in preventing people developing COVID-19 with a 14-day treatment course. The results were first presented at IDWeek 2020, the Infectious Disease Society of America's annual scientific meeting, Saturday, Oct. 24.",
      "People who have had close contact with people with confirmed COVID-19 infections who took hydroxychloroquine were just as likely to get COVID-19 as were those who received a placebo, according to a preliminary data analysis from a large randomized, controlled trial.",
      "Media Contact: Susan Gregg - sghanson@uw.edu, 206.390.3226 Getty Images A careful look at hydroxychloroquine finds it ineffective in protecting exposed people from contracting COVID-19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence suggests that hydroxychloroquine does not offer any benefit in preventing people from developing COVID-19. The claim 'Hydroxychloroquine appears to prevent covid-19' is contradicted by the presented data.",
    "confidence": 0.98
  },
  {
    "id": "covid_fact-000196",
    "statement": "Hydroxychloroquine is to prevent covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The additional data we have today provides strong evidence that hydroxychloroquine offers no benefit in preventing people developing COVID-19 with a 14-day treatment course. The results were first presented at IDWeek 2020, the Infectious Disease Society of America's annual scientific meeting, Saturday, Oct. 24.",
      "People who have had close contact with people with confirmed COVID-19 infections who took hydroxychloroquine were just as likely to get COVID-19 as were those who received a placebo, according to a preliminary data analysis from a large randomized, controlled trial.",
      "Media Contact: Susan Gregg - sghanson@uw.edu, 206.390.3226 Getty Images A careful look at hydroxychloroquine finds it ineffective in protecting exposed people from contracting COVID-19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided indicates that hydroxychloroquine does not offer a benefit in preventing people from developing COVID-19 after exposure to the virus. However, this does not imply that it can be used to treat or cure COVID-19, which is what 'Hydroxychloroquine is to prevent covid-19' claim states.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000197",
    "statement": "Transmission of sars-cov-2 in domestic cats imposes a narrow bottleneck.",
    "label": "SUPPORTED",
    "evidences": [
      "SARS-CoV-2 transmission is defined by a narrow bottleneck.",
      "Transmission of SARS-CoV-2 in cats involved a narrow bottleneck, with new infections founded by fewer than ten viruses.",
      "While estimates of the size of the SARS- CoV-2 transmission bottleneck remain highly discordant in humans, we find very narrow transmission bottlenecks in cats, involving transmission of only 2-5 viruses."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that the transmission of SARS-CoV-2 in domestic cats is characterized by a narrow bottleneck, with new infections founded by fewer than ten viruses.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000198",
    "statement": "Transmission of sars-cov-2 in domestic cats imposes a global bottleneck.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "SARS-CoV-2 transmission is defined by a narrow bottleneck.",
      "Transmission of SARS-CoV-2 in cats involved a narrow bottleneck, with new infections founded by fewer than ten viruses.",
      "While estimates of the size of the SARS- CoV-2 transmission bottleneck remain highly discordant in humans, we find very narrow transmission bottlenecks in cats, involving transmission of only 2-5 viruses."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided discusses the transmission bottleneck of SARS-CoV-2 in cats, but it does not directly state or imply that this bottleneck imposes a global bottleneck for human transmission of the virus.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000199",
    "statement": "Transmission of sars-cov-2 in domestic cats imposes a major bottleneck.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "SARS-CoV-2 transmission is defined by a narrow bottleneck.",
      "Transmission of SARS-CoV-2 in cats involved a narrow bottleneck, with new infections founded by fewer than ten viruses.",
      "While estimates of the size of the SARS- CoV-2 transmission bottleneck remain highly discordant in humans, we find very narrow transmission bottlenecks in cats, involving transmission of only 2-5 viruses."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests that the transmission of SARS-CoV-2 in domestic cats involves a narrow bottleneck, with new infections founded by fewer than ten viruses. This aligns with the claim that transmission of SARS-CoV-2 in domestic cats imposes a major bottleneck.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000200",
    "statement": "Transmission of sars-cov-2 in domestic cats imposes a common bottleneck.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "SARS-CoV-2 transmission is defined by a narrow bottleneck.",
      "Transmission of SARS-CoV-2 in cats involved a narrow bottleneck, with new infections founded by fewer than ten viruses.",
      "While estimates of the size of the SARS- CoV-2 transmission bottleneck remain highly discordant in humans, we find very narrow transmission bottlenecks in cats, involving transmission of only 2-5 viruses."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly indicates that the transmission of SARS-CoV-2 in domestic cats involves a narrow bottleneck with few viruses involved in new infections. This aligns with the claim made.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000201",
    "statement": "California state epidemiologist statement recommending providers pause administration of single lot of moderna covid-19 vaccine.",
    "label": "SUPPORTED",
    "evidences": [
      "California state epidemiologist Dr. Erica Pan issued a statement Sunday recommending providers pause the administration of lot 041L20A of the Moderna COVID-19 vaccine due to possible allergic reactions that are being investigated.",
      "Updated: 10:06 PM PST Jan 18, 2021 KCRA Staff UPDATE: Pause lifted on batch of Moderna COVID-19 vaccines, health officials sayORIGINAL STORY: California's top epidemiologist has asked providers to stop giving shots from a batch of the Moderna COVID-19 vaccine as the state investigates reports of allergic reactions.",
      "SACRAMENTO, Calif. -- UPDATE: Pause lifted on batch of Moderna COVID-19 vaccines, health officials say Advertisement ORIGINAL STORY: California's top epidemiologist has asked providers to stop giving shots from a batch of the Moderna COVID-19 vaccine as the state investigates reports of allergic reactions."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that California's top epidemiologist Dr. Erica Pan recommended providers to pause the administration of a specific lot (041L20A) of Moderna COVID-19 vaccine due to possible allergic reactions being investigated.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000202",
    "statement": "California state epidemiologist statement recommending providers include administration of single lot of moderna covid-19 vaccine.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "California state epidemiologist Dr. Erica Pan issued a statement Sunday recommending providers pause the administration of lot 041L20A of the Moderna COVID-19 vaccine due to possible allergic reactions that are being investigated.",
      "Updated: 10:06 PM PST Jan 18, 2021 KCRA Staff UPDATE: Pause lifted on batch of Moderna COVID-19 vaccines, health officials sayORIGINAL STORY: California's top epidemiologist has asked providers to stop giving shots from a batch of the Moderna COVID-19 vaccine as the state investigates reports of allergic reactions.",
      "SACRAMENTO, Calif. -- UPDATE: Pause lifted on batch of Moderna COVID-19 vaccines, health officials say Advertisement ORIGINAL STORY: California's top epidemiologist has asked providers to stop giving shots from a batch of the Moderna COVID-19 vaccine as the state investigates reports of allergic reactions."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided states that California's top epidemiologist Dr. Erica Pan recommended providers to pause the administration of a specific lot (041L20A) of Moderna COVID-19 vaccine due to possible allergic reactions being investigated. This directly supports the claim.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000203",
    "statement": "Baricitinib restrains the immune dysregulation in covid-19 patients",
    "label": "SUPPORTED",
    "evidences": [
      "Here, we provide evidences on the efficacy of baricitinib, a JAK1/JAK2 inhibitor, in correcting the immune abnormalities observed in patients hospitalized with COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided directly states that baricitinib, a JAK1/JAK2 inhibitor, is effective in correcting immune abnormalities observed in patients hospitalized with COVID-19.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000204",
    "statement": "Uncitinib restrains the immune dysregulation in covid-19 patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Here, we provide evidences on the efficacy of baricitinib, a JAK1/JAK2 inhibitor, in correcting the immune abnormalities observed in patients hospitalized with COVID-19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided discusses the efficacy of baricitinib (a JAK1/JAK2 inhibitor) in correcting immune abnormalities observed in COVID-19 patients. However, it does not explicitly mention or prove that Uncitinib has the same effect.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000205",
    "statement": "Excitinib restrains the immune dysregulation in covid-19 patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Here, we provide evidences on the efficacy of baricitinib, a JAK1/JAK2 inhibitor, in correcting the immune abnormalities observed in patients hospitalized with COVID-19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided only supports the efficacy of baricitinib (a JAK1/JAK2 inhibitor) in correcting immune abnormalities observed in COVID-19 patients, not Excitinib.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000206",
    "statement": "Us covid-19 deaths poorly predicted by ihme model",
    "label": "SUPPORTED",
    "evidences": [
      "Seventy percent of US states had an actual death rate outside the 95 percent prediction interval for that state, casting doubt on whether the model is suitable to inform COVID-19 resource allocation.",
      "Credit: Pixabay An international group of renowned statisticians from the University of Sydney, Northwestern University and the University of Texas have collaborated to fully investigate the predictive performance of the COVID-19 model developed by Institute for Health Metrics and Evaluation (IHME)  which provides forecasts for ventilator use and hospital beds in the United States.",
      "I am concerned that if the UW-IHME model has had difficulty in predicting the next day, how will the predictions fair over the long term, said Professor Tanner.",
      "Published on pre-publication server arXiv, the researchers found that the IHME model substantially underestimates the uncertainty associated with COVID-19 deaths."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that a substantial number of US states had actual death rates outside the 95 percent prediction interval provided by the IHME model, which suggests poor prediction accuracy for COVID-19 deaths in those states. The researchers' findings also imply that the IHME model underestimates the uncertainty associated with COVID-19 deaths.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000207",
    "statement": "Us covid-19 deaths as predicted by ihme model",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Seventy percent of US states had an actual death rate outside the 95 percent prediction interval for that state, casting doubt on whether the model is suitable to inform COVID-19 resource allocation.",
      "Credit: Pixabay An international group of renowned statisticians from the University of Sydney, Northwestern University and the University of Texas have collaborated to fully investigate the predictive performance of the COVID-19 model developed by Institute for Health Metrics and Evaluation (IHME)  which provides forecasts for ventilator use and hospital beds in the United States.",
      "I am concerned that if the UW-IHME model has had difficulty in predicting the next day, how will the predictions fair over the long term, said Professor Tanner.",
      "Published on pre-publication server arXiv, the researchers found that the IHME model substantially underestimates the uncertainty associated with COVID-19 deaths."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not directly support a prediction of COVID-19 deaths in the United States. Instead, it suggests that the IHME model has underestimated the uncertainty associated with COVID-19 deaths. This does not necessarily mean that the predictions made by the IHME model for COVID-19 deaths are incorrect.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000208",
    "statement": "Us covid-19 deaths previously predicted by ihme model",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Seventy percent of US states had an actual death rate outside the 95 percent prediction interval for that state, casting doubt on whether the model is suitable to inform COVID-19 resource allocation.",
      "Credit: Pixabay An international group of renowned statisticians from the University of Sydney, Northwestern University and the University of Texas have collaborated to fully investigate the predictive performance of the COVID-19 model developed by Institute for Health Metrics and Evaluation (IHME)  which provides forecasts for ventilator use and hospital beds in the United States.",
      "I am concerned that if the UW-IHME model has had difficulty in predicting the next day, how will the predictions fair over the long term, said Professor Tanner.",
      "Published on pre-publication server arXiv, the researchers found that the IHME model substantially underestimates the uncertainty associated with COVID-19 deaths."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not directly show that the US COVID-19 deaths previously predicted by the IHME model are incorrect. Instead, it states that 70% of US states had an actual death rate outside the 95 percent prediction interval for that state, which suggests a lack of precision in the model's predictions. However, this does not necessarily imply errors in the overall deaths predicted by the model.",
    "confidence": 0.85
  },
  {
    "id": "covid_fact-000209",
    "statement": "Us covid-19 deaths were predicted by ihme model",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Seventy percent of US states had an actual death rate outside the 95 percent prediction interval for that state, casting doubt on whether the model is suitable to inform COVID-19 resource allocation.",
      "Credit: Pixabay An international group of renowned statisticians from the University of Sydney, Northwestern University and the University of Texas have collaborated to fully investigate the predictive performance of the COVID-19 model developed by Institute for Health Metrics and Evaluation (IHME)  which provides forecasts for ventilator use and hospital beds in the United States.",
      "I am concerned that if the UW-IHME model has had difficulty in predicting the next day, how will the predictions fair over the long term, said Professor Tanner.",
      "Published on pre-publication server arXiv, the researchers found that the IHME model substantially underestimates the uncertainty associated with COVID-19 deaths."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that the IHME model substantially underestimates the uncertainty associated with COVID-19 deaths and seventy percent of US states had an actual death rate outside the 95 percent prediction interval for that state. This suggests that the IHME model's predictions for COVID-19 deaths in the US were not accurate, casting doubt on its ability to inform resource allocation.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000210",
    "statement": "China 's changing coronavirus case count is not unusual in an outbreak , health official says",
    "label": "SUPPORTED",
    "evidences": [
      "Its not unusual to count things in different ways as the epidemic evolves, said Sylvie Briand, WHO director of the infectious hazards management department.",
      "Confusion over how China is counting cases of infections is making it harder to know how coronavirus is spreading, even as China is officially reporting that the numbers of new cases reported in recent days have fallen sharply.",
      "\"Its not unusual to count things in different ways as the epidemic evolves, said Sylvie Briand, WHO director of the infectious hazards management department.\"",
      "Asked by reporters about the potential impact of the coronavirus on the economy and whether he anticipates it being similar to the effect of SARS, Kudlow said, I understand the risks, and I understand these things could change quickly, but right now what we know is theres barely any impact here at home. \"The human toll in my opinion is more important than the statistics [Chinas] getting hurt very badly, he added. \""
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "While the statement by Sylvie Briand suggests that it is not unusual to count things in different ways as an outbreak evolves, this does not necessarily mean that China's changing coronavirus case count is not unusual. The statement provides no direct evidence supporting or contradicting this claim.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000211",
    "statement": "China's changing coronavirus case count is not available in an outbreak, health official says",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Its not unusual to count things in different ways as the epidemic evolves, said Sylvie Briand, WHO director of the infectious hazards management department.",
      "Confusion over how China is counting cases of infections is making it harder to know how coronavirus is spreading, even as China is officially reporting that the numbers of new cases reported in recent days have fallen sharply.",
      "\"Its not unusual to count things in different ways as the epidemic evolves, said Sylvie Briand, WHO director of the infectious hazards management department.\"",
      "Asked by reporters about the potential impact of the coronavirus on the economy and whether he anticipates it being similar to the effect of SARS, Kudlow said, I understand the risks, and I understand these things could change quickly, but right now what we know is theres barely any impact here at home. \"The human toll in my opinion is more important than the statistics [Chinas] getting hurt very badly, he added. \""
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim is about China's changing coronavirus case count being not available in an outbreak and this statement does not directly address the availability of the data, but rather discusses inconsistencies in how the data is counted. The WHO official's statement indicates that there is confusion in counting methods, making it harder to know the true extent of the epidemic.",
    "confidence": 0.6
  },
  {
    "id": "covid_fact-000212",
    "statement": "China's changing coronavirus case count is very unusual in an outbreak, health official says",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Its not unusual to count things in different ways as the epidemic evolves, said Sylvie Briand, WHO director of the infectious hazards management department.",
      "Confusion over how China is counting cases of infections is making it harder to know how coronavirus is spreading, even as China is officially reporting that the numbers of new cases reported in recent days have fallen sharply.",
      "\"Its not unusual to count things in different ways as the epidemic evolves, said Sylvie Briand, WHO director of the infectious hazards management department.\"",
      "Asked by reporters about the potential impact of the coronavirus on the economy and whether he anticipates it being similar to the effect of SARS, Kudlow said, I understand the risks, and I understand these things could change quickly, but right now what we know is theres barely any impact here at home. \"The human toll in my opinion is more important than the statistics [Chinas] getting hurt very badly, he added. \""
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The statement provided does not explicitly state that China's changing coronavirus case count is unusual in an outbreak. Instead, it suggests that there may be confusion about how the cases are being counted, which is a common issue during an epidemic as methods often evolve over time. However, the statement does not provide clear evidence to definitively conclude that the changing case count is or isn't unusual.",
    "confidence": 0.5
  },
  {
    "id": "covid_fact-000213",
    "statement": "China's changing coronavirus case count is particularly unusual in an outbreak, health official says",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Its not unusual to count things in different ways as the epidemic evolves, said Sylvie Briand, WHO director of the infectious hazards management department.",
      "Confusion over how China is counting cases of infections is making it harder to know how coronavirus is spreading, even as China is officially reporting that the numbers of new cases reported in recent days have fallen sharply.",
      "\"Its not unusual to count things in different ways as the epidemic evolves, said Sylvie Briand, WHO director of the infectious hazards management department.\"",
      "Asked by reporters about the potential impact of the coronavirus on the economy and whether he anticipates it being similar to the effect of SARS, Kudlow said, I understand the risks, and I understand these things could change quickly, but right now what we know is theres barely any impact here at home. \"The human toll in my opinion is more important than the statistics [Chinas] getting hurt very badly, he added. \""
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not directly state that China's changing coronavirus case count is particularly unusual in an outbreak. Instead, it suggests that different methods for counting cases are common as an epidemic evolves, which does not necessarily imply an unusual change in the case count.",
    "confidence": 0.65
  },
  {
    "id": "covid_fact-000214",
    "statement": "Results released for antibody and covid-19 testing of boston residents",
    "label": "SUPPORTED",
    "evidences": [
      "Mayor Martin J. Walsh, together with Massachusetts General Hospital (MGH), and the Boston Public Health Commission (BPHC), today announced the study to evaluate community exposure to COVID-19 through a representative sampling of asymptomatic Boston residents resulted in 9.9% testing positive for antibodies and 2.6% of currently asymptomatic individuals testing positive for COVID-19.",
      "In conclusion, approximately 1 in 10 residents in this study have developed antibodies and approximately 1 in 40 currently asymptomatic individuals are positive for COVID-19 and potentially infectious."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided mentions the results of antibody and covid-19 testing of Boston residents, and specifically states that 9.9% tested positive for antibodies and 2.6% of currently asymptomatic individuals tested positive for COVID-19.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000215",
    "statement": "Results released for antibody and covid-19 production of boston residents",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Mayor Martin J. Walsh, together with Massachusetts General Hospital (MGH), and the Boston Public Health Commission (BPHC), today announced the study to evaluate community exposure to COVID-19 through a representative sampling of asymptomatic Boston residents resulted in 9.9% testing positive for antibodies and 2.6% of currently asymptomatic individuals testing positive for COVID-19.",
      "In conclusion, approximately 1 in 10 residents in this study have developed antibodies and approximately 1 in 40 currently asymptomatic individuals are positive for COVID-19 and potentially infectious."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that a study was conducted on a representative sampling of asymptomatic Boston residents for antibodies related to COVID-19. The results showed that approximately 1 in 10 residents tested positive for antibodies and about 1 in 40 currently asymptomatic individuals tested positive for COVID-19. This supports the claim that the results for antibody and COVID-19 production of Boston residents were released.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000216",
    "statement": "Vulnerable populations , such as older adults and those with underlying medical conditions , should wear face masks if available .",
    "label": "SUPPORTED",
    "evidences": [
      "Wearing a face covering can help to reduce the chance that those who may not know they are sick will spread the infection to others.",
      "Perhaps it would also be rational to recommend that people in quarantine wear face masks if they need to leave home for any reason, to prevent potential asymptomatic or presymptomatic transmission."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that wearing face masks can help reduce the chance of spreading infection, particularly for those who may not know they are sick. This recommendation is especially relevant for vulnerable populations such as older adults and those with underlying medical conditions due to their increased risk from COVID-19.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000217",
    "statement": "Vulnerable populations, such as older adults and those with underlying medical conditions, not wear face masks if available.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Wearing a face covering can help to reduce the chance that those who may not know they are sick will spread the infection to others.",
      "Perhaps it would also be rational to recommend that people in quarantine wear face masks if they need to leave home for any reason, to prevent potential asymptomatic or presymptomatic transmission."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim is about vulnerable populations not wearing face masks if available, while the evidence provided suggests that wearing a face covering can help reduce the chance of spreading infection to others, and it may also be rational for people in quarantine to wear face masks when leaving home to prevent potential asymptomatic or presymptomatic transmission. The claim is contradictory to the evidence as it suggests not wearing masks in situations where the evidence indicates they should be worn.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000218",
    "statement": "The differing immune system responses of patients with covid-19 can help predict who will experience moderate and severe consequences of disease , according to a new study",
    "label": "SUPPORTED",
    "evidences": [
      "Tables show the immune parameters that have been reported to differ between mild and severe COVID-19.",
      "(Express Photo: Amit Chakravarty) A new study suggests that the differing immune system responses of Covid-19 patients can help predict who will experience moderate and severe consequences of disease.",
      "The findings may help identify individuals at high risk of severe illness early in their hospitalization and suggest drugs to treat COVID-19.",
      "More carefully defining distinct classes of T cell response types in COVID-19 and delineating how pre-existing conditions, co-morbidities, race, immune health status and other variables influence T cell responses should reveal novel opportunities for treatment and prevention."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence in the form of a study suggests that there are differences in immune system responses between mild and severe COVID-19 cases. This implies that by analyzing these responses, it might be possible to predict the severity of disease for individual patients.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000219",
    "statement": "The differing immune system responses of patients with covid-19 cannot help predict who will experience moderate and severe consequences of disease, according to a new study",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Tables show the immune parameters that have been reported to differ between mild and severe COVID-19.",
      "(Express Photo: Amit Chakravarty) A new study suggests that the differing immune system responses of Covid-19 patients can help predict who will experience moderate and severe consequences of disease.",
      "The findings may help identify individuals at high risk of severe illness early in their hospitalization and suggest drugs to treat COVID-19.",
      "More carefully defining distinct classes of T cell response types in COVID-19 and delineating how pre-existing conditions, co-morbidities, race, immune health status and other variables influence T cell responses should reveal novel opportunities for treatment and prevention."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided in this case is a description of a new study suggesting that the differing immune system responses of Covid-19 patients can help predict who will experience moderate and severe consequences of disease. However, the provided data (tables showing the immune parameters) does not show any correlation or clear pattern between these immune parameters and the severity of the disease. To verify this claim, one would need more concrete data demonstrating a correlation between specific immune system responses and disease severity in Covid-19 patients.",
    "confidence": 0.85
  },
  {
    "id": "covid_fact-000220",
    "statement": "The differing immune system responses of patients with covid-19 can help predict who will experience moderate and severe consequences of disease, according to a previous study",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Tables show the immune parameters that have been reported to differ between mild and severe COVID-19.",
      "(Express Photo: Amit Chakravarty) A new study suggests that the differing immune system responses of Covid-19 patients can help predict who will experience moderate and severe consequences of disease.",
      "The findings may help identify individuals at high risk of severe illness early in their hospitalization and suggest drugs to treat COVID-19.",
      "More carefully defining distinct classes of T cell response types in COVID-19 and delineating how pre-existing conditions, co-morbidities, race, immune health status and other variables influence T cell responses should reveal novel opportunities for treatment and prevention."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that the study suggests a correlation between varying immune system responses in Covid-19 patients and their experience of moderate to severe consequences of the disease. This claim is supported by the information presented.",
    "confidence": 0.85
  },
  {
    "id": "covid_fact-000221",
    "statement": "Father with motor neurone disease dies from coronavirus in uk",
    "label": "SUPPORTED",
    "evidences": [
      "Wednesday 18 March 2020 09:36, UK COVID-19 Coronavirus Image: Craig Ruston was battling motor neurone disease."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not confirm or deny the claim that a specific individual with motor neurone disease died from coronavirus in the UK. The evidence only establishes that an individual named Craig Ruston was battling motor neurone disease.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000222",
    "statement": "Father with motor neurone disease originated from coronavirus in uk",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Wednesday 18 March 2020 09:36, UK COVID-19 Coronavirus Image: Craig Ruston was battling motor neurone disease."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not indicate that the individual with motor neurone disease originated from coronavirus in the UK.",
    "confidence": 0.05
  },
  {
    "id": "covid_fact-000223",
    "statement": "Father with motor neurone disease differs from coronavirus in uk",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Wednesday 18 March 2020 09:36, UK COVID-19 Coronavirus Image: Craig Ruston was battling motor neurone disease."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not indicate a difference between a father with motor neurone disease and coronavirus in the UK. The evidence only mentions a man named Craig Ruston who had motor neurone disease, but there is no mention of him having coronavirus or any comparison being made.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000224",
    "statement": "Yale 's rapid covid-19 saliva test receives fda emergency use authorization",
    "label": "SUPPORTED",
    "evidences": [
      "Stat: FDA Clears Saliva Test For Covid-19, Opening Door To Wider Testing The Food and Drug Administration on Saturday authorized emergency use of a new and inexpensive saliva test for Covid-19 that could greatly expand testing capacity.",
      "A new saliva-based laboratory diagnostic test for the novel coronavirus developed by researchers at Yale University's School of Public Health has been granted an emergency use authorization by the Food and Drug Administration.",
      "While FDA has seen variable performance in tests using saliva, Yale School of Public Health submitted data with its EUA request from which the FDA determined that Yales test meets the criteria for emergency authorization when used to test saliva samples for SARS-CoV-2, the virus that causes COVID-19 infection.",
      "NEW HAVEN, Conn. \\- A new saliva-based laboratory diagnostic test for the novel coronavirus developed by researchers at Yale University's School of Public Health has been granted an emergency use authorization by the Food and Drug Administration.",
      "Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization to Yale School of Public Health for SalivaDirect, Which Uses a New Method of Saliva Sample Processing 1."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided states that the Food and Drug Administration has granted emergency use authorization to a new saliva-based laboratory diagnostic test for Covid-19 developed by researchers at Yale University's School of Public Health. Therefore, it is supported that Yale's rapid covid-19 saliva test receives FDA emergency use authorization.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000225",
    "statement": "Yale's rapid covid-19 saliva test without fda emergency use authorization",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Stat: FDA Clears Saliva Test For Covid-19, Opening Door To Wider Testing The Food and Drug Administration on Saturday authorized emergency use of a new and inexpensive saliva test for Covid-19 that could greatly expand testing capacity.",
      "A new saliva-based laboratory diagnostic test for the novel coronavirus developed by researchers at Yale University's School of Public Health has been granted an emergency use authorization by the Food and Drug Administration.",
      "While FDA has seen variable performance in tests using saliva, Yale School of Public Health submitted data with its EUA request from which the FDA determined that Yales test meets the criteria for emergency authorization when used to test saliva samples for SARS-CoV-2, the virus that causes COVID-19 infection.",
      "NEW HAVEN, Conn. \\- A new saliva-based laboratory diagnostic test for the novel coronavirus developed by researchers at Yale University's School of Public Health has been granted an emergency use authorization by the Food and Drug Administration.",
      "Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization to Yale School of Public Health for SalivaDirect, Which Uses a New Method of Saliva Sample Processing 1."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided clearly states that the Food and Drug Administration (FDA) has granted emergency use authorization for a new saliva test for COVID-19 developed by researchers at Yale University's School of Public Health. This directly supports the claim that Yale has a rapid covid-19 saliva test without FDA emergency use authorization.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000226",
    "statement": "The antiviral compound remdesivir potently inhibits rna-dependent rna polymerase from middle east respiratory syndrome coronavirus",
    "label": "SUPPORTED",
    "evidences": [
      "Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase.",
      "Remdesivir (RDV) is an investigational compound with a broad spectrum of antiviral activities against RNA viruses, including severe acute respiratory syndrome-CoV and Middle East respiratory syndrome (MERS-CoV)."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that remdesivir inhibits human endemic and zoonotic deltacoronaviruses, which includes MERS-CoV. As MERS-CoV RNA dependent RNA polymerase is a component of the virus, if remdesivir inhibits this virus it can also be said to potently inhibit rna-dependent rna polymerase from Middle East respiratory syndrome coronavirus.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000227",
    "statement": "The antiviral compound remdesivir potently binds rna-dependent rna polymerase from middle east respiratory syndrome coronavirus",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase.",
      "Remdesivir (RDV) is an investigational compound with a broad spectrum of antiviral activities against RNA viruses, including severe acute respiratory syndrome-CoV and Middle East respiratory syndrome (MERS-CoV)."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence indicates that remdesivir has been shown to inhibit the RNA dependent RNA polymerase from MERS-CoV, which is a type of coronavirus. This directly supports the claim that the antiviral compound remdesivir potently binds rna-dependent rna polymerase from middle east respiratory syndrome coronavirus.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000228",
    "statement": "Trials of oxford coronavirus vaccine begin in kenya",
    "label": "SUPPORTED",
    "evidences": [
      "Following the necessary approvals from regulators, as well as the national ministry of health, and Kilifi county, the first volunteers for the trial have recently received their vaccinations.",
      "The trial in Kenya will initially involve 40 frontline workers in Kilifi County.",
      "Professor Andy Pollard, Director of the Oxford Vaccine Group and Chief Investigator of the Oxford Vaccine Trial, said: Were excited to see our colleagues in Kenya today joining those around the world in helping us to evaluate the ChAdOx1 nCov-2019 Oxford coronavirus vaccine, as it is important to evaluate the vaccine in as many different populations as possible. Kenya joins a number of countries including the United Kingdom, South Africa and Brazil who are running trials to evaluate the ChAdOx1 nCoV-19 vaccine, with over 20,000 volunteers now taking part in trials across these countries."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides clear information that the trials for the Oxford coronavirus vaccine have begun in Kenya, as stated by Professor Andy Pollard, Director of the Oxford Vaccine Group. The trial is specifically mentioned and the number of initial volunteers (40 frontline workers) is given.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000229",
    "statement": "Lack of oxford coronavirus vaccine begin in kenya",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Following the necessary approvals from regulators, as well as the national ministry of health, and Kilifi county, the first volunteers for the trial have recently received their vaccinations.",
      "The trial in Kenya will initially involve 40 frontline workers in Kilifi County.",
      "Professor Andy Pollard, Director of the Oxford Vaccine Group and Chief Investigator of the Oxford Vaccine Trial, said: Were excited to see our colleagues in Kenya today joining those around the world in helping us to evaluate the ChAdOx1 nCov-2019 Oxford coronavirus vaccine, as it is important to evaluate the vaccine in as many different populations as possible. Kenya joins a number of countries including the United Kingdom, South Africa and Brazil who are running trials to evaluate the ChAdOx1 nCoV-19 vaccine, with over 20,000 volunteers now taking part in trials across these countries."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that the Oxford coronavirus vaccine trial is beginning in Kenya. The trial involves 40 frontline workers in Kilifi County and Professor Andy Pollard, Director of the Oxford Vaccine Group, has confirmed this. Additionally, the trial in Kenya joins other trials taking place in multiple countries for the same vaccine.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000230",
    "statement": "Trials of oxford coronavirus vaccine begin in great",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Following the necessary approvals from regulators, as well as the national ministry of health, and Kilifi county, the first volunteers for the trial have recently received their vaccinations.",
      "The trial in Kenya will initially involve 40 frontline workers in Kilifi County.",
      "Professor Andy Pollard, Director of the Oxford Vaccine Group and Chief Investigator of the Oxford Vaccine Trial, said: Were excited to see our colleagues in Kenya today joining those around the world in helping us to evaluate the ChAdOx1 nCov-2019 Oxford coronavirus vaccine, as it is important to evaluate the vaccine in as many different populations as possible. Kenya joins a number of countries including the United Kingdom, South Africa and Brazil who are running trials to evaluate the ChAdOx1 nCoV-19 vaccine, with over 20,000 volunteers now taking part in trials across these countries."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly indicates that the Trials of Oxford coronavirus vaccine are beginning in Great Britain and other countries such as Kenya, as stated by Professor Andy Pollard, Director of the Oxford Vaccine Group and Chief Investigator of the Oxford Vaccine Trial. The trial in Kenya is specifically mentioned, with volunteers receiving vaccinations.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000231",
    "statement": "Pandemic infection rates are deterministic but can not be modeled",
    "label": "SUPPORTED",
    "evidences": [
      "Model predictions fail because the observed infection rates are beyond modeling: any model that uses fixed rates or uses memory or averages of past rates cannot reproduce the data on active infections.",
      "SUMMARYREFERENCES The pandemic infection rates to two to three decimal places are an example of complexity: the infection rates can be calculated daily from the infections but they cannot be modeled and predicted from fixed initial conditions.",
      "Second, model building does not and cannot reflect real epidemic data because the only correct rates emerge day by day in the daily data, cannot be usefully forecast for more than a few days in advance, and cannot be forecast at all correctly near a peak."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided suggests that it is challenging to accurately model pandemic infection rates due to their complexity and unpredictability. However, the statement 'Pandemic infection rates are deterministic but can not be modeled' is contradictory as deterministic systems, by definition, can be modeled.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000232",
    "statement": "Pandemic infection rates are deterministic but can then be modeled",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Model predictions fail because the observed infection rates are beyond modeling: any model that uses fixed rates or uses memory or averages of past rates cannot reproduce the data on active infections.",
      "SUMMARYREFERENCES The pandemic infection rates to two to three decimal places are an example of complexity: the infection rates can be calculated daily from the infections but they cannot be modeled and predicted from fixed initial conditions.",
      "Second, model building does not and cannot reflect real epidemic data because the only correct rates emerge day by day in the daily data, cannot be usefully forecast for more than a few days in advance, and cannot be forecast at all correctly near a peak."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim states that pandemic infection rates are deterministic but can then be modeled. The evidence indicates that while the infection rates can be calculated from the data, they cannot be predicted with accuracy or certainty using models due to their complexity and unpredictability, particularly near a peak.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000233",
    "statement": "Pandemic infection rates are deterministic but can therefore be modeled",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Model predictions fail because the observed infection rates are beyond modeling: any model that uses fixed rates or uses memory or averages of past rates cannot reproduce the data on active infections.",
      "SUMMARYREFERENCES The pandemic infection rates to two to three decimal places are an example of complexity: the infection rates can be calculated daily from the infections but they cannot be modeled and predicted from fixed initial conditions.",
      "Second, model building does not and cannot reflect real epidemic data because the only correct rates emerge day by day in the daily data, cannot be usefully forecast for more than a few days in advance, and cannot be forecast at all correctly near a peak."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim states that pandemic infection rates are deterministic but cannot be modeled due to their complexity and unpredictability. The evidence supports this by stating that model predictions fail because the observed infection rates are beyond modeling and that model building does not reflect real epidemic data accurately, especially near a peak.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000234",
    "statement": "Pandemic infection rates are deterministic but can also be modeled",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Model predictions fail because the observed infection rates are beyond modeling: any model that uses fixed rates or uses memory or averages of past rates cannot reproduce the data on active infections.",
      "SUMMARYREFERENCES The pandemic infection rates to two to three decimal places are an example of complexity: the infection rates can be calculated daily from the infections but they cannot be modeled and predicted from fixed initial conditions.",
      "Second, model building does not and cannot reflect real epidemic data because the only correct rates emerge day by day in the daily data, cannot be usefully forecast for more than a few days in advance, and cannot be forecast at all correctly near a peak."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that while pandemic infection rates can be calculated daily from the infections, they are not predictable or modelable using fixed initial conditions or memories/averages of past rates. This suggests that while the rates can be considered deterministic (i.e., they can be calculated based on the available data), they exhibit complex and unpredictable behavior over time, making them difficult to model accurately.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000235",
    "statement": "New coronavirus variant is identified in uk.",
    "label": "SUPPORTED",
    "evidences": [
      "England's Chief Medical Officer Prof Chris Whitty said current coronavirus swab tests would detect the new variant that has been found predominantly in Kent and neighbouring areas in recent weeks.",
      "The early landscape of coronavirus disease 2019 vaccine development in the UK and rest of the world.",
      "It is thought the variant either emerged in a patient in the UK or has been imported from a country with a lower ability to monitor coronavirus mutations.",
      "A number of variants have already been detected in the UK.",
      "Matt Hancock said the new variant of coronavirus \"may be associated\" with the faster spread in the south-east of England."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that a new coronavirus variant has been identified predominantly in Kent and neighbouring areas in recent weeks, and England's Chief Medical Officer Prof Chris Whitty confirmed that current coronavirus swab tests would detect this variant. The fact that a number of variants have already been detected in the UK also supports this claim.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000236",
    "statement": "No coronavirus variant is identified in uk.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "England's Chief Medical Officer Prof Chris Whitty said current coronavirus swab tests would detect the new variant that has been found predominantly in Kent and neighbouring areas in recent weeks.",
      "The early landscape of coronavirus disease 2019 vaccine development in the UK and rest of the world.",
      "It is thought the variant either emerged in a patient in the UK or has been imported from a country with a lower ability to monitor coronavirus mutations.",
      "A number of variants have already been detected in the UK.",
      "Matt Hancock said the new variant of coronavirus \"may be associated\" with the faster spread in the south-east of England."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided mentions that a new variant has been found predominantly in Kent and neighbouring areas in recent weeks, but it does not state that no coronavirus variant is identified anywhere within the UK. Furthermore, it also mentions that a number of variants have already been detected in the UK.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000237",
    "statement": "The coronavirus has mutated and appears to be more contagious now , new study finds",
    "label": "SUPPORTED",
    "evidences": [
      "The coronavirus has mutated and May52020 COVID19 KEY POINTS: The coronavirus that emerged in Wuhan, China, has mutated and the new, dominant strain spreading across the U.S. appears to be even more contagious, according to a new study.",
      "If the coronavirus doesnt subside in the summer like the seasonal flu, it could mutate further and potentially limit the effectiveness of the coronavirus vaccines being developed by scientists around the world, the researchers warned.",
      "The coronavirus that emerged in Wuhan, China, over four months ago has since mutated and the new, dominant strain spreading across the U.S. appears to be even more contagious, according to a new study."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim that the coronavirus has mutated and appears to be more contagious now, as stated in the evidence, is supported by the information provided.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000238",
    "statement": "The coronavirus has mutated and appears to be more contagious before, new study finds",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The coronavirus has mutated and May52020 COVID19 KEY POINTS: The coronavirus that emerged in Wuhan, China, has mutated and the new, dominant strain spreading across the U.S. appears to be even more contagious, according to a new study.",
      "If the coronavirus doesnt subside in the summer like the seasonal flu, it could mutate further and potentially limit the effectiveness of the coronavirus vaccines being developed by scientists around the world, the researchers warned.",
      "The coronavirus that emerged in Wuhan, China, over four months ago has since mutated and the new, dominant strain spreading across the U.S. appears to be even more contagious, according to a new study."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided states that the coronavirus has mutated and the new dominant strain spreading across the US appears to be more contagious. This directly supports the claim that the coronavirus has mutated and is more contagious.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000239",
    "statement": "Two known therapies could be useful as adjuvant therapy in critical patients infected by covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "Obviously clinical trials are necessaries, but due to the potential benefit of these two therapies we highly recommended to add to the therapeutic arsenal."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "While the evidence suggests a recommendation for consideration of two potential therapies due to their potential benefit in critical COVID-19 patients, it does not provide direct experimental evidence supporting their effectiveness as adjuvant therapy for COVID-19. Clinical trials are necessary to confirm this claim.",
    "confidence": 0.25
  },
  {
    "id": "covid_fact-000240",
    "statement": "Many known therapies could be useful as adjuvant therapy in critical patients infected by covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Obviously clinical trials are necessaries, but due to the potential benefit of these two therapies we highly recommended to add to the therapeutic arsenal."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim is not directly supported by the provided evidence because it only mentions two therapies as potentially useful without any actual data or studies demonstrating their effectiveness in treating COVID-19. While it may suggest a recommendation for further investigation, it does not provide enough evidence to conclusively support the claim.",
    "confidence": 0.5
  },
  {
    "id": "covid_fact-000241",
    "statement": "Several known therapies could be useful as adjuvant therapy in critical patients infected by covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Obviously clinical trials are necessaries, but due to the potential benefit of these two therapies we highly recommended to add to the therapeutic arsenal."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence suggests a recommendation for further exploration of certain therapies as adjuvant therapy in COVID-19 patients. However, it does not provide any empirical data or results from clinical trials that demonstrate the efficacy of these therapies against COVID-19.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000242",
    "statement": "All known therapies could be useful as adjuvant therapy in critical patients infected by covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Obviously clinical trials are necessaries, but due to the potential benefit of these two therapies we highly recommended to add to the therapeutic arsenal."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not support the claim that all known therapies could be useful as adjuvant therapy in critical patients infected by COVID-19. The text only mentions two specific therapies and highlights their potential benefits but does not provide enough information to conclude that all known therapies are effective.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000243",
    "statement": "Protein structure and sequence reanalysis of 2019-ncov genome refutes snakes as its intermediate host and the unique similarity between its spike protein insertions and hiv-1",
    "label": "SUPPORTED",
    "evidences": [
      "In this Communication, we first analyzed two recent studies that concluded that snakes are the intermediate hosts of 2019-nCoV and that the 2019-nCoV spike protein insertions share a unique similarity to HIV-1."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence states that two studies concluded snakes are the intermediate hosts of 2019-nCoV and that the spike protein insertions share a unique similarity with HIV-1. However, this statement presents new claims (i.e., that the conclusions in these studies are incorrect) without providing any additional evidence to refute those findings.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000244",
    "statement": "Protein structure and sequence reanalysis of 2019-ncov genome refutes bats as its intermediate host and the unique similarity between its spike protein insertions and hiv-1",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In this Communication, we first analyzed two recent studies that concluded that snakes are the intermediate hosts of 2019-nCoV and that the 2019-nCoV spike protein insertions share a unique similarity to HIV-1."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not directly support the claim that protein structure and sequence reanalysis of 2019-ncov genome refutes bats as its intermediate host and the unique similarity between its spike protein insertions and hiv-1. Instead, it mentions two studies that conclude the opposite, i.e., snakes are the intermediate hosts and there is a unique similarity between 2019-nCoV spike protein insertions and HIV-1.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000245",
    "statement": "Mhra suspends recruitment to covid-19 hydroxychloroquine trials",
    "label": "SUPPORTED",
    "evidences": [
      "We followed the emerging concerns about use of hydroxychloroquine in COVID-19, and took into consideration the results from two different trials, including the UKs RECOVERY trial which has provided convincing evidence of no meaningful mortality benefit in hospitalised patients with COVID-19.",
      "The MHRA took into consideration the results released from the RECOVERY trial, showing no beneficial effect of hydroxychloroquine in patients hospitalised with COVID-19, and a New England Journal of Medicine publication using hydroxychloroquine as postexposure prophylaxis of COVID-19, concluding that hydroxychloroquine did not prevent illness compatible with Covid-19 or confirmed infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that the MHRA (Medicines and Healthcare products Regulatory Agency) has taken into account results from two trials, including the RECOVERY trial, which showed no beneficial effect of hydroxychloroquine in patients hospitalised with COVID-19. The lack of benefits suggested by these trials likely led to the suspension of recruitment to covid-19 hydroxychloroquine trials.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000246",
    "statement": "Mhra acts recruitment to covid-19 hydroxychloroquine trials",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We followed the emerging concerns about use of hydroxychloroquine in COVID-19, and took into consideration the results from two different trials, including the UKs RECOVERY trial which has provided convincing evidence of no meaningful mortality benefit in hospitalised patients with COVID-19.",
      "The MHRA took into consideration the results released from the RECOVERY trial, showing no beneficial effect of hydroxychloroquine in patients hospitalised with COVID-19, and a New England Journal of Medicine publication using hydroxychloroquine as postexposure prophylaxis of COVID-19, concluding that hydroxychloroquine did not prevent illness compatible with Covid-19 or confirmed infection."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not directly show that the MHRA (Medicines and Healthcare products Regulatory Agency) actively recruited for COVID-19 hydroxychloroquine trials. The evidence discusses the consideration of results from trials involving hydroxychloroquine, but it does not state that the MHRA participated in these trials as a recruiter.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000247",
    "statement": "Mhra 1990s recruitment to covid-19 hydroxychloroquine trials",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We followed the emerging concerns about use of hydroxychloroquine in COVID-19, and took into consideration the results from two different trials, including the UKs RECOVERY trial which has provided convincing evidence of no meaningful mortality benefit in hospitalised patients with COVID-19.",
      "The MHRA took into consideration the results released from the RECOVERY trial, showing no beneficial effect of hydroxychloroquine in patients hospitalised with COVID-19, and a New England Journal of Medicine publication using hydroxychloroquine as postexposure prophylaxis of COVID-19, concluding that hydroxychloroquine did not prevent illness compatible with Covid-19 or confirmed infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided mentions that the results from two trials, including the RECOVERY trial, were taken into consideration by the MHRA when evaluating hydroxychloroquine for COVID-19. The RECOVERY trial was conducted in the 2000s (2020), but the evidence is suggesting that the MHRA considered the results of this trial in the 1990s, which would not be possible unless the MHRA had access to the data before the trial's completion.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000248",
    "statement": "Mhra 1980s recruitment to covid-19 hydroxychloroquine trials",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We followed the emerging concerns about use of hydroxychloroquine in COVID-19, and took into consideration the results from two different trials, including the UKs RECOVERY trial which has provided convincing evidence of no meaningful mortality benefit in hospitalised patients with COVID-19.",
      "The MHRA took into consideration the results released from the RECOVERY trial, showing no beneficial effect of hydroxychloroquine in patients hospitalised with COVID-19, and a New England Journal of Medicine publication using hydroxychloroquine as postexposure prophylaxis of COVID-19, concluding that hydroxychloroquine did not prevent illness compatible with Covid-19 or confirmed infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests that the MHRA (Medicines and Healthcare products Regulatory Agency) did consider the results from two different trials, including the RECOVERY trial, regarding hydroxychloroquine in COVID-19 treatment. These trials demonstrated no beneficial effect of hydroxychloroquine in patients hospitalised with COVID-19.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000249",
    "statement": "Transcriptional profiling reveals trpm5-expressing cells involved in viral infection in the olfactory epithelium",
    "label": "SUPPORTED",
    "evidences": [
      "Specialized chemosensory epithelial cells that express the transient receptor potential cation channel subfamily M member 5 (TRPM5) are found throughout the airways and intestinal epithelium and are involved in responses to viral infection.",
      "Our study provides new insights into a potential role for TRPM5-expressing cells in viral infection of the olfactory epithelium.",
      "We find profuse expression of transcripts involved in inflammation, immunity and viral infection in TRPM5-expressing microvillous cells and olfactory sensory neurons."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided mentions that TRPM5-expressing cells are involved in responses to viral infection and the study provides new insights into a potential role for these cells in viral infection of the olfactory epithelium. Furthermore, it is stated that transcripts involved in inflammation, immunity, and viral infection are expressed in TRPM5-expressing microvillous cells and olfactory sensory neurons.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000250",
    "statement": "Transcriptional profiling reveals trpm5-deficient cells involved in viral infection in the olfactory epithelium",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Specialized chemosensory epithelial cells that express the transient receptor potential cation channel subfamily M member 5 (TRPM5) are found throughout the airways and intestinal epithelium and are involved in responses to viral infection.",
      "Our study provides new insights into a potential role for TRPM5-expressing cells in viral infection of the olfactory epithelium.",
      "We find profuse expression of transcripts involved in inflammation, immunity and viral infection in TRPM5-expressing microvillous cells and olfactory sensory neurons."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided discusses a study that investigates the potential role of TRPM5-expressing cells in viral infection of the olfactory epithelium. It mentions transcriptional profiling revealing expression of inflammation, immunity, and viral infection transcripts in these cells, which supports the claim.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000251",
    "statement": "Transcriptional profiling reveals trpm5-depleted cells involved in viral infection in the olfactory epithelium",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Specialized chemosensory epithelial cells that express the transient receptor potential cation channel subfamily M member 5 (TRPM5) are found throughout the airways and intestinal epithelium and are involved in responses to viral infection.",
      "Our study provides new insights into a potential role for TRPM5-expressing cells in viral infection of the olfactory epithelium.",
      "We find profuse expression of transcripts involved in inflammation, immunity and viral infection in TRPM5-expressing microvillous cells and olfactory sensory neurons."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that the study finds profuse expression of transcripts involved in inflammation, immunity, and viral infection in TRPM5-expressing cells (microvillous cells and olfactory sensory neurons) in the olfactory epithelium. This suggests that these cells are involved in viral infection.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000252",
    "statement": "Immunal profiling reveals trpm5-expressing cells involved in viral infection in the olfactory epithelium",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Specialized chemosensory epithelial cells that express the transient receptor potential cation channel subfamily M member 5 (TRPM5) are found throughout the airways and intestinal epithelium and are involved in responses to viral infection.",
      "Our study provides new insights into a potential role for TRPM5-expressing cells in viral infection of the olfactory epithelium.",
      "We find profuse expression of transcripts involved in inflammation, immunity and viral infection in TRPM5-expressing microvillous cells and olfactory sensory neurons."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence describes a study on the role of TRPM5-expressing cells in viral infection, specifically in the olfactory epithelium. The study finds profuse expression of transcripts related to inflammation, immunity and viral infection in these cells, suggesting that they play a role in viral infections.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000253",
    "statement": "Aprotinin inhibits sars-cov-2 replication",
    "label": "SUPPORTED",
    "evidences": [
      "In conclusion, therapeutic aprotinin concentrations exert anti-SARS-CoV-2 activity.",
      "Herein, we showed that the protease inhibitor aprotinin (but not the protease inhibitor SERPINA1/alpha-1 antitrypsin) inhibited SARS-CoV-2 replication in therapeutically achievable concentrations.",
      "Aprotinin displayed anti-SARS-CoV-2 activity in different cell types (Caco2, Calu-3, and primary bronchial epithelial cell air-liquid interface cultures) and against four virus isolates."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows that aprotinin inhibits SARS-CoV-2 replication in therapeutically achievable concentrations. The study demonstrates this by showing its anti-SARS-CoV-2 activity in multiple cell types and against several virus isolates.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000254",
    "statement": "Aprotinin 1980s sars-cov-2 replication",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In conclusion, therapeutic aprotinin concentrations exert anti-SARS-CoV-2 activity.",
      "Herein, we showed that the protease inhibitor aprotinin (but not the protease inhibitor SERPINA1/alpha-1 antitrypsin) inhibited SARS-CoV-2 replication in therapeutically achievable concentrations.",
      "Aprotinin displayed anti-SARS-CoV-2 activity in different cell types (Caco2, Calu-3, and primary bronchial epithelial cell air-liquid interface cultures) and against four virus isolates."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided only shows that aprotinin inhibits SARS-CoV-2 replication in laboratory conditions, not that it had any role in the replication of SARS-CoV-2 in the 1980s.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000255",
    "statement": "Aprotinin (s sars-cov-2 replication",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In conclusion, therapeutic aprotinin concentrations exert anti-SARS-CoV-2 activity.",
      "Herein, we showed that the protease inhibitor aprotinin (but not the protease inhibitor SERPINA1/alpha-1 antitrypsin) inhibited SARS-CoV-2 replication in therapeutically achievable concentrations.",
      "Aprotinin displayed anti-SARS-CoV-2 activity in different cell types (Caco2, Calu-3, and primary bronchial epithelial cell air-liquid interface cultures) and against four virus isolates."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides direct support for the claim that therapeutic aprotinin concentrations exert anti-SARS-CoV-2 activity.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000256",
    "statement": "Aprotinin 1970s sars-cov-2 replication",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In conclusion, therapeutic aprotinin concentrations exert anti-SARS-CoV-2 activity.",
      "Herein, we showed that the protease inhibitor aprotinin (but not the protease inhibitor SERPINA1/alpha-1 antitrypsin) inhibited SARS-CoV-2 replication in therapeutically achievable concentrations.",
      "Aprotinin displayed anti-SARS-CoV-2 activity in different cell types (Caco2, Calu-3, and primary bronchial epithelial cell air-liquid interface cultures) and against four virus isolates."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence shows that aprotinin inhibits SARS-CoV-2 replication in lab conditions. However, the claim states that this occurred during the 1970s when SARS-CoV-2 (also known as SARS coronavirus 2) did not exist yet. The first identified case of SARS-CoV-2 was in late 2019.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000257",
    "statement": "Homozygous l-sign plays a protective role in sars coronavirus infection",
    "label": "SUPPORTED",
    "evidences": [
      "Homozygous L-SIGN (CLEC4M) plays a protective role in SARS coronavirus infection.",
      "Thus, homozygosity for L-SIGN plays a protective role during SARS infection.",
      "Homozygous L-SIGN ( CLEC4M ) plays a protective role in SARS coronavirus infection.",
      "This observation confirms that homozygous L-SIGN does have a protective role in SARS-CoV infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence states that Homozygous L-SIGN (CLEC4M) plays a protective role in SARS coronavirus infection. Therefore, it supports the claim that homozygosity for L-SIGN plays a protective role during SARS infection.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000258",
    "statement": "Homozygous l-atpase plays a protective role in sars coronavirus infection",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Homozygous L-SIGN (CLEC4M) plays a protective role in SARS coronavirus infection.",
      "Thus, homozygosity for L-SIGN plays a protective role during SARS infection.",
      "Homozygous L-SIGN ( CLEC4M ) plays a protective role in SARS coronavirus infection.",
      "This observation confirms that homozygous L-SIGN does have a protective role in SARS-CoV infection."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence mentions Homozygous L-SIGN (CLEC4M) playing a protective role in SARS coronavirus infection, but it does not explicitly state that homozygous l-atpase plays the same role. While they share similar naming conventions, l-ATPase and CLEC4M (L-SIGN) are different proteins.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000259",
    "statement": "The us doesnt have enough hospital beds for a bad coronavirus outbreak.",
    "label": "SUPPORTED",
    "evidences": [
      "Cuomo warns US won't have enough hospital beds for coronavirus pandemic Published Mon, Mar 16 202011:27 AM EDTUpdated Mon, Mar 16 202012:18 PM EDT Berkeley Lovelace Jr.@BerkeleyJr ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email New York Gov.",
      "Dillinger March.13.2020 at 12:32 pm >>America Doesn't Have Enough Hospital Beds To Fight the Coronavirus virus impervious to the little wheels.",
      "Earlier in the outbreak, doctors warned that a larger outbreak of the new coronavirus across the U.S. could overwhelm emergency rooms and quickly cause supply shortages of some crucial medical supplies."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that New York Governor Cuomo has warned that America doesn't have enough hospital beds for a potential coronavirus pandemic. This aligns with the claim.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000260",
    "statement": "The usset have enough hospital beds for a bad coronavirus outbreak.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Cuomo warns US won't have enough hospital beds for coronavirus pandemic Published Mon, Mar 16 202011:27 AM EDTUpdated Mon, Mar 16 202012:18 PM EDT Berkeley Lovelace Jr.@BerkeleyJr ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email New York Gov.",
      "Dillinger March.13.2020 at 12:32 pm >>America Doesn't Have Enough Hospital Beds To Fight the Coronavirus virus impervious to the little wheels.",
      "Earlier in the outbreak, doctors warned that a larger outbreak of the new coronavirus across the U.S. could overwhelm emergency rooms and quickly cause supply shortages of some crucial medical supplies."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence indicates that there is a warning about the possibility of insufficient hospital beds during a potential coronavirus pandemic in the United States. However, this statement does not provide concrete information about whether 'the usset' (presumably a typo and meant to refer to the US) currently has enough hospital beds for such an outbreak.",
    "confidence": 0.85
  },
  {
    "id": "covid_fact-000261",
    "statement": "The uswt have enough hospital beds for a bad coronavirus outbreak.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Cuomo warns US won't have enough hospital beds for coronavirus pandemic Published Mon, Mar 16 202011:27 AM EDTUpdated Mon, Mar 16 202012:18 PM EDT Berkeley Lovelace Jr.@BerkeleyJr ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email New York Gov.",
      "Dillinger March.13.2020 at 12:32 pm >>America Doesn't Have Enough Hospital Beds To Fight the Coronavirus virus impervious to the little wheels.",
      "Earlier in the outbreak, doctors warned that a larger outbreak of the new coronavirus across the U.S. could overwhelm emergency rooms and quickly cause supply shortages of some crucial medical supplies."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided indicates that there have been warnings about a potential lack of hospital beds for a large coronavirus outbreak in the US, but it does not specifically state whether or not the US Women's National Team (USWNT) has enough hospital beds. Therefore, we cannot confirm or deny the claim based on the given evidence.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000262",
    "statement": "The usert have enough hospital beds for a bad coronavirus outbreak.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Cuomo warns US won't have enough hospital beds for coronavirus pandemic Published Mon, Mar 16 202011:27 AM EDTUpdated Mon, Mar 16 202012:18 PM EDT Berkeley Lovelace Jr.@BerkeleyJr ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email New York Gov.",
      "Dillinger March.13.2020 at 12:32 pm >>America Doesn't Have Enough Hospital Beds To Fight the Coronavirus virus impervious to the little wheels.",
      "Earlier in the outbreak, doctors warned that a larger outbreak of the new coronavirus across the U.S. could overwhelm emergency rooms and quickly cause supply shortages of some crucial medical supplies."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence states that there is a warning about the potential lack of hospital beds for a large coronavirus outbreak in the U.S., but it does not provide specific information about the current number or capacity of hospital beds for any user. To evaluate this claim, we would need data showing the number of hospital beds available and comparing it to the estimated need during a bad coronavirus outbreak.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000263",
    "statement": "La doctor seeing 100 % success with hydroxychloroquine and zinc to treat covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "LA doctor seeing success with hydroxychloroquine to treat COVID-19 - YouTube AboutPressCopyrightContact usCreatorsAdvertiseDevelopersTermsPrivacyPolicy & SafetyHow YouTube worksTest new features (C) 2021 Google LLC [DOI]: Digital Object Identifier [ISSN]: International Standard Serial Number [.",
      "Dr. Anthony Cardillo said he has seen very promising results when prescribing hydroxychloroquine in combination with zinc for the most severely-ill COVID-19 patients.",
      "SO, the \"drug cocktail\" to treat COVID-19 patients is : hydroxychloroquine+azithromycin+ZINC SULFATE.",
      "Treatment with HCQ and zinc only  Dr. Cardillo LA doctor seeing success with hydroxychloroquine to treat COVID-19 https://abc7news.com/coronavirus-drug-covid-19-malaria- hydroxychloroquine/6079864/ 2\\."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "While the provided evidence indicates that a doctor named Dr. Anthony Cardillo has seen success in treating COVID-19 patients with hydroxychloroquine and zinc, it does not provide sufficient evidence to support the claim that he sees 100% success. The claim would require data demonstrating that all patients treated by this method have recovered, which is not provided in the given evidence.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000264",
    "statement": "La doctor seeing 80 % success with hydroxychloroquine and zinc to treat covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "LA doctor seeing success with hydroxychloroquine to treat COVID-19 - YouTube AboutPressCopyrightContact usCreatorsAdvertiseDevelopersTermsPrivacyPolicy & SafetyHow YouTube worksTest new features (C) 2021 Google LLC [DOI]: Digital Object Identifier [ISSN]: International Standard Serial Number [.",
      "Dr. Anthony Cardillo said he has seen very promising results when prescribing hydroxychloroquine in combination with zinc for the most severely-ill COVID-19 patients.",
      "SO, the \"drug cocktail\" to treat COVID-19 patients is : hydroxychloroquine+azithromycin+ZINC SULFATE.",
      "Treatment with HCQ and zinc only  Dr. Cardillo LA doctor seeing success with hydroxychloroquine to treat COVID-19 https://abc7news.com/coronavirus-drug-covid-19-malaria- hydroxychloroquine/6079864/ 2\\."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that Dr. Anthony Cardillo has seen success with hydroxychloroquine in combination with zinc for the most severely-ill COVID-19 patients. No information about azithromycin was mentioned in this particular context.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000265",
    "statement": "La doctor seeing 60 % success with hydroxychloroquine and zinc to treat covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "LA doctor seeing success with hydroxychloroquine to treat COVID-19 - YouTube AboutPressCopyrightContact usCreatorsAdvertiseDevelopersTermsPrivacyPolicy & SafetyHow YouTube worksTest new features (C) 2021 Google LLC [DOI]: Digital Object Identifier [ISSN]: International Standard Serial Number [.",
      "Dr. Anthony Cardillo said he has seen very promising results when prescribing hydroxychloroquine in combination with zinc for the most severely-ill COVID-19 patients.",
      "SO, the \"drug cocktail\" to treat COVID-19 patients is : hydroxychloroquine+azithromycin+ZINC SULFATE.",
      "Treatment with HCQ and zinc only  Dr. Cardillo LA doctor seeing success with hydroxychloroquine to treat COVID-19 https://abc7news.com/coronavirus-drug-covid-19-malaria- hydroxychloroquine/6079864/ 2\\."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that Dr. Anthony Cardillo has seen success with hydroxychloroquine in combination with zinc for the most severely-ill COVID-19 patients. No other drug (azithromycin) is explicitly mentioned to be part of this treatment regimen as claimed.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000266",
    "statement": "La doctor seeing 70 % success with hydroxychloroquine and zinc to treat covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "LA doctor seeing success with hydroxychloroquine to treat COVID-19 - YouTube AboutPressCopyrightContact usCreatorsAdvertiseDevelopersTermsPrivacyPolicy & SafetyHow YouTube worksTest new features (C) 2021 Google LLC [DOI]: Digital Object Identifier [ISSN]: International Standard Serial Number [.",
      "Dr. Anthony Cardillo said he has seen very promising results when prescribing hydroxychloroquine in combination with zinc for the most severely-ill COVID-19 patients.",
      "SO, the \"drug cocktail\" to treat COVID-19 patients is : hydroxychloroquine+azithromycin+ZINC SULFATE.",
      "Treatment with HCQ and zinc only  Dr. Cardillo LA doctor seeing success with hydroxychloroquine to treat COVID-19 https://abc7news.com/coronavirus-drug-covid-19-malaria- hydroxychloroquine/6079864/ 2\\."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not explicitly state the percentage of success with hydroxychloroquine and zinc in treating COVID-19. It only mentions that Dr. Anthony Cardillo has seen promising results when prescribing hydroxychloroquine combined with zinc for severely ill patients. The claim suggests a 70% success rate, but this number is not supported by the evidence.",
    "confidence": 0.5
  },
  {
    "id": "covid_fact-000267",
    "statement": "Repurposing existing drugs for covid-19 a more rapid alternative to a vaccine , say researchers",
    "label": "SUPPORTED",
    "evidences": [
      "Although clinical trials found it to be insufficiently effective at treating Ebola, clinical trials in the USA have suggested the drug may be beneficial for treating patients hospitalised with COVID-19, and the FDA has now approved it for emergency use.",
      "> \"[Repurposed drugs] will have already been shown to be safe and so, if they > can now be shown to be effective in COVID-19, they could be brought to > clinical use relatively quickly\" > > Anthony Davenport Since the emergence of the SARS-CoV-2 virus in late 2019, more than 3.5 million people are known to have been infected, leading to over 240,000 deaths worldwide from COVID-19, the disease caused by the novel coronavirus.",
      "While we're waiting for a vaccine, drugs currently being used to treat other illnesses can be investigated as treatments for COVID-19  in other words repurposed, said Dr Steve Alexander from the University of Nottingham.",
      "These treatments will have already been shown to be safe and so, if they can now be shown to be effective in COVID-19, they could be brought to clinical use relatively quickly. One promising candidate is remdesivir, a drug originally developed for Ebola."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that researchers are indeed investigating existing drugs as alternatives to a vaccine for COVID-19, such as remdesivir, which was originally developed for Ebola. The FDA has also approved it for emergency use in treating hospitalized COVID-19 patients. This indicates a more rapid alternative to a vaccine is being pursued.",
    "confidence": 0.85
  },
  {
    "id": "covid_fact-000268",
    "statement": "Repurposing existing drugs for covid-19 a less rapid alternative to a vaccine, say researchers",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Although clinical trials found it to be insufficiently effective at treating Ebola, clinical trials in the USA have suggested the drug may be beneficial for treating patients hospitalised with COVID-19, and the FDA has now approved it for emergency use.",
      "> \"[Repurposed drugs] will have already been shown to be safe and so, if they > can now be shown to be effective in COVID-19, they could be brought to > clinical use relatively quickly\" > > Anthony Davenport Since the emergence of the SARS-CoV-2 virus in late 2019, more than 3.5 million people are known to have been infected, leading to over 240,000 deaths worldwide from COVID-19, the disease caused by the novel coronavirus.",
      "While we're waiting for a vaccine, drugs currently being used to treat other illnesses can be investigated as treatments for COVID-19  in other words repurposed, said Dr Steve Alexander from the University of Nottingham.",
      "These treatments will have already been shown to be safe and so, if they can now be shown to be effective in COVID-19, they could be brought to clinical use relatively quickly. One promising candidate is remdesivir, a drug originally developed for Ebola."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided supports the claim that repurposing existing drugs for COVID-19 is a less rapid alternative to a vaccine, as stated by Anthony Davenport and Dr Steve Alexander. The example provides direct quotes stating that treatments already known to be safe could potentially be shown effective in COVID-19 and brought to clinical use relatively quickly, which aligns with the claim.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000269",
    "statement": "68 per cent of patients hospitalized for severe covid-19 , who were treated with compassionate-use remdesivir , showed clinical improvement",
    "label": "SUPPORTED",
    "evidences": [
      "Although data from several ongoing randomized, controlled trials will soon provide more informative evidence regarding the safety and efficacy of remdesivir for Covid-19, the outcomes observed in this compassionate-use program are the best currently available data."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided discusses that data from ongoing randomized, controlled trials will soon provide more informative evidence regarding the safety and efficacy of remdesivir for Covid-19. However, it does not directly state or imply the percentage of patients hospitalized for severe covid-19 who were treated with compassionate-use remdesivir that showed clinical improvement.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000270",
    "statement": "68 per cent of patients hospitalized for severe covid-19, who were treated with compassionate-use remdesivir, without clinical improvement",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Although data from several ongoing randomized, controlled trials will soon provide more informative evidence regarding the safety and efficacy of remdesivir for Covid-19, the outcomes observed in this compassionate-use program are the best currently available data."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided is not sufficient to support the claim that 68% of patients hospitalized for severe COVID-19, who were treated with compassionate-use remdesivir, did not show clinical improvement. The statement mentions that data from ongoing trials will provide more informative evidence but does not present any specific numbers or percentages related to the compassionate-use program.",
    "confidence": 0.85
  },
  {
    "id": "covid_fact-000271",
    "statement": "Years of life lost due to the psychosocial consequences of covid19 mitigation strategies based on swiss data",
    "label": "SUPPORTED",
    "evidences": [
      "Methods We used years of life lost (YLL) as the main outcome measure as applied to Switzerland as an exemplar.",
      "Results The study projects that the average person would suffer 0.205 YLL due to psychosocial consequence of COVID-19 mitigation measures."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides a quantitative result that supports the claim about the number of years of life lost due to psychosocial consequences of COVID-19 mitigation strategies based on Swiss data.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000272",
    "statement": "Years of life increases due to the psychosocial consequences of covid19 mitigation strategies based on swiss data",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Methods We used years of life lost (YLL) as the main outcome measure as applied to Switzerland as an exemplar.",
      "Results The study projects that the average person would suffer 0.205 YLL due to psychosocial consequence of COVID-19 mitigation measures."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence presents a study using Years of Life Lost (YLL) as the main outcome measure to project the impact of psychosocial consequences of COVID-19 mitigation measures on life expectancy in Switzerland. The results indicate an average loss of 0.205 YLL per person.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000273",
    "statement": "Years of life remains due to the psychosocial consequences of covid19 mitigation strategies based on swiss data",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Methods We used years of life lost (YLL) as the main outcome measure as applied to Switzerland as an exemplar.",
      "Results The study projects that the average person would suffer 0.205 YLL due to psychosocial consequence of COVID-19 mitigation measures."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided presents a study that projects the average person in Switzerland would suffer 0.205 Years of Life Lost (YLL) due to psychosocial consequences of COVID-19 mitigation measures. This implies that the claim is supported by this specific study.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000274",
    "statement": "Years of life occurred due to the psychosocial consequences of covid19 mitigation strategies based on swiss data",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Methods We used years of life lost (YLL) as the main outcome measure as applied to Switzerland as an exemplar.",
      "Results The study projects that the average person would suffer 0.205 YLL due to psychosocial consequence of COVID-19 mitigation measures."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides a quantitative result (0.205 years of life lost) due to psychosocial consequences of COVID-19 mitigation strategies, as applied to Switzerland.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000275",
    "statement": "Astrazeneca covid-19 vaccine study is put on hold",
    "label": "SUPPORTED",
    "evidences": [
      "A spokesperson for AstraZeneca, a frontrunner in the race for a Covid-19 vaccine, said in a statement that the companys standard review process triggered a pause to vaccination to allow review of safety data. In a follow-up statement, AstraZeneca said it initiated the study hold.",
      "AstraZenecas is the first Phase 3 Covid-19 vaccine trial known to have been put on hold."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided states that AstraZeneca's standard review process triggered a pause in vaccination to allow for the review of safety data, and later on, AstraZeneca initiated the study hold. This implies that the AstraZeneca COVID-19 vaccine study was indeed put on hold.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000276",
    "statement": "Astrazeneca covid-19 vaccine study is put on!",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "A spokesperson for AstraZeneca, a frontrunner in the race for a Covid-19 vaccine, said in a statement that the companys standard review process triggered a pause to vaccination to allow review of safety data. In a follow-up statement, AstraZeneca said it initiated the study hold.",
      "AstraZenecas is the first Phase 3 Covid-19 vaccine trial known to have been put on hold."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not indicate that the AstraZeneca COVID-19 vaccine study has been completed. The claim is about the study being 'put on', which implies completion, but the data only shows a pause to allow review of safety data.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000277",
    "statement": "Astrazeneca covid-19 vaccine study is put on.\"",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "A spokesperson for AstraZeneca, a frontrunner in the race for a Covid-19 vaccine, said in a statement that the companys standard review process triggered a pause to vaccination to allow review of safety data. In a follow-up statement, AstraZeneca said it initiated the study hold.",
      "AstraZenecas is the first Phase 3 Covid-19 vaccine trial known to have been put on hold."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim states that the AstraZeneca COVID-19 vaccine study has been paused. The evidence provided indicates that AstraZeneca indeed initiated a 'study hold' due to safety concerns, which implies pausing the study.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000278",
    "statement": "Astrazeneca covid-19 vaccine study is put on.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "A spokesperson for AstraZeneca, a frontrunner in the race for a Covid-19 vaccine, said in a statement that the companys standard review process triggered a pause to vaccination to allow review of safety data. In a follow-up statement, AstraZeneca said it initiated the study hold.",
      "AstraZenecas is the first Phase 3 Covid-19 vaccine trial known to have been put on hold."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that AstraZeneca initiated a study hold for their Phase 3 Covid-19 vaccine trial in order to review safety data. Therefore, it is reasonable to conclude that the AstraZeneca covid-19 vaccine study was put on hold.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000279",
    "statement": "Giuliani-promoted covid-19 therapy from celularity nabs fda speedy trial start",
    "label": "SUPPORTED",
    "evidences": [
      "Trials need to be EXPEDITED. It seems he got his wish: Today, New Jersey-based Celularity said it has been given the all-clear from the FDA to start its clinical trial of CYNK-001, its allogeneic, off-the-shelf, cryopreserved natural killer cell therapy to be used in a phase 1/2 study in up to 86 patients with COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence mentions that Celularity has received FDA approval to start a clinical trial of its therapy (CYNK-01) for COVID-19. Giuliani being associated with the promotion of this therapy is not explicitly stated but implied since he is mentioned in an earlier context and the article discusses his role in promoting treatments for COVID-19.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000280",
    "statement": "Giuliani-free covid-19 therapy from celularity nabs fda speedy trial start",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Trials need to be EXPEDITED. It seems he got his wish: Today, New Jersey-based Celularity said it has been given the all-clear from the FDA to start its clinical trial of CYNK-001, its allogeneic, off-the-shelf, cryopreserved natural killer cell therapy to be used in a phase 1/2 study in up to 86 patients with COVID-19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not clearly indicate that the therapy is 'Giuliani-free'. The focus of the information is on the FDA approval for the trial of CYNK-001, a COVID-19 treatment, and does not mention any association with Rudy Giuliani.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000281",
    "statement": "Mucus production stimulated by ifn-ahr signaling triggers hypoxia of covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "Together, these results suggest that mucus is likely to be produced in the lung epithelial cells of COVID-19 patients.",
      "7: A schematic for AhR-upregulated mucins in the hypoxia of COVID-19 patients.",
      "1a), suggesting that mucus-like substance might be present in the BAL of COVID-19 patients."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that there is an upregulation of mucus production in lung epithelial cells of COVID-19 patients due to IFN-AHR signaling (1a), and a schematic shows this connection with hypoxia (7). The presence of mucus can lead to airway obstruction, which can contribute to hypoxia. Therefore, it is reasonable to assume that the increased mucus production stimulated by IFN-AHR signaling may trigger hypoxia in COVID-19 patients.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000282",
    "statement": "Mucus production stimulated by ifn-ahr signaling prevents hypoxia of covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Together, these results suggest that mucus is likely to be produced in the lung epithelial cells of COVID-19 patients.",
      "7: A schematic for AhR-upregulated mucins in the hypoxia of COVID-19 patients.",
      "1a), suggesting that mucus-like substance might be present in the BAL of COVID-19 patients."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided suggests that mucus production may be stimulated by ifn-ahr signaling in COVID-19 patients and that mucus might be present in the BAL (Bronchoalveolar lavage) of these patients. However, it does not directly prove or disprove that this mucus production prevents hypoxia (lack of oxygen) in COVID-19 patients.",
    "confidence": 0.4
  },
  {
    "id": "covid_fact-000283",
    "statement": "Mucus damage stimulated by ifn-ahr signaling triggers hypoxia of covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Together, these results suggest that mucus is likely to be produced in the lung epithelial cells of COVID-19 patients.",
      "7: A schematic for AhR-upregulated mucins in the hypoxia of COVID-19 patients.",
      "1a), suggesting that mucus-like substance might be present in the BAL of COVID-19 patients."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided suggests that mucus is produced in the lung epithelial cells of COVID-19 patients and there are indications of AhR-upregulated mucins which might be present in the Bronchoalveolar lavage (BAL) of COVID-19 patients. However, it does not directly provide evidence that mucus damage stimulated by ifn-ahr signaling triggers hypoxia in COVID-19.",
    "confidence": 0.6
  },
  {
    "id": "covid_fact-000284",
    "statement": "Gilead has suspended access to remdesivir",
    "label": "SUPPORTED",
    "evidences": [
      "To stem demand, Gilead will pivot from accepting compassionate- use requests to only providing treatment through expanded access programs.",
      "Before the suspension, Gileads remdesivir appeared to be offered to individual patients for emergency use."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence shows that Gilead is changing the way they provide remdesivir (from individual compassionate-use requests to expanded access programs), which might imply a decrease in availability. However, it does not explicitly state that remdesivir has been suspended.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000285",
    "statement": "Gilead has allowed access to remdesivir",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "To stem demand, Gilead will pivot from accepting compassionate- use requests to only providing treatment through expanded access programs.",
      "Before the suspension, Gileads remdesivir appeared to be offered to individual patients for emergency use."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence suggests that Gilead has changed its approach from accepting compassionate-use requests to providing treatment through expanded access programs. However, it does not explicitly state that they have allowed access to remdesivir at the time of the change.",
    "confidence": 0.5
  },
  {
    "id": "covid_fact-000286",
    "statement": "Gilead has received access to remdesivir",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "To stem demand, Gilead will pivot from accepting compassionate- use requests to only providing treatment through expanded access programs.",
      "Before the suspension, Gileads remdesivir appeared to be offered to individual patients for emergency use."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not directly confirm that Gilead has received access to remdesivir. It only shows that the company is changing its approach to providing treatment from compassionate use requests to expanded access programs. This change does not necessarily mean they have obtained new access to remdesivir.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000287",
    "statement": "Gilead has provided access to remdesivir",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "To stem demand, Gilead will pivot from accepting compassionate- use requests to only providing treatment through expanded access programs.",
      "Before the suspension, Gileads remdesivir appeared to be offered to individual patients for emergency use."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence does not indicate that Gilead has actually provided access to remdesivir for a significant number of patients. It only states that the company is changing its policy from accepting compassionate-use requests to providing treatment through expanded access programs.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000288",
    "statement": "Immune cell activation in severe covid-19 resembles lupus .",
    "label": "SUPPORTED",
    "evidences": [
      "The scientists found that patients with severe COVID-19 displayed many of these hallmarks of extrafollicular B cell responses associated with lupus.",
      "The critically-ill COVID-19 patients who survived and recovered from the infection also showed lingering symptoms similar to those experienced by lupus patients during acute flare-ups."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence shows that the immune response in severe COVID-19 resembles some aspects of lupus, but it does not directly support the claim that it resembles lupus overall. The evidence describes similarities between the two conditions, but it does not establish that they are identical or even closely enough related to conclude that a patient with severe COVID-19 has developed lupus.",
    "confidence": 0.7
  },
  {
    "id": "covid_fact-000289",
    "statement": "Immune cell death in severe covid-19 resembles lupus.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The scientists found that patients with severe COVID-19 displayed many of these hallmarks of extrafollicular B cell responses associated with lupus.",
      "The critically-ill COVID-19 patients who survived and recovered from the infection also showed lingering symptoms similar to those experienced by lupus patients during acute flare-ups."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence indicates that the immune responses in severe COVID-19 may resemble some aspects of lupus and that some patients show similar lingering symptoms. However, this does not directly support the claim that immune cell death in severe COVID-19 precisely resembles lupus, as the evidence is indirect and more research would be needed to establish a definitive connection between the two conditions.",
    "confidence": 0.5
  },
  {
    "id": "covid_fact-000290",
    "statement": "Cdc forecasts up to 100,000 more covid-19 deaths in the next few weeks.",
    "label": "SUPPORTED",
    "evidences": [
      "Thursday, January 21st 2021, 7:46 AM EST By CNN Newswire New CDC director Dr. Rochelle Walensky The United States could face as many as 100,000 more COVID-19 deaths in less than a month, according to the US Centers for Disease Control and Prevention."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided directly states that Dr. Rochelle Walensky, the new director of the US Centers for Disease Control and Prevention (CDC), stated that the United States could face as many as 100,000 more COVID-19 deaths in less than a month.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000291",
    "statement": "Cdc forecasts up to 100,000 more covid-19 deaths in the next few decades.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Thursday, January 21st 2021, 7:46 AM EST By CNN Newswire New CDC director Dr. Rochelle Walensky The United States could face as many as 100,000 more COVID-19 deaths in less than a month, according to the US Centers for Disease Control and Prevention."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence directly states that the new CDC director, Dr. Rochelle Walensky, predicts up to 100,000 more COVID-19 deaths in less than a month.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000292",
    "statement": "Cdc forecasts up to 100,000 more covid-19 deaths in the next few years.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Thursday, January 21st 2021, 7:46 AM EST By CNN Newswire New CDC director Dr. Rochelle Walensky The United States could face as many as 100,000 more COVID-19 deaths in less than a month, according to the US Centers for Disease Control and Prevention."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is supported by the evidence as stated in the source. The new CDC director explicitly states that up to 100,000 more COVID-19 deaths could occur within a month of the statement.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000293",
    "statement": "Cdc forecasts up to 100,000 more covid-19 deaths in the next few century.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Thursday, January 21st 2021, 7:46 AM EST By CNN Newswire New CDC director Dr. Rochelle Walensky The United States could face as many as 100,000 more COVID-19 deaths in less than a month, according to the US Centers for Disease Control and Prevention."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence is a direct statement from the new CDC director that the United States could face as many as 100,000 more COVID-19 deaths in less than a month.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000294",
    "statement": "Gaps in early surveillance of coronavirus led to record-breaking us trajectory",
    "label": "SUPPORTED",
    "evidences": [
      "As illustrated in the COVID-19 study, while public health officials must work quickly to understand how a new virus functions, without appropriate testing or coordinated response strategies the risk grows for infections to go unreported.",
      "The study provides insight into how limited testing and gaps in surveillance during the initial phase of the epidemic resulted in so many cases going undetected.",
      "The potential for misdiagnosis and the limitations of surveillance are huge issues across infectious diseases, especially emerging infectious diseases, he added."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests that limited testing and gaps in surveillance during the initial phase of the coronavirus epidemic could have led to many cases going undetected. This could have contributed to the record-breaking trajectory of COVID-19 cases in the US.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000295",
    "statement": "Efforts in early surveillance of coronavirus led to record-breaking us trajectory",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "As illustrated in the COVID-19 study, while public health officials must work quickly to understand how a new virus functions, without appropriate testing or coordinated response strategies the risk grows for infections to go unreported.",
      "The study provides insight into how limited testing and gaps in surveillance during the initial phase of the epidemic resulted in so many cases going undetected.",
      "The potential for misdiagnosis and the limitations of surveillance are huge issues across infectious diseases, especially emerging infectious diseases, he added."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not directly support the claim about a 'record-breaking US trajectory' as a result of efforts in early surveillance of coronavirus. Instead, it focuses on the limitations and issues of surveillance during the initial phase of the epidemic, highlighting the potential for undetected cases. To make the connection to the 'US trajectory', more specific data or context about the impact of these issues on the US would be required.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000296",
    "statement": "Immunosuppression is associated with a lower risk of moderate to severe acute respiratory distress syndrome in covid-19 .",
    "label": "SUPPORTED",
    "evidences": [
      "CONCLUSIONS : In our cohort of COVID-19 patients, immunosuppression was associated with a lower risk of moderate-severe ARDS."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided directly supports the claim that immunosuppression is associated with a lower risk of moderate to severe acute respiratory distress syndrome in COVID-19.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000297",
    "statement": "Immunosuppression is associated with a increased risk of moderate to severe acute respiratory distress syndrome in covid-19.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "CONCLUSIONS : In our cohort of COVID-19 patients, immunosuppression was associated with a lower risk of moderate-severe ARDS."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided shows the opposite of the claim, that immunosuppression is associated with a lower risk of moderate-severe ARDS in COVID-19 patients.",
    "confidence": 0.99
  },
  {
    "id": "covid_fact-000298",
    "statement": "Immunosuppression is associated with a higher risk of moderate to severe acute respiratory distress syndrome in covid-19.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "CONCLUSIONS : In our cohort of COVID-19 patients, immunosuppression was associated with a lower risk of moderate-severe ARDS."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided shows that in the specific cohort studied, immunosuppression was associated with a lower risk of moderate-severe ARDS in COVID-19 patients. However, this does not support the general claim that immunosuppression is associated with a higher risk of moderate to severe acute respiratory distress syndrome (ARDS) in COVID-19 as the conclusion directly contradicts the claim.",
    "confidence": 0.99
  },
  {
    "id": "covid_fact-000299",
    "statement": "Immunosuppression is associated with a high risk of moderate to severe acute respiratory distress syndrome in covid-19.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "CONCLUSIONS : In our cohort of COVID-19 patients, immunosuppression was associated with a lower risk of moderate-severe ARDS."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided indicates that in the specific cohort studied, immunosuppression was associated with a lower risk of moderate-severe ARDS in COVID-19 patients. However, this does not necessarily mean it is associated with a high risk in all COVID-19 patients, as the findings are based on the particular study's population.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000300",
    "statement": "Human soluble ace2 improves the effect of remdesivir in sars-cov-2 infection",
    "label": "SUPPORTED",
    "evidences": [
      "A, B (A) Remdesivir and (B) hrsACE2 inhibition of SARSCoV2 infections of Vero E6 cells.",
      "A Treatment of SARSCoV2 (106 PFU) infected VeroE6 cells with human recombinant soluble ACE 2 (hrsACE2) (200 \u00b5g/ml) and remdesivir (Remd."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows that treatment of SARS-CoV2 infected cells with human recombinant soluble ACE2 (hrsACE2) and remdesivir was tested. This suggests that hrsACE2 may improve the effect of remdesivir in SARS-CoV-2 infection.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000301",
    "statement": "Human soluble ace2 inhibits the effect of remdesivir in sars-cov-2 infection",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "A, B (A) Remdesivir and (B) hrsACE2 inhibition of SARSCoV2 infections of Vero E6 cells.",
      "A Treatment of SARSCoV2 (106 PFU) infected VeroE6 cells with human recombinant soluble ACE 2 (hrsACE2) (200 \u00b5g/ml) and remdesivir (Remd."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not directly support the claim about the interaction between human soluble ACE2 and remdesivir in SARS-CoV-2 infection. The evidence only mentions treatment of Vero E6 cells with hrsACE2 and remdesivir, but it does not provide information on how this affects the infection or if there is an inhibitory effect.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000302",
    "statement": "Human soluble ace2 blocked the effect of remdesivir in sars-cov-2 infection",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "A, B (A) Remdesivir and (B) hrsACE2 inhibition of SARSCoV2 infections of Vero E6 cells.",
      "A Treatment of SARSCoV2 (106 PFU) infected VeroE6 cells with human recombinant soluble ACE 2 (hrsACE2) (200 \u00b5g/ml) and remdesivir (Remd."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not directly show that human soluble ACE2 blocked the effect of remdesivir in SARS-CoV-2 infection. The statement suggests a correlation between hrsACE2 inhibition and SARSCoV2 infections treated with remdesivir, but it does not necessarily imply that hrsACE2 blocks the effect of remdesivir.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000303",
    "statement": "Human soluble ace2 reduces the effect of remdesivir in sars-cov-2 infection",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "A, B (A) Remdesivir and (B) hrsACE2 inhibition of SARSCoV2 infections of Vero E6 cells.",
      "A Treatment of SARSCoV2 (106 PFU) infected VeroE6 cells with human recombinant soluble ACE 2 (hrsACE2) (200 \u00b5g/ml) and remdesivir (Remd."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided shows that remdesivir and hrsACE2 have independent effects on SARS-CoV2 infections in Vero E6 cells. However, it does not show the interaction between human soluble ACE2 and remdesivir, specifically reducing the effect of remdesivir during an infection. More research is needed to support this claim.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000304",
    "statement": "A five day course of ivermectin for the treatment of covid-19 may reduce the duration of illness",
    "label": "SUPPORTED",
    "evidences": [
      "Ivermectin may be effective for the treatment of early-onset mild COVID-19 in adult patients.",
      "Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial.",
      "A 5-day course of ivermectin was found to be safe and effective in treating adult patients with mild COVID-19.",
      "A 5-day course of ivermectin resulted in an earlier clearance of the virus compared to placebo ( p = 0.005), thus indicating that early intervention with this agent may limit viral replication within the host."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided in the form of studies and trials indicates that a 5-day course of ivermectin may reduce the duration of illness for adult patients with early-onset mild COVID-19. The studies found that this treatment is safe and effective, leading to an earlier clearance of the virus compared to placebo.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000305",
    "statement": "A five years course of ivermectin for the treatment of covid-19 may reduce the duration of illness",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Ivermectin may be effective for the treatment of early-onset mild COVID-19 in adult patients.",
      "Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial.",
      "A 5-day course of ivermectin was found to be safe and effective in treating adult patients with mild COVID-19.",
      "A 5-day course of ivermectin resulted in an earlier clearance of the virus compared to placebo ( p = 0.005), thus indicating that early intervention with this agent may limit viral replication within the host."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "While the provided evidence suggests that a 5-day course of ivermectin can be effective in treating early-onset mild COVID-19 and may lead to an earlier clearance of the virus, it does not provide enough information to confirm or refute the claim that a five years course of ivermectin for the treatment of Covid-19 may reduce the duration of illness. The evidence is limited to a 5-day course and does not extend to five years.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000306",
    "statement": "A five year course of ivermectin for the treatment of covid-19 may reduce the duration of illness",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Ivermectin may be effective for the treatment of early-onset mild COVID-19 in adult patients.",
      "Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial.",
      "A 5-day course of ivermectin was found to be safe and effective in treating adult patients with mild COVID-19.",
      "A 5-day course of ivermectin resulted in an earlier clearance of the virus compared to placebo ( p = 0.005), thus indicating that early intervention with this agent may limit viral replication within the host."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests a five-year course of ivermectin for the treatment of COVID-19 may reduce the duration of illness because it was found to be effective in treating adult patients with mild COVID-19 and led to an earlier clearance of the virus compared to placebo.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000307",
    "statement": "A fivemonth course of ivermectin for the treatment of covid-19 may reduce the duration of illness",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Ivermectin may be effective for the treatment of early-onset mild COVID-19 in adult patients.",
      "Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial.",
      "A 5-day course of ivermectin was found to be safe and effective in treating adult patients with mild COVID-19.",
      "A 5-day course of ivermectin resulted in an earlier clearance of the virus compared to placebo ( p = 0.005), thus indicating that early intervention with this agent may limit viral replication within the host."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided in the form of studies and trials suggests that a five-month course of Ivermectin for treating Covid-19 may reduce the duration of illness. This is based on findings of safety, effectiveness, and earlier clearance of the virus compared to placebo.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000308",
    "statement": "Brd4-bound enhancers drive cell intrinsic sex differences in glioblastoma",
    "label": "SUPPORTED",
    "evidences": [
      "These observations led us to hypothesize that Brd4-bound enhancers might underlie sex differences in stem cell function and tumorigenicity in GBM.",
      "We report that sex-biased Brd4 activity drive sex differences in GBM and render male and female tumor cells differentially sensitive to BET inhibitors.",
      "These sex- biased gene expression patterns were also evident in human glioblastoma stem cells (GSCs).",
      "In an established isogenic murine model of glioblastoma, we discovered correlated transcriptome-wide sex differences in gene expression, H3K27ac marks, large Brd4-bound enhancer usage, and Brd4 localization to Myc and p53 genomic binding sites.",
      "Thus, for the first time, Brd4 activity is revealed to drive a sex differences in stem cell and tumorigenic phenotype, resulting in diametrically opposite responses to BET inhibition in male and female GBM cells."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence presents a series of experiments and observations that demonstrate sex-biased Brd4 activity drives sex differences in glioblastoma (GBM) and renders male and female tumor cells differentially sensitive to BET inhibitors. This suggests that Brd4-bound enhancers could be responsible for the observed cell intrinsic sex differences in GBM.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000309",
    "statement": "Brd4-bound enhancers drive cell surface sex differences in glioblastoma",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These observations led us to hypothesize that Brd4-bound enhancers might underlie sex differences in stem cell function and tumorigenicity in GBM.",
      "We report that sex-biased Brd4 activity drive sex differences in GBM and render male and female tumor cells differentially sensitive to BET inhibitors.",
      "These sex- biased gene expression patterns were also evident in human glioblastoma stem cells (GSCs).",
      "In an established isogenic murine model of glioblastoma, we discovered correlated transcriptome-wide sex differences in gene expression, H3K27ac marks, large Brd4-bound enhancer usage, and Brd4 localization to Myc and p53 genomic binding sites.",
      "Thus, for the first time, Brd4 activity is revealed to drive a sex differences in stem cell and tumorigenic phenotype, resulting in diametrically opposite responses to BET inhibition in male and female GBM cells."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests that there are sex differences in glioblastoma (GBM) driven by Brd4 activity. The text indicates that these sex-biased gene expression patterns were also evident in human GBM stem cells and an isogenic murine model of glioblastoma, where correlated transcriptome-wide sex differences in gene expression, H3K27ac marks, large Brd4-bound enhancer usage, and Brd4 localization to Myc and p53 genomic binding sites were discovered. This implies that Brd4-bound enhancers drive cell surface sex differences in glioblastoma.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000310",
    "statement": "Il-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome",
    "label": "SUPPORTED",
    "evidences": [
      "Our in vitro data indicate that endothelial IL-6 trans- signaling formed an inflammation circuit for robust IL-6, IL-8, and MCP-1 production and promoted PAI-1 production; additionally, an IL-6 signaling blockade by the human monoclonal antibody tocilizumab blunted endothelial cell activation."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly states that IL-6 trans-signaling promotes PAI-1 production in vascular endothelial cells.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000311",
    "statement": "Il-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine development syndrome",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our in vitro data indicate that endothelial IL-6 trans- signaling formed an inflammation circuit for robust IL-6, IL-8, and MCP-1 production and promoted PAI-1 production; additionally, an IL-6 signaling blockade by the human monoclonal antibody tocilizumab blunted endothelial cell activation."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that IL-6 trans-signaling promotes PAI-1 production from vascular endothelial cells and this effect can be blunted by an IL-6 signaling blockade. Therefore, it is supported that Il-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine development syndrome.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000312",
    "statement": "Il-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine production syndrome",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our in vitro data indicate that endothelial IL-6 trans- signaling formed an inflammation circuit for robust IL-6, IL-8, and MCP-1 production and promoted PAI-1 production; additionally, an IL-6 signaling blockade by the human monoclonal antibody tocilizumab blunted endothelial cell activation."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence directly states that endothelial IL-6 trans-signaling promotes PAI-1 production. Additionally, it mentions that an IL-6 signaling blockade blunts endothelial cell activation, which is consistent with a role for IL-6 in cytokine production syndrome.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000313",
    "statement": "Il-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine differentiation syndrome",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our in vitro data indicate that endothelial IL-6 trans- signaling formed an inflammation circuit for robust IL-6, IL-8, and MCP-1 production and promoted PAI-1 production; additionally, an IL-6 signaling blockade by the human monoclonal antibody tocilizumab blunted endothelial cell activation."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly indicates that IL-6 trans-signaling promotes PAI-1 production in vascular endothelial cells and this production can be blunted by an IL-6 signaling blockade. This suggests a causal relationship between IL-6 trans-signaling and PAI-1 induction.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000314",
    "statement": "Fauci says he wears a mask to be a symbol of what 'you should be doing '",
    "label": "SUPPORTED",
    "evidences": [
      "Fauci said he believes that while wearing a mask is not \"100% effective,\" it is a valuable safeguard and shows \"respect for another person.\"",
      "\"I want to protect myself and protect others, and also because I want to make it be a symbol for people to see that that's the kind of thing you should be doing,\" Fauci, the nation's top infectious disease expert and a member of the White House's coronavirus task force, told CNN's Jim Sciutto on \"Newsroom.\""
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that Fauci explicitly said he wears a mask to be a symbol of what 'you should be doing'. This aligns with the claim.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000315",
    "statement": "Fauci says he wears a point to be a symbol of what 'you should be doing '",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Fauci said he believes that while wearing a mask is not \"100% effective,\" it is a valuable safeguard and shows \"respect for another person.\"",
      "\"I want to protect myself and protect others, and also because I want to make it be a symbol for people to see that that's the kind of thing you should be doing,\" Fauci, the nation's top infectious disease expert and a member of the White House's coronavirus task force, told CNN's Jim Sciutto on \"Newsroom.\""
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that Fauci specifically says he wears a mask 'to be a symbol for people to see that that's the kind of thing you should be doing.' This directly supports the claim.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000316",
    "statement": "Fauci says he wears a license to be a symbol of what 'you should be doing '",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Fauci said he believes that while wearing a mask is not \"100% effective,\" it is a valuable safeguard and shows \"respect for another person.\"",
      "\"I want to protect myself and protect others, and also because I want to make it be a symbol for people to see that that's the kind of thing you should be doing,\" Fauci, the nation's top infectious disease expert and a member of the White House's coronavirus task force, told CNN's Jim Sciutto on \"Newsroom.\""
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "Fauci explicitly states that he wears a mask 'to make it be a symbol for people to see that that's the kind of thing you should be doing.' This implies that Fauci uses his mask as a symbol to demonstrate proper safety behavior during the pandemic.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000317",
    "statement": "Fauci says he wears a question to be a symbol of what 'you should be doing '",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Fauci said he believes that while wearing a mask is not \"100% effective,\" it is a valuable safeguard and shows \"respect for another person.\"",
      "\"I want to protect myself and protect others, and also because I want to make it be a symbol for people to see that that's the kind of thing you should be doing,\" Fauci, the nation's top infectious disease expert and a member of the White House's coronavirus task force, told CNN's Jim Sciutto on \"Newsroom.\""
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "Fauci explicitly stated that wearing a mask is to protect others and himself, and also as a symbol of what 'you should be doing.' This aligns with the claim.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000318",
    "statement": "Iga dominates the early neutralizing antibody response to sars-cov-2",
    "label": "SUPPORTED",
    "evidences": [
      "Our results show that human IgA antibodies are often detectable before the appearance of SARS-CoV-2-specific IgG and suggest a role for IgA antibodies in early virus neutralization.",
      "Our results show that serum IgA, particularly anti-RBD IgA, are detected earlier compared with IgG, and the dramatic plasmablast expansion that follows SARS-CoV-2 infection is dominated by IgA-secreting cells (Fig.",
      "Early SARS- CoV-2-specific humoral responses were dominated by IgA antibodies."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence shows that IgA antibodies are detected earlier and dominate the early response to SARS-CoV-2 infection compared to IgG. This suggests that Iga dominates the early neutralizing antibody response to sars-cov-2.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000319",
    "statement": "Iga dominates the full neutralizing antibody response to sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our results show that human IgA antibodies are often detectable before the appearance of SARS-CoV-2-specific IgG and suggest a role for IgA antibodies in early virus neutralization.",
      "Our results show that serum IgA, particularly anti-RBD IgA, are detected earlier compared with IgG, and the dramatic plasmablast expansion that follows SARS-CoV-2 infection is dominated by IgA-secreting cells (Fig.",
      "Early SARS- CoV-2-specific humoral responses were dominated by IgA antibodies."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that human IgA antibodies are detectable earlier than IgG in response to SARS-CoV-2 infection and that the plasmablast expansion following the infection is dominated by IgA-secreting cells. This suggests that Iga plays a significant role in the early neutralizing response to SARS-CoV-2.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000320",
    "statement": "Iga dominates the enhanced neutralizing antibody response to sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our results show that human IgA antibodies are often detectable before the appearance of SARS-CoV-2-specific IgG and suggest a role for IgA antibodies in early virus neutralization.",
      "Our results show that serum IgA, particularly anti-RBD IgA, are detected earlier compared with IgG, and the dramatic plasmablast expansion that follows SARS-CoV-2 infection is dominated by IgA-secreting cells (Fig.",
      "Early SARS- CoV-2-specific humoral responses were dominated by IgA antibodies."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows that in response to SARS-CoV-2 infection, the early humoral response is dominated by IgA antibodies. This suggests that Iga plays a significant role in the neutralizing antibody response to SARS-CoV-2.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000321",
    "statement": "Iga dominates the effective neutralizing antibody response to sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our results show that human IgA antibodies are often detectable before the appearance of SARS-CoV-2-specific IgG and suggest a role for IgA antibodies in early virus neutralization.",
      "Our results show that serum IgA, particularly anti-RBD IgA, are detected earlier compared with IgG, and the dramatic plasmablast expansion that follows SARS-CoV-2 infection is dominated by IgA-secreting cells (Fig.",
      "Early SARS- CoV-2-specific humoral responses were dominated by IgA antibodies."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows that in response to SARS-CoV-2 infection, IgA antibodies appear earlier than IgG and there is a significant expansion of IgA-secreting cells. This suggests that Iga dominates the effective neutralizing antibody response to sars-cov-2 at an early stage of infection.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000322",
    "statement": "Fda authorizes first diagnostic test for screening of people without known or suspected covid-19 infection",
    "label": "SUPPORTED",
    "evidences": [
      "Last month, the FDA posted updated templates with recommendations for test developers to demonstrate validation for a test to be authorized for screening of asymptomatic people, as well as for sample pooling.",
      "The FDA reissued the LabCorp COVID-19 RT-PCR Test EUA to expand use of the test to anyone, after the company provided scientific data showing the tests ability to detect SARS-CoV-2 in a general, asymptomatic population.",
      "Additionally, the data reviewed by the FDA demonstrated that the test is as accurate in the broader asymptomatic population as it is among people suspected to have COVID-19.",
      "Until now, molecular diagnostic tests have generally been authorized for people suspected of having COVID-19 by their health care provider, which has allowed asymptomatic people to be tested, when warranted, at the discretion of the health care provider."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that the FDA has reissued a test (LabCorp COVID-19 RT-PCR Test) for authorization to screen asymptomatic people, which means it is now authorized for testing individuals without known or suspected Covid-19 infection.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000323",
    "statement": "Fda authorizes another diagnostic test for screening of people without known or suspected covid-19 infection",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Last month, the FDA posted updated templates with recommendations for test developers to demonstrate validation for a test to be authorized for screening of asymptomatic people, as well as for sample pooling.",
      "The FDA reissued the LabCorp COVID-19 RT-PCR Test EUA to expand use of the test to anyone, after the company provided scientific data showing the tests ability to detect SARS-CoV-2 in a general, asymptomatic population.",
      "Additionally, the data reviewed by the FDA demonstrated that the test is as accurate in the broader asymptomatic population as it is among people suspected to have COVID-19.",
      "Until now, molecular diagnostic tests have generally been authorized for people suspected of having COVID-19 by their health care provider, which has allowed asymptomatic people to be tested, when warranted, at the discretion of the health care provider."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that the FDA reissued a test for COVID-19 to expand its use to anyone and reviewed data demonstrating that the test is accurate in an asymptomatic population. This suggests that the FDA has authorized another diagnostic test for screening of people without known or suspected COVID-19 infection.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000324",
    "statement": "Johnson & johnson pauses covid-19 vaccine trials due to sick subject",
    "label": "SUPPORTED",
    "evidences": [
      "This is the second time trials for a Covid-19 vaccine trial have been paused over a safety concern."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence does not specify which specific company's Covid-19 vaccine trials were paused, nor does it mention Johnson & Johnson. While it is possible that multiple companies are experiencing similar issues, this claim cannot be definitively supported or refuted based on the given information.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000325",
    "statement": "Johnson & johnson developed covid-19 vaccine trials due to sick subject",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "This is the second time trials for a Covid-19 vaccine trial have been paused over a safety concern."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence does not provide information about the development or creation of the COVID-19 vaccine by Johnson & Johnson, nor does it suggest that the sickness of a subject caused the trials to be paused.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000326",
    "statement": "Asymptomatic cases may not be infectious , wuhan study indicates.",
    "label": "SUPPORTED",
    "evidences": [
      "In summary, the detection rate of asymptomatic positive cases in the post- lockdown Wuhan was very low (0.303/10,000), and there was no evidence that the identified asymptomatic positive cases were infectious."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence shows a very low detection rate of asymptomatic positive cases in post-lockdown Wuhan (0.303/10,000), and no evidence that these identified asymptomatic positive cases were infectious.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000327",
    "statement": "Asymptomatic cases may also be infectious, wuhan study indicates.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In summary, the detection rate of asymptomatic positive cases in the post- lockdown Wuhan was very low (0.303/10,000), and there was no evidence that the identified asymptomatic positive cases were infectious."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided indicates that the detection rate of asymptomatic positive cases in post-lockdown Wuhan was very low and there was no evidence that these identified asymptomatic positive cases were infectious. However, the claim states that 'asymptomatic cases may also be infectious', which contradicts the information given.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000328",
    "statement": "Asymptomatic cases may only be infectious, wuhan study indicates.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In summary, the detection rate of asymptomatic positive cases in the post- lockdown Wuhan was very low (0.303/10,000), and there was no evidence that the identified asymptomatic positive cases were infectious."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence indicates that in the post-lockdown Wuhan study, there was no evidence that asymptomatic positive cases were infectious. However, this does not necessarily mean that all asymptomatic cases are only infectious, as the study may not have been comprehensive enough to capture all cases or the transmission dynamics in other settings.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000329",
    "statement": "Asymptomatic cases may still be infectious, wuhan study indicates.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In summary, the detection rate of asymptomatic positive cases in the post- lockdown Wuhan was very low (0.303/10,000), and there was no evidence that the identified asymptomatic positive cases were infectious."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence states that the detection rate of asymptomatic positive cases in post-lockdown Wuhan was very low and there was no evidence that these identified cases were infectious. This goes against the claim that asymptomatic cases may still be infectious.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000330",
    "statement": "Robust ace2 protein expression localizes to the motile cilia of the respiratory tract epithelia and is not increased by ace inhibitors or angiotensin receptor blockers",
    "label": "SUPPORTED",
    "evidences": [
      "We further determined whether ACE2 expression in the cilia of upper respiratory cells was influenced by patient demographics, clinical characteristics, co-morbidities, or medication use, and found no evidence that the use of angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARBs) increases ACE2 protein expression.",
      "ACE2 expression in the nasal cilia is not increased in patients taking angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARBs), but potentially decreased in ACEI patients."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not state that the ACE2 protein expression localizes to the motile cilia of the respiratory tract epithelia. The claim can only be supported if further evidence or studies are presented that prove this specific localization.",
    "confidence": 0.7
  },
  {
    "id": "covid_fact-000331",
    "statement": "Robust ace2 protein expression localizes to the motile cilia of the respiratory tract epithelia and is significantly increased by ace inhibitors or angiotensin receptor blockers",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We further determined whether ACE2 expression in the cilia of upper respiratory cells was influenced by patient demographics, clinical characteristics, co-morbidities, or medication use, and found no evidence that the use of angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARBs) increases ACE2 protein expression.",
      "ACE2 expression in the nasal cilia is not increased in patients taking angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARBs), but potentially decreased in ACEI patients."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not support the claim that robust ace2 protein expression localizes to the motile cilia of the respiratory tract epithelia and is significantly increased by ace inhibitors or angiotensin receptor blockers. Instead, it indicates that ACE2 expression in the nasal cilia is not increased in patients taking angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARBs), but potentially decreased in ACEI patients.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000332",
    "statement": "Robust ace2 protein expression localizes to the motile cilia of the respiratory tract epithelia and is greatly increased by ace inhibitors or angiotensin receptor blockers",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We further determined whether ACE2 expression in the cilia of upper respiratory cells was influenced by patient demographics, clinical characteristics, co-morbidities, or medication use, and found no evidence that the use of angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARBs) increases ACE2 protein expression.",
      "ACE2 expression in the nasal cilia is not increased in patients taking angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARBs), but potentially decreased in ACEI patients."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not support the claim that Robust ace2 protein expression localizes to the motile cilia of the respiratory tract epithelia and is greatly increased by ace inhibitors or angiotensin receptor blockers. Instead, it suggests that ACE2 expression in the nasal cilia is not increased in patients taking angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARBs), but potentially decreased in ACEI patients.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000333",
    "statement": "Robust ace2 protein expression localizes to the motile cilia of the respiratory tract epithelia and is further increased by ace inhibitors or angiotensin receptor blockers",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We further determined whether ACE2 expression in the cilia of upper respiratory cells was influenced by patient demographics, clinical characteristics, co-morbidities, or medication use, and found no evidence that the use of angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARBs) increases ACE2 protein expression.",
      "ACE2 expression in the nasal cilia is not increased in patients taking angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARBs), but potentially decreased in ACEI patients."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided states that ACE2 expression in the nasal cilia is not increased in patients taking angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARBs). However, it does not clearly state that Robust ace2 protein expression localizes to the motile cilia of the respiratory tract epithelia. Furthermore, the evidence suggests a potential decrease in ACE2 expression in ACEI patients, which contradicts the claim.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000334",
    "statement": "A consensus covid-19 immune signature combines immuno-protection with discrete sepsis-like traits associated with poor prognosis",
    "label": "SUPPORTED",
    "evidences": [
      "The core signature conspicuously blended adaptive B cell responses typical of virus infection or vaccination with discrete traits hitherto associated with sepsis, including monocyte and dendritic cell dampening, and hyperactivation and depletion of discrete T cell subsets."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence describes a consensus covid-19 immune signature that combines adaptive B cell responses (typical of virus infection or vaccination) with traits associated with sepsis such as monocyte and dendritic cell dampening and T cell subset depletion/hyperactivation. These findings suggest the support for the claim.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000335",
    "statement": "A novel covid-19 immune signature combines immuno-protection with discrete sepsis-like traits associated with poor prognosis",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The core signature conspicuously blended adaptive B cell responses typical of virus infection or vaccination with discrete traits hitherto associated with sepsis, including monocyte and dendritic cell dampening, and hyperactivation and depletion of discrete T cell subsets."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence describes a novel covid-19 immune signature that combines adaptive B cell responses (typical of virus infection or vaccination) with traits associated with sepsis (monocyte and dendritic cell dampening, T cell depletion, and activation). This suggests support for the claim.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000336",
    "statement": "A unique covid-19 immune signature combines immuno-protection with discrete sepsis-like traits associated with poor prognosis",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The core signature conspicuously blended adaptive B cell responses typical of virus infection or vaccination with discrete traits hitherto associated with sepsis, including monocyte and dendritic cell dampening, and hyperactivation and depletion of discrete T cell subsets."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that the 'unique covid-19 immune signature' combines immuno-protection characteristics typical of virus infection or vaccination with discrete traits associated with sepsis such as monocyte and dendritic cell dampening, T cell subsets hyperactivation, and depletion. This suggests support for the claim.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000337",
    "statement": "The institute for disease modeling puts the cfr at 0.94 %",
    "label": "SUPPORTED",
    "evidences": [
      "With this additional adjustment and using the same methodology and data from the original version of this report, the corrected estimate of the infection-fatality-ratio (IFR) is 0.94 (0.37, 2.9) percent.",
      "In this report, we use a small amount of linelist data with complete disease progression information from early in the outbreak to estimate the delays between case confirmation and death, and then the time and age-adjusted confirmed-CFR."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is directly stated in the evidence as 'the corrected estimate of the infection-fatality-ratio (IFR) is 0.94 (0.37, 2.9) percent'.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000338",
    "statement": "The institute for disease transmission puts the cfr at 0.94 %",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "With this additional adjustment and using the same methodology and data from the original version of this report, the corrected estimate of the infection-fatality-ratio (IFR) is 0.94 (0.37, 2.9) percent.",
      "In this report, we use a small amount of linelist data with complete disease progression information from early in the outbreak to estimate the delays between case confirmation and death, and then the time and age-adjusted confirmed-CFR."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is directly stated in the evidence: 'the corrected estimate of the infection-fatality-ratio (IFR) is 0.94 (0.37, 2.9) percent'.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000339",
    "statement": "The institute for disease surveillance puts the cfr at 0.94 %",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "With this additional adjustment and using the same methodology and data from the original version of this report, the corrected estimate of the infection-fatality-ratio (IFR) is 0.94 (0.37, 2.9) percent.",
      "In this report, we use a small amount of linelist data with complete disease progression information from early in the outbreak to estimate the delays between case confirmation and death, and then the time and age-adjusted confirmed-CFR."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided in this report directly states that the corrected estimate of the infection-fatality-ratio (IFR) is 0.94 (0.37, 2.9) percent. This is a clear indication that the institute for disease surveillance puts the cfr at 0.94 %.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000340",
    "statement": "The institute for disease detection puts the cfr at 0.94 %",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "With this additional adjustment and using the same methodology and data from the original version of this report, the corrected estimate of the infection-fatality-ratio (IFR) is 0.94 (0.37, 2.9) percent.",
      "In this report, we use a small amount of linelist data with complete disease progression information from early in the outbreak to estimate the delays between case confirmation and death, and then the time and age-adjusted confirmed-CFR."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is directly supported by the evidence as it states that the corrected estimate of the infection-fatality-ratio (IFR) is 0.94 (0.37, 2.9) percent, which is equivalent to stating the cfr at 0.94%.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000341",
    "statement": "Evolutionary arms race between virus and host drives genetic diversity in bat sars related coronavirus spike genes",
    "label": "SUPPORTED",
    "evidences": [
      "It is speculated that the interaction between bat ACE2 and SARSr-CoV spike proteins drives diversity.",
      "These results suggest that the SARSr-CoV spike protein and R. sinicus ACE2 may have coevolved over time and experienced selection pressure from each other, triggering the evolutionary arms race dynamics."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that there is an interaction between bat ACE2 and SARSr-CoV spike proteins, which is speculated to drive diversity. This interaction can be seen as part of an evolutionary arms race dynamics where the virus (SARSr-CoV) adapts to infect the host (bat), and in response, the host evolves to resist infection by producing changes in its genes, particularly the ACE2 gene that interacts with the SARSr-CoV spike protein. This evolutionary process can lead to genetic diversity within both the virus and host populations.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000342",
    "statement": "Evolutionary arms race between virus and coronavirus drives genetic diversity in bat sars related coronavirus spike genes",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "It is speculated that the interaction between bat ACE2 and SARSr-CoV spike proteins drives diversity.",
      "These results suggest that the SARSr-CoV spike protein and R. sinicus ACE2 may have coevolved over time and experienced selection pressure from each other, triggering the evolutionary arms race dynamics."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests that the SARSr-CoV spike protein and R. sinicus ACE2 have coevolved over time, indicating an evolutionary arms race between the virus and coronavirus. This coevolution is inferred to drive diversity in the bat SARS related coronavirus spike genes.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000343",
    "statement": "Evolutionary arms race between virus and viruses drives genetic diversity in bat sars related coronavirus spike genes",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "It is speculated that the interaction between bat ACE2 and SARSr-CoV spike proteins drives diversity.",
      "These results suggest that the SARSr-CoV spike protein and R. sinicus ACE2 may have coevolved over time and experienced selection pressure from each other, triggering the evolutionary arms race dynamics."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that there is an interaction between bat ACE2 and SARSr-CoV spike proteins, which is a key factor in the infection process of these viruses. The mention of 'evolutionary arms race dynamics' indicates a continuous adaptation or evolution of the virus and its host (ACE2) to outsmart each other, driving genetic diversity. This is consistent with an evolutionary arms race between virus and viruses.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000344",
    "statement": "Evolutionary arms race between virus and virus drives genetic diversity in bat sars related coronavirus spike genes",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "It is speculated that the interaction between bat ACE2 and SARSr-CoV spike proteins drives diversity.",
      "These results suggest that the SARSr-CoV spike protein and R. sinicus ACE2 may have coevolved over time and experienced selection pressure from each other, triggering the evolutionary arms race dynamics."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that there is a selective interaction between bat ACE2 and SARSr-CoV spike proteins, implying an evolutionary arms race dynamics driven by this interaction. This is consistent with the claim that an evolutionary arms race between virus and virus drives genetic diversity in bat SARS-related coronavirus spike genes.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000345",
    "statement": "Active monitoring of persons exposed to patients with confirmed covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "On January 20, state and local health departments in the United States, in collaboration with teams deployed from CDC, began identifying and monitoring all persons considered to have had close contact with patients with confirmed COVID-19 ( 2 ).",
      "The duration of time in the same airspace after the patient with confirmed COVID-19 was applied differently by health jurisdictions."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that on January 20, health departments in the United States began monitoring persons who had close contact with patients with confirmed COVID-19. This directly supports the claim of active monitoring.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000346",
    "statement": "Active monitoring of persons exposed to patients without confirmed covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "On January 20, state and local health departments in the United States, in collaboration with teams deployed from CDC, began identifying and monitoring all persons considered to have had close contact with patients with confirmed COVID-19 ( 2 ).",
      "The duration of time in the same airspace after the patient with confirmed COVID-19 was applied differently by health jurisdictions."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence directly supports the claim that active monitoring of persons exposed to patients without confirmed COVID-19 is being done in collaboration with CDC and health departments. The differences in duration of time in the same airspace after the patient with confirmed COVID-19 indicate variations in application, but do not contradict the fact that monitoring is taking place.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000347",
    "statement": "Convalescent plasma to treat covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "The investigational convalescent plasma is intended for the treatment of hospitalized patients with COVID-19.",
      "Effectiveness of convalescent plasma therapy in severe COVID-19 patients.",
      "Convalescent plasma for COVID-19: a randomized clinical trial.",
      "Expanded access to convalescent plasma for the treatment of patients with COVID-19.",
      "Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates multiple clinical trials and studies on the use of convalescent plasma for treating COVID-19 patients, which suggests that the claim is supported.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000348",
    "statement": "Unvalescent plasma to treat covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The investigational convalescent plasma is intended for the treatment of hospitalized patients with COVID-19.",
      "Effectiveness of convalescent plasma therapy in severe COVID-19 patients.",
      "Convalescent plasma for COVID-19: a randomized clinical trial.",
      "Expanded access to convalescent plasma for the treatment of patients with COVID-19.",
      "Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided discusses the investigation, clinical trials, and expanded access to convalescent plasma for the treatment of patients with COVID-19. This suggests that there is ongoing research on the use of unvalescent plasma (convalescent plasma) as a potential treatment for COVID-19.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000349",
    "statement": "Convalescent antibiotics to treat covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The investigational convalescent plasma is intended for the treatment of hospitalized patients with COVID-19.",
      "Effectiveness of convalescent plasma therapy in severe COVID-19 patients.",
      "Convalescent plasma for COVID-19: a randomized clinical trial.",
      "Expanded access to convalescent plasma for the treatment of patients with COVID-19.",
      "Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided discusses the use and effectiveness of convalescent plasma in treating COVID-19 patients. This includes references to randomized clinical trials and studies on its treatment of severe COVID-19 patients.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000350",
    "statement": "Subvalescent plasma to treat covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The investigational convalescent plasma is intended for the treatment of hospitalized patients with COVID-19.",
      "Effectiveness of convalescent plasma therapy in severe COVID-19 patients.",
      "Convalescent plasma for COVID-19: a randomized clinical trial.",
      "Expanded access to convalescent plasma for the treatment of patients with COVID-19.",
      "Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided discusses the use of convalescent plasma for the treatment of COVID-19 patients. Several studies are mentioned, including randomized clinical trials and a propensity score-matched control study, which suggest that convalescent plasma may have some effectiveness in treating severe COVID-19. However, it's important to note that more research is likely needed to confirm these findings and understand the optimal use of this treatment.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000351",
    "statement": "Man , 25 , catches coronavirus twice in first such us case",
    "label": "SUPPORTED",
    "evidences": [
      "Photograph: John Locher/AP Press Association Tue 13 Oct 2020 01.24 EDT Researchers in the US have reported the countrys first confirmed case of coronavirus reinfection.",
      "Genetic sequencing of the virus showed he was infected twice by different strains of Sars-CoV-2, according to researchers.",
      "A 25-year-old man with no known immune disorders or underlying conditions was infected with Covid-19 on two separate occasions, according to a study published in the Lancet Infectious Diseases journal.",
      "Photograph: John Locher/AP The man required hospitalisation and oxygen support the second time he caught coronavirus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided in the form of a news article from AP Press Association and a publication in The Lancet Infectious Diseases journal clearly indicates that a 25-year-old man in the US was infected with Covid-19 twice, making it the first confirmed case of coronavirus reinfection.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000352",
    "statement": "13, 25, catches coronavirus twice in first such us case",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Photograph: John Locher/AP Press Association Tue 13 Oct 2020 01.24 EDT Researchers in the US have reported the countrys first confirmed case of coronavirus reinfection.",
      "Genetic sequencing of the virus showed he was infected twice by different strains of Sars-CoV-2, according to researchers.",
      "A 25-year-old man with no known immune disorders or underlying conditions was infected with Covid-19 on two separate occasions, according to a study published in the Lancet Infectious Diseases journal.",
      "Photograph: John Locher/AP The man required hospitalisation and oxygen support the second time he caught coronavirus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence directly states that a 25-year-old man was infected with Covid-19 on two separate occasions, and this case is the first confirmed case of coronavirus reinfection in the US as reported by researchers.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000353",
    "statement": "2, 25, catches coronavirus twice in first such us case",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Photograph: John Locher/AP Press Association Tue 13 Oct 2020 01.24 EDT Researchers in the US have reported the countrys first confirmed case of coronavirus reinfection.",
      "Genetic sequencing of the virus showed he was infected twice by different strains of Sars-CoV-2, according to researchers.",
      "A 25-year-old man with no known immune disorders or underlying conditions was infected with Covid-19 on two separate occasions, according to a study published in the Lancet Infectious Diseases journal.",
      "Photograph: John Locher/AP The man required hospitalisation and oxygen support the second time he caught coronavirus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that a 25-year-old man was infected with Covid-19 on two separate occasions, according to a study published in the Lancet Infectious Diseases journal. This supports the claim of him catching coronavirus twice.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000354",
    "statement": "19, 25, catches coronavirus twice in first such us case",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Photograph: John Locher/AP Press Association Tue 13 Oct 2020 01.24 EDT Researchers in the US have reported the countrys first confirmed case of coronavirus reinfection.",
      "Genetic sequencing of the virus showed he was infected twice by different strains of Sars-CoV-2, according to researchers.",
      "A 25-year-old man with no known immune disorders or underlying conditions was infected with Covid-19 on two separate occasions, according to a study published in the Lancet Infectious Diseases journal.",
      "Photograph: John Locher/AP The man required hospitalisation and oxygen support the second time he caught coronavirus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided in the form of a news article from The Guardian states that researchers have reported the first confirmed case of coronavirus reinfection in the US. The man in question is identified as being 25 years old and was infected twice with different strains of Sars-CoV-2. Furthermore, the man required hospitalization and oxygen support the second time he caught coronavirus.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000355",
    "statement": "Black , hispanic communities struggle in covid-19 vaccine rollout across the u.s .",
    "label": "SUPPORTED",
    "evidences": [
      "Black and Latino people also report higher levels of vaccine hesitancy and distrust compared to white Americans, according to a recent survey by the COVID Collaborative, a coalition of national experts on health, education and the economy.",
      "Fueled by a dark history of medical experimentation and unequal access to care, people in Black and Latino communities struggling with high Covid-19 rates are among those least likely to get vaccinated, health advocates say.",
      "The damage inflicted by the Tuskegee Study and ongoing health care disparities, including lack of access to affordable medical care and to expensive pharmaceutical drugs, continues today as Blacks and Latinos remain leery of potential vaccines, advocates say."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that Black and Hispanic communities are less likely to get vaccinated due to historical factors such as the Tuskegee Study and ongoing healthcare disparities, which includes lack of access to affordable medical care and expensive pharmaceuticals. This could potentially lead to a struggle in the COVID-19 vaccine rollout in these communities.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000356",
    "statement": "2, hispanic communities struggle in covid-19 vaccine rollout across the u.s.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Black and Latino people also report higher levels of vaccine hesitancy and distrust compared to white Americans, according to a recent survey by the COVID Collaborative, a coalition of national experts on health, education and the economy.",
      "Fueled by a dark history of medical experimentation and unequal access to care, people in Black and Latino communities struggling with high Covid-19 rates are among those least likely to get vaccinated, health advocates say.",
      "The damage inflicted by the Tuskegee Study and ongoing health care disparities, including lack of access to affordable medical care and to expensive pharmaceutical drugs, continues today as Blacks and Latinos remain leery of potential vaccines, advocates say."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides data (a recent survey) showing that Black and Latino people report higher levels of vaccine hesitancy compared to white Americans. It also explains the underlying reasons for this hesitancy, which are tied to historical medical experimentation and health disparities in these communities.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000357",
    "statement": "6, hispanic communities struggle in covid-19 vaccine rollout across the u.s.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Black and Latino people also report higher levels of vaccine hesitancy and distrust compared to white Americans, according to a recent survey by the COVID Collaborative, a coalition of national experts on health, education and the economy.",
      "Fueled by a dark history of medical experimentation and unequal access to care, people in Black and Latino communities struggling with high Covid-19 rates are among those least likely to get vaccinated, health advocates say.",
      "The damage inflicted by the Tuskegee Study and ongoing health care disparities, including lack of access to affordable medical care and to expensive pharmaceutical drugs, continues today as Blacks and Latinos remain leery of potential vaccines, advocates say."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence discusses higher levels of vaccine hesitancy and distrust among Black and Latino communities compared to white Americans, as well as their struggles with high Covid-19 rates. However, it does not directly provide data or concrete examples that specifically demonstrate these challenges in the vaccine rollout across the U.S., limiting the claim's support.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000358",
    "statement": "3, hispanic communities struggle in covid-19 vaccine rollout across the u.s.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Black and Latino people also report higher levels of vaccine hesitancy and distrust compared to white Americans, according to a recent survey by the COVID Collaborative, a coalition of national experts on health, education and the economy.",
      "Fueled by a dark history of medical experimentation and unequal access to care, people in Black and Latino communities struggling with high Covid-19 rates are among those least likely to get vaccinated, health advocates say.",
      "The damage inflicted by the Tuskegee Study and ongoing health care disparities, including lack of access to affordable medical care and to expensive pharmaceutical drugs, continues today as Blacks and Latinos remain leery of potential vaccines, advocates say."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided discusses the higher levels of vaccine hesitancy and distrust among Black and Latino communities compared to white Americans, and mentions the historical context of medical experimentation and unequal access to care as factors contributing to this hesitancy. However, it does not directly provide evidence that 'hispanic communities' struggle in the COVID-19 vaccine rollout across the U.S., as the claim states.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000359",
    "statement": "Past covid-19 infection provides some immunity but people may still carry and transmit virus.",
    "label": "SUPPORTED",
    "evidences": [
      "The PHE also warned that although those with antibodies have some protection from becoming ill with COVID-19 themselves, early evidence from the next stage of the study suggests that some of these individuals carry high levels of virus and could continue to transmit the virus to others.",
      "Published 14 January 2021 From: Public Health England People infected with COVID-19 in the past are likely to be protected against reinfection for several months, a Public Health England (PHE) study has found, although experts cautioned those with immunity may still be able carry the virus in their nose and throat and therefore have a risk of transmitting to others.",
      "PHE also warned that although those with antibodies have some protection from becoming ill with COVID-19 themselves, early evidence from the next stage of the study suggests that some of these individuals carry high levels of virus and could continue to transmit the virus to others.",
      "But a small number of people with antibodies may still be able to carry and transmit COVID-19 according to the study.",
      "iStock London, January 14 An official UK study released on Thursday concludes that a past COVID-19 infection provides some immunity for at least five months, but people may still carry and transmit coronavirus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that past COVID-19 infection provides some protection against reinfection for several months, but it also warns that some of these individuals may carry high levels of the virus and could continue to transmit the virus to others.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000360",
    "statement": "Past covid-19 infection provides some immunity but people cannot still carry and transmit virus.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The PHE also warned that although those with antibodies have some protection from becoming ill with COVID-19 themselves, early evidence from the next stage of the study suggests that some of these individuals carry high levels of virus and could continue to transmit the virus to others.",
      "Published 14 January 2021 From: Public Health England People infected with COVID-19 in the past are likely to be protected against reinfection for several months, a Public Health England (PHE) study has found, although experts cautioned those with immunity may still be able carry the virus in their nose and throat and therefore have a risk of transmitting to others.",
      "PHE also warned that although those with antibodies have some protection from becoming ill with COVID-19 themselves, early evidence from the next stage of the study suggests that some of these individuals carry high levels of virus and could continue to transmit the virus to others.",
      "But a small number of people with antibodies may still be able to carry and transmit COVID-19 according to the study.",
      "iStock London, January 14 An official UK study released on Thursday concludes that a past COVID-19 infection provides some immunity for at least five months, but people may still carry and transmit coronavirus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that while people with past COVID-19 infection have some protection from reinfection for several months, they may still carry and transmit the virus to others.",
    "confidence": 0.85
  },
  {
    "id": "covid_fact-000361",
    "statement": "Systematic analysis of innate immune antagonism reveals vulnerabilities of sars-cov-2",
    "label": "SUPPORTED",
    "evidences": [
      "Overall our analyses revealed that IFN-\u03b3 and IFN-\u03bb1 signalling are antagonised the least, leaving SARS-CoV-2 highly susceptible to these two cytokines."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows that the systematic analysis of innate immune antagonism towards SARS-CoV-2 reveals vulnerabilities to IFN-\u03b3 and IFN-\u03bb1 cytokines, which suggests that these two cytokines could potentially be effective in combating or treating SARS-CoV-2.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000362",
    "statement": "Systematic analysis of cellular immune antagonism reveals vulnerabilities of sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Overall our analyses revealed that IFN-\u03b3 and IFN-\u03bb1 signalling are antagonised the least, leaving SARS-CoV-2 highly susceptible to these two cytokines."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence presented shows that the systematic analysis of cellular immune antagonism suggests that SARS-CoV-2 is highly susceptible to IFN-\u03b3 and IFN-\u03bb1 cytokines. This supports the claim that vulnerabilities of SARS-CoV-2 are revealed through a systematic analysis of cellular immune antagonism.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000363",
    "statement": "Systematic analysis of adaptive immune antagonism reveals vulnerabilities of sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Overall our analyses revealed that IFN-\u03b3 and IFN-\u03bb1 signalling are antagonised the least, leaving SARS-CoV-2 highly susceptible to these two cytokines."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence shows a systematic analysis of adaptive immune antagonism towards SARS-CoV-2, and it reveals that IFN-\u03b3 and IFN-\u03bb1 signalling are the least antagonized. This suggests that SARS-CoV-2 is vulnerable to these two cytokines.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000364",
    "statement": "Systematic analysis of antiviral immune antagonism reveals vulnerabilities of sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Overall our analyses revealed that IFN-\u03b3 and IFN-\u03bb1 signalling are antagonised the least, leaving SARS-CoV-2 highly susceptible to these two cytokines."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests that SARS-CoV-2 is susceptible to IFN-\u03b3 and IFN-\u03bb1 cytokines because they antagonize the system least. This implies that a systematic analysis of antiviral immune antagonism has revealed vulnerabilities of SARS-CoV-2.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000365",
    "statement": "Trial to promote recovery from covid-19 with ivermectin or endocrine therapy",
    "label": "SUPPORTED",
    "evidences": [
      "This will be a randomized, open-label study to determine if bicalutamide improves the rate of clinical improvement in patients with COVID-19.",
      "This will be a randomized, open-label study to determine if bicalutamide or ivermectin improves the time to clinical improvement in patients with COVID-19 over historical controls."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided only mentions a study for bicalutamide and ivermectin in the context of improving the time to clinical improvement for COVID-19 patients, but it does not mention any connection or promotion of recovery from COVID-19 specifically with endocrine therapy.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000366",
    "statement": "Trial to no recovery from covid-19 with ivermectin or endocrine therapy",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "This will be a randomized, open-label study to determine if bicalutamide improves the rate of clinical improvement in patients with COVID-19.",
      "This will be a randomized, open-label study to determine if bicalutamide or ivermectin improves the time to clinical improvement in patients with COVID-19 over historical controls."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence does not mention ivermectin or endocrine therapy in relation to recovery from COVID-19. Instead, it refers to a study for determining the effect of bicalutamide on clinical improvement in patients with COVID-19.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000367",
    "statement": "Coronavirus vaccines leap through safety trials",
    "label": "SUPPORTED",
    "evidences": [
      "Vaccines expose the immune system to components of a virus  the coronavirus spike protein, in the case of nearly all COVID-19 vaccines  in the hope of teaching it how to react against a real infection in the future.",
      "In the past few days, scientists working at feverish pace to develop vaccines against the coronavirus have released a flood of data from their first human trials.",
      "The vaccine is inducing the kind of immune responses that we think are inducing protection against coronavirus, said Sarah Gilbert, a vaccinologist co-leading the Oxford effort, in a press briefing announcing the results.",
      "But they suggest that the candidate vaccines are broadly safe, and offer the first hints that vaccines can summon immune responses similar to those of people who have been infected with the virus.",
      "Its definitely plausible that theres more than one way to protect against this virus. The nature of the immune response that protects  or fails to protect  against COVID-19 will become clearer when efficacy trials deliver their first results."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided suggests that the vaccines are safe and can induce immune responses, but it does not definitively show that they 'leap through safety trials'. The claim implies a rapid or accelerated process of vaccine development which is not evident from this evidence.",
    "confidence": 0.5
  },
  {
    "id": "covid_fact-000368",
    "statement": "Coronavirus vaccines remain through safety trials",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Vaccines expose the immune system to components of a virus  the coronavirus spike protein, in the case of nearly all COVID-19 vaccines  in the hope of teaching it how to react against a real infection in the future.",
      "In the past few days, scientists working at feverish pace to develop vaccines against the coronavirus have released a flood of data from their first human trials.",
      "The vaccine is inducing the kind of immune responses that we think are inducing protection against coronavirus, said Sarah Gilbert, a vaccinologist co-leading the Oxford effort, in a press briefing announcing the results.",
      "But they suggest that the candidate vaccines are broadly safe, and offer the first hints that vaccines can summon immune responses similar to those of people who have been infected with the virus.",
      "Its definitely plausible that theres more than one way to protect against this virus. The nature of the immune response that protects  or fails to protect  against COVID-19 will become clearer when efficacy trials deliver their first results."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim is about the current status of Coronavirus vaccines being in safety trials, but the evidence only discusses initial human trials and immune responses induced by the vaccine, not the completion or ongoing nature of safety trials.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000369",
    "statement": "Coronavirus vaccines work through safety trials",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Vaccines expose the immune system to components of a virus  the coronavirus spike protein, in the case of nearly all COVID-19 vaccines  in the hope of teaching it how to react against a real infection in the future.",
      "In the past few days, scientists working at feverish pace to develop vaccines against the coronavirus have released a flood of data from their first human trials.",
      "The vaccine is inducing the kind of immune responses that we think are inducing protection against coronavirus, said Sarah Gilbert, a vaccinologist co-leading the Oxford effort, in a press briefing announcing the results.",
      "But they suggest that the candidate vaccines are broadly safe, and offer the first hints that vaccines can summon immune responses similar to those of people who have been infected with the virus.",
      "Its definitely plausible that theres more than one way to protect against this virus. The nature of the immune response that protects  or fails to protect  against COVID-19 will become clearer when efficacy trials deliver their first results."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided mentions safety trials and the induction of immune responses in human trials, but it does not explicitly state that vaccines work through these trials. Efficacy trials (which test if a vaccine actually protects against the disease) are mentioned as providing more information on this topic.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000370",
    "statement": "Couple diagnosed with coronavirus flew on delta , hawaiian airlines flights , carriers confirm",
    "label": "SUPPORTED",
    "evidences": [
      "Delta Air Lines and Hawaiian Airlines have confirmed that a couple diagnosed with the coronavirus traveled on their flights in and around Hawaii earlier this month.",
      "Delta and Hawaiian Airlines have both since confirmed they are communicating with the U.S. Centers for Disease Control and Prevention (CDC) in the wake of the couples recent coronavirus diagnosis."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly states that a couple diagnosed with coronavirus traveled on Delta and Hawaiian Airlines flights.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000371",
    "statement": "Mice diagnosed with coronavirus flew on delta, hawaiian airlines flights, carriers confirm",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Delta Air Lines and Hawaiian Airlines have confirmed that a couple diagnosed with the coronavirus traveled on their flights in and around Hawaii earlier this month.",
      "Delta and Hawaiian Airlines have both since confirmed they are communicating with the U.S. Centers for Disease Control and Prevention (CDC) in the wake of the couples recent coronavirus diagnosis."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence only confirms that a couple diagnosed with coronavirus traveled on Delta and Hawaiian Airlines flights. It does not provide any information about mice being involved.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000372",
    "statement": "Dogs diagnosed with coronavirus flew on delta, hawaiian airlines flights, carriers confirm",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Delta Air Lines and Hawaiian Airlines have confirmed that a couple diagnosed with the coronavirus traveled on their flights in and around Hawaii earlier this month.",
      "Delta and Hawaiian Airlines have both since confirmed they are communicating with the U.S. Centers for Disease Control and Prevention (CDC) in the wake of the couples recent coronavirus diagnosis."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not specify that dogs were diagnosed with the coronavirus and flew on the mentioned airlines.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000373",
    "statement": "Cats diagnosed with coronavirus flew on delta, hawaiian airlines flights, carriers confirm",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Delta Air Lines and Hawaiian Airlines have confirmed that a couple diagnosed with the coronavirus traveled on their flights in and around Hawaii earlier this month.",
      "Delta and Hawaiian Airlines have both since confirmed they are communicating with the U.S. Centers for Disease Control and Prevention (CDC) in the wake of the couples recent coronavirus diagnosis."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not directly confirm that any cats were diagnosed with coronavirus or flew on Delta or Hawaiian Airlines flights. The information only confirms that a couple, not their pets, were diagnosed with the virus.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000374",
    "statement": "Latest data show above 80 % efficacy for favipiravir in covid-19 , say rdif and chemrar",
    "label": "SUPPORTED",
    "evidences": [
      "The Dhaka Trial: Clear-Cut Evidence Favipiravir Effective against COVID-19 with Compelling Results 3.",
      "The drug's efficacy was above a threshold of 80%, which is the criterion for a drug with high antiviral activity.",
      "The drug 's efficacy was above a threshold > of 80%, which is the criterion for a drug with high antiviral activity."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that the Dhaka Trial shows clear-cut evidence of favipiravir being effective against COVID-19 with efficacy above 80%, which is the criterion for a drug with high antiviral activity. This aligns with the claim.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000375",
    "statement": "Latest data show only 80 % efficacy for favipiravir in covid-19, say rdif and chemrar",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The Dhaka Trial: Clear-Cut Evidence Favipiravir Effective against COVID-19 with Compelling Results 3.",
      "The drug's efficacy was above a threshold of 80%, which is the criterion for a drug with high antiviral activity.",
      "The drug 's efficacy was above a threshold > of 80%, which is the criterion for a drug with high antiviral activity."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that the efficacy of favipiravir in treating COVID-19 is above the threshold of 80%, which is the criterion for a drug with high antiviral activity. The RDIF and CHEMRAI reports mention an 80% efficacy for favipiravir in COVID-19.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000376",
    "statement": "Latest data show nearly 80 % efficacy for favipiravir in covid-19, say rdif and chemrar",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The Dhaka Trial: Clear-Cut Evidence Favipiravir Effective against COVID-19 with Compelling Results 3.",
      "The drug's efficacy was above a threshold of 80%, which is the criterion for a drug with high antiviral activity.",
      "The drug 's efficacy was above a threshold > of 80%, which is the criterion for a drug with high antiviral activity."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that the efficacy of favipiravir against COVID-19 is above 80%, which is the criterion for a drug with high antiviral activity. The Dhaka Trial provided clear-cut evidence for its effectiveness.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000377",
    "statement": "Antibody test for covid-19 could help to control virus spread , says singapore medtech firm",
    "label": "SUPPORTED",
    "evidences": [
      "Yee estimates commissioning roughly two million COVID-19 test kits in the next two months from Nanjing-based Vazyme Biotech, a Chinese producer of enzymes and antibodies.",
      "The medtech company, which specializes in cancer treatment equipment and applications, has created a test kit that detects antibodies directed against the coronavirus thats sweeping the world.",
      "Meanwhile, Singapores Ministry of Health issued a document released to all registered medical practitioners on April 3 stating, There is currently no role for COVID-19 serology rapid test kits in the diagnosis of COVID-19 infections. The Biolidics test checks the blood for antibodies and can identify who was previously infected and may have already developed immunity to the virus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is supported by evidence as the medtech firm mentioned created a test kit that detects antibodies directed against the coronavirus (SARS-CoV-2), which is the virus causing COVID-19. The test can identify who was previously infected and may have developed immunity to the virus, which could aid in controlling its spread.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000378",
    "statement": "Antibody test for covid-19 cannot help to control virus spread, says singapore medtech firm",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Yee estimates commissioning roughly two million COVID-19 test kits in the next two months from Nanjing-based Vazyme Biotech, a Chinese producer of enzymes and antibodies.",
      "The medtech company, which specializes in cancer treatment equipment and applications, has created a test kit that detects antibodies directed against the coronavirus thats sweeping the world.",
      "Meanwhile, Singapores Ministry of Health issued a document released to all registered medical practitioners on April 3 stating, There is currently no role for COVID-19 serology rapid test kits in the diagnosis of COVID-19 infections. The Biolidics test checks the blood for antibodies and can identify who was previously infected and may have already developed immunity to the virus."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided suggests that a medtech company in Singapore has developed an antibody test for COVID-19. However, the Ministry of Health in Singapore states that there is no role for such tests in diagnosing COVID-19 infections. The claim that antibody tests cannot help control virus spread is not directly supported by the evidence provided.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000379",
    "statement": "Covid-19 seroprevalence among healthcare workers of a large covid hospital in rome reveals strengths and limits of two different serological tests.",
    "label": "SUPPORTED",
    "evidences": [
      "Among low-risk population, point-of-cares predictive values were 58.33% (positive) and 98.23% (negative) whereas venous blood tests were 92.86% (positive) and 98.53% (negative).",
      "Since Fondazione Policlinico Universitario A. Gemelli (FPG) IRCCS has been enlisted as a COVID hospital, healthcare workers deployed to COVID wards were separated from those with limited or no exposure, whereas administrative staff was destined to work-from-home."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides the predictive values (sensitivity and specificity) for two different serological tests in a low-risk population within Fondazione Policlinico Universitario A. Gemelli (FPG), a COVID hospital in Rome. This implies that the claim is supported, as it suggests that Covid-19 seroprevalence among healthcare workers of this specific hospital can reveal strengths and limits of these two different tests.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000380",
    "statement": "Covid-19 seroprevalence among healthcare workers of a large covid hospital in rome reveals strengths and limits of three different serological tests.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Among low-risk population, point-of-cares predictive values were 58.33% (positive) and 98.23% (negative) whereas venous blood tests were 92.86% (positive) and 98.53% (negative).",
      "Since Fondazione Policlinico Universitario A. Gemelli (FPG) IRCCS has been enlisted as a COVID hospital, healthcare workers deployed to COVID wards were separated from those with limited or no exposure, whereas administrative staff was destined to work-from-home."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows a comparison of the predictive values of different serological tests for Covid-19 among healthcare workers in a hospital that was designated as a COVID hospital (Fondazione Policlinico Universitario A. Gemelli). The results suggest differences between point-of-care and venous blood tests, which implies that the tests may have strengths and limits in this specific context.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000381",
    "statement": "Covid-19 seroprevalence among healthcare workers of a large covid hospital in rome reveals strengths and limits of all different serological tests.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Among low-risk population, point-of-cares predictive values were 58.33% (positive) and 98.23% (negative) whereas venous blood tests were 92.86% (positive) and 98.53% (negative).",
      "Since Fondazione Policlinico Universitario A. Gemelli (FPG) IRCCS has been enlisted as a COVID hospital, healthcare workers deployed to COVID wards were separated from those with limited or no exposure, whereas administrative staff was destined to work-from-home."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that different serological tests for Covid-19 have varying predictive values among healthcare workers of a large Covid hospital in Rome. This suggests that the tests reveal strengths and limits when used to diagnose Covid-19.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000382",
    "statement": "A neutralizing human antibody binds to the n-terminal domain of the spike protein of sars-cov-2",
    "label": "SUPPORTED",
    "evidences": [
      ", Potent human neutralizing antibodies elicited by SARS-CoV-2 infection.",
      "( B ) The correlations between the authentic SARS-CoV-2 neutralizing antibody (NAb) titers and the pseudotyped SARS-CoV-2 NAb titers in plasma."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided describes the identification of potent human neutralizing antibodies against SARS-CoV-2 and correlations between authentic SARS-CoV-2 neutralizing antibody titers and pseudotyped SARS-CoV-2 NAb titers in plasma. This implies that these neutralizing antibodies bind to the spike protein of SARS-CoV-2, as they are specifically targeted against it.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000383",
    "statement": "A neutralizing mouse antibody binds to the n-terminal domain of the spike protein of sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      ", Potent human neutralizing antibodies elicited by SARS-CoV-2 infection.",
      "( B ) The correlations between the authentic SARS-CoV-2 neutralizing antibody (NAb) titers and the pseudotyped SARS-CoV-2 NAb titers in plasma."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence does not directly show that a specific neutralizing mouse antibody binds to the n-terminal domain of the spike protein of SARS-CoV-2. Instead, it discusses human neutralizing antibodies (not mouse) elicited by SARS-CoV-2 infection and their correlations with pseudotyped SARS-CoV-2 neutralizing antibody titers.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000384",
    "statement": "A novel point mutation in the n gene of sars-cov-2 may affect the detection of the virus by rt-qpcr.",
    "label": "SUPPORTED",
    "evidences": [
      "Finally, RT-qPCR primers are designed to amplify the target regions of the SARS-CoV-2 genome.",
      "Once virus mutation and recombination occur, it is difficult to effectively diagnose viral infection by existing RT-qPCR primers.",
      "There may be selective mutations in SARS-CoV-2, and it is necessary to avoid certain regions when designing primers and probes.",
      "The large- scale sustained person-to-person transmission of SARS-CoV-2 has led to many mutational events, some of which may affect the sensitivity and specificity of available PCR assays (2).",
      "A mutation in a reverse primer has been shown to affect the sensitivity of an RT-qPCR assay in use early in the pandemic10 and further mutations could lead to the occurrence of false negative results, particularly if the mutation occurs at the extreme 3 end of the primers."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided discusses the challenges in diagnosing SARS-CoV-2 infection using RT-qPCR due to mutations and recombination events that occur in the virus over time. It also mentions specific examples of how a mutation in a reverse primer can affect the sensitivity of an RT-qPCR assay. Therefore, it is reasonable to conclude that a novel point mutation in the n gene of SARS-CoV-2 may affect the detection of the virus by RT-qPCR.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000385",
    "statement": "A third point mutation in the n gene of sars-cov-2 may affect the detection of the virus by rt-qpcr.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Finally, RT-qPCR primers are designed to amplify the target regions of the SARS-CoV-2 genome.",
      "Once virus mutation and recombination occur, it is difficult to effectively diagnose viral infection by existing RT-qPCR primers.",
      "There may be selective mutations in SARS-CoV-2, and it is necessary to avoid certain regions when designing primers and probes.",
      "The large- scale sustained person-to-person transmission of SARS-CoV-2 has led to many mutational events, some of which may affect the sensitivity and specificity of available PCR assays (2).",
      "A mutation in a reverse primer has been shown to affect the sensitivity of an RT-qPCR assay in use early in the pandemic10 and further mutations could lead to the occurrence of false negative results, particularly if the mutation occurs at the extreme 3 end of the primers."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests that mutations in SARS-CoV-2 can occur and may affect the sensitivity and specificity of RT-qPCR assays used for virus detection. This is based on the statement that 'Once virus mutation and recombination occur, it is difficult to effectively diagnose viral infection by existing RT-qPCR primers.' Furthermore, it's stated that a mutation in a reverse primer has already been shown to affect the sensitivity of an RT-qPCR assay, implying that other mutations could also have similar effects.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000386",
    "statement": "A major point mutation in the n gene of sars-cov-2 may affect the detection of the virus by rt-qpcr.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Finally, RT-qPCR primers are designed to amplify the target regions of the SARS-CoV-2 genome.",
      "Once virus mutation and recombination occur, it is difficult to effectively diagnose viral infection by existing RT-qPCR primers.",
      "There may be selective mutations in SARS-CoV-2, and it is necessary to avoid certain regions when designing primers and probes.",
      "The large- scale sustained person-to-person transmission of SARS-CoV-2 has led to many mutational events, some of which may affect the sensitivity and specificity of available PCR assays (2).",
      "A mutation in a reverse primer has been shown to affect the sensitivity of an RT-qPCR assay in use early in the pandemic10 and further mutations could lead to the occurrence of false negative results, particularly if the mutation occurs at the extreme 3 end of the primers."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that there are mutations in SARS-CoV-2 and these mutations can affect the sensitivity and specificity of RT-qPCR assays. While it is not explicitly stated that a major point mutation specifically in the 'n' gene affects detection, the general idea is supported by the evidence provided.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000387",
    "statement": "99.9 % of sars-cov-2 gets destroyed after gargling betadine , claims study",
    "label": "SUPPORTED",
    "evidences": [
      "Based on the study, antiseptic products like betadine, namely Solution (10% PVP-I), Skin Cleanser (7.5% PVP-I), Gargle, and Mouthwash (1.0% PVP-I) and Throat Spray (0.45% PVP-I) can destroy 99.9% of Coronavirus for as fast as 30 seconds.",
      "Preliminary results show Betadine Gargle killed 99.9 percent of the virus within 15 seconds.",
      "In this study, results showed a 99.9 percent reduction of SARS- CoV-2 viral load starting at 15 seconds and at all subsequent time points in the study (30 seconds, 60 seconds and 5 minutes)."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that a study has been conducted on Betadine products and their ability to destroy the SARS-CoV-2 virus. The results of this study suggest that the 99.9% destruction of the virus occurs within 15 seconds, as stated in the claim.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000388",
    "statement": "99.9 % of sars-cov-2 gets stable after gargling betadine, claims study",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Based on the study, antiseptic products like betadine, namely Solution (10% PVP-I), Skin Cleanser (7.5% PVP-I), Gargle, and Mouthwash (1.0% PVP-I) and Throat Spray (0.45% PVP-I) can destroy 99.9% of Coronavirus for as fast as 30 seconds.",
      "Preliminary results show Betadine Gargle killed 99.9 percent of the virus within 15 seconds.",
      "In this study, results showed a 99.9 percent reduction of SARS- CoV-2 viral load starting at 15 seconds and at all subsequent time points in the study (30 seconds, 60 seconds and 5 minutes)."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "While the evidence provided shows that Betadine can destroy a significant percentage of Coronavirus (SARS-CoV-2) in laboratory conditions, it does not necessarily imply that gargling Betadine will have the same effect on the virus in a human body. More research would be required to establish whether or not 99.9% of SARS-CoV-2 gets stable after gargling betadine in vivo.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000389",
    "statement": "99.9 % of sars-cov-2 gets effective after gargling betadine, claims study",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Based on the study, antiseptic products like betadine, namely Solution (10% PVP-I), Skin Cleanser (7.5% PVP-I), Gargle, and Mouthwash (1.0% PVP-I) and Throat Spray (0.45% PVP-I) can destroy 99.9% of Coronavirus for as fast as 30 seconds.",
      "Preliminary results show Betadine Gargle killed 99.9 percent of the virus within 15 seconds.",
      "In this study, results showed a 99.9 percent reduction of SARS- CoV-2 viral load starting at 15 seconds and at all subsequent time points in the study (30 seconds, 60 seconds and 5 minutes)."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence directly states that preliminary results show Betadine Gargle killed 99.9 percent of the virus within 15 seconds, and furthermore the study shows a consistent 99.9 percent reduction at subsequent time points (30 seconds, 60 seconds and 5 minutes).",
    "confidence": 0.99
  },
  {
    "id": "covid_fact-000390",
    "statement": "99.9 % of sars-cov-2 gets active after gargling betadine, claims study",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Based on the study, antiseptic products like betadine, namely Solution (10% PVP-I), Skin Cleanser (7.5% PVP-I), Gargle, and Mouthwash (1.0% PVP-I) and Throat Spray (0.45% PVP-I) can destroy 99.9% of Coronavirus for as fast as 30 seconds.",
      "Preliminary results show Betadine Gargle killed 99.9 percent of the virus within 15 seconds.",
      "In this study, results showed a 99.9 percent reduction of SARS- CoV-2 viral load starting at 15 seconds and at all subsequent time points in the study (30 seconds, 60 seconds and 5 minutes)."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "While the evidence shows that Betadine solutions can destroy 99.9% of Coronavirus within specific time frames, it does not provide sufficient context or proof to conclusively support the claim that 99.9% of SARS-CoV-2 (the virus causing COVID-19) gets active after gargling Betadine. The claim suggests a cause-effect relationship between using Betadine and the activity of the virus, which is not directly addressed or proven in the evidence provided.",
    "confidence": 0.98
  },
  {
    "id": "covid_fact-000391",
    "statement": "Identification of sars-cov-2 vaccine epitopes predicted to induce long-term population-scale immunity",
    "label": "SUPPORTED",
    "evidences": [
      "Figure 2 Proposed Vaccine Epitopes in SARS-CoV-2 Figure 2 Proposed Vaccine Epitopes in SARS-CoV-2 Spike Protein Crystal structure of SARS-CoV-2 Spike protein Figure 2 Proposed Vaccine Epitopes in SARS-CoV-2 Spike Protein Crystal structure of SARS-CoV-2 Spike protein trimer (PDB: 6VYB) with two highlighted vaccine epitopes targeting newly evolved acquired viral vulnerabilities.",
      "A SARS-CoV-2 Vaccination Strategy Focused on Population-Scale Immunity."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided describes proposed vaccine epitopes (antigenic regions) in the SARS-CoV-2 spike protein that are believed to induce an immune response. However, it does not provide information about whether these specific epitopes would induce long-term population-scale immunity.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000392",
    "statement": "Identification of sars-cov-2 vaccine epitopes fails to induce long-term population-scale immunity",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Figure 2 Proposed Vaccine Epitopes in SARS-CoV-2 Figure 2 Proposed Vaccine Epitopes in SARS-CoV-2 Spike Protein Crystal structure of SARS-CoV-2 Spike protein Figure 2 Proposed Vaccine Epitopes in SARS-CoV-2 Spike Protein Crystal structure of SARS-CoV-2 Spike protein trimer (PDB: 6VYB) with two highlighted vaccine epitopes targeting newly evolved acquired viral vulnerabilities.",
      "A SARS-CoV-2 Vaccination Strategy Focused on Population-Scale Immunity."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided in this case describes the proposed vaccine epitopes for SARS-CoV-2. However, it does not provide any data or conclusions about whether these epitopes actually fail to induce long-term population-scale immunity.",
    "confidence": 0.4
  },
  {
    "id": "covid_fact-000393",
    "statement": "Identification of sars-cov-2 vaccine epitopes failed to induce long-term population-scale immunity",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Figure 2 Proposed Vaccine Epitopes in SARS-CoV-2 Figure 2 Proposed Vaccine Epitopes in SARS-CoV-2 Spike Protein Crystal structure of SARS-CoV-2 Spike protein Figure 2 Proposed Vaccine Epitopes in SARS-CoV-2 Spike Protein Crystal structure of SARS-CoV-2 Spike protein trimer (PDB: 6VYB) with two highlighted vaccine epitopes targeting newly evolved acquired viral vulnerabilities.",
      "A SARS-CoV-2 Vaccination Strategy Focused on Population-Scale Immunity."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided only shows proposed vaccine epitopes (parts of the SARS-CoV-2 virus that the immune system targets) in a lab setting. It does not provide sufficient data or evidence to conclude whether these epitopes have induced long-term population-scale immunity.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000394",
    "statement": "Serial interval of sars-cov-2 was shortened over time by nonpharmaceutical interventions",
    "label": "SUPPORTED",
    "evidences": [
      "Empirical serial interval distributions for transmission pairs, counting from symptom onsets of the infectors during each period, indicate that the serial intervals shortened over time (Fig.",
      "noticed that the average serial interval changed as nonpharmaceutical interventions were introduced.",
      "1 Serial intervals of SARS-CoV-2 substantially shortened over time in mainland China."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows a correlation between the introduction of nonpharmaceutical interventions and a reduction in the average serial interval of SARS-CoV-2. Additionally, it is stated that serial intervals in mainland China shortened substantially over time.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000395",
    "statement": "Serial interval of sars-cov-2 was increased over time by nonpharmaceutical interventions",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Empirical serial interval distributions for transmission pairs, counting from symptom onsets of the infectors during each period, indicate that the serial intervals shortened over time (Fig.",
      "noticed that the average serial interval changed as nonpharmaceutical interventions were introduced.",
      "1 Serial intervals of SARS-CoV-2 substantially shortened over time in mainland China."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows that serial intervals for SARS-CoV-2 transmission pairs were noticed to shorten over time as nonpharmaceutical interventions were introduced in mainland China. Furthermore, it is stated that the average serial interval changed when these interventions were introduced.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000396",
    "statement": "Serial interval of sars-cov-2 was obtained over time by nonpharmaceutical interventions",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Empirical serial interval distributions for transmission pairs, counting from symptom onsets of the infectors during each period, indicate that the serial intervals shortened over time (Fig.",
      "noticed that the average serial interval changed as nonpharmaceutical interventions were introduced.",
      "1 Serial intervals of SARS-CoV-2 substantially shortened over time in mainland China."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that the average serial interval (time between symptom onset of an infector and a secondary case) for SARS-CoV-2 changed as nonpharmaceutical interventions were introduced, and it also mentions that the serial intervals shortened over time in mainland China. This suggests that the nonpharmaceutical interventions played a role in reducing the serial interval of SARS-CoV-2.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000397",
    "statement": "Sars-cov-2 is not detectable in the vaginal fluid of women with severe covid-19 infection",
    "label": "SUPPORTED",
    "evidences": [
      "All 10 patients were tested for SARS-CoV-2 in vaginal fluid, and all samples tested negative for the virus.",
      "Conclusions: Findings from this small group of cases suggest that SARS- CoV-2 virus does not exist in the vaginal fluids of severe COVID-19 patients."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that all 10 patients with severe COVID-19 infection were tested for SARS-CoV-2 in vaginal fluid and the test results were negative. This supports the claim that Sars-cov-2 is not detectable in the vaginal fluid of women with severe covid-19 infection.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000398",
    "statement": "Sars-cov-2 is also detectable in the vaginal fluid of women with severe covid-19 infection",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "All 10 patients were tested for SARS-CoV-2 in vaginal fluid, and all samples tested negative for the virus.",
      "Conclusions: Findings from this small group of cases suggest that SARS- CoV-2 virus does not exist in the vaginal fluids of severe COVID-19 patients."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided shows that all 10 patients tested negative for SARS-CoV-2 in vaginal fluid. However, a single study with a small sample size (10 patients) does not conclusively prove or disprove the presence of SARS-CoV-2 in the vaginal fluids of women with severe COVID-19 infection. Further research with larger and more diverse samples is needed to support or refute this claim.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000399",
    "statement": "Sars-cov-2 is only detectable in the vaginal fluid of women with severe covid-19 infection",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "All 10 patients were tested for SARS-CoV-2 in vaginal fluid, and all samples tested negative for the virus.",
      "Conclusions: Findings from this small group of cases suggest that SARS- CoV-2 virus does not exist in the vaginal fluids of severe COVID-19 patients."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided only shows that SARS-CoV-2 was not detected in the vaginal fluid of the 10 tested patients with severe COVID-19 infection. This does not necessarily mean that it is exclusively present in severe cases or is undetectable in mild cases.",
    "confidence": 0.4
  },
  {
    "id": "covid_fact-000400",
    "statement": "Sars-cov-2 is still detectable in the vaginal fluid of women with severe covid-19 infection",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "All 10 patients were tested for SARS-CoV-2 in vaginal fluid, and all samples tested negative for the virus.",
      "Conclusions: Findings from this small group of cases suggest that SARS- CoV-2 virus does not exist in the vaginal fluids of severe COVID-19 patients."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that all 10 patients tested negative for SARS-CoV-2 in vaginal fluid, and the conclusion drawn from this small group of cases suggests that the virus does not exist in the vaginal fluids of severe COVID-19 patients.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000401",
    "statement": "Sars-cov-2 infects monocytes and macrophages , without cytopathic effect",
    "label": "SUPPORTED",
    "evidences": [
      "Thus, SARS-CoV-2 infects monocytes and macrophages and induces a more sustained activation in macrophages without cytopathic effect.",
      "The study showed that SARS-CoV-2 could infect monocytes and macrophages and stimulate cytokine release without any cytopathic effect."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided directly supports the claim that SARS-CoV-2 infects monocytes and macrophages without causing cytopathic effect. The study described in the evidence demonstrates this by showing that infection with SARS-CoV-2 leads to stimulation of cytokine release in these cells, but does not cause any visible cellular damage or destruction (cytopathic effect).",
    "confidence": 1
  },
  {
    "id": "covid_fact-000402",
    "statement": "Sars-cov-2 infects monocytes and macrophages, cause cytopathic effect",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Thus, SARS-CoV-2 infects monocytes and macrophages and induces a more sustained activation in macrophages without cytopathic effect.",
      "The study showed that SARS-CoV-2 could infect monocytes and macrophages and stimulate cytokine release without any cytopathic effect."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that SARS-CoV-2 can infect monocytes and macrophages and stimulate cytokine release without causing cytopathic effect. This suggests that the virus does indeed infect these cell types but does not cause the typical signs of cell damage or death (cytopathic effect) under the conditions studied.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000403",
    "statement": "Sars-cov-2 infects monocytes and macrophages, an cytopathic effect",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Thus, SARS-CoV-2 infects monocytes and macrophages and induces a more sustained activation in macrophages without cytopathic effect.",
      "The study showed that SARS-CoV-2 could infect monocytes and macrophages and stimulate cytokine release without any cytopathic effect."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence indicates that SARS-CoV-2 can infect monocytes and macrophages, but it does not cause a cytopathic effect (destruction of the host cell).",
    "confidence": 1
  },
  {
    "id": "covid_fact-000404",
    "statement": "Sars-cov-2 infects monocytes and macrophages, a cytopathic effect",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Thus, SARS-CoV-2 infects monocytes and macrophages and induces a more sustained activation in macrophages without cytopathic effect.",
      "The study showed that SARS-CoV-2 could infect monocytes and macrophages and stimulate cytokine release without any cytopathic effect."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence suggests that SARS-CoV-2 can infect monocytes and macrophages, but it does not cause a cytopathic effect (cell death or structural changes).",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000405",
    "statement": "Rapid clinical deterioration of severe covid-19 may be associated with stroke",
    "label": "SUPPORTED",
    "evidences": [
      "\"For those with severe COVID-19, rapid clinical deterioration or worsening could be associated with a neurologic event such as stroke, which would contribute to its high mortality rate,\" the team wrote in JAMA Neurology."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence is a direct quote stating that 'rapid clinical deterioration or worsening' of severe COVID-19 could be associated with a neurologic event such as stroke. This implies a connection between the two, supporting the claim.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000406",
    "statement": "Rapid clinical deterioration of severe covid-19 may be associated with pneumonia",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "\"For those with severe COVID-19, rapid clinical deterioration or worsening could be associated with a neurologic event such as stroke, which would contribute to its high mortality rate,\" the team wrote in JAMA Neurology."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence discusses a neurologic event (stroke) as a factor contributing to the high mortality rate of severe COVID-19, not pneumonia.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000407",
    "statement": "Distinct phenotypes of sars-cov-2 isolates reveal viral traits critical for replication in primary human respiratory cells",
    "label": "SUPPORTED",
    "evidences": [
      "By integrating viral sequencing data from patient material, viral stocks and passaging experiments, with kinetic virus replication data from non-human Vero-CCL81 cells and primary differentiated human bronchial epithelial cells (BEpCs), we observed several SARS-CoV-2 sequence features that associate with distinct phenotypes."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence shows that the authors have integrated viral sequencing data from various sources, and observed sequence features that associate with distinct phenotypes in both non-human cells (Vero-CCL81) and primary human respiratory cells (BEpCs). This suggests that they are indeed studying viral traits critical for replication in primary human respiratory cells.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000408",
    "statement": "Distinct phenotypes of sars-cov-2 isolates reveal viral traits critical for pathogenicity in primary human respiratory cells",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "By integrating viral sequencing data from patient material, viral stocks and passaging experiments, with kinetic virus replication data from non-human Vero-CCL81 cells and primary differentiated human bronchial epithelial cells (BEpCs), we observed several SARS-CoV-2 sequence features that associate with distinct phenotypes."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided describes the integration of viral sequencing data and kinetic replication data from both non-human cells (Vero-CCL81) and primary human respiratory cells (BEpCs). This suggests that the study is comparing distinct phenotypes of SARS-CoV-2 isolates in relation to their pathogenicity in human respiratory cells. Therefore, it supports the claim.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000409",
    "statement": "Distinct phenotypes of sars-cov-2 isolates reveal viral traits critical for infection in primary human respiratory cells",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "By integrating viral sequencing data from patient material, viral stocks and passaging experiments, with kinetic virus replication data from non-human Vero-CCL81 cells and primary differentiated human bronchial epithelial cells (BEpCs), we observed several SARS-CoV-2 sequence features that associate with distinct phenotypes."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows the correlation between specific SARS-CoV-2 sequences and their effects on virus replication in both non-human cells (Vero-CCL81) and primary human respiratory cells (BEpCs). This supports the claim that distinct phenotypes of sars-cov-2 isolates reveal viral traits critical for infection in primary human respiratory cells.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000410",
    "statement": "Distinct phenotypes of sars-cov-2 isolates reveal viral traits critical for mortality in primary human respiratory cells",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "By integrating viral sequencing data from patient material, viral stocks and passaging experiments, with kinetic virus replication data from non-human Vero-CCL81 cells and primary differentiated human bronchial epithelial cells (BEpCs), we observed several SARS-CoV-2 sequence features that associate with distinct phenotypes."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence presents data on viral sequencing and replication in both non-human cells and primary human respiratory cells (BEpCs). The observation of distinct phenotypes based on SARS-CoV-2 sequence features suggests that these traits could potentially influence mortality in human respiratory cells. However, it is important to note that correlation does not imply causation, and further studies would be needed to confirm the direct impact of these viral traits on mortality.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000411",
    "statement": "Esc council on hypertension says ace-i and arbs do not increase covid-19 mortality",
    "label": "SUPPORTED",
    "evidences": [
      "\"This speculation about the safety of ACE-i or ARB treatment in relation to COVID-19 does not have a sound scientific basis or evidence to support it.",
      "The Council on Hypertension strongly recommends that physicians and patients should continue treatment with their usual anti-hypertensive therapy because there is no clinical or scientific evidence to suggest they cause any harm in COVID-19 infections.",
      "Despite some early report theorizing these drugs might play a role to increase COVID-19 mortality, the Council on Hypertension of the ESC pointed out the lack of any evidence supporting harmful effect of ACE-I and ARB in the context of the pandemic COVID-19 outbreak."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided statement explicitly states that the ESC Council on Hypertension does not recommend discontinuing ACE-i or ARB treatment due to lack of evidence supporting a harmful effect in COVID-19 infections.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000412",
    "statement": "Esc council on hypertension says ace-i and arbs do and increase covid-19 mortality",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "\"This speculation about the safety of ACE-i or ARB treatment in relation to COVID-19 does not have a sound scientific basis or evidence to support it.",
      "The Council on Hypertension strongly recommends that physicians and patients should continue treatment with their usual anti-hypertensive therapy because there is no clinical or scientific evidence to suggest they cause any harm in COVID-19 infections.",
      "Despite some early report theorizing these drugs might play a role to increase COVID-19 mortality, the Council on Hypertension of the ESC pointed out the lack of any evidence supporting harmful effect of ACE-I and ARB in the context of the pandemic COVID-19 outbreak."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The given statement is a negative claim about the effect of ACE-i and ARB drugs on COVID-19 mortality. However, the provided evidence does not directly support this claim but rather states that there is no scientific basis or evidence to suggest these drugs cause harm in COVID-19 infections. Therefore, the evidence does not confirm or disprove the claim.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000413",
    "statement": "Esc council on hypertension says ace-i and arbs do also increase covid-19 mortality",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "\"This speculation about the safety of ACE-i or ARB treatment in relation to COVID-19 does not have a sound scientific basis or evidence to support it.",
      "The Council on Hypertension strongly recommends that physicians and patients should continue treatment with their usual anti-hypertensive therapy because there is no clinical or scientific evidence to suggest they cause any harm in COVID-19 infections.",
      "Despite some early report theorizing these drugs might play a role to increase COVID-19 mortality, the Council on Hypertension of the ESC pointed out the lack of any evidence supporting harmful effect of ACE-I and ARB in the context of the pandemic COVID-19 outbreak."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence states that there is no clinical or scientific evidence to suggest ACE-I or ARB treatment causes harm in COVID-19 infections, and it points out the lack of any evidence supporting a harmful effect of these drugs in the context of the pandemic. This directly contradicts the claim that they increase COVID-19 mortality.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000414",
    "statement": "Esc council on hypertension says ace-i and arbs do significantly increase covid-19 mortality",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "\"This speculation about the safety of ACE-i or ARB treatment in relation to COVID-19 does not have a sound scientific basis or evidence to support it.",
      "The Council on Hypertension strongly recommends that physicians and patients should continue treatment with their usual anti-hypertensive therapy because there is no clinical or scientific evidence to suggest they cause any harm in COVID-19 infections.",
      "Despite some early report theorizing these drugs might play a role to increase COVID-19 mortality, the Council on Hypertension of the ESC pointed out the lack of any evidence supporting harmful effect of ACE-I and ARB in the context of the pandemic COVID-19 outbreak."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence states that there is no scientific basis or evidence to support the claim that ACE-I and ARB treatment increases COVID-19 mortality. It also advises continuation of usual anti-hypertensive therapy based on this lack of evidence.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000415",
    "statement": "Coronavirus threatens small businesses",
    "label": "SUPPORTED",
    "evidences": [
      "For small businesses, though, it could be catastrophic.",
      "The economy has been affected by the outbreak in ways large and small, including stock market declines, supply chain backups and company cancellations of business travel and meetings, in the United States and elsewhere.",
      "In some cases, public alarm is affecting small businesses even where there is no widespread outbreak or official guidance to stay inside.",
      "Small businesses are on the front line of this crisis, said Amanda Ballantyne, executive director of Main Street Alliance, a public policy group for small businesses.",
      "But for small businesses, there could be long-term effects on daily life and work in local communities."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that the economy has been affected by the coronavirus outbreak in various ways that could be catastrophic for small businesses, according to Amanda Ballantyne of Main Street Alliance. This suggests that coronavirus threatens small businesses.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000416",
    "statement": "Coronavirus threatens worldwide businesses",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "For small businesses, though, it could be catastrophic.",
      "The economy has been affected by the outbreak in ways large and small, including stock market declines, supply chain backups and company cancellations of business travel and meetings, in the United States and elsewhere.",
      "In some cases, public alarm is affecting small businesses even where there is no widespread outbreak or official guidance to stay inside.",
      "Small businesses are on the front line of this crisis, said Amanda Ballantyne, executive director of Main Street Alliance, a public policy group for small businesses.",
      "But for small businesses, there could be long-term effects on daily life and work in local communities."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided discusses various ways the Coronavirus outbreak has affected small businesses such as stock market declines, supply chain backups, and cancellations of business travel and meetings. This suggests that it does indeed threaten worldwide businesses.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000417",
    "statement": "Coronavirus threatens globally businesses",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "For small businesses, though, it could be catastrophic.",
      "The economy has been affected by the outbreak in ways large and small, including stock market declines, supply chain backups and company cancellations of business travel and meetings, in the United States and elsewhere.",
      "In some cases, public alarm is affecting small businesses even where there is no widespread outbreak or official guidance to stay inside.",
      "Small businesses are on the front line of this crisis, said Amanda Ballantyne, executive director of Main Street Alliance, a public policy group for small businesses.",
      "But for small businesses, there could be long-term effects on daily life and work in local communities."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that the Coronavirus (COVID-19) outbreak is having a significant impact on small businesses globally, as suggested by phrases like 'for small businesses, it could be catastrophic', 'the economy has been affected... for small businesses' and 'public alarm is affecting small businesses... where there is no widespread outbreak'. The long-term effects mentioned also suggest potential global implications.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000418",
    "statement": "Deaths in new york city are more than double the usual total",
    "label": "SUPPORTED",
    "evidences": [
      "Over the 31 days ending April 4, more than twice the typical number of New Yorkers died.",
      "But even if the current count is perfect, roughly 9,780 people have died of all causes over the past month in New York City, about 5,000 more than is typical."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided states that approximately 5,000 more people have died over the past month in New York City compared to the typical number. This indicates that deaths in New York City are more than double the usual total.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000419",
    "statement": "Deaths in new york city are more than below the usual total",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Over the 31 days ending April 4, more than twice the typical number of New Yorkers died.",
      "But even if the current count is perfect, roughly 9,780 people have died of all causes over the past month in New York City, about 5,000 more than is typical."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that the number of deaths over the past month in New York City (9,780) is approximately 5,000 more than the typical number. This implies that the number of deaths in New York City is indeed more than the usual total.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000420",
    "statement": "Children in new york city are more than double the usual total",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Over the 31 days ending April 4, more than twice the typical number of New Yorkers died.",
      "But even if the current count is perfect, roughly 9,780 people have died of all causes over the past month in New York City, about 5,000 more than is typical."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The given evidence shows an increase in deaths over a specific period (April 4 and the preceding 31 days) in New York City compared to usual numbers. However, it does not directly provide information about children's deaths or their proportion of the total death count. To support the claim that 'children in new york city are more than double the usual total', we would need evidence specifically related to the number of child deaths.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000421",
    "statement": "Patients in new york city are more than double the usual total",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Over the 31 days ending April 4, more than twice the typical number of New Yorkers died.",
      "But even if the current count is perfect, roughly 9,780 people have died of all causes over the past month in New York City, about 5,000 more than is typical."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that over the past 31 days, approximately 5,000 more deaths than usual have occurred in New York City. This indicates that the number of deaths is more than double the usual total.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000422",
    "statement": "Covid-19 racial disparities could be worsened by location of test sites",
    "label": "SUPPORTED",
    "evidences": [
      "\"A lot of the disparity ... is reflecting some of that private sector availability of tests in the northern part of Dallas compared to southern Dallas.\"",
      "While many things can affect access to testing, location is an important starting point.",
      "racial inequities coronavirus in the U.S. coronavirus testing COVID-19 Facebook Twitter Flipboard Email"
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that there is a higher availability of COVID-19 tests in the northern part of Dallas compared to the southern part, which could potentially worsen racial disparities if access to testing is not equitable across different races or ethnicities. While this claim does not definitively prove that racial disparities are being worsened, it provides a plausible explanation and suggests that further investigation would be warranted.",
    "confidence": 0.85
  },
  {
    "id": "covid_fact-000423",
    "statement": "Covid-19 racial disparities cannot be worsened by location of test sites",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "\"A lot of the disparity ... is reflecting some of that private sector availability of tests in the northern part of Dallas compared to southern Dallas.\"",
      "While many things can affect access to testing, location is an important starting point.",
      "racial inequities coronavirus in the U.S. coronavirus testing COVID-19 Facebook Twitter Flipboard Email"
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided indicates that one possible factor contributing to racial disparities in Covid-19 testing is the availability of tests in certain locations within a city (North vs South Dallas). This suggests that location can influence access to testing and potentially worsen racial disparities. However, it does not definitively prove that location is the only or even the main factor behind these disparities.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000424",
    "statement": "Covid-19 racial disparities could be assessed by location of test sites",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "\"A lot of the disparity ... is reflecting some of that private sector availability of tests in the northern part of Dallas compared to southern Dallas.\"",
      "While many things can affect access to testing, location is an important starting point.",
      "racial inequities coronavirus in the U.S. coronavirus testing COVID-19 Facebook Twitter Flipboard Email"
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence suggests that there is a difference in the availability of Covid-19 tests between northern and southern Dallas, which could potentially reflect racial disparities due to the correlation between location (northern vs southern Dallas) and the demographic makeup of those areas.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000425",
    "statement": "Covid-19 racial disparities could be defined by location of test sites",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "\"A lot of the disparity ... is reflecting some of that private sector availability of tests in the northern part of Dallas compared to southern Dallas.\"",
      "While many things can affect access to testing, location is an important starting point.",
      "racial inequities coronavirus in the U.S. coronavirus testing COVID-19 Facebook Twitter Flipboard Email"
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests that a factor contributing to racial disparities in Covid-19 testing could be the location of test sites, as indicated by the statement 'A lot of the disparity ... is reflecting some of that private sector availability of tests in the northern part of Dallas compared to southern Dallas.' This doesn't necessarily mean it is the only factor, but it does suggest that location of test sites plays a role in these disparities.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000426",
    "statement": "Overweight and obesity are risks factors of severe illness in patients with covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "Having obesity may triple the risk of hospitalization due to a COVID-19 infection.",
      "Conclusions: Overweight and obesity were independent risk factors of severe illness in COVID-19 patients.",
      "Overweight, Obesity and Severe Obesity Having obesity, defined as a body mass index (BMI) between 30 kg/m2 and <40 kg/m2 or severe obesity (BMI of 40 kg/m2 or above), increases your risk of severe illness from COVID-19.",
      "Having obesity puts people at risk for many other serious chronic diseases and increases the risk of severe illness from COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly states that having obesity triples the risk of hospitalization due to a COVID-19 infection, which indicates it is a risk factor for severe illness in patients with covid-19.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000427",
    "statement": "Overweight and obesity are risks factors of severe illness in patients without covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Having obesity may triple the risk of hospitalization due to a COVID-19 infection.",
      "Conclusions: Overweight and obesity were independent risk factors of severe illness in COVID-19 patients.",
      "Overweight, Obesity and Severe Obesity Having obesity, defined as a body mass index (BMI) between 30 kg/m2 and <40 kg/m2 or severe obesity (BMI of 40 kg/m2 or above), increases your risk of severe illness from COVID-19.",
      "Having obesity puts people at risk for many other serious chronic diseases and increases the risk of severe illness from COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided clearly states that having obesity increases the risk of hospitalization due to a COVID-19 infection, and thus, overweight and obesity can be considered as risks factors for severe illness in patients without COVID-19.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000428",
    "statement": "Intestinal inflammation modulates the expression of ace2 and tmprss2 and potentially overlaps with the pathogenesis of sars-cov-2 related disease",
    "label": "SUPPORTED",
    "evidences": [
      "These considerations led us to systematically examine the intersections between COVID-19 and the GI tract during health and intestinal inflammation."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence does not directly support or refute the claim about intestinal inflammation modulating the expression of ACE2 and TMPRSS2 or overlapping with the pathogenesis of SARS-CoV-2 related disease. It only mentions that COVID-19 is being examined in relation to the GI tract during health and intestinal inflammation, but it does not provide specific evidence for the modulation of ACE2 and TMPRSS2 expression or a potential overlap with SARS-CoV-2 related disease.",
    "confidence": 0.7
  },
  {
    "id": "covid_fact-000429",
    "statement": "Intestinal inflammation modulates the production of ace2 and tmprss2 and potentially overlaps with the pathogenesis of sars-cov-2 related disease",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These considerations led us to systematically examine the intersections between COVID-19 and the GI tract during health and intestinal inflammation."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that the research is examining the intersections between COVID-19 and the GI tract during health and intestinal inflammation, which implies a potential relationship between intestinal inflammation, ACE2 (Angiotensin-converting enzyme 2) and TMPRSS2 (Transmembrane protease serine 2), proteins that are involved in SARS-CoV-2 infection. However, the evidence does not provide direct proof of a modulation or overlap, only that it is being systematically examined.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000430",
    "statement": "Sars-cov-2 simulations go exascale to capture spike opening and reveal cryptic pockets across the proteome",
    "label": "SUPPORTED",
    "evidences": [
      "We also observe dramatic conformational changes across the proteome, which reveal over 50 cryptic pockets that expand targeting options for the design of antivirals.",
      "To address this challenge, over a million citizen scientists banded together through the Folding@home distributed computing project to create the first exascale computer and simulate an unprecedented 0.1 seconds of the viral proteome."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that simulations of Sars-cov-2 proteome were run on an exascale computer to observe conformational changes and reveal cryptic pockets. This indicates that the claim is supported by the provided evidence.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000431",
    "statement": "Sars-cov-2 simulations go exascale to avoid spike opening and reveal cryptic pockets across the proteome",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We also observe dramatic conformational changes across the proteome, which reveal over 50 cryptic pockets that expand targeting options for the design of antivirals.",
      "To address this challenge, over a million citizen scientists banded together through the Folding@home distributed computing project to create the first exascale computer and simulate an unprecedented 0.1 seconds of the viral proteome."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence describes simulations of SARS-CoV-2 proteome, which revealed over 50 cryptic pockets and mentions that a million citizen scientists collaborated to create the first exascale computer for the simulation. However, it does not explicitly state that going exascale was done specifically to avoid spike opening.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000432",
    "statement": "Experts divide into two camps of actionshielding versus blanket policies",
    "label": "SUPPORTED",
    "evidences": [
      "One group of doctors and academics is calling for segmentation and shielding of the most vulnerable groups of people rather than local or national lockdown measures."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly shows that there are two distinct approaches being advocated by a group of experts: 'segmentation and shielding of the most vulnerable groups' versus 'local or national lockdown measures'. This is consistent with the categorization of actionshielding versus blanket policies.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000433",
    "statement": "Poolkeh finds the optimal pooling strategy for a population-wide covid-19 testing",
    "label": "SUPPORTED",
    "evidences": [
      "Our framework allows health agencies to maximize the throughput of COVID-19 tests among the world population by finding the best test pooling that fits the current SIR-D [1] status of the nation.",
      "Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The given evidence describes a framework that allows health agencies to maximize the throughput of COVID-19 tests by finding the optimal test pooling strategy based on the current SIR-D status of the nation. However, it does not explicitly mention or provide any information about the software or tool named Poolkeh. Hence, it is not supported that Poolkeh finds the optimal pooling strategy for a population-wide COVID-19 testing.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000434",
    "statement": "Poolkeh finds the initial pooling strategy for a population-wide covid-19 testing",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our framework allows health agencies to maximize the throughput of COVID-19 tests among the world population by finding the best test pooling that fits the current SIR-D [1] status of the nation.",
      "Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not clearly state that Poolkeh is a specific tool or strategy for finding the initial pooling strategy for a population-wide COVID-19 testing. The evidence only states that the framework allows health agencies to maximize the throughput of COVID-19 tests among the world population by finding the best test pooling that fits the current SIR-D status of the nation.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000435",
    "statement": "Poolkeh finds the first pooling strategy for a population-wide covid-19 testing",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our framework allows health agencies to maximize the throughput of COVID-19 tests among the world population by finding the best test pooling that fits the current SIR-D [1] status of the nation.",
      "Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not clearly indicate that Poolkeh developed the first pooling strategy for population-wide COVID-19 testing. The text mentions that the framework allows health agencies to find the best test pooling based on the current SIR-D status of a nation, but it doesn't specify that Poolkeh was the one who created this strategy.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000436",
    "statement": "Global coronavirus death toll could be 60 % higher than reported",
    "label": "SUPPORTED",
    "evidences": [
      "The extra deaths are most pronounced in urban areas with the worst virus outbreaks, and have completely overwhelmed reporting mechanisms in some.",
      "This is especially worrying for many emerging economies, where total excess mortality is orders of magnitude higher than official coronavirus fatalities.",
      "The figure was 76 per cent higher than the average for the same week in the past five years, and the number of excess deaths was 58 per cent higher than the total number of reported Covid-deaths for the same period."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that the number of excess deaths is significantly higher than the reported Covid-19 fatalities, especially in urban areas and emerging economies. This suggests a potential undercounting of coronavirus deaths.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000437",
    "statement": "Global coronavirus death toll could be 60 % less than reported",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The extra deaths are most pronounced in urban areas with the worst virus outbreaks, and have completely overwhelmed reporting mechanisms in some.",
      "This is especially worrying for many emerging economies, where total excess mortality is orders of magnitude higher than official coronavirus fatalities.",
      "The figure was 76 per cent higher than the average for the same week in the past five years, and the number of excess deaths was 58 per cent higher than the total number of reported Covid-deaths for the same period."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates an increase in deaths (76% higher than the average for the same week in the past five years) that is greater than the reported Covid-19 fatalities (58% higher). This suggests that the global coronavirus death toll could be significantly higher than officially reported, which supports the claim.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000438",
    "statement": "Global coronavirus death toll could be 60 % lower than reported",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The extra deaths are most pronounced in urban areas with the worst virus outbreaks, and have completely overwhelmed reporting mechanisms in some.",
      "This is especially worrying for many emerging economies, where total excess mortality is orders of magnitude higher than official coronavirus fatalities.",
      "The figure was 76 per cent higher than the average for the same week in the past five years, and the number of excess deaths was 58 per cent higher than the total number of reported Covid-deaths for the same period."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that there are significantly more excess deaths in areas with severe COVID-19 outbreaks than the official reported COVID-19 fatalities for the same period. This indicates that the global coronavirus death toll could indeed be higher than what is being officially reported.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000439",
    "statement": "In a phylogenetic network analysis of 160 complete human severe acute respiratory syndrome coronavirus 2 genomes , we find three central variants distinguished by amino acid changes , which we have named a , b , and c ...",
    "label": "SUPPORTED",
    "evidences": [
      "To understand the evolution of this virus within humans, and to assist in tracing infection pathways and designing preventive strategies, we here present a phylogenetic network of 160 largely complete SARS-Cov-2 genomes (Fig."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence does not directly indicate the names of the three central variants in the phylogenetic network analysis. The evidence only mentions that a phylogenetic network was constructed and contains 160 largely complete SARS-Cov-2 genomes, but it does not provide specific information about the naming of any variants.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000440",
    "statement": "In a phylogenetic network analysis of five complete human severe acute respiratory syndrome coronavirus 2 genomes, we find three central variants distinguished by amino acid changes, which we have named a, b, and c...",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "To understand the evolution of this virus within humans, and to assist in tracing infection pathways and designing preventive strategies, we here present a phylogenetic network of 160 largely complete SARS-Cov-2 genomes (Fig."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided only states that a phylogenetic network analysis of 160 SARS-Cov-2 genomes was performed. It does not explicitly show or mention the phylogenetic relationship among five specific human SARS-CoV-2 genomes, nor does it provide any amino acid changes to support the naming of variants 'a', 'b', and 'c'.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000441",
    "statement": "In a phylogenetic network analysis of four complete human severe acute respiratory syndrome coronavirus 2 genomes, we find three central variants distinguished by amino acid changes, which we have named a, b, and c...",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "To understand the evolution of this virus within humans, and to assist in tracing infection pathways and designing preventive strategies, we here present a phylogenetic network of 160 largely complete SARS-Cov-2 genomes (Fig."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not directly support the claim about the specific phylogenetic network analysis of four complete human SARS-CoV-2 genomes and their amino acid changes (a, b, c). The evidence only indicates that a phylogenetic network of 160 largely complete SARS-CoV-2 genomes is presented, but it does not provide the details about the specific four genomes mentioned in the claim.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000442",
    "statement": "In a phylogenetic network analysis of six complete human severe acute respiratory syndrome coronavirus 2 genomes, we find three central variants distinguished by amino acid changes, which we have named a, b, and c...",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "To understand the evolution of this virus within humans, and to assist in tracing infection pathways and designing preventive strategies, we here present a phylogenetic network of 160 largely complete SARS-Cov-2 genomes (Fig."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence does not directly support the claim as it only mentions a phylogenetic network analysis of 160 largely complete SARS-Cov-2 genomes. The claim specifies six complete human genomes and names three central variants (a, b, and c) within this set. While the evidence suggests that the analysis may contain these variants, it does not provide sufficient information to confirm or disprove their existence or centrality in the network as stated in the claim.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000443",
    "statement": "The cellular immune response to covid-19 deciphered by single cell multi-omics across three uk centres.",
    "label": "SUPPORTED",
    "evidences": [
      "Together, these data detail the cellular processes present in peripheral blood during an acute immune response to COVID-19, and serve as a template for multi-omic single cell data integration across multiple centers to rapidly build powerful resources to help combat diseases such as COVID-19.",
      "Full single cell transcriptomes coupled with quantification of 188 cell surface proteins, and T and B lymphocyte antigen receptor repertoires have provided several insights into COVID-19: 1. a new non-classical monocyte state that sequesters platelets and replenishes the alveolar macrophage pool; 2. platelet activation accompanied by early priming towards megakaryopoiesis in immature haematopoietic stem/progenitor cells and expansion of megakaryocyte-primed progenitors; 3. increased clonally expanded CD8+ effector:effector memory T cells, and proliferating CD4+ and CD8+ T cells in patients with more severe disease; and 4. relative increase of IgA plasmablasts in asymptomatic stages that switches to expansion of IgG plasmablasts and plasma cells, accompanied with higher incidence of BCR sharing, as disease severity increases.",
      "To characterise the systemic host immune response to SARS-CoV-2, we performed single-cell RNA- sequencing coupled with analysis of cell surface proteins, providing molecular profiling of over 800,000 peripheral blood mononuclear cells from a cohort of 130 patients with COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided describes a study that analyzes the cellular immune response to COVID-19 using single-cell multi-omics across three UK centers. This directly supports the claim.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000444",
    "statement": "The cellular immune response to covid-19 deciphered by single cell multi-omics across two uk centres.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Together, these data detail the cellular processes present in peripheral blood during an acute immune response to COVID-19, and serve as a template for multi-omic single cell data integration across multiple centers to rapidly build powerful resources to help combat diseases such as COVID-19.",
      "Full single cell transcriptomes coupled with quantification of 188 cell surface proteins, and T and B lymphocyte antigen receptor repertoires have provided several insights into COVID-19: 1. a new non-classical monocyte state that sequesters platelets and replenishes the alveolar macrophage pool; 2. platelet activation accompanied by early priming towards megakaryopoiesis in immature haematopoietic stem/progenitor cells and expansion of megakaryocyte-primed progenitors; 3. increased clonally expanded CD8+ effector:effector memory T cells, and proliferating CD4+ and CD8+ T cells in patients with more severe disease; and 4. relative increase of IgA plasmablasts in asymptomatic stages that switches to expansion of IgG plasmablasts and plasma cells, accompanied with higher incidence of BCR sharing, as disease severity increases.",
      "To characterise the systemic host immune response to SARS-CoV-2, we performed single-cell RNA- sequencing coupled with analysis of cell surface proteins, providing molecular profiling of over 800,000 peripheral blood mononuclear cells from a cohort of 130 patients with COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided details single cell multi-omics data integration on peripheral blood during an acute immune response to COVID-19, which includes findings such as non-classical monocyte state sequestering platelets, platelet activation, increased clonally expanded CD8+ effector:effector memory T cells, and relative increase of IgA/IgG plasmablasts. This strongly suggests the claim that the cellular immune response to COVID-19 has been deciphered through single cell multi-omics across two UK centres.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000445",
    "statement": "University of oxford resumes vaccine trial",
    "label": "SUPPORTED",
    "evidences": [
      "The University of Oxford, which has partnered with pharmaceutical giant AstraZeneca to pilot the study, said that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) had recommended that its trials resume after an independent committee review of safety data triggered a pause last week.",
      "He tweeted: Good news for everyone the Oxford vaccine trials are back up and running."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is supported by the provided evidence. The University of Oxford has indeed resumed its vaccine trial after a pause due to safety concerns. The tweet also supports this claim.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000446",
    "statement": "Lack of oxford resumes vaccine trial",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The University of Oxford, which has partnered with pharmaceutical giant AstraZeneca to pilot the study, said that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) had recommended that its trials resume after an independent committee review of safety data triggered a pause last week.",
      "He tweeted: Good news for everyone the Oxford vaccine trials are back up and running."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not directly state that the University of Oxford or AstraZeneca lack an Oxford resume for their vaccine trial. Instead, it indicates that they have resumed their trials following a pause.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000447",
    "statement": "Development of oxford resumes vaccine trial",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The University of Oxford, which has partnered with pharmaceutical giant AstraZeneca to pilot the study, said that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) had recommended that its trials resume after an independent committee review of safety data triggered a pause last week.",
      "He tweeted: Good news for everyone the Oxford vaccine trials are back up and running."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is supported by the evidence because the text states that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has recommended resuming trials for the Oxford vaccine, following a pause. This implies that development of the Oxford vaccine trial is ongoing.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000448",
    "statement": "Slight reduction in sars-cov-2 exposure viral load due to masking results in a significant reduction in transmission with widespread implementation",
    "label": "SUPPORTED",
    "evidences": [
      "Our model predicts that moderately efficacious masks will lower exposure viral load 10-fold among people who get infected despite masking, potentially limiting infection severity.",
      "Slight increases in mask adherence and/or efficacy above current levels would reduce the effective reproductive number (Re) substantially below 1, particularly if implemented comprehensively in potential super-spreader environments.",
      "These results highlight the primacy of masking relative to other biomedical interventions under consideration for limiting the extent of the COVID-19 pandemic prior to widespread implementation of a vaccine.",
      "Our model quantitatively links mask efficacy to reductions in viral load and subsequent transmission risk.",
      "Our results reinforce that the use of masks by both a potential transmitter and exposed person substantially reduces the probability of successful transmission, even if masks only lower exposure viral load by 50%."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests that masking is effective in reducing the viral load of SARS-CoV-2, which can potentially limit infection severity and transmission. The model predicts a substantial reduction in the effective reproductive number (Re) when mask adherence and/or efficacy are increased, especially in potential super-spreader environments. Furthermore, the results show that using masks by both a potential transmitter and exposed person significantly reduces the probability of successful transmission.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000449",
    "statement": "High reduction in sars-cov-2 exposure viral load due to masking results in a significant reduction in transmission with widespread implementation",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our model predicts that moderately efficacious masks will lower exposure viral load 10-fold among people who get infected despite masking, potentially limiting infection severity.",
      "Slight increases in mask adherence and/or efficacy above current levels would reduce the effective reproductive number (Re) substantially below 1, particularly if implemented comprehensively in potential super-spreader environments.",
      "These results highlight the primacy of masking relative to other biomedical interventions under consideration for limiting the extent of the COVID-19 pandemic prior to widespread implementation of a vaccine.",
      "Our model quantitatively links mask efficacy to reductions in viral load and subsequent transmission risk.",
      "Our results reinforce that the use of masks by both a potential transmitter and exposed person substantially reduces the probability of successful transmission, even if masks only lower exposure viral load by 50%."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests that masks can significantly reduce exposure to SARS-CoV-2, potentially limiting infection severity and reducing the effective reproductive number (Re) below 1. This implies a high reduction in transmission with widespread implementation of masks.",
    "confidence": 0.98
  },
  {
    "id": "covid_fact-000450",
    "statement": "Significant reduction in sars-cov-2 exposure viral load due to masking results in a significant reduction in transmission with widespread implementation",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our model predicts that moderately efficacious masks will lower exposure viral load 10-fold among people who get infected despite masking, potentially limiting infection severity.",
      "Slight increases in mask adherence and/or efficacy above current levels would reduce the effective reproductive number (Re) substantially below 1, particularly if implemented comprehensively in potential super-spreader environments.",
      "These results highlight the primacy of masking relative to other biomedical interventions under consideration for limiting the extent of the COVID-19 pandemic prior to widespread implementation of a vaccine.",
      "Our model quantitatively links mask efficacy to reductions in viral load and subsequent transmission risk.",
      "Our results reinforce that the use of masks by both a potential transmitter and exposed person substantially reduces the probability of successful transmission, even if masks only lower exposure viral load by 50%."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided in this claim suggests that masks can significantly reduce the exposure to SARS-CoV-2 viral load and thus transmission risk, as supported by mathematical modeling. The model indicates a substantial reduction in the effective reproductive number (Re) of the virus with widespread implementation, especially in potential super-spreader environments. Furthermore, it highlights that mask use by both a transmitter and exposed person can substantially reduce the probability of successful transmission.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000451",
    "statement": "National smoking rates correlate inversely with covid-19 mortality",
    "label": "SUPPORTED",
    "evidences": [
      "Discussion These findings add support to the finding of an inverse relationship between current smoking and seriously symptomatic COVID-19.",
      "Results A highly significant inverse correlation between current daily smoking prevalence and COVID-19 mortality rate was noted for the group of hot countries (R=-.718, p = .0002), cold countries (R=-.567, p=.0046), and the combined group (R=-.324, p=.0207)."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides statistical data showing a significant inverse correlation between current daily smoking prevalence and COVID-19 mortality rate in both hot and cold countries, as well as when considering all countries together.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000452",
    "statement": "National smoking rates correlate closely with covid-19 mortality",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Discussion These findings add support to the finding of an inverse relationship between current smoking and seriously symptomatic COVID-19.",
      "Results A highly significant inverse correlation between current daily smoking prevalence and COVID-19 mortality rate was noted for the group of hot countries (R=-.718, p = .0002), cold countries (R=-.567, p=.0046), and the combined group (R=-.324, p=.0207)."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides statistical correlation between current daily smoking prevalence and COVID-19 mortality rate in both hot and cold countries, as well as when pooling data for all countries. However, it does not prove causation and other factors may also contribute to the observed relationship.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000453",
    "statement": "National smoking rates correlate closerly with covid-19 mortality",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Discussion These findings add support to the finding of an inverse relationship between current smoking and seriously symptomatic COVID-19.",
      "Results A highly significant inverse correlation between current daily smoking prevalence and COVID-19 mortality rate was noted for the group of hot countries (R=-.718, p = .0002), cold countries (R=-.567, p=.0046), and the combined group (R=-.324, p=.0207)."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows a significant inverse correlation between current daily smoking prevalence and COVID-19 mortality rate. This suggests that lower smoking rates correlate with higher COVID-19 mortality, as more smokers may have less severe symptoms.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000454",
    "statement": "National smoking rates correlate greaterly with covid-19 mortality",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Discussion These findings add support to the finding of an inverse relationship between current smoking and seriously symptomatic COVID-19.",
      "Results A highly significant inverse correlation between current daily smoking prevalence and COVID-19 mortality rate was noted for the group of hot countries (R=-.718, p = .0002), cold countries (R=-.567, p=.0046), and the combined group (R=-.324, p=.0207)."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows a statistically significant inverse correlation between current daily smoking prevalence and COVID-19 mortality rate in both hot and cold countries, as well as when considering the combined group. This suggests that higher smoking rates may be associated with lower COVID-19 mortality rates.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000455",
    "statement": "Cryptic transmission of novel coronavirus sars-cov-2 revealed by genomic epidemiology",
    "label": "SUPPORTED",
    "evidences": [
      "Genome sequencing of SARS-CoV-2 strains allows for the reconstruction of transmission history connecting these infections.",
      "Toggle navigation bedford lab blog papers projects team Cryptic transmission of novel coronavirus revealed by genomic epidemiology 2 Mar 2020 by Trevor Bedford The field of genomic epidemiology focuses on using the genetic sequences of pathogens to understand patterns of transmission and spread.",
      "Cryptic transmission of novel coronavirus revealed by genomic epidemiology 2 Mar 2020 by Trevor Bedford The field of genomic epidemiology focuses on using the genetic sequences of pathogens to understand patterns of transmission and spread."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that genome sequencing of SARS-CoV-2 strains allows for the reconstruction of transmission history connecting infections. This is consistent with the claim that cryptic transmission of novel coronavirus SARS-CoV-2 has been revealed by genomic epidemiology.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000456",
    "statement": "Viral transmission of novel coronavirus sars-cov-2 revealed by genomic epidemiology",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Genome sequencing of SARS-CoV-2 strains allows for the reconstruction of transmission history connecting these infections.",
      "Toggle navigation bedford lab blog papers projects team Cryptic transmission of novel coronavirus revealed by genomic epidemiology 2 Mar 2020 by Trevor Bedford The field of genomic epidemiology focuses on using the genetic sequences of pathogens to understand patterns of transmission and spread.",
      "Cryptic transmission of novel coronavirus revealed by genomic epidemiology 2 Mar 2020 by Trevor Bedford The field of genomic epidemiology focuses on using the genetic sequences of pathogens to understand patterns of transmission and spread."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided demonstrates that genome sequencing of SARS-CoV-2 strains allows for the reconstruction of transmission history, implying viral transmission of SARS-CoV-2 is being revealed by genomic epidemiology.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000457",
    "statement": "Phylogenetic transmission of novel coronavirus sars-cov-2 revealed by genomic epidemiology",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Genome sequencing of SARS-CoV-2 strains allows for the reconstruction of transmission history connecting these infections.",
      "Toggle navigation bedford lab blog papers projects team Cryptic transmission of novel coronavirus revealed by genomic epidemiology 2 Mar 2020 by Trevor Bedford The field of genomic epidemiology focuses on using the genetic sequences of pathogens to understand patterns of transmission and spread.",
      "Cryptic transmission of novel coronavirus revealed by genomic epidemiology 2 Mar 2020 by Trevor Bedford The field of genomic epidemiology focuses on using the genetic sequences of pathogens to understand patterns of transmission and spread."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided mentions 'the reconstruction of transmission history connecting these infections' which directly supports the claim that phylogenetic transmission of novel coronavirus SARS-CoV-2 can be revealed by genomic epidemiology.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000458",
    "statement": "Initial transmission of novel coronavirus sars-cov-2 revealed by genomic epidemiology",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Genome sequencing of SARS-CoV-2 strains allows for the reconstruction of transmission history connecting these infections.",
      "Toggle navigation bedford lab blog papers projects team Cryptic transmission of novel coronavirus revealed by genomic epidemiology 2 Mar 2020 by Trevor Bedford The field of genomic epidemiology focuses on using the genetic sequences of pathogens to understand patterns of transmission and spread.",
      "Cryptic transmission of novel coronavirus revealed by genomic epidemiology 2 Mar 2020 by Trevor Bedford The field of genomic epidemiology focuses on using the genetic sequences of pathogens to understand patterns of transmission and spread."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that the genome sequencing of SARS-CoV-2 allows for the reconstruction of its transmission history, which implies that the initial transmission of the novel coronavirus SARS-CoV-2 has been revealed by genomic epidemiology.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000459",
    "statement": "Nurses and other union workers authorize oct. 7 strike against east bay hospitals",
    "label": "SUPPORTED",
    "evidences": [
      "Photo: Paul Chinn / The Chronicle Employees in the Alameda Health System -- which largely serves minority communities -- plan to begin a five-day strike on Oct. 7, the California Nurses Association announced Saturday."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides direct information that employees in the Alameda Health System plan to start a five-day strike on Oct. 7, which is a union action led by nurses (as stated in California Nurses Association).",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000460",
    "statement": "Nurses and other union workers authorize dr. 7 strike against east bay hospitals",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Photo: Paul Chinn / The Chronicle Employees in the Alameda Health System -- which largely serves minority communities -- plan to begin a five-day strike on Oct. 7, the California Nurses Association announced Saturday."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that employees in the Alameda Health System, which includes nurses and other union workers, have announced a five-day strike starting on October 7. This aligns with the claim that nurses and other union workers are authorizing a strike against East Bay Hospitals.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000461",
    "statement": "Nurses and other union workers authorize s. 7 strike against east bay hospitals",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Photo: Paul Chinn / The Chronicle Employees in the Alameda Health System -- which largely serves minority communities -- plan to begin a five-day strike on Oct. 7, the California Nurses Association announced Saturday."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly states that employees in the Alameda Health System, which includes nurses and other union workers, are planning a five-day strike starting on Oct. 7, as announced by the California Nurses Association.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000462",
    "statement": "Serological surveys in reunion island of the first hospitalized patients revealed that long-lived immunoglobulin g antibodies specific against sars-cov2 virus are rapidly vanishing in severe cases",
    "label": "SUPPORTED",
    "evidences": [
      "In conclusion, serological testing may be helpful for the diagnosis of patients with negative RT-PCR results and for the identification of asymptomatic cases.",
      "Serological surveys were thoroughly performed over 2 month period by assessing IgG and IgM responses by immunofluorescence, immunoblot, Western blot and conventional ELISA using clinical RUN isolates of SARS-CoV-2 immobilized on 96 well plates.",
      "While the IgM and, unexpectedly, the IgG responses were readily detected early during the course of the disease (5-7 days post-first symptoms), our results (n=3-5 and over the full dilution set of the plasma 1/200 to 1/12800) demonstrated a significant decrease (over 2.5-fold) of IgG levels in severe (ICU) hospitalized patients (exemplified in patient 1) by WB and ELISA."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows that serological surveys were conducted to assess IgG and IgM responses in hospitalized patients with SARS-CoV-2 infection. The results demonstrated a significant decrease (over 2.5-fold) of IgG levels in severe (ICU) hospitalized patients, indicating that long-lived immunoglobulin g antibodies specific against the SARS-CoV-2 virus are rapidly vanishing in severe cases.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000463",
    "statement": "Serological surveys in reunion island of the first hospitalized patients revealed that long-lived immunoglobulin g antibodies specific against sars-cov2 virus are rapidly circulating in severe cases",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In conclusion, serological testing may be helpful for the diagnosis of patients with negative RT-PCR results and for the identification of asymptomatic cases.",
      "Serological surveys were thoroughly performed over 2 month period by assessing IgG and IgM responses by immunofluorescence, immunoblot, Western blot and conventional ELISA using clinical RUN isolates of SARS-CoV-2 immobilized on 96 well plates.",
      "While the IgM and, unexpectedly, the IgG responses were readily detected early during the course of the disease (5-7 days post-first symptoms), our results (n=3-5 and over the full dilution set of the plasma 1/200 to 1/12800) demonstrated a significant decrease (over 2.5-fold) of IgG levels in severe (ICU) hospitalized patients (exemplified in patient 1) by WB and ELISA."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence discusses serological testing for SARS-CoV-2 immunoglobulin G (IgG) and IgM responses in hospitalized patients on Reunion Island. The testing was done over a two-month period, and the results showed a significant decrease in IgG levels in severe cases, particularly in patient 1, as demonstrated by Western blot (WB) and ELISA. This suggests that long-lived IgG antibodies specific against SARS-CoV-2 are circulating in severe cases.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000464",
    "statement": "Serological surveys in reunion island of the first hospitalized patients revealed that long-lived immunoglobulin g antibodies specific against sars-cov2 virus are rapidly produced in severe cases",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In conclusion, serological testing may be helpful for the diagnosis of patients with negative RT-PCR results and for the identification of asymptomatic cases.",
      "Serological surveys were thoroughly performed over 2 month period by assessing IgG and IgM responses by immunofluorescence, immunoblot, Western blot and conventional ELISA using clinical RUN isolates of SARS-CoV-2 immobilized on 96 well plates.",
      "While the IgM and, unexpectedly, the IgG responses were readily detected early during the course of the disease (5-7 days post-first symptoms), our results (n=3-5 and over the full dilution set of the plasma 1/200 to 1/12800) demonstrated a significant decrease (over 2.5-fold) of IgG levels in severe (ICU) hospitalized patients (exemplified in patient 1) by WB and ELISA."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence describes serological surveys performed over a two-month period on hospitalized patients with COVID-19. The surveys assessed IgG and IgM responses to the SARS-CoV-2 virus, which are antibodies specific against the virus. Additionally, the evidence indicates that these antibodies were rapidly produced in severe cases (ICU patients) and levels decreased significantly by Western Blot (WB) and ELISA over time. Therefore, it supports the claim that long-lived immunoglobulin g antibodies specific against SARS-CoV-2 are rapidly produced in severe cases.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000465",
    "statement": "Serological surveys in reunion island of the first hospitalized patients revealed that long-lived immunoglobulin g antibodies specific against sars-cov2 virus are rapidly transmitted in severe cases",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In conclusion, serological testing may be helpful for the diagnosis of patients with negative RT-PCR results and for the identification of asymptomatic cases.",
      "Serological surveys were thoroughly performed over 2 month period by assessing IgG and IgM responses by immunofluorescence, immunoblot, Western blot and conventional ELISA using clinical RUN isolates of SARS-CoV-2 immobilized on 96 well plates.",
      "While the IgM and, unexpectedly, the IgG responses were readily detected early during the course of the disease (5-7 days post-first symptoms), our results (n=3-5 and over the full dilution set of the plasma 1/200 to 1/12800) demonstrated a significant decrease (over 2.5-fold) of IgG levels in severe (ICU) hospitalized patients (exemplified in patient 1) by WB and ELISA."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence does not directly support the claim that long-lived immunoglobulin g antibodies specific against SARS-CoV-2 virus are rapidly transmitted in severe cases. The evidence demonstrates a significant decrease of IgG levels in severe hospitalized patients, but it does not provide information about the rapid transmission of these antibodies.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000466",
    "statement": "Moderna announces first participants dosed in phase 2/3 study of covid-19 vaccine candidate in adolescents",
    "label": "SUPPORTED",
    "evidences": [
      "We are encouraged by the interim and primary analyses of the Phase 3 COVE study in adults ages 18 and above and this adolescent study will help us assess the potential safety and immunogenicity of our COVID-19 vaccine candidate in this important younger age population.",
      "We hope we will be able to provide a safe vaccine to provide protection to adolescents so they can return to school in a normal setting. This randomized, controlled Phase 2/3 study will evaluate the safety, reactogenicity and immunogenicity of two vaccinations of mRNA-1273 given 28 days apart."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that Moderna is conducting a Phase 2/3 study of its COVID-19 vaccine candidate in adolescents, implying that some participants have already been dosed.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000467",
    "statement": "Moderna announces all participants dosed in phase 2/3 study of covid-19 vaccine candidate in adolescents",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We are encouraged by the interim and primary analyses of the Phase 3 COVE study in adults ages 18 and above and this adolescent study will help us assess the potential safety and immunogenicity of our COVID-19 vaccine candidate in this important younger age population.",
      "We hope we will be able to provide a safe vaccine to provide protection to adolescents so they can return to school in a normal setting. This randomized, controlled Phase 2/3 study will evaluate the safety, reactogenicity and immunogenicity of two vaccinations of mRNA-1273 given 28 days apart."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided indicates that Moderna is conducting a Phase 2/3 study on its COVID-19 vaccine candidate in adolescents to assess safety and immunogenicity. However, it does not directly state that all participants have been dosed in the study.",
    "confidence": 0.5
  },
  {
    "id": "covid_fact-000468",
    "statement": "Moderna announces from participants dosed in phase 2/3 study of covid-19 vaccine candidate in adolescents",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We are encouraged by the interim and primary analyses of the Phase 3 COVE study in adults ages 18 and above and this adolescent study will help us assess the potential safety and immunogenicity of our COVID-19 vaccine candidate in this important younger age population.",
      "We hope we will be able to provide a safe vaccine to provide protection to adolescents so they can return to school in a normal setting. This randomized, controlled Phase 2/3 study will evaluate the safety, reactogenicity and immunogenicity of two vaccinations of mRNA-1273 given 28 days apart."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that Moderna is planning a study to evaluate the safety and immunogenicity of its COVID-19 vaccine candidate in adolescents (12-17 years old), but it does not provide information on whether any participants from this age group have already been dosed in the phase 2/3 study.",
    "confidence": 0.5
  },
  {
    "id": "covid_fact-000469",
    "statement": "Sars-cov-2 receptor ace2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues",
    "label": "SUPPORTED",
    "evidences": [
      "We identify ACE2 and TMPRSS2 co-expressing cells within lung type II pneumocytes, ileal absorptive enterocytes, and nasal goblet secretory cells.",
      "SARS-CoV-2 spike (S) protein binds angiotensin-converting enzyme 2 (ACE2), and in concert with host proteases, principally transmembrane serine protease 2 (TMPRSS2), promotes cellular entry.",
      "Our data suggest that SARS-CoV-2 could exploit species- specific interferon-driven upregulation of ACE2, a tissue-protective mediator during lung injury, to enhance infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides direct support for the claim that SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. The data shows identification of ACE2 and TMPRSS2 co-expressing cells, which are relevant to SARS-CoV-2 entry, in lung type II pneumocytes, ileal absorptive enterocytes, and nasal goblet secretory cells. Additionally, the text suggests that SARS-CoV-2 could exploit interferon-driven upregulation of ACE2, which is a tissue-protective mediator during lung injury.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000470",
    "statement": "Sars-cov-2 receptor ace2 is an interferon-stimulated gene in canine airway epithelial cells and is detected in specific cell subsets across tissues",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We identify ACE2 and TMPRSS2 co-expressing cells within lung type II pneumocytes, ileal absorptive enterocytes, and nasal goblet secretory cells.",
      "SARS-CoV-2 spike (S) protein binds angiotensin-converting enzyme 2 (ACE2), and in concert with host proteases, principally transmembrane serine protease 2 (TMPRSS2), promotes cellular entry.",
      "Our data suggest that SARS-CoV-2 could exploit species- specific interferon-driven upregulation of ACE2, a tissue-protective mediator during lung injury, to enhance infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides information about the expression of ACE2 and TMPRSS2 in specific cell subsets across tissues (lung type II pneumocytes, ileal absorptive enterocytes, and nasal goblet secretory cells). Furthermore, it mentions that SARS-CoV-2 could exploit species-specific interferon-driven upregulation of ACE2, suggesting that ACE2 may be an interferon-stimulated gene in canine airway epithelial cells. The evidence does not specify the confidence level for the detection of ACE2 in specific cell subsets across tissues, but it implies that ACE2 is present and potentially upregulated.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000471",
    "statement": "Sars-cov-2 receptor ace2 is an interferon-stimulated gene in human airway epithelial cells and is detected in many cell subsets across tissues",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We identify ACE2 and TMPRSS2 co-expressing cells within lung type II pneumocytes, ileal absorptive enterocytes, and nasal goblet secretory cells.",
      "SARS-CoV-2 spike (S) protein binds angiotensin-converting enzyme 2 (ACE2), and in concert with host proteases, principally transmembrane serine protease 2 (TMPRSS2), promotes cellular entry.",
      "Our data suggest that SARS-CoV-2 could exploit species- specific interferon-driven upregulation of ACE2, a tissue-protective mediator during lung injury, to enhance infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence suggests that ACE2, the SARS-CoV-2 receptor, is detected in multiple cell subsets across tissues, including the lung type II pneumocytes which are part of airway epithelial cells. Additionally, it mentions that ACE2 expression can be upregulated by interferons, which are known to be stimulated in response to viral infections.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000472",
    "statement": "Sars-cov-2 receptor ace2 is an interferon-stimulated gene in human airway epithelial cells and is detected in multiple cell subsets across tissues",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We identify ACE2 and TMPRSS2 co-expressing cells within lung type II pneumocytes, ileal absorptive enterocytes, and nasal goblet secretory cells.",
      "SARS-CoV-2 spike (S) protein binds angiotensin-converting enzyme 2 (ACE2), and in concert with host proteases, principally transmembrane serine protease 2 (TMPRSS2), promotes cellular entry.",
      "Our data suggest that SARS-CoV-2 could exploit species- specific interferon-driven upregulation of ACE2, a tissue-protective mediator during lung injury, to enhance infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows that ACE2, the receptor for Sars-Cov-2, is expressed in multiple cell subsets across tissues including lung type II pneumocytes, ileal absorptive enterocytes, and nasal goblet secretory cells. Furthermore, it also suggests that the expression of ACE2 is upregulated by interferons which are known to be stimulated during viral infections. This aligns with the claim that Sars-Cov-2 receptor Ace2 is an interferon-stimulated gene in human airway epithelial cells.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000473",
    "statement": "Structure of sars-cov-2 orf8 , a rapidly evolving coronavirus protein implicated in immune evasion",
    "label": "SUPPORTED",
    "evidences": [
      "Together the presence of these interfaces shows how SARS-CoV-2 ORF8 can form unique large- scale assemblies not possible for SARS-CoV, potentially mediating unique immune suppression and evasion activities."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that the structure of SARS-CoV-2 ORF8 can form unique large-scale assemblies not possible for SARS-CoV, potentially mediating immune suppression and evasion activities. This supports the claim that SARS-CoV-2 ORF8 is a rapidly evolving coronavirus protein implicated in immune evasion.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000474",
    "statement": "Loss of sars-cov-2 orf8, a rapidly evolving coronavirus protein implicated in immune evasion",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Together the presence of these interfaces shows how SARS-CoV-2 ORF8 can form unique large- scale assemblies not possible for SARS-CoV, potentially mediating unique immune suppression and evasion activities."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that the ORF8 protein of SARS-CoV-2 (the virus causing COVID-19) is involved in unique large-scale assemblies which may mediate immune suppression and evasion activities. This supports the claim that loss of sars-cov-2 orf8 is a rapidly evolving coronavirus protein implicated in immune evasion.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000475",
    "statement": "Mutation of sars-cov-2 orf8, a rapidly evolving coronavirus protein implicated in immune evasion",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Together the presence of these interfaces shows how SARS-CoV-2 ORF8 can form unique large- scale assemblies not possible for SARS-CoV, potentially mediating unique immune suppression and evasion activities."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests that the ORF8 protein of SARS-CoV-2 is rapidly evolving and can form unique large-scale assemblies not possible for SARS-CoV. This could potentially mediate unique immune suppression and evasion activities, which aligns with the claim about mutation of sars-cov-2 ORF8 and its role in immune evasion.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000476",
    "statement": "Activation of sars-cov-2 orf8, a rapidly evolving coronavirus protein implicated in immune evasion",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Together the presence of these interfaces shows how SARS-CoV-2 ORF8 can form unique large- scale assemblies not possible for SARS-CoV, potentially mediating unique immune suppression and evasion activities."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests that SARS-CoV-2 ORF8 forms unique large-scale assemblies and may mediate immune suppression and evasion activities. This implies the activation of the specific protein (ORF8) implicated in these functions.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000477",
    "statement": "Israel is arresting palestine 's doctors fighting covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "Outlining Israels work to mitigate the impact of COVID-19 across the region, he said it is providing resources to the United Nations response, facilitating the flow of medical supplies and food into Gaza and conducting medical trainings for Palestinian health workers."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not directly support the claim that Israel is arresting Palestine's doctors fighting COVID-19. While it mentions cooperation in providing resources and medical trainings, there is no mention or indication of any arrests.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000478",
    "statement": "China is arresting palestine's doctors fighting covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Outlining Israels work to mitigate the impact of COVID-19 across the region, he said it is providing resources to the United Nations response, facilitating the flow of medical supplies and food into Gaza and conducting medical trainings for Palestinian health workers."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not mention any arrests by China of doctors from Palestine fighting COVID-19. The focus is on Israel's actions related to the region and the COVID-19 pandemic.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000479",
    "statement": "Israel is called palestine's doctors fighting covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Outlining Israels work to mitigate the impact of COVID-19 across the region, he said it is providing resources to the United Nations response, facilitating the flow of medical supplies and food into Gaza and conducting medical trainings for Palestinian health workers."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim states that Israel is referred to as 'Palestine's doctors fighting COVID-19', which contradicts the evidence provided, as it outlines actions taken by Israel in response to COVID-19 within the region without making any claims about being referred to as 'Palestine's doctors'. The given evidence doesn't support a direct relationship between Israel and Palestine being doctors fighting COVID-19.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000480",
    "statement": "Identification of an existing japanese pancreatitis drug , nafamostat , which is expected to prevent the transmission of new coronavirus infection",
    "label": "SUPPORTED",
    "evidences": [
      "The University of Tokyo plans to launch clinical trials in April 2020 in order to evaluate the effectiveness of these two drugs for treating COVID-19.",
      "Both Nafamostat and Camostat were developed in Japan as treatments for pancreatitis and some other diseases.",
      "According to the new research, Nafamostat can prevent the fusion of the envelope of the virus with host cell surface membranes, the first step in infection with the causative virus SARS-CoV-2.",
      "Nafamostat mesylate (brand name: Fusan), which is the drug used to treat acute pancreatitis, may effectively block the requisite viral entry process the new coronavirus (SARS-CoV-2) uses to spread and cause disease (COVID-19)."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that Nafamostat is a drug developed in Japan for treating pancreatitis and some other diseases. It also mentions new research indicating that Nafamostat can prevent the fusion of the envelope of the virus with host cell surface membranes, which is the first step in infection with the causative virus SARS-CoV-2. The article further states that a brand name for Nafamostat is Fusan, which is used to treat acute pancreatitis. Therefore, it can be reasonably concluded that Nafamostat is an existing Japanese drug and may help prevent the transmission of new coronavirus infection.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000481",
    "statement": "Loss of an existing japanese pancreatitis drug, nafamostat, which is expected to prevent the transmission of new coronavirus infection",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The University of Tokyo plans to launch clinical trials in April 2020 in order to evaluate the effectiveness of these two drugs for treating COVID-19.",
      "Both Nafamostat and Camostat were developed in Japan as treatments for pancreatitis and some other diseases.",
      "According to the new research, Nafamostat can prevent the fusion of the envelope of the virus with host cell surface membranes, the first step in infection with the causative virus SARS-CoV-2.",
      "Nafamostat mesylate (brand name: Fusan), which is the drug used to treat acute pancreatitis, may effectively block the requisite viral entry process the new coronavirus (SARS-CoV-2) uses to spread and cause disease (COVID-19)."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided suggests that Nafamostat has potential in preventing the fusion of the virus with host cell surface membranes and blocking the viral entry process of SARS-CoV-2. However, this evidence does not directly support the claim that Nafamostat can prevent the transmission of new coronavirus infection.",
    "confidence": 0.4
  },
  {
    "id": "covid_fact-000482",
    "statement": "Sars-cov-2 infection of human ace2-transgenic mice causes severe lung inflammation and impaired function",
    "label": "SUPPORTED",
    "evidences": [
      "In summary, we found that SARS-CoV-2 infection of K18-hACE2-transgenic mice supports robust viral replication in the lung, which leads to severe immune cell infiltration, inflammation and pulmonary disease.",
      "Binding of the SARS-CoV-2 spike protein to human angiotensin I-converting enzyme 2 (hACE2) primarily targets the virus to type II pneumocytes within the lung, resulting in injury, inflammation and subsequent respiratory distress1,2.",
      "The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows that the infection of human ACE2-transgenic mice with SARS-CoV-2 results in robust viral replication in the lung leading to severe immune cell infiltration, inflammation and pulmonary disease. This supports the claim.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000483",
    "statement": "Sars-cov-2 infection of human ace2-transgenic mice prevented severe lung inflammation and impaired function",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In summary, we found that SARS-CoV-2 infection of K18-hACE2-transgenic mice supports robust viral replication in the lung, which leads to severe immune cell infiltration, inflammation and pulmonary disease.",
      "Binding of the SARS-CoV-2 spike protein to human angiotensin I-converting enzyme 2 (hACE2) primarily targets the virus to type II pneumocytes within the lung, resulting in injury, inflammation and subsequent respiratory distress1,2.",
      "The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided shows that the SARS-CoV-2 infection in hACE2-transgenic mice leads to severe immune cell infiltration, inflammation and pulmonary disease. This contradicts the claim that infection prevents severe lung inflammation and impaired function.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000484",
    "statement": "Sars-cov-2 infection of human ace2-transgenic patients causes severe lung inflammation and impaired function",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In summary, we found that SARS-CoV-2 infection of K18-hACE2-transgenic mice supports robust viral replication in the lung, which leads to severe immune cell infiltration, inflammation and pulmonary disease.",
      "Binding of the SARS-CoV-2 spike protein to human angiotensin I-converting enzyme 2 (hACE2) primarily targets the virus to type II pneumocytes within the lung, resulting in injury, inflammation and subsequent respiratory distress1,2.",
      "The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence describes a study on K18-hACE2-transgenic mice infected with SARS-CoV-2, which shows that the infection leads to severe immune cell infiltration, inflammation and pulmonary disease. This directly supports the claim about Sars-cov-2 infection causing severe lung inflammation and impaired function in human ACE2 transgenic patients.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000485",
    "statement": "Sars-cov-2 infection of human ace2-transgenic mice inhibited severe lung inflammation and impaired function",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In summary, we found that SARS-CoV-2 infection of K18-hACE2-transgenic mice supports robust viral replication in the lung, which leads to severe immune cell infiltration, inflammation and pulmonary disease.",
      "Binding of the SARS-CoV-2 spike protein to human angiotensin I-converting enzyme 2 (hACE2) primarily targets the virus to type II pneumocytes within the lung, resulting in injury, inflammation and subsequent respiratory distress1,2.",
      "The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not explicitly state that the infection of human ACE2-transgenic mice with SARS-CoV-2 inhibited severe lung inflammation and impaired function. Instead, it indicates that such an infection leads to severe immune cell infiltration, inflammation, and pulmonary disease. Therefore, while there may be some potential for such an effect, the evidence does not conclusively support this claim.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000486",
    "statement": "Thrombotic microvascular injury is not mediated by thrombotic microangiopathy despite systemic complement activation in covid-19 patients",
    "label": "SUPPORTED",
    "evidences": [
      "Interestingly, none the 8 patients had signs of mechanical hemolytic anemia (median value of hemoglobin : 10,5 gr/dL[IQR : 8,1 - 11,9], median value of haptoglobuline 4,49 [IQR 3,55-4,66], none of the patients has schistocyte) and thrombocytopenia (median value: 348000/mL [IQR : 266 000 - 401 000).",
      "In summary, this study show moderate activation of complement and coagulation with presence of thrombotic microvascular injury in patients with severe COVID-19 without evidence of systemic thrombotic microangiopathy."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence indicates that the patients had moderate activation of complement and coagulation with presence of thrombotic microvascular injury in severe COVID-19 cases. However, the evidence does not explicitly prove or disprove whether thrombotic microvascular injury is mediated by thrombotic microangiopathy in these patients.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000487",
    "statement": "Thrombotic microvascular injury is mainly mediated by thrombotic microangiopathy despite systemic complement activation in covid-19 patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Interestingly, none the 8 patients had signs of mechanical hemolytic anemia (median value of hemoglobin : 10,5 gr/dL[IQR : 8,1 - 11,9], median value of haptoglobuline 4,49 [IQR 3,55-4,66], none of the patients has schistocyte) and thrombocytopenia (median value: 348000/mL [IQR : 266 000 - 401 000).",
      "In summary, this study show moderate activation of complement and coagulation with presence of thrombotic microvascular injury in patients with severe COVID-19 without evidence of systemic thrombotic microangiopathy."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that there is no evidence of mechanical hemolytic anemia or schistocytes (signs of thrombotic microangiopathy) in the COVID-19 patients studied. Additionally, while the complement and coagulation systems are moderately activated, the focus remains on thrombotic microvascular injury rather than systemic thrombotic microangiopathy.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000488",
    "statement": "Thrombotic microvascular injury is primarily mediated by thrombotic microangiopathy despite systemic complement activation in covid-19 patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Interestingly, none the 8 patients had signs of mechanical hemolytic anemia (median value of hemoglobin : 10,5 gr/dL[IQR : 8,1 - 11,9], median value of haptoglobuline 4,49 [IQR 3,55-4,66], none of the patients has schistocyte) and thrombocytopenia (median value: 348000/mL [IQR : 266 000 - 401 000).",
      "In summary, this study show moderate activation of complement and coagulation with presence of thrombotic microvascular injury in patients with severe COVID-19 without evidence of systemic thrombotic microangiopathy."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that the patients did not exhibit signs of mechanical hemolytic anemia, schistocytes or thrombocytopenia, which are typically associated with thrombotic microangiopathy. Instead, there is evidence of thrombotic microvascular injury and moderate activation of complement and coagulation in these patients with severe COVID-19. Therefore, it can be inferred that the primary mediator of thrombotic microvascular injury in these cases may not necessarily be thrombotic microangiopathy.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000489",
    "statement": "Thrombotic microvascular injury is also mediated by thrombotic microangiopathy despite systemic complement activation in covid-19 patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Interestingly, none the 8 patients had signs of mechanical hemolytic anemia (median value of hemoglobin : 10,5 gr/dL[IQR : 8,1 - 11,9], median value of haptoglobuline 4,49 [IQR 3,55-4,66], none of the patients has schistocyte) and thrombocytopenia (median value: 348000/mL [IQR : 266 000 - 401 000).",
      "In summary, this study show moderate activation of complement and coagulation with presence of thrombotic microvascular injury in patients with severe COVID-19 without evidence of systemic thrombotic microangiopathy."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that the study found moderate activation of complement and coagulation with presence of thrombotic microvascular injury in patients with severe COVID-19, without signs of mechanical hemolytic anemia or thrombocytopenia, which are typically associated with systemic thrombotic microangiopathy. This supports the claim that thrombotic microvascular injury can occur independently of systemic thrombotic microangiopathy in COVID-19 patients.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000490",
    "statement": "Serum amyloid p inhibits single stranded rna-induced lung inflammation , lung damage , and cytokine storm in mice",
    "label": "SUPPORTED",
    "evidences": [
      "Together, these results suggest that aspiration of ORN06 is a simple model for both COVID-19 as well as cytokine storm in general, and that SAP is a potential therapeutic for diseases with COVID-19-like symptoms as well as diseases that generate a cytokine storm.",
      "A serum protein called serum amyloid P (SAP) has a calming effect on the innate immune system and shows efficacy as a therapeutic for fibrosis in animal models and clinical trials."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests that Serum Amyloid P (SAP) has a calming effect on the innate immune system, which could potentially help in preventing inflammation, lung damage, and cytokine storm. The statement about SAP being a potential therapeutic for diseases with COVID-19-like symptoms and diseases that generate a cytokine storm is also supported by the context of the evidence.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000491",
    "statement": "Serum amyloid p inhibits single stranded rna-induced lung inflammation, lung damage, and cytokine storm in patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Together, these results suggest that aspiration of ORN06 is a simple model for both COVID-19 as well as cytokine storm in general, and that SAP is a potential therapeutic for diseases with COVID-19-like symptoms as well as diseases that generate a cytokine storm.",
      "A serum protein called serum amyloid P (SAP) has a calming effect on the innate immune system and shows efficacy as a therapeutic for fibrosis in animal models and clinical trials."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that serum amyloid P (SAP) has a calming effect on the innate immune system and shows efficacy as a therapeutic for fibrosis in animal models and clinical trials. It also suggests that SAP is a potential therapeutic for diseases with COVID-19-like symptoms as well as diseases that generate a cytokine storm. Single stranded RNA, lung inflammation, lung damage, and cytokine storm are associated with COVID-19. Therefore, it can be inferred that SAP inhibits single stranded RNA-induced lung inflammation, lung damage, and cytokine storm.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000492",
    "statement": "Fda approves the emergency use of chloroquine phosphate and hydroxychloroquine sulfate for treatment of covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "The U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) to BARDA to allow hydroxychloroquine sulfate and Resochin donated to the Strategic National Stockpile (SNS) to be distributed and prescribed by doctors to hospitalized teen and adult patients with COVID-19, as appropriate, when a clinical trial is not available or feasible."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence explicitly states that the FDA issued an EUA for hydroxychloroquine sulfate to be used in the treatment of COVID-19 under certain conditions. Therefore, it is supported that the claim is true.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000493",
    "statement": "Fdaines the emergency use of chloroquine phosphate and hydroxychloroquine sulfate for treatment of covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) to BARDA to allow hydroxychloroquine sulfate and Resochin donated to the Strategic National Stockpile (SNS) to be distributed and prescribed by doctors to hospitalized teen and adult patients with COVID-19, as appropriate, when a clinical trial is not available or feasible."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence states that the FDA issued an Emergency Use Authorization (EUA) for hydroxychloroquine sulfate to treat COVID-19. This implies that it can be used for emergency situations where a clinical trial is not available or feasible.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000494",
    "statement": "Fdaards the emergency use of chloroquine phosphate and hydroxychloroquine sulfate for treatment of covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) to BARDA to allow hydroxychloroquine sulfate and Resochin donated to the Strategic National Stockpile (SNS) to be distributed and prescribed by doctors to hospitalized teen and adult patients with COVID-19, as appropriate, when a clinical trial is not available or feasible."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that the FDA issued an Emergency Use Authorization (EUA) for the use of hydroxychloroquine sulfate for treatment of COVID-19 in hospitalized teen and adult patients. This implies that the emergency use of chloroquine phosphate (which is a prodrug of hydroxychloroquine) would also be supported under this EUA.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000495",
    "statement": "Fdaasts the emergency use of chloroquine phosphate and hydroxychloroquine sulfate for treatment of covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) to BARDA to allow hydroxychloroquine sulfate and Resochin donated to the Strategic National Stockpile (SNS) to be distributed and prescribed by doctors to hospitalized teen and adult patients with COVID-19, as appropriate, when a clinical trial is not available or feasible."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is supported by the evidence provided because the FDA issued an Emergency Use Authorization (EUA) for hydroxychloroquine sulfate to be used in treating COVID-19 when a clinical trial is not available or feasible.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000496",
    "statement": "Genomic epidemiology reveals transmission patterns and dynamics of sars-cov-2 in aotearoa new zealand",
    "label": "SUPPORTED",
    "evidences": [
      "d The sampling location and proportion of SARS-CoV-2 genomes sampled from each viral genomic lineage is shown on the map of New Zealand.",
      "Notably, the genomic diversity of SARS-CoV-2 sequences sampled in New Zealand represented nearly all of the genomic diversity present in the global viral population, with nine second-level A and B lineages from a proposed global SARS-CoV-2 genomic nomenclature17 identified.",
      "3: Genomic transmission lineages of SARS-CoV-2 in New Zealand.",
      "2: Genomic diversity of SARS-CoV-2 in New Zealand."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows the genomic diversity of SARS-CoV-2 sequences sampled in New Zealand which represents nearly all of the global viral population's genomic diversity. Furthermore, it identifies nine different second-level lineages of SARS-CoV-2 in New Zealand. This indicates that the transmission patterns and dynamics of SARS-CoV-2 within Aotearoa New Zealand are being analyzed through genomic epidemiology.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000497",
    "statement": "Genomic epidemiology reveals evolutionary patterns and dynamics of sars-cov-2 in aotearoa new zealand",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "d The sampling location and proportion of SARS-CoV-2 genomes sampled from each viral genomic lineage is shown on the map of New Zealand.",
      "Notably, the genomic diversity of SARS-CoV-2 sequences sampled in New Zealand represented nearly all of the genomic diversity present in the global viral population, with nine second-level A and B lineages from a proposed global SARS-CoV-2 genomic nomenclature17 identified.",
      "3: Genomic transmission lineages of SARS-CoV-2 in New Zealand.",
      "2: Genomic diversity of SARS-CoV-2 in New Zealand."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that genomic samples of SARS-CoV-2 were collected from various locations within New Zealand and analyzed to determine the genomic diversity and transmission lineages present. This is a typical approach in genomic epidemiology, used for understanding the evolutionary patterns and dynamics of pathogens like SARS-CoV-2.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000498",
    "statement": "Cross-species transmission of the newly identified coronavirus 2019-ncov",
    "label": "SUPPORTED",
    "evidences": [
      "Results obtained from our analyses suggest that the 2019-nCoV may appear to be a recombinant virus between the bat coronavirus and an origin- unknown coronavirus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests that the 2019-nCoV is a recombinant virus between a bat coronavirus and an origin-unknown coronavirus, indicating a possible cross-species transmission.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000499",
    "statement": "Cross-species transmission of the newly identified coronavirus e-ncov",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Results obtained from our analyses suggest that the 2019-nCoV may appear to be a recombinant virus between the bat coronavirus and an origin- unknown coronavirus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that the 2019-nCoV may be a recombinant virus between bat coronavirus and an unknown origin virus. This implies that there could have been cross-species transmission of the newly identified coronavirus.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000500",
    "statement": "Cross-species transmission of the previously identified coronavirus 2019-ncov",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Results obtained from our analyses suggest that the 2019-nCoV may appear to be a recombinant virus between the bat coronavirus and an origin- unknown coronavirus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that the 2019-nCoV may have recombined with another coronavirus, and one of its potential sources is bats. Therefore, it appears to support the claim of cross-species transmission of the virus.",
    "confidence": 0.85
  },
  {
    "id": "covid_fact-000501",
    "statement": "Cross-species transmission of the newly identified coronavirus b-ncov",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Results obtained from our analyses suggest that the 2019-nCoV may appear to be a recombinant virus between the bat coronavirus and an origin- unknown coronavirus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that the 2019-nCoV may be a recombinant virus between bat coronavirus and an unknown origin coronavirus, implying that cross-species transmission of this newly identified coronavirus is supported by this analysis.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000502",
    "statement": "Recurrent deletions in the sars-cov-2 spike glycoprotein drive antibody escape.",
    "label": "SUPPORTED",
    "evidences": [
      "Share Natural deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape Kevin R. McCarthy, Linda J. Rennick, Sham Nambulli, Lindsey R. Robinson- McCarthy, William G. Bain, Ghady Haidar, W. Paul Duprex bioRxiv 2020.11.19.389916; doi: https://doi.org/10.1101/2020.11.19.389916 Share This Article: Copy Citation Tools Natural deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape Kevin R. McCarthy, Linda J. Rennick, Sham Nambulli, Lindsey R. Robinson- McCarthy, William G. Bain, Ghady Haidar, W. Paul Duprex bioRxiv 2020.11.19.389916; doi: https://doi.org/10.1101/2020.11.19.389916 ",
      "Natural deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided is a preprint article titled 'Natural deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape'. The title of the article suggests that the study investigates how deletions in the SARS-CoV-2 spike glycoprotein contribute to antibody escape, which is consistent with the claim.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000503",
    "statement": "Recurrent deletions in the sars-cov-2 spike glycoprotein prevent antibody escape.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Share Natural deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape Kevin R. McCarthy, Linda J. Rennick, Sham Nambulli, Lindsey R. Robinson- McCarthy, William G. Bain, Ghady Haidar, W. Paul Duprex bioRxiv 2020.11.19.389916; doi: https://doi.org/10.1101/2020.11.19.389916 Share This Article: Copy Citation Tools Natural deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape Kevin R. McCarthy, Linda J. Rennick, Sham Nambulli, Lindsey R. Robinson- McCarthy, William G. Bain, Ghady Haidar, W. Paul Duprex bioRxiv 2020.11.19.389916; doi: https://doi.org/10.1101/2020.11.19.389916 ",
      "Natural deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence describes a research study that suggests natural deletions in the SARS-CoV-2 spike glycoprotein may drive antibody escape. However, it does not provide direct evidence that recurrent deletions prevent antibody escape, as stated in the claim.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000504",
    "statement": "Recurrent deletions in the sars-cov-2 spike glycoprotein drive antibody reactivity.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Share Natural deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape Kevin R. McCarthy, Linda J. Rennick, Sham Nambulli, Lindsey R. Robinson- McCarthy, William G. Bain, Ghady Haidar, W. Paul Duprex bioRxiv 2020.11.19.389916; doi: https://doi.org/10.1101/2020.11.19.389916 Share This Article: Copy Citation Tools Natural deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape Kevin R. McCarthy, Linda J. Rennick, Sham Nambulli, Lindsey R. Robinson- McCarthy, William G. Bain, Ghady Haidar, W. Paul Duprex bioRxiv 2020.11.19.389916; doi: https://doi.org/10.1101/2020.11.19.389916 ",
      "Natural deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided is a preprint article titled 'Natural deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape'. The title implies that the study investigates how deletions in the SARS-CoV-2 spike glycoprotein can lead to evasion of antibodies, which suggests that recurrent deletions in the said protein do indeed impact antibody reactivity.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000505",
    "statement": "Recurrent deletions in the sars-cov-2 spike glycoprotein drive antibody production.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Share Natural deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape Kevin R. McCarthy, Linda J. Rennick, Sham Nambulli, Lindsey R. Robinson- McCarthy, William G. Bain, Ghady Haidar, W. Paul Duprex bioRxiv 2020.11.19.389916; doi: https://doi.org/10.1101/2020.11.19.389916 Share This Article: Copy Citation Tools Natural deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape Kevin R. McCarthy, Linda J. Rennick, Sham Nambulli, Lindsey R. Robinson- McCarthy, William G. Bain, Ghady Haidar, W. Paul Duprex bioRxiv 2020.11.19.389916; doi: https://doi.org/10.1101/2020.11.19.389916 ",
      "Natural deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided is a preprint study that investigates natural deletions in the SARS-CoV-2 spike glycoprotein and their impact on antibody escape. The presence of such deletions supports the claim that these deletions can drive antibody production.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000506",
    "statement": "Sars-coronavirus-1 open reading frame-8b triggers intracellular stress pathways and activates nlrp3 inflammasomes",
    "label": "SUPPORTED",
    "evidences": [
      "Here, we identify several mechanisms by which a SARS-CoV open reading frame (ORF) activates intracellular stress pathways and targets the innate immune response."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides information about mechanisms by which a SARS-CoV open reading frame activates intracellular stress pathways and targets the innate immune response. This implies that Sars-coronavirus-1 open reading frame-8b triggers intracellular stress pathways and activates nlrp3 inflammasomes.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000507",
    "statement": "Sars-coronavirus-1 open reading frame-8b inhibits intracellular stress pathways and activates nlrp3 inflammasomes",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Here, we identify several mechanisms by which a SARS-CoV open reading frame (ORF) activates intracellular stress pathways and targets the innate immune response."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests that a SARS-CoV open reading frame (ORF) activates intracellular stress pathways and targets the innate immune response. The term 'Sars-coronavirus-1 open reading frame-8b' mentioned in the claim is similar to 'a SARS-CoV open reading frame' found in the evidence, implying they refer to the same entity. Furthermore, the claim explicitly states that this open reading frame activates intracellular stress pathways and targets the innate immune response, which aligns with the mechanisms identified in the evidence.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000508",
    "statement": "A chest-ct and clinical chemistry based flowchart for rapid covid-19 triage at emergency departments",
    "label": "SUPPORTED",
    "evidences": [
      "Conclusion This flowchart, based on radiology (CO-RADS) and clinical chemistry parameters (lab-corona-score), results in a rapid and accurate diagnosis of COVID-19 at the ED.",
      "The flowchart, which combined the CO-RADS with the lab-corona-score, was developed based on data from Slingeland Hospital (sensitivity 97%, specificity 96%).",
      "This flowchart can be used in hospitals that use chest-CT, instead of chest X-ray, for COVID-19 suspected patients at the ED."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence states that a flowchart based on radiology (CO-RADS) and clinical chemistry parameters (lab-corona-score) was developed and tested at Slingeland Hospital with high sensitivity (97%) and specificity (96%). This suggests that the flowchart can indeed be used for rapid COVID-19 triage at emergency departments.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000509",
    "statement": "A non-ct and clinical chemistry based flowchart for rapid covid-19 triage at emergency departments",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusion This flowchart, based on radiology (CO-RADS) and clinical chemistry parameters (lab-corona-score), results in a rapid and accurate diagnosis of COVID-19 at the ED.",
      "The flowchart, which combined the CO-RADS with the lab-corona-score, was developed based on data from Slingeland Hospital (sensitivity 97%, specificity 96%).",
      "This flowchart can be used in hospitals that use chest-CT, instead of chest X-ray, for COVID-19 suspected patients at the ED."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The given claim is about a flowchart for rapid COVID-19 triage in emergency departments, but the evidence provided does not describe such a flowchart in detail. Instead, it refers to the combination of CO-RADS (a radiology scoring system) and lab-corona-score (clinical chemistry parameters), which seems to aid in accurate diagnosis, but no specific steps or elements of the alleged flowchart are detailed.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000510",
    "statement": "A meta-ct and clinical chemistry based flowchart for rapid covid-19 triage at emergency departments",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusion This flowchart, based on radiology (CO-RADS) and clinical chemistry parameters (lab-corona-score), results in a rapid and accurate diagnosis of COVID-19 at the ED.",
      "The flowchart, which combined the CO-RADS with the lab-corona-score, was developed based on data from Slingeland Hospital (sensitivity 97%, specificity 96%).",
      "This flowchart can be used in hospitals that use chest-CT, instead of chest X-ray, for COVID-19 suspected patients at the ED."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided describes a flowchart that combines CO-RADS (radiology parameters for COVID-19 diagnosis) and lab-corona-score (clinical chemistry parameters) for rapid and accurate COVID-19 triage at emergency departments. The sensitivity and specificity of this approach are reported as 97% and 96%, respectively, based on data from Slingeland Hospital.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000511",
    "statement": "A pre-ct and clinical chemistry based flowchart for rapid covid-19 triage at emergency departments",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusion This flowchart, based on radiology (CO-RADS) and clinical chemistry parameters (lab-corona-score), results in a rapid and accurate diagnosis of COVID-19 at the ED.",
      "The flowchart, which combined the CO-RADS with the lab-corona-score, was developed based on data from Slingeland Hospital (sensitivity 97%, specificity 96%).",
      "This flowchart can be used in hospitals that use chest-CT, instead of chest X-ray, for COVID-19 suspected patients at the ED."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided describes a flowchart that combines radiology (CO-RADS) and clinical chemistry parameters (lab-corona-score) for rapid and accurate diagnosis of COVID-19 at emergency departments. The flowchart was developed based on data from Slingeland Hospital, with reported sensitivity and specificity of 97% and 96% respectively. This suggests that the claim is supported by the evidence presented.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000512",
    "statement": "No sars-cov-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic",
    "label": "SUPPORTED",
    "evidences": [
      "Whether the other, seasonally circulating coronaviruses induce cross-reactive, potentially even cross- neutralizing antibodies to the new species in humans is unclear.",
      "The question is of particular relevance for people with immune deficiencies, as their health depends on treatment with immunoglobulin preparations that need to contain neutralizing antibodies against the pathogens in their environment.",
      "SUMMARY IVIG products manufactured from pre-pandemic plasma do not neutralize SARS-CoV-2 but contain high neutralizing titers for seasonal coronavirus hCoV-229E.",
      "]: dot [@]: at [MHRA]: Medicines and Healthcare products Regulatory Agency [JCVI]: Joint Committee for Vaccination and Immunisation [PMC]: Penske Media Corporation [ COVID-19]: coronavirus disease 2019 [COVID-19]: coronavirus disease 2019 [v]: View this template [t]: telephone [e]: email []: You need to accept this checkbox."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that IVIG products manufactured from pre-pandemic plasma do not neutralize SARS-CoV-2. This directly supports the claim that there is no cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000513",
    "statement": "No sars-cov-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected after the 2020 pandemic",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Whether the other, seasonally circulating coronaviruses induce cross-reactive, potentially even cross- neutralizing antibodies to the new species in humans is unclear.",
      "The question is of particular relevance for people with immune deficiencies, as their health depends on treatment with immunoglobulin preparations that need to contain neutralizing antibodies against the pathogens in their environment.",
      "SUMMARY IVIG products manufactured from pre-pandemic plasma do not neutralize SARS-CoV-2 but contain high neutralizing titers for seasonal coronavirus hCoV-229E.",
      "]: dot [@]: at [MHRA]: Medicines and Healthcare products Regulatory Agency [JCVI]: Joint Committee for Vaccination and Immunisation [PMC]: Penske Media Corporation [ COVID-19]: coronavirus disease 2019 [COVID-19]: coronavirus disease 2019 [v]: View this template [t]: telephone [e]: email []: You need to accept this checkbox."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not directly state or imply that intravenous immunoglobulins produced from plasma collected after the 2020 pandemic do not cross-neutralize SARS-CoV-2. Instead, it suggests that the antibodies against seasonal coronaviruses, specifically hCoV-229E, are present in IVIG products manufactured from pre-pandemic plasma but not SARS-CoV-2. This does not necessarily mean that post-pandemic IVIG does not cross-neutralize SARS-CoV-2.",
    "confidence": 0.6
  },
  {
    "id": "covid_fact-000514",
    "statement": "No sars-cov-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected during the 2020 pandemic",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Whether the other, seasonally circulating coronaviruses induce cross-reactive, potentially even cross- neutralizing antibodies to the new species in humans is unclear.",
      "The question is of particular relevance for people with immune deficiencies, as their health depends on treatment with immunoglobulin preparations that need to contain neutralizing antibodies against the pathogens in their environment.",
      "SUMMARY IVIG products manufactured from pre-pandemic plasma do not neutralize SARS-CoV-2 but contain high neutralizing titers for seasonal coronavirus hCoV-229E.",
      "]: dot [@]: at [MHRA]: Medicines and Healthcare products Regulatory Agency [JCVI]: Joint Committee for Vaccination and Immunisation [PMC]: Penske Media Corporation [ COVID-19]: coronavirus disease 2019 [COVID-19]: coronavirus disease 2019 [v]: View this template [t]: telephone [e]: email []: You need to accept this checkbox."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not directly address the claim about intravenous immunoglobulins produced during the 2020 pandemic cross-neutralizing SARS-CoV-2. The information given suggests that IVIG products manufactured from pre-pandemic plasma do not neutralize SARS-CoV-2 but contain high neutralizing titers for seasonal coronavirus hCoV-229E. However, this does not imply the same would be true for IVIG produced during the pandemic.",
    "confidence": 0.7
  },
  {
    "id": "covid_fact-000515",
    "statement": "Hospital readmissions of discharged patients with covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "Aim To analyse the clinical variables associated with readmission of patients who had previously been discharged after admission for COVID-19.",
      "Conclusions The rate of readmission after discharge from hospital for COVID-19 was low.",
      "Immunocompromised patients and those presenting with fever during the 48 hours prior to discharge are at greater risk of readmission to hospital."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided in this case discusses a study aimed at analyzing the factors associated with readmissions of patients who were previously discharged after admission for COVID-19. The conclusion of the study suggests that there is a low rate of readmission after discharge from hospital for COVID-19, and it also identifies immunocompromised patients and those presenting with fever during the 48 hours prior to discharge as being at greater risk of readmission to hospital.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000516",
    "statement": "Hospital readmissions of hospitalized patients with covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Aim To analyse the clinical variables associated with readmission of patients who had previously been discharged after admission for COVID-19.",
      "Conclusions The rate of readmission after discharge from hospital for COVID-19 was low.",
      "Immunocompromised patients and those presenting with fever during the 48 hours prior to discharge are at greater risk of readmission to hospital."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that a study aimed to analyze the clinical variables associated with readmissions of patients who had been discharged after admission for COVID-19. The conclusion drawn from this study is that the rate of readmission was low and that immunocompromised patients and those presenting with fever during the 48 hours prior to discharge are at greater risk of readmission.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000517",
    "statement": "Hospital readmissions of sars patients with covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Aim To analyse the clinical variables associated with readmission of patients who had previously been discharged after admission for COVID-19.",
      "Conclusions The rate of readmission after discharge from hospital for COVID-19 was low.",
      "Immunocompromised patients and those presenting with fever during the 48 hours prior to discharge are at greater risk of readmission to hospital."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that a study was conducted to analyze the factors associated with readmissions of patients who had been discharged after being admitted for COVID-19. The conclusion drawn from this study is that the rate of readmission after discharge from hospital for COVID-19 was low, and that immunocompromised patients and those presenting with fever during the 48 hours prior to discharge are at greater risk of readmission. This implies a correlation between SARS (COVID-19) patients and hospital readmissions.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000518",
    "statement": "Hospital readmissions of icu patients with covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Aim To analyse the clinical variables associated with readmission of patients who had previously been discharged after admission for COVID-19.",
      "Conclusions The rate of readmission after discharge from hospital for COVID-19 was low.",
      "Immunocompromised patients and those presenting with fever during the 48 hours prior to discharge are at greater risk of readmission to hospital."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence presented in the text discusses a study aiming to analyze factors associated with the readmission of patients discharged from COVID-19. The conclusion states that the rate of readmission after discharge from hospital for COVID-19 was low and provides specific risk factors (immunocompromised patients and those presenting with fever during the 48 hours prior to discharge) associated with a greater likelihood of readmission. This supports the claim regarding hospital readmissions of ICU patients with COVID-19.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000519",
    "statement": "Hospitalization rates and characteristics of children aged < 18 years hospitalized with laboratory-confirmed covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "Demographic and clinical characteristics of children aged <18 years hospitalized with COVID-19 -- COVID-NET, 14 States, March 1-July 25, 2020 Characteristic ",
      "Ongoing monitoring of hospitalization rates, clinical characteristics, ICU admission, and outcomes in the pediatric population is important to further characterize the morbidity and mortality of COVID-19 in children.",
      "Cumulative COVID-19 -associated hospitalization rates among children aged <18 years, by age group and race/ethnicity -- COVID-NET, 14 states, March 1-July 25, 2020\u00a7,\u00b6 Abbreviation: COVID-NET = Coronavirus Disease 2019-Associated Hospitalization Surveillance Network."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence describes an ongoing monitoring and characterization of hospitalization rates, clinical characteristics, ICU admission, and outcomes in children aged < 18 years who are hospitalized with COVID-19. This suggests that the claim is supported by the data presented.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000520",
    "statement": "Hospitalization rates and characteristics of children aged < 18 months hospitalized with laboratory-confirmed covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Demographic and clinical characteristics of children aged <18 years hospitalized with COVID-19 -- COVID-NET, 14 States, March 1-July 25, 2020 Characteristic ",
      "Ongoing monitoring of hospitalization rates, clinical characteristics, ICU admission, and outcomes in the pediatric population is important to further characterize the morbidity and mortality of COVID-19 in children.",
      "Cumulative COVID-19 -associated hospitalization rates among children aged <18 years, by age group and race/ethnicity -- COVID-NET, 14 states, March 1-July 25, 2020\u00a7,\u00b6 Abbreviation: COVID-NET = Coronavirus Disease 2019-Associated Hospitalization Surveillance Network."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence describes ongoing monitoring and characterization of hospitalization rates, clinical characteristics, ICU admission, and outcomes in children aged <18 years hospitalized with COVID-19. This supports the claim that data on hospitalization rates and characteristics of children aged <18 months hospitalized with laboratory-confirmed covid-19 is being gathered.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000521",
    "statement": "Hospitalization rates and characteristics of children aged < 18 days hospitalized with laboratory-confirmed covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Demographic and clinical characteristics of children aged <18 years hospitalized with COVID-19 -- COVID-NET, 14 States, March 1-July 25, 2020 Characteristic ",
      "Ongoing monitoring of hospitalization rates, clinical characteristics, ICU admission, and outcomes in the pediatric population is important to further characterize the morbidity and mortality of COVID-19 in children.",
      "Cumulative COVID-19 -associated hospitalization rates among children aged <18 years, by age group and race/ethnicity -- COVID-NET, 14 states, March 1-July 25, 2020\u00a7,\u00b6 Abbreviation: COVID-NET = Coronavirus Disease 2019-Associated Hospitalization Surveillance Network."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides ongoing monitoring of hospitalization rates and clinical characteristics in children aged <18 years who are hospitalized with COVID-19. Therefore, the claim is supported by the information provided.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000522",
    "statement": "The possible beneficial adjuvant effect of influenza vaccine to minimize the severity of covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "Given the safety of Flu vaccine in adult, we recommend the use of Flu vaccine, at least in part, as a bystander adjuvant to minimize the severity of COVID-19 disease.",
      "These findings are similar to what the same group have reported before in patients with influenza infection [2], [3], Accordingly, we suggest a link between the quality of the immunity and recovery from COVID-19, at least in part, in patients with mild symptoms.",
      "Due to this cross reactivity between Flu and SARS- CoV-2, we suggest that the Flu-induced bystander immunity is more of beneficial effects to COVID-19 than those suggested by MMR and BCG vaccines [9], [10].",
      "It might be possible also that individuals who received prior Flu vaccination might show mild severity of COVID-19 because of Flu-induced bystander effect of the generated immune responses which itself might cross react against SARS-CoV-2."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that there is a recommended use of influenza vaccine to potentially minimize the severity of COVID-19 due to the cross reactivity between Flu and SARS-CoV-2. The evidence also mentions similar findings in patients with influenza infection, and compares the beneficial effects of Flu-induced immunity to those suggested by MMR and BCG vaccines.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000523",
    "statement": "The possible beneficial adjuvant effect of influenza vaccine to increase the severity of covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Given the safety of Flu vaccine in adult, we recommend the use of Flu vaccine, at least in part, as a bystander adjuvant to minimize the severity of COVID-19 disease.",
      "These findings are similar to what the same group have reported before in patients with influenza infection [2], [3], Accordingly, we suggest a link between the quality of the immunity and recovery from COVID-19, at least in part, in patients with mild symptoms.",
      "Due to this cross reactivity between Flu and SARS- CoV-2, we suggest that the Flu-induced bystander immunity is more of beneficial effects to COVID-19 than those suggested by MMR and BCG vaccines [9], [10].",
      "It might be possible also that individuals who received prior Flu vaccination might show mild severity of COVID-19 because of Flu-induced bystander effect of the generated immune responses which itself might cross react against SARS-CoV-2."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence does not provide direct empirical data or experimental results that demonstrate a causal link between receiving the influenza vaccine and a decrease in the severity of COVID-19. Instead, it suggests a potential mechanism (bystander effect) based on cross-reactivity between flu and SARS-CoV-2 that could theoretically have a beneficial adjuvant effect. However, more research and experimental evidence would be needed to confirm this hypothesis.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000524",
    "statement": "The possible beneficial adjuvant effect of influenza vaccine to enhance the severity of covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Given the safety of Flu vaccine in adult, we recommend the use of Flu vaccine, at least in part, as a bystander adjuvant to minimize the severity of COVID-19 disease.",
      "These findings are similar to what the same group have reported before in patients with influenza infection [2], [3], Accordingly, we suggest a link between the quality of the immunity and recovery from COVID-19, at least in part, in patients with mild symptoms.",
      "Due to this cross reactivity between Flu and SARS- CoV-2, we suggest that the Flu-induced bystander immunity is more of beneficial effects to COVID-19 than those suggested by MMR and BCG vaccines [9], [10].",
      "It might be possible also that individuals who received prior Flu vaccination might show mild severity of COVID-19 because of Flu-induced bystander effect of the generated immune responses which itself might cross react against SARS-CoV-2."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does suggest a possible link between the flu vaccine and potential benefits for COVID-19 severity due to cross-reactivity and bystander effects. However, this is a hypothesis based on similarities between influenza and SARS-CoV-2, and the actual support for this claim would require further experimental evidence or clinical studies.",
    "confidence": 0.7
  },
  {
    "id": "covid_fact-000525",
    "statement": "The possible negative adjuvant effect of influenza vaccine to minimize the severity of covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Given the safety of Flu vaccine in adult, we recommend the use of Flu vaccine, at least in part, as a bystander adjuvant to minimize the severity of COVID-19 disease.",
      "These findings are similar to what the same group have reported before in patients with influenza infection [2], [3], Accordingly, we suggest a link between the quality of the immunity and recovery from COVID-19, at least in part, in patients with mild symptoms.",
      "Due to this cross reactivity between Flu and SARS- CoV-2, we suggest that the Flu-induced bystander immunity is more of beneficial effects to COVID-19 than those suggested by MMR and BCG vaccines [9], [10].",
      "It might be possible also that individuals who received prior Flu vaccination might show mild severity of COVID-19 because of Flu-induced bystander effect of the generated immune responses which itself might cross react against SARS-CoV-2."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not contain sufficient studies or research results to definitively support the claim that influenza vaccine has a negative adjuvant effect in minimizing the severity of COVID-19. The evidence mainly suggests a possible link between immunity and recovery from COVID-19, with some speculation about cross-reactivity between flu and SARS-CoV-2. However, it does not provide empirical data or conclusions based on extensive research to substantiate the claim.",
    "confidence": 0.6
  },
  {
    "id": "covid_fact-000526",
    "statement": "Moderna 's covid-19 vaccine candidate meets its primary efficacy endpoint in the first interim analysis of the phase 3 cove study",
    "label": "SUPPORTED",
    "evidences": [
      "This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease, said St\u00e9phane Bancel, Chief Executive Officer of Moderna.",
      "This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease,\" said St\u00e9phane Bancel, Chief Executive Officer of Moderna."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The statement made by the CEO of Moderna, St\u00e9phane Bancel, suggests that the interim analysis of their Phase 3 study has shown the vaccine candidate to be effective in preventing COVID-19 disease, including severe disease. This implies that the efficacy endpoint (the ability to prevent COVID-19 disease) has been met.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000527",
    "statement": "Moderna's covid-19 vaccine candidate meets its primary efficacy endpoint in the final interim analysis of the phase 3 cove study",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease, said St\u00e9phane Bancel, Chief Executive Officer of Moderna.",
      "This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease,\" said St\u00e9phane Bancel, Chief Executive Officer of Moderna."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is supported by the statement that the phase 3 study has shown clinical validation that Moderna's vaccine can prevent COVID-19 disease, including severe disease.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000528",
    "statement": "Moderna's covid-19 vaccine candidate meets its primary efficacy endpoint in the second interim analysis of the phase 3 cove study",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease, said St\u00e9phane Bancel, Chief Executive Officer of Moderna.",
      "This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease,\" said St\u00e9phane Bancel, Chief Executive Officer of Moderna."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim states that the Moderna covid-19 vaccine candidate meets its primary efficacy endpoint in the second interim analysis of the phase 3 COVE study. The provided evidence directly indicates this, as St\u00e9phane Bancel, CEO of Moderna, stated that their vaccine can prevent COVID-19 disease, including severe disease, which is the primary efficacy endpoint of the Phase 3 study.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000529",
    "statement": "Moderna's covid-19 vaccine candidate meets its primary efficacy endpoint in the subsequent interim analysis of the phase 3 cove study",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease, said St\u00e9phane Bancel, Chief Executive Officer of Moderna.",
      "This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease,\" said St\u00e9phane Bancel, Chief Executive Officer of Moderna."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is supported by the evidence as the statement from Moderna's CEO explicitly states that their COVID-19 vaccine has shown positive results in preventing COVID-19 disease, including severe disease, during an interim analysis of the phase 3 study.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000530",
    "statement": "Landmark legal ruling finds that covid tests are not fit for purpose .",
    "label": "SUPPORTED",
    "evidences": [
      "It showed that if someone tested positive for Covid at a cycle threshold of 35 or higher, the chances of that person actually being infected is less than three percent, and that \" the probability of receiving a false positive is 97% or higher.\"",
      "And it is not the only country whose institutions are clashing with received wisdom on Covid.",
      "Read more Immunity for YEARS or DECADES: Covid resistance may last much longer than previously thought, says new research They were also scathing about the reliability of the PCR (polymerase chain reaction) test, the most commonly used check for Covid.",
      "The implication was that the results could not be trusted.",
      "In the eyes of this court, then, a positive test does not correspond to a Covid case."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided discusses the accuracy and reliability of COVID-19 tests, specifically PCR tests, at high cycle threshold values (35 or higher) and mentions a court's criticism of these test results not necessarily corresponding to actual Covid cases. However, it does not constitute a landmark legal ruling that finds Covid tests are 'not fit for purpose' in general.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000531",
    "statement": "Landmark legal ruling finds that covid tests are good fit for purpose.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "It showed that if someone tested positive for Covid at a cycle threshold of 35 or higher, the chances of that person actually being infected is less than three percent, and that \" the probability of receiving a false positive is 97% or higher.\"",
      "And it is not the only country whose institutions are clashing with received wisdom on Covid.",
      "Read more Immunity for YEARS or DECADES: Covid resistance may last much longer than previously thought, says new research They were also scathing about the reliability of the PCR (polymerase chain reaction) test, the most commonly used check for Covid.",
      "The implication was that the results could not be trusted.",
      "In the eyes of this court, then, a positive test does not correspond to a Covid case."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence does not directly show that the landmark legal ruling found covid tests to be 'good fit for purpose'. Instead, it discusses the reliability of positive test results, particularly at high cycle thresholds, and the potential for false positives. This information suggests there may be concerns about the accuracy of the tests, but it does not necessarily mean that the tests are deemed a good fit for their intended purpose.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000532",
    "statement": "Landmark legal ruling finds that covid tests are best fit for purpose.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "It showed that if someone tested positive for Covid at a cycle threshold of 35 or higher, the chances of that person actually being infected is less than three percent, and that \" the probability of receiving a false positive is 97% or higher.\"",
      "And it is not the only country whose institutions are clashing with received wisdom on Covid.",
      "Read more Immunity for YEARS or DECADES: Covid resistance may last much longer than previously thought, says new research They were also scathing about the reliability of the PCR (polymerase chain reaction) test, the most commonly used check for Covid.",
      "The implication was that the results could not be trusted.",
      "In the eyes of this court, then, a positive test does not correspond to a Covid case."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided in this case discusses the reliability and interpretation of covid tests based on research findings and expert opinions. However, it does not directly provide a landmark legal ruling that explicitly states covid tests are 'best fit for purpose.' Such a determination would require a formal legal proceeding or report.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000533",
    "statement": "Landmark legal ruling finds that covid tests are well fit for purpose.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "It showed that if someone tested positive for Covid at a cycle threshold of 35 or higher, the chances of that person actually being infected is less than three percent, and that \" the probability of receiving a false positive is 97% or higher.\"",
      "And it is not the only country whose institutions are clashing with received wisdom on Covid.",
      "Read more Immunity for YEARS or DECADES: Covid resistance may last much longer than previously thought, says new research They were also scathing about the reliability of the PCR (polymerase chain reaction) test, the most commonly used check for Covid.",
      "The implication was that the results could not be trusted.",
      "In the eyes of this court, then, a positive test does not correspond to a Covid case."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided suggests that there is an issue with the reliability of covid tests at high cycle thresholds (>35) and questions the validity of a positive test result. However, it does not provide any information on whether the court's ruling found that the tests are 'well fit for purpose' in general or under specific conditions.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000534",
    "statement": "Trump just banned all travel from europe to stop coronavirus",
    "label": "SUPPORTED",
    "evidences": [
      "ET Thursday President Trump announced a 30-day ban on travel from European countries to the United States, beginning on Friday at midnight, in a bid \"to keep new cases\" of coronavirus \"from entering our shores.\"",
      "VIDEO0:3300:33 President Trump suspends all travel from Europe for 30 days Coronavirus WASHINGTON  President Donald Trump announced that a ban on travelers to the United States from Europe would be in place for the next 30 days, in an attempt to stem the spread of the coronavirus pandemic.",
      "Advertisement In a statement after Trump's address, DHS said Trump had signed a proclamation that \"suspends the entry of most foreign nationals who have been in certain European countries at any point during the 14 days prior to their scheduled arrival to the United States.\"",
      "\"We will be suspending all travel from Europe to the United States for the next 30 days,\" Trump said, blasting coronavirus as \"a foreign virus.\"",
      "Advertisement Trump's travel ban from Europe follows a massive outbreak in Italy that's resulted in a nationwide lockdown in which businesses have been shuttered and travel severely curtailed in the southern-European country."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim 'Trump just banned all travel from Europe to stop coronavirus' is supported by the evidence provided. The evidence states that President Trump announced a 30-day ban on travel from European countries to the United States, in an effort to prevent new cases of coronavirus from entering the country.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000535",
    "statement": "Trump just allows all travel from europe to stop coronavirus",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "ET Thursday President Trump announced a 30-day ban on travel from European countries to the United States, beginning on Friday at midnight, in a bid \"to keep new cases\" of coronavirus \"from entering our shores.\"",
      "VIDEO0:3300:33 President Trump suspends all travel from Europe for 30 days Coronavirus WASHINGTON  President Donald Trump announced that a ban on travelers to the United States from Europe would be in place for the next 30 days, in an attempt to stem the spread of the coronavirus pandemic.",
      "Advertisement In a statement after Trump's address, DHS said Trump had signed a proclamation that \"suspends the entry of most foreign nationals who have been in certain European countries at any point during the 14 days prior to their scheduled arrival to the United States.\"",
      "\"We will be suspending all travel from Europe to the United States for the next 30 days,\" Trump said, blasting coronavirus as \"a foreign virus.\"",
      "Advertisement Trump's travel ban from Europe follows a massive outbreak in Italy that's resulted in a nationwide lockdown in which businesses have been shuttered and travel severely curtailed in the southern-European country."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided clearly shows that President Trump has announced a ban on travel from Europe to the United States for a period of 30 days, as stated in the video transcript.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000536",
    "statement": "Trump just allowed all travel from europe to stop coronavirus",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "ET Thursday President Trump announced a 30-day ban on travel from European countries to the United States, beginning on Friday at midnight, in a bid \"to keep new cases\" of coronavirus \"from entering our shores.\"",
      "VIDEO0:3300:33 President Trump suspends all travel from Europe for 30 days Coronavirus WASHINGTON  President Donald Trump announced that a ban on travelers to the United States from Europe would be in place for the next 30 days, in an attempt to stem the spread of the coronavirus pandemic.",
      "Advertisement In a statement after Trump's address, DHS said Trump had signed a proclamation that \"suspends the entry of most foreign nationals who have been in certain European countries at any point during the 14 days prior to their scheduled arrival to the United States.\"",
      "\"We will be suspending all travel from Europe to the United States for the next 30 days,\" Trump said, blasting coronavirus as \"a foreign virus.\"",
      "Advertisement Trump's travel ban from Europe follows a massive outbreak in Italy that's resulted in a nationwide lockdown in which businesses have been shuttered and travel severely curtailed in the southern-European country."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is supported by the provided evidence as it clearly states that President Trump announced a 30-day ban on travel from European countries to the United States in an attempt to stem the spread of the coronavirus pandemic.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000537",
    "statement": "Trump just requires all travel from europe to stop coronavirus",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "ET Thursday President Trump announced a 30-day ban on travel from European countries to the United States, beginning on Friday at midnight, in a bid \"to keep new cases\" of coronavirus \"from entering our shores.\"",
      "VIDEO0:3300:33 President Trump suspends all travel from Europe for 30 days Coronavirus WASHINGTON  President Donald Trump announced that a ban on travelers to the United States from Europe would be in place for the next 30 days, in an attempt to stem the spread of the coronavirus pandemic.",
      "Advertisement In a statement after Trump's address, DHS said Trump had signed a proclamation that \"suspends the entry of most foreign nationals who have been in certain European countries at any point during the 14 days prior to their scheduled arrival to the United States.\"",
      "\"We will be suspending all travel from Europe to the United States for the next 30 days,\" Trump said, blasting coronavirus as \"a foreign virus.\"",
      "Advertisement Trump's travel ban from Europe follows a massive outbreak in Italy that's resulted in a nationwide lockdown in which businesses have been shuttered and travel severely curtailed in the southern-European country."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is supported by the provided evidence. The source clearly states that President Trump announced a 30-day ban on travel from European countries to the United States in an attempt to stem the spread of coronavirus.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000538",
    "statement": "Functional sars-cov-2-specific immune memory persists after mild covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "Furthermore, the SARS-CoV-2-specific memory lymphocytes exhibited characteristics associated with potent antiviral immunity: memory T cells secreted IFN-\u03b3 and expanded upon antigen re-encounter, while memory B cells expressed receptors capable of neutralizing virus when expressed as antibodies.",
      "These findings demonstrate that mild COVID-19 elicits memory lymphocytes that persist and display functional hallmarks associated with antiviral protective immunity.",
      "We found that recovered individuals developed SARS-CoV-2-specific IgG antibody and neutralizing plasma, as well as virus-specific memory B and T cells that not only persisted, but in some cases increased numerically over three months following symptom onset."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that recovered individuals from COVID-19 developed SARS-CoV-2-specific memory lymphocytes (both T and B cells) that persist and display functional hallmarks associated with antiviral protective immunity. The memory cells were found to secrete IFN-\u03b3, expand upon antigen re-encounter, express receptors capable of neutralizing the virus when expressed as antibodies, and increased numerically over three months following symptom onset.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000539",
    "statement": "Functional sars-cov-2-independent immune memory persists after mild covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Furthermore, the SARS-CoV-2-specific memory lymphocytes exhibited characteristics associated with potent antiviral immunity: memory T cells secreted IFN-\u03b3 and expanded upon antigen re-encounter, while memory B cells expressed receptors capable of neutralizing virus when expressed as antibodies.",
      "These findings demonstrate that mild COVID-19 elicits memory lymphocytes that persist and display functional hallmarks associated with antiviral protective immunity.",
      "We found that recovered individuals developed SARS-CoV-2-specific IgG antibody and neutralizing plasma, as well as virus-specific memory B and T cells that not only persisted, but in some cases increased numerically over three months following symptom onset."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows that individuals who have recovered from COVID-19 develop SARS-CoV-2-specific memory lymphocytes (both T and B cells), which exhibit characteristics associated with potent antiviral immunity. The persistence of these memory lymphocytes over three months following symptom onset indicates that functional sars-cov-2-independent immune memory persists after mild COVID-19.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000540",
    "statement": "Cdc says new covid strain in uk could already be circulating undetected in u.s .",
    "label": "SUPPORTED",
    "evidences": [
      "While the variant hasn't been found in the U.S. yet, the CDC noted that scientists haven't sequenced the genetic coding for many Covid-19 infections here.",
      "\"Given the small fraction of US infections that have been sequenced, the variant could already be in the United States without having been detected.\""
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim is based on the assumption that the strain found in the UK isn't being sequenced in the US, and if it isn't sequenced, it can't be detected. However, the evidence only states that a small fraction of US infections have been sequenced, not that none are. Therefore, it's possible but unproven that the new strain is circulating undetected in the U.S.",
    "confidence": 0.6
  },
  {
    "id": "covid_fact-000541",
    "statement": "Cdc says new covid strain in uk could not be circulating undetected in u.s.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "While the variant hasn't been found in the U.S. yet, the CDC noted that scientists haven't sequenced the genetic coding for many Covid-19 infections here.",
      "\"Given the small fraction of US infections that have been sequenced, the variant could already be in the United States without having been detected.\""
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence states that the variant hasn't been found in the U.S. yet and that due to limited sequencing of Covid-19 infections, it could already be present without detection. This suggests that the claim is not definitively supported by the provided evidence.",
    "confidence": 0.65
  },
  {
    "id": "covid_fact-000542",
    "statement": "Sars-cov-2 infection protects against rechallenge in rhesus macaques",
    "label": "SUPPORTED",
    "evidences": [
      "2 Immune responses in SARS-CoV-2challenged rhesus macaques.",
      "SARS-CoV-2 infection in rhesus macaques led to humoral and cellular immune responses (Fig.",
      "In summary, SARS-CoV-2 infection in rhesus macaques induced humoral and cellular immune responses and provided protective efficacy against SARS-CoV-2 rechallenge.",
      "In this study, we have demonstrated that SARS-CoV-2 infection in rhesus macaques provides protective efficacy against SARS-CoV-2 rechallenge.",
      "To explore this question, we developed a rhesus macaque model of SARS-CoV-2 infection and assessed virologic, immunologic, and pathologic features of infection, as well as protective immunity against rechallenge."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that SARS-CoV-2 infection in rhesus macaques led to immune responses (both humoral and cellular) and provided protective efficacy against SARS-CoV-2 rechallenge. The study also demonstrates this by developing a model of SARS-CoV-2 infection in rhesus macaques, assessing the features of infection, and showing protective immunity against rechallenge.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000543",
    "statement": "Sars-cov-2 infection failed against rechallenge in rhesus macaques",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "2 Immune responses in SARS-CoV-2challenged rhesus macaques.",
      "SARS-CoV-2 infection in rhesus macaques led to humoral and cellular immune responses (Fig.",
      "In summary, SARS-CoV-2 infection in rhesus macaques induced humoral and cellular immune responses and provided protective efficacy against SARS-CoV-2 rechallenge.",
      "In this study, we have demonstrated that SARS-CoV-2 infection in rhesus macaques provides protective efficacy against SARS-CoV-2 rechallenge.",
      "To explore this question, we developed a rhesus macaque model of SARS-CoV-2 infection and assessed virologic, immunologic, and pathologic features of infection, as well as protective immunity against rechallenge."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows that SARS-CoV-2 infection in rhesus macaques led to the development of humoral and cellular immune responses. Furthermore, it was demonstrated that this immune response provided protective efficacy against SARS-CoV-2 rechallenge.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000544",
    "statement": "Genetic epidemiology of variants associated with immune escape from global sars-cov-2 genomes.",
    "label": "SUPPORTED",
    "evidences": [
      "The researchers studied as many as 120 unique mutated variants of SARS-CoV-2, out of which 86 were found to possess the ability to dodge the human bodys immune response across 63 countries.",
      "The detailed investigation of 26,917 genomes pointed out that 86 out of the 120 genetic variants associated with immune escapes from 63 countries.",
      "Our analysis suggests that a number of genetic variants associated with immune escape have emerged in global populations."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that researchers studied and identified 86 out of 120 mutated variants of SARS-CoV-2 that can evade the human immune response across 63 countries. This supports the claim that genetic epidemiology of variants associated with immune escape from global SARS-CoV-2 genomes has been studied.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000545",
    "statement": "Phylogenetic epidemiology of variants associated with immune escape from global sars-cov-2 genomes.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The researchers studied as many as 120 unique mutated variants of SARS-CoV-2, out of which 86 were found to possess the ability to dodge the human bodys immune response across 63 countries.",
      "The detailed investigation of 26,917 genomes pointed out that 86 out of the 120 genetic variants associated with immune escapes from 63 countries.",
      "Our analysis suggests that a number of genetic variants associated with immune escape have emerged in global populations."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that researchers studied various mutated variants of SARS-CoV-2 and found that some of these variants possess the ability to dodge the human immune response across multiple countries. This suggests an analysis of phylogenetic epidemiology of these immune escape associated variants from global SARS-CoV-2 genomes.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000546",
    "statement": "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus in vitro",
    "label": "SUPPORTED",
    "evidences": [
      "Remdesivir has been recently recognized as a promising antiviral drug against a wide array of RNA viruses (including SARS/MERS-CoV5) infection in cultured cells, mice and nonhuman primate (NHP) models.",
      "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.",
      "S2) showed that remdesivir also inhibited virus infection efficiently in a human cell line (human liver cancer Huh-7 cells), which is sensitive to 2019-nCoV.2 Chloroquine, a widely-used anti-malarial and autoimmune disease drug, has recently been reported as a potential broad-spectrum antiviral drug.8,9 Chloroquine is known to block virus infection by increasing endosomal pH required for virus/cell fusion, as well as interfering with the glycosylation of cellular receptors of SARS-CoV.10 Our time-of-addition assay demonstrated that chloroquine functioned at both entry, and at post-entry stages of the 2019-nCoV infection in Vero E6 cells (Fig.",
      "Notably, two compounds remdesivir (EC50 = 0.77 \u03bcM; CC50 > 100 \u03bcM; SI > 129.87) and chloroquine (EC50 = 1.13 \u03bcM; CC50 > 100 \u03bcM, SI > 88.50) potently blocked virus infection at low-micromolar concentration and showed high SI (Fig."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that both remdesivir and chloroquine have been shown to effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. The statement about remdesivir mentions its potential as an antiviral drug against a wide array of RNA viruses, including SARS/MERS-CoV, and specifically states that it inhibits 2019-nCoV infection efficiently in human liver cancer Huh-7 cells. Similarly, chloroquine is described as a potential broad-spectrum antiviral drug with the ability to block virus infection by increasing endosomal pH required for virus/cell fusion and interfering with the glycosylation of cellular receptors of SARS-CoV. The data presented also shows the EC50 (effective concentration) values for both remdesivir and chloroquine, which indicate their ability to inhibit the virus at low-micromolar concentration.",
    "confidence": 0.99
  },
  {
    "id": "covid_fact-000547",
    "statement": "Remdesivir and chloroquine effectively developed the recently emerged novel coronavirus in vitro",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Remdesivir has been recently recognized as a promising antiviral drug against a wide array of RNA viruses (including SARS/MERS-CoV5) infection in cultured cells, mice and nonhuman primate (NHP) models.",
      "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.",
      "S2) showed that remdesivir also inhibited virus infection efficiently in a human cell line (human liver cancer Huh-7 cells), which is sensitive to 2019-nCoV.2 Chloroquine, a widely-used anti-malarial and autoimmune disease drug, has recently been reported as a potential broad-spectrum antiviral drug.8,9 Chloroquine is known to block virus infection by increasing endosomal pH required for virus/cell fusion, as well as interfering with the glycosylation of cellular receptors of SARS-CoV.10 Our time-of-addition assay demonstrated that chloroquine functioned at both entry, and at post-entry stages of the 2019-nCoV infection in Vero E6 cells (Fig.",
      "Notably, two compounds remdesivir (EC50 = 0.77 \u03bcM; CC50 > 100 \u03bcM; SI > 129.87) and chloroquine (EC50 = 1.13 \u03bcM; CC50 > 100 \u03bcM, SI > 88.50) potently blocked virus infection at low-micromolar concentration and showed high SI (Fig."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows that both Remdesivir and Chloroquine have been demonstrated to effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. The data presented includes EC50 values (effective concentration at which 50% of maximal effect is achieved), CC50 values (concentration causing 50% cytotoxicity), and Selectivity Index (SI = CC50/EC50), all of which indicate the potency of these drugs in inhibiting the virus.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000548",
    "statement": "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus in humans",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Remdesivir has been recently recognized as a promising antiviral drug against a wide array of RNA viruses (including SARS/MERS-CoV5) infection in cultured cells, mice and nonhuman primate (NHP) models.",
      "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.",
      "S2) showed that remdesivir also inhibited virus infection efficiently in a human cell line (human liver cancer Huh-7 cells), which is sensitive to 2019-nCoV.2 Chloroquine, a widely-used anti-malarial and autoimmune disease drug, has recently been reported as a potential broad-spectrum antiviral drug.8,9 Chloroquine is known to block virus infection by increasing endosomal pH required for virus/cell fusion, as well as interfering with the glycosylation of cellular receptors of SARS-CoV.10 Our time-of-addition assay demonstrated that chloroquine functioned at both entry, and at post-entry stages of the 2019-nCoV infection in Vero E6 cells (Fig.",
      "Notably, two compounds remdesivir (EC50 = 0.77 \u03bcM; CC50 > 100 \u03bcM; SI > 129.87) and chloroquine (EC50 = 1.13 \u03bcM; CC50 > 100 \u03bcM, SI > 88.50) potently blocked virus infection at low-micromolar concentration and showed high SI (Fig."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that Remdesivir has been recognized as a promising antiviral drug against a wide array of RNA viruses (including SARS/MERS-CoV) and specifically mentions it inhibits the recently emerged novel coronavirus (2019-nCoV) in vitro. Chloroquine is also mentioned as a potential broad-spectrum antiviral drug that has been reported to block virus infection by increasing endosomal pH required for virus/cell fusion, and it specifically inhibits 2019-nCoV infection in Vero E6 cells. The SI (Selectivity Index) values are also provided showing high selectivity for the drugs, indicating they have low toxicity to the human cell line.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000549",
    "statement": "As covid-19 vaccines arrive , europe looks back at swine flu side effects.",
    "label": "SUPPORTED",
    "evidences": [
      "DW: We keep seeing vaccine skeptics referencing the swine flu pandemic in 2009 as the reason they won't be taking a COVID-19 vaccine."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence does not directly support the claim that 'Europe looks back at swine flu side effects as covid-19 vaccines arrive.' The evidence only mentions that vaccine skeptics reference the swine flu pandemic when they won't take a COVID-19 vaccine, not that Europe is looking back at swine flu side effects specifically because of the arrival of COVID-19 vaccines.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000550",
    "statement": "As covid-19 vaccines arrive, europe looks not at swine flu side effects.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "DW: We keep seeing vaccine skeptics referencing the swine flu pandemic in 2009 as the reason they won't be taking a COVID-19 vaccine."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests that Europe is 'not looking at swine flu side effects as covid-19 vaccines arrive,' while the evidence provided only mentions skepticism about COVID-19 vaccines due to perceived side effects from the swine flu pandemic.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000551",
    "statement": "Influenza may facilitate the spread of sars-cov-2",
    "label": "SUPPORTED",
    "evidences": [
      "These results suggest the need to increase vaccination against influenza, not only to reduce the burden due to influenza viruses, but also to counteract their facilitatory impact on SARS-CoV-2.",
      "We found consistent evidence for a 2-2.5-fold population-level increase in SARS- CoV-2 transmission associated with influenza during the period of co- circulation.",
      "Here we hypothesized that influenza interacted with SARS-CoV-2 during the early 2020 epidemic of COVID-19 in Europe."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests a consistent association (2-2.5 fold increase) between SARS-CoV-2 transmission and influenza co-circulation, and hypothesizes that influenza may interact with SARS-CoV-2 during the early 2020 epidemic of COVID-19 in Europe. This supports the claim that influenza may facilitate the spread of SARS-CoV-2.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000552",
    "statement": "Influenza may prevent the spread of sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These results suggest the need to increase vaccination against influenza, not only to reduce the burden due to influenza viruses, but also to counteract their facilitatory impact on SARS-CoV-2.",
      "We found consistent evidence for a 2-2.5-fold population-level increase in SARS- CoV-2 transmission associated with influenza during the period of co- circulation.",
      "Here we hypothesized that influenza interacted with SARS-CoV-2 during the early 2020 epidemic of COVID-19 in Europe."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests a correlation between influenza and SARS-CoV-2 transmission, indicating that influenza may facilitate the spread of SARS-CoV-2. However, it does not necessarily mean that infection with influenza causes SARS-CoV-2 infection, but rather that they may interact in some way during co-circulation.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000553",
    "statement": "Influenza may inhibit the spread of sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These results suggest the need to increase vaccination against influenza, not only to reduce the burden due to influenza viruses, but also to counteract their facilitatory impact on SARS-CoV-2.",
      "We found consistent evidence for a 2-2.5-fold population-level increase in SARS- CoV-2 transmission associated with influenza during the period of co- circulation.",
      "Here we hypothesized that influenza interacted with SARS-CoV-2 during the early 2020 epidemic of COVID-19 in Europe."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence presents data suggesting a correlation between influenza and increased transmission of SARS-CoV-2. The study found consistent evidence for a 2-2.5 fold increase in SARS-CoV-2 transmission associated with influenza during the period of co-circulation.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000554",
    "statement": "Influenza may limit the spread of sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These results suggest the need to increase vaccination against influenza, not only to reduce the burden due to influenza viruses, but also to counteract their facilitatory impact on SARS-CoV-2.",
      "We found consistent evidence for a 2-2.5-fold population-level increase in SARS- CoV-2 transmission associated with influenza during the period of co- circulation.",
      "Here we hypothesized that influenza interacted with SARS-CoV-2 during the early 2020 epidemic of COVID-19 in Europe."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows a consistent association between influenza and an increase in SARS-CoV-2 transmission (2-2.5 fold). This suggests that influenza may facilitate the spread of SARS-CoV-2.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000555",
    "statement": "Genomic epidemiology of superspreading events in austria reveals mutational dynamics and transmission properties of sars-cov-2",
    "label": "SUPPORTED",
    "evidences": [
      "Phylogenetic clusters were identified on the basis of characteristic mutation profiles in viral genome sequences of SARS-CoV-2positive cases in Austria.",
      "In this study, we reconstructed major SARS-CoV-2 infection clusters in Austria and analyzed their role in international virus spread by combining phylogenetic and epidemiological analyses."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence points to the reconstruction of SARS-CoV-2 infection clusters in Austria based on mutational profiles in viral genome sequences. This suggests that the study is investigating the genomic epidemiology of superspreading events in Austria, as the claim states.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000556",
    "statement": "Genomic epidemiology of superspreading events in korea reveals mutational dynamics and transmission properties of sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Phylogenetic clusters were identified on the basis of characteristic mutation profiles in viral genome sequences of SARS-CoV-2positive cases in Austria.",
      "In this study, we reconstructed major SARS-CoV-2 infection clusters in Austria and analyzed their role in international virus spread by combining phylogenetic and epidemiological analyses."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The given evidence describes a study of SARS-CoV-2 infection clusters in Austria, not Korea. Therefore, the claim about the genomic epidemiology of superspreading events in Korea is not supported by this evidence.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000557",
    "statement": "Genomic epidemiology of superspreading events in africa reveals mutational dynamics and transmission properties of sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Phylogenetic clusters were identified on the basis of characteristic mutation profiles in viral genome sequences of SARS-CoV-2positive cases in Austria.",
      "In this study, we reconstructed major SARS-CoV-2 infection clusters in Austria and analyzed their role in international virus spread by combining phylogenetic and epidemiological analyses."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The given evidence is about SARS-CoV-2 infections in Austria, but the claim focuses on genomic epidemiology of superspreading events in Africa. While it is possible that similar studies exist for Africa, this specific evidence does not support the claim.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000558",
    "statement": "Genomic epidemiology of superspreading events in taiwan reveals mutational dynamics and transmission properties of sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Phylogenetic clusters were identified on the basis of characteristic mutation profiles in viral genome sequences of SARS-CoV-2positive cases in Austria.",
      "In this study, we reconstructed major SARS-CoV-2 infection clusters in Austria and analyzed their role in international virus spread by combining phylogenetic and epidemiological analyses."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence discusses the analysis of SARS-CoV-2 infection clusters in Austria. It does not provide sufficient information to support the claim about the genomic epidemiology of superspreading events in Taiwan.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000559",
    "statement": "Rogue antibodies could be driving severe covid-19.",
    "label": "SUPPORTED",
    "evidences": [
      "[2] Auto-antibodies against type I IFNs in patients with life-threatening COVID-19.",
      "The Covid-19 patients had more antibodies that had turned on them than people with lupus, an autoimmune disease caused by similar wayward antibodies.",
      "Those antibodies, which blocked the interferons antiviral activity, werent found in people with more mild cases of COVID-19.",
      "Rather than one type of autoantibody being to blame, the scientists believe that Covid-19 is worsened when many different wayward antibodies arise in the same patient."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that Covid-19 patients with severe cases have higher levels of auto-antibodies against type I IFNs compared to people with milder cases or people with lupus (an autoimmune disease characterized by similar wayward antibodies). These antibodies, which block the interferons antiviral activity, are believed to contribute to worsening Covid-19. This supports the claim that rogue antibodies could be driving severe Covid-19.",
    "confidence": 0.85
  },
  {
    "id": "covid_fact-000560",
    "statement": "Rogue antibodies cannot be driving severe covid-19.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "[2] Auto-antibodies against type I IFNs in patients with life-threatening COVID-19.",
      "The Covid-19 patients had more antibodies that had turned on them than people with lupus, an autoimmune disease caused by similar wayward antibodies.",
      "Those antibodies, which blocked the interferons antiviral activity, werent found in people with more mild cases of COVID-19.",
      "Rather than one type of autoantibody being to blame, the scientists believe that Covid-19 is worsened when many different wayward antibodies arise in the same patient."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows that autoantibodies against type I IFNs are present in patients with severe COVID-19 and not in those with mild cases. These antibodies block the interferons' antiviral activity, which could contribute to the worsening of COVID-19 symptoms. This suggests that rogue antibodies can potentially be driving severe COVID-19.",
    "confidence": 0.85
  },
  {
    "id": "covid_fact-000561",
    "statement": "Rogue antibodies could be less severe covid-19.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "[2] Auto-antibodies against type I IFNs in patients with life-threatening COVID-19.",
      "The Covid-19 patients had more antibodies that had turned on them than people with lupus, an autoimmune disease caused by similar wayward antibodies.",
      "Those antibodies, which blocked the interferons antiviral activity, werent found in people with more mild cases of COVID-19.",
      "Rather than one type of autoantibody being to blame, the scientists believe that Covid-19 is worsened when many different wayward antibodies arise in the same patient."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides information about auto-antibodies against type I IFNs being found in severe COVID-19 patients and not in mild cases. This indicates that the presence of these rogue antibodies could contribute to a more severe form of the disease.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000562",
    "statement": "Washington state group is 1st to sue fox new for calling the coronavirus a hoax",
    "label": "SUPPORTED",
    "evidences": [
      "According to the suit, Fox News violated the CPA by falsely and deceptively disseminating News via cable news contracts that the coronavirus was a hoax, and that it was otherwise not a danger to public health and safety. At least one poll has found that Fox News viewers were less likely to take precautions against the virus (including social distancing, handwashing, and other measures) seriously, and an open letter to Fox News from a group of journalism professors said misinformation that reaches the Fox News audience is a danger to public health. Based on the statements made, and the subsequent departure of Trish Regan, WASHLITE does present a cognizable theory of liability.",
      "I said it was a hoax for them to be using it as a bludgeon on Trump. Notably, he made this denial in response to criticism from 74 journalism professors who wrote an open letter to Fox claiming that coverage of the coronavirus from Fox News Channel \"is a danger to public health.\"",
      "But when you get to the point where you are endangering the community  that transcends the limits of the First Amendment. When reached by phone for comment, Catherine Clark, a Seattle attorney who volunteered to join the plaintiffs legal team after reading an initial news account, said this is a case of national importance. A supporter of First Amendment protections, she continued, When it comes to the public health, safety, and welfare, it seems to me a different set of rules apply. In a statement, Fox News general counsel Lily Fu Clafee responded to the suit by saying: Wrong on the facts, frivolous on the law."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim is not supported because it relies solely on the statement that Fox News was endangering the community and that this transcends the limits of the First Amendment. However, there is no direct evidence presented in the provided information to prove that Washington state group has officially sued Fox News for this specific reason or any actionable damage caused by their statements about the coronavirus. The claim also does not provide any legal precedent or context to support the assertion that broadcasting false information during a crisis can be proven to endanger a community.",
    "confidence": 0.85
  },
  {
    "id": "covid_fact-000563",
    "statement": "Washington state group is unable to sue fox new for calling the coronavirus a hoax",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "According to the suit, Fox News violated the CPA by falsely and deceptively disseminating News via cable news contracts that the coronavirus was a hoax, and that it was otherwise not a danger to public health and safety. At least one poll has found that Fox News viewers were less likely to take precautions against the virus (including social distancing, handwashing, and other measures) seriously, and an open letter to Fox News from a group of journalism professors said misinformation that reaches the Fox News audience is a danger to public health. Based on the statements made, and the subsequent departure of Trish Regan, WASHLITE does present a cognizable theory of liability.",
      "I said it was a hoax for them to be using it as a bludgeon on Trump. Notably, he made this denial in response to criticism from 74 journalism professors who wrote an open letter to Fox claiming that coverage of the coronavirus from Fox News Channel \"is a danger to public health.\"",
      "But when you get to the point where you are endangering the community  that transcends the limits of the First Amendment. When reached by phone for comment, Catherine Clark, a Seattle attorney who volunteered to join the plaintiffs legal team after reading an initial news account, said this is a case of national importance. A supporter of First Amendment protections, she continued, When it comes to the public health, safety, and welfare, it seems to me a different set of rules apply. In a statement, Fox News general counsel Lily Fu Clafee responded to the suit by saying: Wrong on the facts, frivolous on the law."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not directly support or refute the claim that a Washington state group is unable to sue Fox News for calling the coronavirus a hoax. The text discusses the potential liability of Fox News under the Consumer Protection Act (CPA), but it does not establish whether a lawsuit would be successful or not. Additionally, while the evidence suggests that some viewers of Fox News may have taken less precautions due to the network's coverage, it does not demonstrate that this has led to specific instances of harm in Washington state.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000564",
    "statement": "Unfounded fears that dogs can spread covid-19 can cause harm",
    "label": "SUPPORTED",
    "evidences": [
      "And, although no evidence exists to indicate that they can either transmit the virus or develop its associated coronavirus disease 2019 (COVID-19), fear among the public that pets might play a role in spreading COVID-19 has resulted in pets being abandoned or even killed.",
      "At this time, there is no evidence that companion animals play a significant role in spreading the virus that causes COVID-19; however, we are still learning about this virus.",
      "According to the World Organisation for Animal Health (OIE), there is no justification in taking measures against companion animals that may compromise their welfare, such as harming them, abandoning them, or euthanizing them based on unfounded fears over COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence states that fear among the public about pets playing a role in spreading COVID-19 is unfounded and yet it has led to harming, abandoning, or euthanizing pets. This implies that unfounded fears can indeed cause harm.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000565",
    "statement": "Unfounded fears that people can spread covid-19 can cause harm",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "And, although no evidence exists to indicate that they can either transmit the virus or develop its associated coronavirus disease 2019 (COVID-19), fear among the public that pets might play a role in spreading COVID-19 has resulted in pets being abandoned or even killed.",
      "At this time, there is no evidence that companion animals play a significant role in spreading the virus that causes COVID-19; however, we are still learning about this virus.",
      "According to the World Organisation for Animal Health (OIE), there is no justification in taking measures against companion animals that may compromise their welfare, such as harming them, abandoning them, or euthanizing them based on unfounded fears over COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that unfounded fears about pets spreading COVID-19 have led to harming, abandoning, or euthanizing them. This clearly demonstrates that such unfounded fears can cause harm.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000566",
    "statement": "Unfounded fears that sars can spread covid-19 can cause harm",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "And, although no evidence exists to indicate that they can either transmit the virus or develop its associated coronavirus disease 2019 (COVID-19), fear among the public that pets might play a role in spreading COVID-19 has resulted in pets being abandoned or even killed.",
      "At this time, there is no evidence that companion animals play a significant role in spreading the virus that causes COVID-19; however, we are still learning about this virus.",
      "According to the World Organisation for Animal Health (OIE), there is no justification in taking measures against companion animals that may compromise their welfare, such as harming them, abandoning them, or euthanizing them based on unfounded fears over COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides clear examples of harm caused by unfounded fears that pets might play a role in spreading COVID-19. While there is no evidence to support this claim, the fear still exists and has resulted in pets being abandoned or killed. This shows that such unfounded fears can cause harm.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000567",
    "statement": "Unfounded fears that hiv can spread covid-19 can cause harm",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "And, although no evidence exists to indicate that they can either transmit the virus or develop its associated coronavirus disease 2019 (COVID-19), fear among the public that pets might play a role in spreading COVID-19 has resulted in pets being abandoned or even killed.",
      "At this time, there is no evidence that companion animals play a significant role in spreading the virus that causes COVID-19; however, we are still learning about this virus.",
      "According to the World Organisation for Animal Health (OIE), there is no justification in taking measures against companion animals that may compromise their welfare, such as harming them, abandoning them, or euthanizing them based on unfounded fears over COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that unfounded fears about pets spreading COVID-19 have resulted in harm to pets (abandonment and killing). This suggests that such unfounded fears can indeed cause harm.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000568",
    "statement": "Sars-cov-2 infection causes transient olfactory dysfunction in mice",
    "label": "SUPPORTED",
    "evidences": [
      "Combined transcriptomic and proteomic analyses reveal the induction of antiviral and inflammatory responses, as well as the downregulation of olfactory receptors in OE from the infected animals.",
      "Herein we demonstrate intranasal inoculation of SARS-CoV-2 induces robust viral replication in the olfactory epithelium (OE), resulting in transient olfactory dysfunction in humanized ACE2 mice."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that SARS-CoV-2 infection causes transient olfactory dysfunction in mouse models with humanized ACE2. The text mentions the downregulation of olfactory receptors and robust viral replication in the olfactory epithelium, both of which suggest an impact on the sense of smell. Furthermore, it is stated that this infection results in transient olfactory dysfunction in these mice.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000569",
    "statement": "Sars-cov-2 infection causes transient olfactory dysfunction in humans",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Combined transcriptomic and proteomic analyses reveal the induction of antiviral and inflammatory responses, as well as the downregulation of olfactory receptors in OE from the infected animals.",
      "Herein we demonstrate intranasal inoculation of SARS-CoV-2 induces robust viral replication in the olfactory epithelium (OE), resulting in transient olfactory dysfunction in humanized ACE2 mice."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence shows that intranasal inoculation of SARS-CoV-2 in humanized ACE2 mice leads to robust viral replication in the olfactory epithelium (OE), resulting in transient olfactory dysfunction. The mentioned downregulation of olfactory receptors also supports this claim.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000570",
    "statement": "Sars-cov-2 infection causes transient olfactory dysfunction in neurons",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Combined transcriptomic and proteomic analyses reveal the induction of antiviral and inflammatory responses, as well as the downregulation of olfactory receptors in OE from the infected animals.",
      "Herein we demonstrate intranasal inoculation of SARS-CoV-2 induces robust viral replication in the olfactory epithelium (OE), resulting in transient olfactory dysfunction in humanized ACE2 mice."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that SARS-CoV-2 infection does cause viral replication in the olfactory epithelium (OE), which is a part of the nervous system responsible for the sense of smell. This infection results in transient olfactory dysfunction in humanized ACE2 mice, as shown by the study.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000571",
    "statement": "1 million pc owners combine their gpu power to fight covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "Almost two decades after it first launched, the uniquely decentralized structure of Folding@home is bringing together more people and computing power than ever to help understand, and hopefully fight, the COVID-19 threat.",
      "Users around the world have donated processing power of over one million personal computers to help Folding@Homea distributed computing project for simulating protein dynamicsto search for new therapies for the coronavirus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that over one million personal computers have been donated to Folding@home, a distributed computing project for simulating protein dynamics. The goal of this project is to find new therapies for the coronavirus (COVID-19). Therefore, it can be inferred that these computer owners are collectively using their GPU power to fight COVID-19.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000572",
    "statement": "1 2 pc owners combine their gpu power to fight covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Almost two decades after it first launched, the uniquely decentralized structure of Folding@home is bringing together more people and computing power than ever to help understand, and hopefully fight, the COVID-19 threat.",
      "Users around the world have donated processing power of over one million personal computers to help Folding@Homea distributed computing project for simulating protein dynamicsto search for new therapies for the coronavirus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that users around the world have donated processing power of over one million personal computers to a distributed computing project (Folding@home) for simulating protein dynamics in order to search for new therapies for the coronavirus. This suggests that the owners of these PCs are pooling their GPU power to contribute to fighting COVID-19.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000573",
    "statement": "1 4 pc owners combine their gpu power to fight covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Almost two decades after it first launched, the uniquely decentralized structure of Folding@home is bringing together more people and computing power than ever to help understand, and hopefully fight, the COVID-19 threat.",
      "Users around the world have donated processing power of over one million personal computers to help Folding@Homea distributed computing project for simulating protein dynamicsto search for new therapies for the coronavirus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that users around the world are donating their personal computer's processing power to Folding@Home, a distributed computing project for simulating protein dynamics. The goal of this project is to search for new therapies for the coronavirus (COVID-19). By combining their computational power in such a way, one could interpret that they are using it to 'fight' COVID-19.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000574",
    "statement": "1 million pc owners lost their gpu power to fight covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Almost two decades after it first launched, the uniquely decentralized structure of Folding@home is bringing together more people and computing power than ever to help understand, and hopefully fight, the COVID-19 threat.",
      "Users around the world have donated processing power of over one million personal computers to help Folding@Homea distributed computing project for simulating protein dynamicsto search for new therapies for the coronavirus."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided discusses users donating their processing power to a distributed computing project to help understand and potentially fight COVID-19. However, it does not state that one million PC owners lost their GPU power specifically for this purpose.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000575",
    "statement": "An alpaca nanobody neutralizes sars-cov-2 by blocking receptor interaction",
    "label": "SUPPORTED",
    "evidences": [
      "Here, we report the isolation and characterization of an alpaca-derived single domain antibody fragment, Ty1, that specifically targets the receptor binding domain (RBD) of the SARS-CoV-2 spike, directly preventing ACE2 engagement."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly states that the alpaca nanobody (Ty1) targets and blocks the receptor binding domain (RBD) of SARS-CoV-2 spike, which is the part that interacts with ACE2. Thus, it neutralizes SARS-CoV-2 by preventing its interaction with the receptor.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000576",
    "statement": "An alpaca nanobody neutralizes sars-cov-2 by activating receptor interaction",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Here, we report the isolation and characterization of an alpaca-derived single domain antibody fragment, Ty1, that specifically targets the receptor binding domain (RBD) of the SARS-CoV-2 spike, directly preventing ACE2 engagement."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided reports the isolation and characterization of an alpaca-derived single domain antibody fragment (Ty1) that specifically targets the receptor binding domain (RBD) of the SARS-CoV-2 spike. This action directly prevents ACE2 engagement, which is a key step in the viral entry into host cells. Thus, it is supported that an alpaca nanobody neutralizes SARS-CoV-2 by activating receptor interaction.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000577",
    "statement": "An alpaca nanobody neutralizes sars-cov-2 by its receptor interaction",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Here, we report the isolation and characterization of an alpaca-derived single domain antibody fragment, Ty1, that specifically targets the receptor binding domain (RBD) of the SARS-CoV-2 spike, directly preventing ACE2 engagement."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly states that an alpaca nanobody (Ty1) targets the receptor binding domain of SARS-CoV-2 spike and directly prevents ACE2 engagement. This directly suggests that it neutralizes SARS-CoV-2 by its receptor interaction.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000578",
    "statement": "An alpaca nanobody neutralizes sars-cov-2 by a receptor interaction",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Here, we report the isolation and characterization of an alpaca-derived single domain antibody fragment, Ty1, that specifically targets the receptor binding domain (RBD) of the SARS-CoV-2 spike, directly preventing ACE2 engagement."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides direct support for the claim that an alpaca nanobody neutralizes SARS-CoV-2 by interacting with its receptor binding domain (RBD) and preventing ACE2 engagement.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000579",
    "statement": "Household studies provide key insights on the transmission of , and susceptibility to , sars-cov-2",
    "label": "SUPPORTED",
    "evidences": [
      "The secondary attack rate for SARS-CoV-2 has been estimated to be approximately twice as high as that of SARS-CoV, 5 Lau JT Lau M Kim JH Tsui HY Tsang T Wong TW Probable secondary infections in households of SARS patients in Hong Kong."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence refers to a study comparing the secondary attack rate (transmission) of SARS-CoV-2 and SARS-CoV. The fact that the study compares transmission rates between these two coronaviruses implies that the study is evaluating factors that influence their transmission, which includes susceptibility.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000580",
    "statement": "Future studies provide key insights on the transmission of, and susceptibility to, sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The secondary attack rate for SARS-CoV-2 has been estimated to be approximately twice as high as that of SARS-CoV, 5 Lau JT Lau M Kim JH Tsui HY Tsang T Wong TW Probable secondary infections in households of SARS patients in Hong Kong."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided is a study that compares the secondary attack rate (transmission) of SARS-CoV-2 to SARS-CoV in households of patients. A higher secondary attack rate indicates easier transmission and thus provides key insights on susceptibility to the virus.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000581",
    "statement": "Inactivating porcine coronavirus before nuclei acid isolation with the temperature higher than 56 \u00b0c damages its genome integrity seriously",
    "label": "SUPPORTED",
    "evidences": [
      "Our results showed that only 50.11% of the detectable viral templates left after the inactivation of 56 \u00b0C for 30 minutes and only 3.36% left after the inactivation of 92 \u00b0C for 5 minutes when the samples were preserved by Hanks solution, one of an isotonic salt solutions currently suggested.",
      "According to The Laboratory Technical Guidelines for Detection 2019-nCoV (Fourth Edition) issued by National Health and Commission of China and The Experts Consensus on Nucleic Acid Detection of 2019-nCoV released by Chinese Society of Laboratory Medicine, the human samples must be placed under 56\u00b0C or higher to inactivate the viruses in order to keep the inspectors from virus infection before the nucleic acids were isolated as the template of qRT-PCR.",
      "We therefore highly recommend to carry out systematic investigation on the impact of high temperature inactivation on the integrity of 2019-nCoV genome and develop a sample preservation solution to protect the detectable templates of 2019-nCoV nucleic acids from high temperature inactivation damage.",
      "However, the detectable templates of viral nucleic acids can be unchanged after the samples were incubated at 56 \u00b0C or higher if the samples were preserved with an optimized solution to protect the RNA from being disrupted."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides data showing that high temperatures (above 56\u00b0C) can significantly reduce the detectable viral templates left after inactivation, suggesting that the genome integrity of the virus may be damaged at these temperatures. The evidence also suggests that an optimized solution can protect RNA from disruption during incubation at these temperatures. Therefore, it is reasonable to conclude that inactivating porcine coronavirus before nuclei acid isolation with a temperature higher than 56\u00b0C could potentially damage its genome integrity.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000582",
    "statement": "Inactivating porcine coronavirus before nuclei acid isolation with the temperature higher than 56 \u00b0c increased its genome integrity seriously",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our results showed that only 50.11% of the detectable viral templates left after the inactivation of 56 \u00b0C for 30 minutes and only 3.36% left after the inactivation of 92 \u00b0C for 5 minutes when the samples were preserved by Hanks solution, one of an isotonic salt solutions currently suggested.",
      "According to The Laboratory Technical Guidelines for Detection 2019-nCoV (Fourth Edition) issued by National Health and Commission of China and The Experts Consensus on Nucleic Acid Detection of 2019-nCoV released by Chinese Society of Laboratory Medicine, the human samples must be placed under 56\u00b0C or higher to inactivate the viruses in order to keep the inspectors from virus infection before the nucleic acids were isolated as the template of qRT-PCR.",
      "We therefore highly recommend to carry out systematic investigation on the impact of high temperature inactivation on the integrity of 2019-nCoV genome and develop a sample preservation solution to protect the detectable templates of 2019-nCoV nucleic acids from high temperature inactivation damage.",
      "However, the detectable templates of viral nucleic acids can be unchanged after the samples were incubated at 56 \u00b0C or higher if the samples were preserved with an optimized solution to protect the RNA from being disrupted."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows that a high temperature (56 \u00b0C) does indeed impact the detectability of viral templates for porcine coronavirus, with only 50.11% remaining after inactivation for 30 minutes. The text also suggests that higher temperatures (higher than 56 \u00b0C) could further reduce the detectability of viral templates. This is consistent with the guidelines and consensus mentioned, which advise inactivating samples at high temperatures to prevent virus infection before nucleic acid isolation.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000583",
    "statement": "Inactivating porcine coronavirus before nuclei acid isolation with the temperature higher than 56 \u00b0c increases its genome integrity seriously",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our results showed that only 50.11% of the detectable viral templates left after the inactivation of 56 \u00b0C for 30 minutes and only 3.36% left after the inactivation of 92 \u00b0C for 5 minutes when the samples were preserved by Hanks solution, one of an isotonic salt solutions currently suggested.",
      "According to The Laboratory Technical Guidelines for Detection 2019-nCoV (Fourth Edition) issued by National Health and Commission of China and The Experts Consensus on Nucleic Acid Detection of 2019-nCoV released by Chinese Society of Laboratory Medicine, the human samples must be placed under 56\u00b0C or higher to inactivate the viruses in order to keep the inspectors from virus infection before the nucleic acids were isolated as the template of qRT-PCR.",
      "We therefore highly recommend to carry out systematic investigation on the impact of high temperature inactivation on the integrity of 2019-nCoV genome and develop a sample preservation solution to protect the detectable templates of 2019-nCoV nucleic acids from high temperature inactivation damage.",
      "However, the detectable templates of viral nucleic acids can be unchanged after the samples were incubated at 56 \u00b0C or higher if the samples were preserved with an optimized solution to protect the RNA from being disrupted."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence shows that inactivating porcine coronavirus before nuclei acid isolation with a temperature higher than 56 \u00b0C does indeed decrease the detectable viral templates. However, the claim specifically states that this increases its genome integrity 'seriously'. The evidence only shows a reduction in detectability, not necessarily an increase in genome degradation or damage.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000584",
    "statement": "Inactivating porcine coronavirus before nuclei acid isolation with the temperature higher than 56 \u00b0c shows its genome integrity seriously",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our results showed that only 50.11% of the detectable viral templates left after the inactivation of 56 \u00b0C for 30 minutes and only 3.36% left after the inactivation of 92 \u00b0C for 5 minutes when the samples were preserved by Hanks solution, one of an isotonic salt solutions currently suggested.",
      "According to The Laboratory Technical Guidelines for Detection 2019-nCoV (Fourth Edition) issued by National Health and Commission of China and The Experts Consensus on Nucleic Acid Detection of 2019-nCoV released by Chinese Society of Laboratory Medicine, the human samples must be placed under 56\u00b0C or higher to inactivate the viruses in order to keep the inspectors from virus infection before the nucleic acids were isolated as the template of qRT-PCR.",
      "We therefore highly recommend to carry out systematic investigation on the impact of high temperature inactivation on the integrity of 2019-nCoV genome and develop a sample preservation solution to protect the detectable templates of 2019-nCoV nucleic acids from high temperature inactivation damage.",
      "However, the detectable templates of viral nucleic acids can be unchanged after the samples were incubated at 56 \u00b0C or higher if the samples were preserved with an optimized solution to protect the RNA from being disrupted."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provides information about the effect of high temperatures on porcine coronavirus templates, but it does not specifically address the integrity of its genome, especially under conditions relevant to SARS-CoV-2 (2019-nCoV). The claim needs to be supported with more direct evidence regarding the effects of specific temperature ranges and preservation solutions on the genomic integrity of SARS-CoV-2.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000585",
    "statement": "Therapeutic anticoagulation is associated with decreased mortality in mechanically ventilated covid-19 patients",
    "label": "SUPPORTED",
    "evidences": [
      "A multivariate Cox proportional hazard regression model with PS weights to adjust for baseline differences found a 79% reduction in death in patients who were therapeutically anticoagulated HR 0.209, [95% Cl (0.10, 0.46), p < 0.001].",
      "Results Propensity score (PS) weighted Kaplan-Meier plot demonstrated a survival advantage (57% vs. 25%) at 35 days from admission to the ICU in patients who received therapeutic anticoagulation for a minimum of 5 days compared to those who received prophylactic anticoagulation during their hospital course.",
      "Conclusions Therapeutic anticoagulation is associated with a survival advantage among patients with COVID-19 who require mechanical ventilation in the ICU."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided is from a study that analyzed the impact of therapeutic anticoagulation on mortality in mechanically ventilated COVID-19 patients. The results show a significant reduction in death (HR 0.209, [95% Cl (0.10, 0.46), p < 0.001]) and a survival advantage (57% vs. 25%) at 35 days from ICU admission for patients who received therapeutic anticoagulation for a minimum of 5 days compared to those who received prophylactic anticoagulation. The conclusion drawn from the study supports the claim.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000586",
    "statement": "Therapeutic anticoagulation is associated with elevated mortality in mechanically ventilated covid-19 patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "A multivariate Cox proportional hazard regression model with PS weights to adjust for baseline differences found a 79% reduction in death in patients who were therapeutically anticoagulated HR 0.209, [95% Cl (0.10, 0.46), p < 0.001].",
      "Results Propensity score (PS) weighted Kaplan-Meier plot demonstrated a survival advantage (57% vs. 25%) at 35 days from admission to the ICU in patients who received therapeutic anticoagulation for a minimum of 5 days compared to those who received prophylactic anticoagulation during their hospital course.",
      "Conclusions Therapeutic anticoagulation is associated with a survival advantage among patients with COVID-19 who require mechanical ventilation in the ICU."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided presents statistical analysis showing a survival advantage for mechanically ventilated COVID-19 patients who received therapeutic anticoagulation. However, correlation does not imply causation, and it is important to consider other factors that could have influenced the outcome. For example, patients receiving therapeutic anticoagulation may have had more severe disease or different comorbidities. To fully support the claim, additional evidence such as randomized controlled trials comparing outcomes between groups with and without therapeutic anticoagulation would be needed.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000587",
    "statement": "Therapeutic anticoagulation is associated with increased mortality in mechanically ventilated covid-19 patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "A multivariate Cox proportional hazard regression model with PS weights to adjust for baseline differences found a 79% reduction in death in patients who were therapeutically anticoagulated HR 0.209, [95% Cl (0.10, 0.46), p < 0.001].",
      "Results Propensity score (PS) weighted Kaplan-Meier plot demonstrated a survival advantage (57% vs. 25%) at 35 days from admission to the ICU in patients who received therapeutic anticoagulation for a minimum of 5 days compared to those who received prophylactic anticoagulation during their hospital course.",
      "Conclusions Therapeutic anticoagulation is associated with a survival advantage among patients with COVID-19 who require mechanical ventilation in the ICU."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided presents statistical analysis results showing a survival advantage for mechanically ventilated COVID-19 patients receiving therapeutic anticoagulation. However, this does not conclusively prove that therapeutic anticoagulation is associated with increased mortality in such patients. The relationship between the two variables should be studied further through additional, well-designed studies to establish a causal connection.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000588",
    "statement": "Therapeutic anticoagulation is associated with high mortality in mechanically ventilated covid-19 patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "A multivariate Cox proportional hazard regression model with PS weights to adjust for baseline differences found a 79% reduction in death in patients who were therapeutically anticoagulated HR 0.209, [95% Cl (0.10, 0.46), p < 0.001].",
      "Results Propensity score (PS) weighted Kaplan-Meier plot demonstrated a survival advantage (57% vs. 25%) at 35 days from admission to the ICU in patients who received therapeutic anticoagulation for a minimum of 5 days compared to those who received prophylactic anticoagulation during their hospital course.",
      "Conclusions Therapeutic anticoagulation is associated with a survival advantage among patients with COVID-19 who require mechanical ventilation in the ICU."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence presents statistical analysis that shows a significant reduction (79%) in death among patients with COVID-19 who required mechanical ventilation in the ICU and were therapeutically anticoagulated for at least 5 days compared to those who received prophylactic anticoagulation. The findings also support this conclusion by demonstrating a survival advantage of 57% vs. 25% at 35 days from admission to the ICU.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000589",
    "statement": "Sars-cov-2 is an unrestricted bioweapon",
    "label": "SUPPORTED",
    "evidences": [
      "It also strengthens our earlier assertion that SARS-CoV-2 is a product of laboratory modification, which can be created in approximately six months using a template virus owned by a laboratory of the People's Liberation Army (PLA).",
      "We therefore define SARS- CoV-2 as an Unrestricted Bioweapon and the current pandemic a result of Unrestricted Biowarfare.",
      "Importantly, while SARS-CoV-2 meets the criteria of a bioweapon specified by the PLA, its impact is well beyond what is conceived for a typical bioweapon."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not conclusively support the claim that SARS-CoV-2 is an 'unrestricted bioweapon'. The statement asserts that SARS-CoV-2 was created in a lab owned by the People's Liberation Army (PLA) in approximately six months, but this does not prove it was designed or used as a weapon. The impact of SARS-CoV-2 is significant, but this does not necessarily mean it was intentionally created for warfare purposes.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000590",
    "statement": "Sars-cov-2 is an spricted bioweapon",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "It also strengthens our earlier assertion that SARS-CoV-2 is a product of laboratory modification, which can be created in approximately six months using a template virus owned by a laboratory of the People's Liberation Army (PLA).",
      "We therefore define SARS- CoV-2 as an Unrestricted Bioweapon and the current pandemic a result of Unrestricted Biowarfare.",
      "Importantly, while SARS-CoV-2 meets the criteria of a bioweapon specified by the PLA, its impact is well beyond what is conceived for a typical bioweapon."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence does not support the claim that SARS-CoV-2 is a spricted (spread unintentionally) bioweapon or the assertion that the current pandemic is a result of Unrestricted Biowarfare. The statement is based on speculation and conjecture, and there is no concrete evidence to support these claims.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000591",
    "statement": "Sars-cov-2 is an sricted bioweapon",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "It also strengthens our earlier assertion that SARS-CoV-2 is a product of laboratory modification, which can be created in approximately six months using a template virus owned by a laboratory of the People's Liberation Army (PLA).",
      "We therefore define SARS- CoV-2 as an Unrestricted Bioweapon and the current pandemic a result of Unrestricted Biowarfare.",
      "Importantly, while SARS-CoV-2 meets the criteria of a bioweapon specified by the PLA, its impact is well beyond what is conceived for a typical bioweapon."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not provide conclusive proof that SARS-CoV-2 is an unconstrained bioweapon created in a Chinese military laboratory. The statement is based on an assertion and lacks empirical evidence to support the claim.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000592",
    "statement": "Sars-cov-2 is an trricted bioweapon",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "It also strengthens our earlier assertion that SARS-CoV-2 is a product of laboratory modification, which can be created in approximately six months using a template virus owned by a laboratory of the People's Liberation Army (PLA).",
      "We therefore define SARS- CoV-2 as an Unrestricted Bioweapon and the current pandemic a result of Unrestricted Biowarfare.",
      "Importantly, while SARS-CoV-2 meets the criteria of a bioweapon specified by the PLA, its impact is well beyond what is conceived for a typical bioweapon."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence does not support the claim that Sars-cov-2 is an unrestricted bioweapon. The claim suggests the virus was created in a lab of the People's Liberation Army (PLA) and deployed as a weapon, but there is no concrete proof or credible scientific consensus to support this assertion.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000593",
    "statement": "Kinetics of antibody responses dictate covid-19 outcome.",
    "label": "SUPPORTED",
    "evidences": [
      "COVID-19 neutralizing antibodies predict disease severity and survival.",
      "Serum antibody kinetics reveals distinct COVID-19 outcomes.",
      "Viral kinetics and antibody responses in patients with COVID-19.",
      "T cell and antibody functional correlates of severe COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests that the kinetics (speed or rate) of the production and response of antibodies to SARS-CoV-2 infection can impact the severity and outcome of COVID-19. This is inferred from the findings that COVID-19 neutralizing antibodies predict disease severity and survival, serum antibody kinetics reveal distinct COVID-19 outcomes, and there are studies on viral kinetics and antibody responses in patients with COVID-19. Additionally, it is mentioned that T cell and antibody functional correlates of severe COVID-19 were also investigated, which further supports the claim.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000594",
    "statement": "Standards of antibody responses dictate covid-19 outcome.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "COVID-19 neutralizing antibodies predict disease severity and survival.",
      "Serum antibody kinetics reveals distinct COVID-19 outcomes.",
      "Viral kinetics and antibody responses in patients with COVID-19.",
      "T cell and antibody functional correlates of severe COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests that the levels and effectiveness of COVID-19 neutralizing antibodies (an aspect of the immune response) are associated with disease severity and outcome. This implies that standards of antibody responses may indeed dictate covid-19 outcome.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000595",
    "statement": "Kinetics of antibody production dictate covid-19 outcome.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "COVID-19 neutralizing antibodies predict disease severity and survival.",
      "Serum antibody kinetics reveals distinct COVID-19 outcomes.",
      "Viral kinetics and antibody responses in patients with COVID-19.",
      "T cell and antibody functional correlates of severe COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests a correlation between the kinetics (rate and pattern) of antibody production in response to COVID-19 infection and the severity of the disease outcome. The evidence mentions that COVID-19 neutralizing antibodies predict disease severity and survival, which implies that the kinetics of antibody production could play a role in determining the outcome of COVID-19.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000596",
    "statement": "Analysiss of antibody responses dictate covid-19 outcome.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "COVID-19 neutralizing antibodies predict disease severity and survival.",
      "Serum antibody kinetics reveals distinct COVID-19 outcomes.",
      "Viral kinetics and antibody responses in patients with COVID-19.",
      "T cell and antibody functional correlates of severe COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that the levels and characteristics of antibodies in response to COVID-19 infection are associated with disease severity and survival. Therefore, it can be concluded that the analysis of antibody responses does dictate COVID-19 outcome.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000597",
    "statement": "Raspberry pi about to boost ventilators for coronavirus victims",
    "label": "SUPPORTED",
    "evidences": [
      "Toms Hardware reports that The Raspberry Pi Foundation is ramping up production of its Pi Zero boards to help supply manufacturers with enough units to keep up with the high demand for ventilators.",
      "Another reason Raspberry Pi boards are ideal for ventilators is the companys ability to supply them quickly."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided mentions that The Raspberry Pi Foundation is increasing production of its Pi Zero boards to help meet the demand for ventilator components, but it does not explicitly state that these boards will be used directly as ventilators or significantly boost their capacity for coronavirus victims.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000598",
    "statement": "Raspberry pi about to avoid ventilators for coronavirus victims",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Toms Hardware reports that The Raspberry Pi Foundation is ramping up production of its Pi Zero boards to help supply manufacturers with enough units to keep up with the high demand for ventilators.",
      "Another reason Raspberry Pi boards are ideal for ventilators is the companys ability to supply them quickly."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim that Raspberry Pi will avoid ventilators for coronavirus victims is not directly supported by the evidence provided. The evidence indicates an increase in production of Raspberry Pi Zero boards to help manufacture ventilators, but it does not imply that Raspberry Pi will replace ventilators or prevent their use.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000599",
    "statement": "Raspberry pi about to take ventilators for coronavirus victims",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Toms Hardware reports that The Raspberry Pi Foundation is ramping up production of its Pi Zero boards to help supply manufacturers with enough units to keep up with the high demand for ventilators.",
      "Another reason Raspberry Pi boards are ideal for ventilators is the companys ability to supply them quickly."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided discusses the Raspberry Pi Foundation ramping up production of its Pi Zero boards for manufacturers due to high demand, but it does not state or imply that Raspberry Pi boards will be used specifically for ventilators for coronavirus victims.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000600",
    "statement": "Raspberry pi about to receive ventilators for coronavirus victims",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Toms Hardware reports that The Raspberry Pi Foundation is ramping up production of its Pi Zero boards to help supply manufacturers with enough units to keep up with the high demand for ventilators.",
      "Another reason Raspberry Pi boards are ideal for ventilators is the companys ability to supply them quickly."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The given evidence indicates that the Raspberry Pi Foundation is increasing production of its Pi Zero boards to help manufacturers with the high demand for ventilators, but it does not explicitly state or imply that the Raspberry Pi about to receive ventilators for coronavirus victims.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000601",
    "statement": "Aerosol particles laden with viruses that cause covid-19 travel over 30m distance",
    "label": "SUPPORTED",
    "evidences": [
      "The results obtained demonstrate that aerosol particles generated by coughing and sneezing can travel over 30 m. Modelling of the evolution of aerosol clouds generated by coughing and sneezing enables us to evaluate the deposition dose of aerosol particles in healthy individuals.",
      "]: dot [@]: at [MHRA]: Medicines and Healthcare products Regulatory Agency [JCVI]: Joint Committee for Vaccination and Immunisation [PMC]: Penske Media Corporation [ COVID-19]: coronavirus disease 2019 [COVID-19]: coronavirus disease 2019 [v]: View this template [t]: telephone [e]: email []: You need to accept this checkbox."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that aerosol particles generated by coughing and sneezing can travel over 30m, which implies that virus-laden aerosols could potentially travel this distance as well. However, the absence of direct statements or studies regarding specific viruses (e.g., SARS-CoV-2) causing COVID-19 in these aerosols should be noted.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000602",
    "statement": "Aerosol particles laden with viruses that cause covid-19 travel within 30m distance",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The results obtained demonstrate that aerosol particles generated by coughing and sneezing can travel over 30 m. Modelling of the evolution of aerosol clouds generated by coughing and sneezing enables us to evaluate the deposition dose of aerosol particles in healthy individuals.",
      "]: dot [@]: at [MHRA]: Medicines and Healthcare products Regulatory Agency [JCVI]: Joint Committee for Vaccination and Immunisation [PMC]: Penske Media Corporation [ COVID-19]: coronavirus disease 2019 [COVID-19]: coronavirus disease 2019 [v]: View this template [t]: telephone [e]: email []: You need to accept this checkbox."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that aerosol particles generated by coughing and sneezing can travel over 30m (as stated in the text). It is reasonable to infer that if viruses causing COVID-19 are present in those aerosols, they would also be able to travel within the same distance.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000603",
    "statement": "Mosaic rbd nanoparticles elicit neutralizing antibodies against sars-cov-2 and zoonotic coronaviruses",
    "label": "SUPPORTED",
    "evidences": [
      "Mice immunized with RBD-nanoparticles, but not soluble antigen, elicited cross-reactive antibody binding and neutralization responses, confirming increased immunogenicity from multimerization.",
      "Mosaic-RBD-nanoparticles elicited antibodies with superior cross-reactive recognition of heterologous RBDs compared to sera from immunizations with homotypic SARS-CoV-2RBD-nanoparticles or antibodies from COVID-19 convalescent human plasmas.",
      "Thus, a single immunization with mosaic-RBD- nanoparticles provides a potential strategy to simultaneously protect against SARS-CoV-2 and emerging zoonotic coronaviruses."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows that mice immunized with Mosaic RBD nanoparticles elicited neutralizing antibodies against SARS-CoV-2 and cross-reactive antibody binding and neutralization responses against zoonotic coronaviruses. This indicates that the claim, 'Mosaic rbd nanoparticles elicit neutralizing antibodies against sars-cov-2 and zoonotic coronaviruses' is supported.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000604",
    "statement": "Mosaic rbd nanoparticles elicit neutralizing antibodies against chs-cov-2 and zoonotic coronaviruses",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Mice immunized with RBD-nanoparticles, but not soluble antigen, elicited cross-reactive antibody binding and neutralization responses, confirming increased immunogenicity from multimerization.",
      "Mosaic-RBD-nanoparticles elicited antibodies with superior cross-reactive recognition of heterologous RBDs compared to sera from immunizations with homotypic SARS-CoV-2RBD-nanoparticles or antibodies from COVID-19 convalescent human plasmas.",
      "Thus, a single immunization with mosaic-RBD- nanoparticles provides a potential strategy to simultaneously protect against SARS-CoV-2 and emerging zoonotic coronaviruses."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that mice immunized with Mosaic RBD nanoparticles produce antibodies that not only neutralize SARS-CoV-2 (chs-cov-2), but also cross-react with heterologous RBDs (different forms of the Receptor Binding Domain). Furthermore, it states that these antibodies provide a potential strategy to protect against both SARS-CoV-2 and emerging zoonotic coronaviruses. Therefore, it supports the claim that Mosaic rbd nanoparticles elicit neutralizing antibodies against chs-cov-2 and zoonotic coronaviruses.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000605",
    "statement": "Mosaic rbd nanoparticles elicit neutralizing antibodies against gps-cov-2 and zoonotic coronaviruses",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Mice immunized with RBD-nanoparticles, but not soluble antigen, elicited cross-reactive antibody binding and neutralization responses, confirming increased immunogenicity from multimerization.",
      "Mosaic-RBD-nanoparticles elicited antibodies with superior cross-reactive recognition of heterologous RBDs compared to sera from immunizations with homotypic SARS-CoV-2RBD-nanoparticles or antibodies from COVID-19 convalescent human plasmas.",
      "Thus, a single immunization with mosaic-RBD- nanoparticles provides a potential strategy to simultaneously protect against SARS-CoV-2 and emerging zoonotic coronaviruses."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that mice immunized with RBD-nanoparticles elicited neutralizing antibodies against SARS-CoV-2 and cross-reactive antibodies against heterologous RBDs (different types of coronaviruses). This suggests that the immunization strategy using mosaic-RBD nanoparticles can potentially protect against not only SARS-CoV-2, but also emerging zoonotic coronaviruses.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000606",
    "statement": "Mosaic rbd nanoparticles elicit neutralizing antibodies against 3s-cov-2 and zoonotic coronaviruses",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Mice immunized with RBD-nanoparticles, but not soluble antigen, elicited cross-reactive antibody binding and neutralization responses, confirming increased immunogenicity from multimerization.",
      "Mosaic-RBD-nanoparticles elicited antibodies with superior cross-reactive recognition of heterologous RBDs compared to sera from immunizations with homotypic SARS-CoV-2RBD-nanoparticles or antibodies from COVID-19 convalescent human plasmas.",
      "Thus, a single immunization with mosaic-RBD- nanoparticles provides a potential strategy to simultaneously protect against SARS-CoV-2 and emerging zoonotic coronaviruses."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that mice immunized with RBD-nanoparticles elicit cross-reactive antibody binding and neutralization responses against heterologous RBDs (3s-cov-2 and zoonotic coronaviruses), confirming increased immunogenicity from multimerization. Furthermore, the evidence indicates that a single immunization with mosaic-RBD nanoparticles provides a potential strategy to simultaneously protect against SARS-CoV-2 and emerging zoonotic coronaviruses.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000607",
    "statement": "South korean city deserted due to super spreading event",
    "label": "SUPPORTED",
    "evidences": [
      "The deserted shopping malls and cinemas of Daegu, a city of 2.5 million people, became one of the most striking images outside China of an outbreak that international authorities are trying to prevent from spreading into a global pandemic.",
      "The deserted shopping malls and cinemas of Daegu, a city of 2.5 million people, became one of the most striking images outside China of an outbreak that international authorities are trying stop from becoming a global pandemic.",
      "Updated: 20 Feb 2020, 06:04 PM IST Hyonhee Shin , Ryan Woo , AP The deserted shopping malls and cinemas of Daegu, a city of 2.5 million people, became one of the most striking images outside China of an outbreak that international authorities are trying to prevent from spreading into a global pandemic Share Via Read Full Story SEOUL/BEIJING : The streets of South Korea's fourth-largest city were abandoned on Thursday, with residents holed up indoors after dozens of people caught the coronavirus in what the authorities described as a \"super-spreading event\" at a church.",
      "South Korea's Centers for Disease Control and Prevention described the outbreak there as a \"super-spreading event\".",
      "Korea's Centers for Disease Control and Prevention described the outbreak there as a \"super-spreading event\"."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that Daegu, South Korea's fourth-largest city, experienced a 'super-spreading event' of the coronavirus. This resulted in the desertion of shopping malls and cinemas within the city, as reported by the Associated Press.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000608",
    "statement": "South korean city started due to super spreading event",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The deserted shopping malls and cinemas of Daegu, a city of 2.5 million people, became one of the most striking images outside China of an outbreak that international authorities are trying to prevent from spreading into a global pandemic.",
      "The deserted shopping malls and cinemas of Daegu, a city of 2.5 million people, became one of the most striking images outside China of an outbreak that international authorities are trying stop from becoming a global pandemic.",
      "Updated: 20 Feb 2020, 06:04 PM IST Hyonhee Shin , Ryan Woo , AP The deserted shopping malls and cinemas of Daegu, a city of 2.5 million people, became one of the most striking images outside China of an outbreak that international authorities are trying to prevent from spreading into a global pandemic Share Via Read Full Story SEOUL/BEIJING : The streets of South Korea's fourth-largest city were abandoned on Thursday, with residents holed up indoors after dozens of people caught the coronavirus in what the authorities described as a \"super-spreading event\" at a church.",
      "South Korea's Centers for Disease Control and Prevention described the outbreak there as a \"super-spreading event\".",
      "Korea's Centers for Disease Control and Prevention described the outbreak there as a \"super-spreading event\"."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that Daegu, South Korea experienced a 'super-spreading event' which caused the desertion of its shopping malls and cinemas. This implies that the city was significantly affected by an outbreak at some point.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000609",
    "statement": "South korean city remained due to super spreading event",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The deserted shopping malls and cinemas of Daegu, a city of 2.5 million people, became one of the most striking images outside China of an outbreak that international authorities are trying to prevent from spreading into a global pandemic.",
      "The deserted shopping malls and cinemas of Daegu, a city of 2.5 million people, became one of the most striking images outside China of an outbreak that international authorities are trying stop from becoming a global pandemic.",
      "Updated: 20 Feb 2020, 06:04 PM IST Hyonhee Shin , Ryan Woo , AP The deserted shopping malls and cinemas of Daegu, a city of 2.5 million people, became one of the most striking images outside China of an outbreak that international authorities are trying to prevent from spreading into a global pandemic Share Via Read Full Story SEOUL/BEIJING : The streets of South Korea's fourth-largest city were abandoned on Thursday, with residents holed up indoors after dozens of people caught the coronavirus in what the authorities described as a \"super-spreading event\" at a church.",
      "South Korea's Centers for Disease Control and Prevention described the outbreak there as a \"super-spreading event\".",
      "Korea's Centers for Disease Control and Prevention described the outbreak there as a \"super-spreading event\"."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly indicates that Daegu, a city in South Korea, experienced a 'super-spreading event' of the coronavirus. This resulted in a large number of people becoming infected and the desertion of shopping malls and cinemas.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000610",
    "statement": "South korean city occurred due to super spreading event",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The deserted shopping malls and cinemas of Daegu, a city of 2.5 million people, became one of the most striking images outside China of an outbreak that international authorities are trying to prevent from spreading into a global pandemic.",
      "The deserted shopping malls and cinemas of Daegu, a city of 2.5 million people, became one of the most striking images outside China of an outbreak that international authorities are trying stop from becoming a global pandemic.",
      "Updated: 20 Feb 2020, 06:04 PM IST Hyonhee Shin , Ryan Woo , AP The deserted shopping malls and cinemas of Daegu, a city of 2.5 million people, became one of the most striking images outside China of an outbreak that international authorities are trying to prevent from spreading into a global pandemic Share Via Read Full Story SEOUL/BEIJING : The streets of South Korea's fourth-largest city were abandoned on Thursday, with residents holed up indoors after dozens of people caught the coronavirus in what the authorities described as a \"super-spreading event\" at a church.",
      "South Korea's Centers for Disease Control and Prevention described the outbreak there as a \"super-spreading event\".",
      "Korea's Centers for Disease Control and Prevention described the outbreak there as a \"super-spreading event\"."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly states that Daegu, South Korea experienced a 'super-spreading event' of the coronavirus outbreak, as described by Korea's Centers for Disease Control and Prevention.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000611",
    "statement": "Scientists see signs of lasting immunity , even after mild infections",
    "label": "SUPPORTED",
    "evidences": [
      "Disease-fighting antibodies, as well as immune cells called B cells and T cells capable of recognizing the virus, appear to persist months after infections have resolved  an encouraging echo of the bodys robust immune response to other viruses.",
      "Scientists who have been monitoring immune responses to the virus are now starting to see encouraging signs of strong, lasting immunity, even in people who developed only mild symptoms of COVID-19, a flurry of new studies suggests.",
      "Disease-fighting antibodies, as well as immune cells called B cells and T cells that are capable of recognizing the virus, appear to persist months after infections have resolved  an encouraging echo of the bodys enduring response to other viruses.",
      "Scientists see signs of lasting immunity to COVID-19, even after mild infections Share: August 18, 2020 ",
      "Scientists who have been monitoring immune responses to the virus are now starting to see encouraging signs of strong, lasting immunity, even in people who developed only mild symptoms of Covid-19, a flurry of new studies suggests."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that disease-fighting antibodies, B cells, and T cells capable of recognizing the virus persist months after infections have resolved, indicating signs of lasting immunity to COVID-19 even after mild infections.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000612",
    "statement": "Scientists no signs of lasting immunity, even after mild infections",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Disease-fighting antibodies, as well as immune cells called B cells and T cells capable of recognizing the virus, appear to persist months after infections have resolved  an encouraging echo of the bodys robust immune response to other viruses.",
      "Scientists who have been monitoring immune responses to the virus are now starting to see encouraging signs of strong, lasting immunity, even in people who developed only mild symptoms of COVID-19, a flurry of new studies suggests.",
      "Disease-fighting antibodies, as well as immune cells called B cells and T cells that are capable of recognizing the virus, appear to persist months after infections have resolved  an encouraging echo of the bodys enduring response to other viruses.",
      "Scientists see signs of lasting immunity to COVID-19, even after mild infections Share: August 18, 2020 ",
      "Scientists who have been monitoring immune responses to the virus are now starting to see encouraging signs of strong, lasting immunity, even in people who developed only mild symptoms of Covid-19, a flurry of new studies suggests."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided mentions the persistence of disease-fighting antibodies, B cells, and T cells that can recognize the virus for months after infections have resolved. This indicates that scientists are seeing signs of lasting immunity to COVID-19 even after mild infections.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000613",
    "statement": "Intrinsic signal amplification by type-iii crispr-cas systems provides a sequence-specific viral diagnostic",
    "label": "SUPPORTED",
    "evidences": [
      "Here we repurposed the type III CRISPR-Cas system for sensitive and sequence specific detection of SARS-CoV-2 in an assay that can be performed in one hour or less."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided directly supports the claim. The experiment demonstrates the use of type III CRISPR-Cas system for sensitive and sequence specific detection of SARS-CoV-2, which can be interpreted as a diagnostic application.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000614",
    "statement": "Intrinsic signal amplification by type-iii crispr-cas systems provides a sequence-independent viral diagnostic",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Here we repurposed the type III CRISPR-Cas system for sensitive and sequence specific detection of SARS-CoV-2 in an assay that can be performed in one hour or less."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence shows the use of a type III CRISPR-Cas system for sensitive and sequence-specific detection of SARS-CoV-2, but it does not directly prove that this method provides a sequence-independent viral diagnostic.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000615",
    "statement": "Intrinsic signal amplification by type-iii crispr-cas systems provides a sequence-free viral diagnostic",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Here we repurposed the type III CRISPR-Cas system for sensitive and sequence specific detection of SARS-CoV-2 in an assay that can be performed in one hour or less."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided directly states that the type III CRISPR-Cas system is being repurposed for sensitive and sequence specific detection of SARS-CoV-2. This implies that the intrinsic signal amplification by type-iii crispr-cas systems can potentially provide a viral diagnostic, though further context might be needed to confirm if it's truly 'sequence-free'.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000616",
    "statement": "Pet dog further tests positive for antibodies for covid-19 virus",
    "label": "SUPPORTED",
    "evidences": [
      "This indicates that the Pomeranian had developed an immune response to the viral infection with antibodies found in the blood."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence shows that the dog has antibodies for the virus, but it does not confirm whether the dog had contracted COVID-19 or if it was exposed to a different coronavirus. To definitively claim that the pet dog had COVID-19, more specific and reliable evidence is required.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000617",
    "statement": "Pet dog further tests negative for antibodies for covid-19 virus",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "This indicates that the Pomeranian had developed an immune response to the viral infection with antibodies found in the blood."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim is that the pet dog tested negative for antibodies for COVID-19 virus, but the evidence provided states that the dog had developed an immune response to the viral infection with antibodies found in the blood. This contradicts the claim and therefore it cannot be supported.",
    "confidence": 0.0
  },
  {
    "id": "covid_fact-000618",
    "statement": "Pet dog further tests except for antibodies for covid-19 virus",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "This indicates that the Pomeranian had developed an immune response to the viral infection with antibodies found in the blood."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided suggests that the dog has developed an immune response (presence of antibodies) to a viral infection, but there is no information about whether it was specifically for the SARS-CoV-2 virus causing COVID-19.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000619",
    "statement": "Dr. vladimir zelenko has now treated 699 coronavirus patients with 100 % success using hydroxychloroquine sulfate , zinc and z-pak",
    "label": "SUPPORTED",
    "evidences": [
      "March 31 Update : Dr. Vladimir Zelenkoprovides important update on three drug regimen of Hydroxychloroquine Sulfate, Zinc and Azithromycin (Z-Pak) he used to effectively treat 699 coronavirus patients with 100% success 0 Shares Share On Facebook Tweet It ",
      "In an exclusive interview with former New York Mayor, Rudy Giuliani, Dr. Vladmir Zelenko shares the results of his latest study, which showed that out of his 699 patients treated, zero patients died, zero patients intubated, and four hospitalizations.",
      "Last Wednesday, we published the success story from Dr. Vladimir Zelenko, a board-certified family practitioner in New York, after he successfully treated 350 coronavirus patients with 100 percent success using a cocktail of drugs: hydroxychloroquine, in combination with azithromycin (Z-Pak), an antibiotic to treat secondary infections, and zinc sulfate.",
      "April 5 Update : Dr. Vladimir Zelenko said in a video interview that acocktail of Hydroxychloroquine, Zinc Sulfate and Azithromycin are showing phenomenon results with 900 coronavirus patients treated.",
      "Now, Dr. Zelenko provides updates on the treatment after he successfully treated 699 COVID-19 patients in New York."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided consists of statements from Dr. Vladimir Zelenko and updates on his treatment of COVID-19 patients, but it does not include peer-reviewed studies or data that can be objectively analyzed to confirm the claim of 100% success in treating 699 coronavirus patients using hydroxychloroquine sulfate, zinc, and z-pak. It is crucial to have such studies for validating medical treatments.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000620",
    "statement": "Dr. vladimir zelenko has now treated 699 coronavirus patients with 10 % success using hydroxychloroquine sulfate, zinc and z-pak",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "March 31 Update : Dr. Vladimir Zelenkoprovides important update on three drug regimen of Hydroxychloroquine Sulfate, Zinc and Azithromycin (Z-Pak) he used to effectively treat 699 coronavirus patients with 100% success 0 Shares Share On Facebook Tweet It ",
      "In an exclusive interview with former New York Mayor, Rudy Giuliani, Dr. Vladmir Zelenko shares the results of his latest study, which showed that out of his 699 patients treated, zero patients died, zero patients intubated, and four hospitalizations.",
      "Last Wednesday, we published the success story from Dr. Vladimir Zelenko, a board-certified family practitioner in New York, after he successfully treated 350 coronavirus patients with 100 percent success using a cocktail of drugs: hydroxychloroquine, in combination with azithromycin (Z-Pak), an antibiotic to treat secondary infections, and zinc sulfate.",
      "April 5 Update : Dr. Vladimir Zelenko said in a video interview that acocktail of Hydroxychloroquine, Zinc Sulfate and Azithromycin are showing phenomenon results with 900 coronavirus patients treated.",
      "Now, Dr. Zelenko provides updates on the treatment after he successfully treated 699 COVID-19 patients in New York."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim is not supported because the evidence provided shows a treatment with 100% success rate initially and later a 90% success rate, but it does not mention the current success rate as 10%. Also, there seems to be discrepancies in the number of patients treated, with the initial report stating 350 patients and the latest update stating 699.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000621",
    "statement": "Dr. vladimir zelenko has now treated 699 coronavirus patients with 5 % success using hydroxychloroquine sulfate, zinc and z-pak",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "March 31 Update : Dr. Vladimir Zelenkoprovides important update on three drug regimen of Hydroxychloroquine Sulfate, Zinc and Azithromycin (Z-Pak) he used to effectively treat 699 coronavirus patients with 100% success 0 Shares Share On Facebook Tweet It ",
      "In an exclusive interview with former New York Mayor, Rudy Giuliani, Dr. Vladmir Zelenko shares the results of his latest study, which showed that out of his 699 patients treated, zero patients died, zero patients intubated, and four hospitalizations.",
      "Last Wednesday, we published the success story from Dr. Vladimir Zelenko, a board-certified family practitioner in New York, after he successfully treated 350 coronavirus patients with 100 percent success using a cocktail of drugs: hydroxychloroquine, in combination with azithromycin (Z-Pak), an antibiotic to treat secondary infections, and zinc sulfate.",
      "April 5 Update : Dr. Vladimir Zelenko said in a video interview that acocktail of Hydroxychloroquine, Zinc Sulfate and Azithromycin are showing phenomenon results with 900 coronavirus patients treated.",
      "Now, Dr. Zelenko provides updates on the treatment after he successfully treated 699 COVID-19 patients in New York."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim is not supported by the provided evidence as it contradicts itself. The original claim states that Dr. Vladimir Zelenko has treated 699 coronavirus patients with a success rate of 5%, but later in the evidence, it states that out of 699 patients treated, zero patients died, zero patients were intubated, and four were hospitalized which implies a 100% success rate. This discrepancy makes it difficult to confirm the initial claim.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000622",
    "statement": "Dr. vladimir zelenko has now treated 699 coronavirus patients with 20 % success using hydroxychloroquine sulfate, zinc and z-pak",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "March 31 Update : Dr. Vladimir Zelenkoprovides important update on three drug regimen of Hydroxychloroquine Sulfate, Zinc and Azithromycin (Z-Pak) he used to effectively treat 699 coronavirus patients with 100% success 0 Shares Share On Facebook Tweet It ",
      "In an exclusive interview with former New York Mayor, Rudy Giuliani, Dr. Vladmir Zelenko shares the results of his latest study, which showed that out of his 699 patients treated, zero patients died, zero patients intubated, and four hospitalizations.",
      "Last Wednesday, we published the success story from Dr. Vladimir Zelenko, a board-certified family practitioner in New York, after he successfully treated 350 coronavirus patients with 100 percent success using a cocktail of drugs: hydroxychloroquine, in combination with azithromycin (Z-Pak), an antibiotic to treat secondary infections, and zinc sulfate.",
      "April 5 Update : Dr. Vladimir Zelenko said in a video interview that acocktail of Hydroxychloroquine, Zinc Sulfate and Azithromycin are showing phenomenon results with 900 coronavirus patients treated.",
      "Now, Dr. Zelenko provides updates on the treatment after he successfully treated 699 COVID-19 patients in New York."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not clearly indicate a 20% success rate for Dr. Vladimir Zelenko's treatment of coronavirus patients using hydroxychloroquine sulfate, zinc, and z-pak. The statements mention that 'zero patients died, zero patients intubated, and four hospitalizations' but do not provide specific percentages or rates related to success.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000623",
    "statement": "Performance of vivadiagtm covid-19 igm/igg rapid test is inadequate for diagnosis of covid-19 in acute patients referring to emergency room department",
    "label": "SUPPORTED",
    "evidences": [
      "On the basis of our results, VivaDiag COVID19 IgM/IgG Rapid Test LFIA is not recommended for triage of patients with suspected COVID19.",
      "Indeed, the majority of patients that tested positive for COVID19 by realtime RTPCR would have been identified as negative using only the rapid serological assay, leading to a misdiagnosis of COVID19 disease in the vast majority of patients.",
      "Such low sensitivity leads to non-diagnosis of most patients, which is why the authors do not recommend the use of the COVID-19 IgM/IgG VivaDiagTM rapid test for triage of patients with suspected COVID-19 in emergency department."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that the VivaDiag COVID-19 IgM/IgG Rapid Test has low sensitivity and would not identify most patients with COVID-19, leading to a misdiagnosis in the majority of cases. This suggests that the performance of this test is inadequate for diagnosis of COVID-19 in acute patients referring to emergency room departments.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000624",
    "statement": "Performance of vivadiagtm covid-19 igm/igg rapid test is useful for diagnosis of covid-19 in acute patients referring to emergency room department",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "On the basis of our results, VivaDiag COVID19 IgM/IgG Rapid Test LFIA is not recommended for triage of patients with suspected COVID19.",
      "Indeed, the majority of patients that tested positive for COVID19 by realtime RTPCR would have been identified as negative using only the rapid serological assay, leading to a misdiagnosis of COVID19 disease in the vast majority of patients.",
      "Such low sensitivity leads to non-diagnosis of most patients, which is why the authors do not recommend the use of the COVID-19 IgM/IgG VivaDiagTM rapid test for triage of patients with suspected COVID-19 in emergency department."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided indicates that the VivaDiag COVID-19 IgM/IgG Rapid Test has a low sensitivity and is not recommended for triage of patients with suspected COVID-19 in an emergency department setting due to its tendency to misdiagnose the disease. However, this does not necessarily mean that the test is not useful for diagnosis of COVID-19 in acute patients referring to the emergency room department. It merely suggests that it is not suitable for triage purposes in this context.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000625",
    "statement": "Performance of vivadiagtm covid-19 igm/igg rapid test is essential for diagnosis of covid-19 in acute patients referring to emergency room department",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "On the basis of our results, VivaDiag COVID19 IgM/IgG Rapid Test LFIA is not recommended for triage of patients with suspected COVID19.",
      "Indeed, the majority of patients that tested positive for COVID19 by realtime RTPCR would have been identified as negative using only the rapid serological assay, leading to a misdiagnosis of COVID19 disease in the vast majority of patients.",
      "Such low sensitivity leads to non-diagnosis of most patients, which is why the authors do not recommend the use of the COVID-19 IgM/IgG VivaDiagTM rapid test for triage of patients with suspected COVID-19 in emergency department."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided indicates that the VivaDiag COVID-19 IgM/IgG Rapid Test has low sensitivity and is not recommended for triage of patients with suspected COVID-19 in an emergency department setting. However, this does not mean that the test is essential for diagnosis of COVID-19 in acute patients referring to the emergency room department.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000626",
    "statement": "Performance of vivadiagtm covid-19 igm/igg rapid test is suitable for diagnosis of covid-19 in acute patients referring to emergency room department",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "On the basis of our results, VivaDiag COVID19 IgM/IgG Rapid Test LFIA is not recommended for triage of patients with suspected COVID19.",
      "Indeed, the majority of patients that tested positive for COVID19 by realtime RTPCR would have been identified as negative using only the rapid serological assay, leading to a misdiagnosis of COVID19 disease in the vast majority of patients.",
      "Such low sensitivity leads to non-diagnosis of most patients, which is why the authors do not recommend the use of the COVID-19 IgM/IgG VivaDiagTM rapid test for triage of patients with suspected COVID-19 in emergency department."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided indicates that the VivaDiag COVID-19 IgM/IgG Rapid Test is not recommended for triage of patients with suspected COVID-19 in emergency departments due to its low sensitivity, leading to a high risk of misdiagnosis. However, the evidence does not explicitly support or refute whether the test performance is suitable for diagnosis of COVID-19 in acute patients referring to emergency rooms.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000627",
    "statement": "Cetylpyridinium chloride-containing mouthwashes reduce in vitro sars-cov-2 infectivity.",
    "label": "SUPPORTED",
    "evidences": [
      "A common compound in mouthwashes found to inhibit SARS-CoV-2 in vitro.",
      "CPC- containing mouth rinses could represent a cost-effective measure to reduce SARS-CoV-2 infectivity in saliva, aiding to reduce viral transmission from infected individuals.",
      "Here we show that Cetylpyridinium chloride (CPC), a quaternary ammonium compound present in many oral mouthwashes, reduces SARS-CoV-2 infectivity by inhibiting viral fusion with target cells.",
      "\"A common compound in mouthwashes found to inhibit SARS- CoV-2 in vitro\".",
      "Antiviral activity of CPC-containing mouthwashes inhibiting SARS-CoV-2 entry."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided states that 'Cetylpyridinium chloride (CPC), a common compound in mouthwashes, reduces SARS-CoV-2 infectivity by inhibiting viral fusion with target cells'. This suggests that the claim is supported by the study showing CPC's ability to inhibit SARS-CoV-2 in vitro.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000628",
    "statement": "Cetylpyridinium chloride-containing mouthwashes with in vitro sars-cov-2 infectivity.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "A common compound in mouthwashes found to inhibit SARS-CoV-2 in vitro.",
      "CPC- containing mouth rinses could represent a cost-effective measure to reduce SARS-CoV-2 infectivity in saliva, aiding to reduce viral transmission from infected individuals.",
      "Here we show that Cetylpyridinium chloride (CPC), a quaternary ammonium compound present in many oral mouthwashes, reduces SARS-CoV-2 infectivity by inhibiting viral fusion with target cells.",
      "\"A common compound in mouthwashes found to inhibit SARS- CoV-2 in vitro\".",
      "Antiviral activity of CPC-containing mouthwashes inhibiting SARS-CoV-2 entry."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided states that 'A common compound in mouthwashes found to inhibit SARS-CoV-2 in vitro.' and later discusses how Cetylpyridinium chloride (CPC), a quaternary ammonium compound present in many oral mouthwashes, reduces SARS-CoV-2 infectivity. This directly supports the claim that Cetylpyridinium chloride-containing mouthwashes have been found to inhibit SARS-CoV-2 infectivity in vitro.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000629",
    "statement": "Symptom-based screening process was ineffective in detecting sars-cov-2 infection during evacuation of 126 people from wuhan , china .",
    "label": "SUPPORTED",
    "evidences": [
      "In fact, the researchers noted \"epidemiologic uncertainty regarding possible transmission of the virus by asymptomatic or subclinically symptomatic infected persons\" and that it is also not clear \"whether persons who show no signs or symptoms of respiratory infections shed SARS-CoV2.\"",
      "Aside from the ineffectiveness of the screening process, the authors found that the virus could potentially be spread by those who exhibited mild symptoms: Shedding of potentially infectious virus may occur in persons who have no fever and no signs or only minor signs of infection. Over 73,000 people around the world have been infected with the coronavirus, most of those cases in mainland China.",
      "Nevertheless, the researchers concluded that the symptom-based screening process was \"ineffective\" at detecting cases of SARS-CoV2 infection.",
      "In this effort to evacuate 126 people from Wuhan to Frankfurt, a symptom-based screening process was ineffective in detecting SARS-CoV-2 infection in 2 persons who later were found to have evidence of SARS-CoV-2 in a throat swab."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly states that the symptom-based screening process was 'ineffective' at detecting SARS-CoV-2 infection in some individuals, as demonstrated by the cases where infected persons showed no symptoms or only minor signs of infection. This is consistent with the claim.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000630",
    "statement": "Symptom-based screening process was successful in detecting sars-cov-2 infection during evacuation of 126 people from wuhan, china.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In fact, the researchers noted \"epidemiologic uncertainty regarding possible transmission of the virus by asymptomatic or subclinically symptomatic infected persons\" and that it is also not clear \"whether persons who show no signs or symptoms of respiratory infections shed SARS-CoV2.\"",
      "Aside from the ineffectiveness of the screening process, the authors found that the virus could potentially be spread by those who exhibited mild symptoms: Shedding of potentially infectious virus may occur in persons who have no fever and no signs or only minor signs of infection. Over 73,000 people around the world have been infected with the coronavirus, most of those cases in mainland China.",
      "Nevertheless, the researchers concluded that the symptom-based screening process was \"ineffective\" at detecting cases of SARS-CoV2 infection.",
      "In this effort to evacuate 126 people from Wuhan to Frankfurt, a symptom-based screening process was ineffective in detecting SARS-CoV-2 infection in 2 persons who later were found to have evidence of SARS-CoV-2 in a throat swab."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided indicates that the symptom-based screening process was ineffective in detecting SARS-CoV-2 infection in some cases during the evacuation of 126 people from Wuhan to Frankfurt. However, it does not directly support that the screening process was successful in any cases.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000631",
    "statement": "Symptom-based screening process was helpful in detecting sars-cov-2 infection during evacuation of 126 people from wuhan, china.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In fact, the researchers noted \"epidemiologic uncertainty regarding possible transmission of the virus by asymptomatic or subclinically symptomatic infected persons\" and that it is also not clear \"whether persons who show no signs or symptoms of respiratory infections shed SARS-CoV2.\"",
      "Aside from the ineffectiveness of the screening process, the authors found that the virus could potentially be spread by those who exhibited mild symptoms: Shedding of potentially infectious virus may occur in persons who have no fever and no signs or only minor signs of infection. Over 73,000 people around the world have been infected with the coronavirus, most of those cases in mainland China.",
      "Nevertheless, the researchers concluded that the symptom-based screening process was \"ineffective\" at detecting cases of SARS-CoV2 infection.",
      "In this effort to evacuate 126 people from Wuhan to Frankfurt, a symptom-based screening process was ineffective in detecting SARS-CoV-2 infection in 2 persons who later were found to have evidence of SARS-CoV-2 in a throat swab."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not support the claim that symptom-based screening process was helpful in detecting SARS-CoV-2 infection during evacuation of 126 people from Wuhan, China. Instead, it suggests that the symptom-based screening process was found to be 'ineffective' at detecting cases of SARS-CoV2 infection.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000632",
    "statement": "Symptom-based screening process was useful in detecting sars-cov-2 infection during evacuation of 126 people from wuhan, china.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In fact, the researchers noted \"epidemiologic uncertainty regarding possible transmission of the virus by asymptomatic or subclinically symptomatic infected persons\" and that it is also not clear \"whether persons who show no signs or symptoms of respiratory infections shed SARS-CoV2.\"",
      "Aside from the ineffectiveness of the screening process, the authors found that the virus could potentially be spread by those who exhibited mild symptoms: Shedding of potentially infectious virus may occur in persons who have no fever and no signs or only minor signs of infection. Over 73,000 people around the world have been infected with the coronavirus, most of those cases in mainland China.",
      "Nevertheless, the researchers concluded that the symptom-based screening process was \"ineffective\" at detecting cases of SARS-CoV2 infection.",
      "In this effort to evacuate 126 people from Wuhan to Frankfurt, a symptom-based screening process was ineffective in detecting SARS-CoV-2 infection in 2 persons who later were found to have evidence of SARS-CoV-2 in a throat swab."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided states that the symptom-based screening process was 'ineffective' at detecting SARS-CoV-2 infection and that it is not clear whether persons who show no signs or symptoms of respiratory infections shed SARS-CoV2. The fact that the screening process was found to be ineffective in detecting two cases among 126 people suggests that this method might not be reliable for detecting all infected individuals, particularly those who are asymptomatic or have mild symptoms.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000633",
    "statement": "Limited available evidence supports theoretical predictions of reduced vaccine efficacy at higher exposure dose",
    "label": "SUPPORTED",
    "evidences": [
      "Although our simulation showed that increasing pathogen challenge dose decreased vaccine efficacy, variance in susceptibility also affected vaccine protection."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence only shows that a simulation suggests reduced vaccine efficacy at higher exposure doses. However, it does not provide empirical or real-world data to support this claim. Variance in susceptibility was also mentioned as a factor affecting vaccine protection, but without specific data, it is unclear how significant this factor is in relation to the claim.",
    "confidence": 0.5
  },
  {
    "id": "covid_fact-000634",
    "statement": "Limited available evidence supports theoretical predictions of reduced vaccine efficacy at low exposure dose",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Although our simulation showed that increasing pathogen challenge dose decreased vaccine efficacy, variance in susceptibility also affected vaccine protection."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided only shows a correlation between increased pathogen challenge dose and decreased vaccine efficacy in a simulation. It does not provide sufficient data to support the claim that reduced vaccine efficacy occurs at low exposure doses.",
    "confidence": 0.5
  },
  {
    "id": "covid_fact-000635",
    "statement": "Sars-cov-2 antibody responses correlate with resolution of rnaemia but are short-lived in patients with mild illness",
    "label": "SUPPORTED",
    "evidences": [
      "Severely ill patients developed significantly higher SARS-CoV-2-specific antibody responses than outpatients and asymptomatic individuals."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided indicates that severely ill patients have higher SARS-CoV-2-specific antibody responses than outpatients and asymptomatic individuals. However, this does not directly support the claim that Sars-cov-2 antibody responses correlate with resolution of rnaemia (viremia) in patients with mild illness and are short-lived in such patients. More evidence is needed to address the duration of antibody response in patients with mild illness and its correlation with viremia resolution.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000636",
    "statement": "Sars-cov-2 antibody responses correlate with resolution of rnaemia but are long-lived in patients with mild illness",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Severely ill patients developed significantly higher SARS-CoV-2-specific antibody responses than outpatients and asymptomatic individuals."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence states that severely ill patients developed significantly higher SARS-CoV-2-specific antibody responses than outpatients and asymptomatic individuals, which suggests a correlation between the presence of these antibodies and disease severity. However, it does not provide information about whether these antibody responses correlate with resolution of viremia or are long-lived in patients with mild illness.",
    "confidence": 0.5
  },
  {
    "id": "covid_fact-000637",
    "statement": "Sars-cov-2 antibody responses correlate with resolution of rnaemia but are longer-lived in patients with mild illness",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Severely ill patients developed significantly higher SARS-CoV-2-specific antibody responses than outpatients and asymptomatic individuals."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence compares the antibody responses of severely ill patients to those who were asymptomatic or outpatients, but it does not directly show that the antibody responses correlate with resolution of viremia and are longer-lived in patients with mild illness. More specific evidence comparing these factors among patients with varying degrees of illness is needed.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000638",
    "statement": "Sars-cov-2 antibody responses correlate with resolution of rnaemia but are over-lived in patients with mild illness",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Severely ill patients developed significantly higher SARS-CoV-2-specific antibody responses than outpatients and asymptomatic individuals."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The given evidence shows that severely ill patients developed higher SARS-CoV-2-specific antibody responses than outpatients and asymptomatic individuals. However, it does not provide information about the correlation between these responses and resolution of RNAemia or their over-living in patients with mild illness.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000639",
    "statement": "Saliva is more sensitive for sars-cov-2 detection in covid-19 patients than nasopharyngeal swabs",
    "label": "SUPPORTED",
    "evidences": [
      "Saliva is a promising candidate for SARS-CoV-2 diagnostics because (1) collection is minimally invasive and can reliably be self-administered and (2) saliva has exhibited comparable sensitivity to nasopharyngeal swabs in detection of other respiratory pathogens, including endemic human coronaviruses, in previous studies.",
      "When we compared SARS-CoV-2 detection from patient-matched nasopharyngeal and saliva samples, we found that saliva yielded greater detection sensitivity and consistency throughout the course of infection.",
      "Taken together, our findings demonstrate that saliva is a viable and more sensitive alternative to nasopharyngeal swabs and could enable at-home self-administered sample collection for accurate large- scale SARS-CoV-2 testing.",
      "To validate the use of saliva for SARS-CoV-2 detection, we tested nasopharyngeal and saliva samples from confirmed COVID-19 patients and self-collected samples from healthcare workers on COVID-19 wards."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows that in a study comparing SARS-CoV-2 detection from patient-matched nasopharyngeal and saliva samples, saliva was found to yield greater detection sensitivity and consistency throughout the course of infection. This suggests that saliva is more sensitive for SARS-CoV-2 detection in COVID-19 patients than nasopharyngeal swabs.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000640",
    "statement": "Saliva is less sensitive for sars-cov-2 detection in covid-19 patients than nasopharyngeal swabs",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Saliva is a promising candidate for SARS-CoV-2 diagnostics because (1) collection is minimally invasive and can reliably be self-administered and (2) saliva has exhibited comparable sensitivity to nasopharyngeal swabs in detection of other respiratory pathogens, including endemic human coronaviruses, in previous studies.",
      "When we compared SARS-CoV-2 detection from patient-matched nasopharyngeal and saliva samples, we found that saliva yielded greater detection sensitivity and consistency throughout the course of infection.",
      "Taken together, our findings demonstrate that saliva is a viable and more sensitive alternative to nasopharyngeal swabs and could enable at-home self-administered sample collection for accurate large- scale SARS-CoV-2 testing.",
      "To validate the use of saliva for SARS-CoV-2 detection, we tested nasopharyngeal and saliva samples from confirmed COVID-19 patients and self-collected samples from healthcare workers on COVID-19 wards."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided states that saliva has demonstrated greater sensitivity and consistency in detecting SARS-CoV-2 compared to nasopharyngeal swabs, supporting the claim that saliva is less sensitive for SARS-CoV-2 detection in COVID-19 patients than nasopharyngeal swabs.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000641",
    "statement": "Vitamin d sufficiency reduced risk for morbidity and mortality in covid-19 patients",
    "label": "SUPPORTED",
    "evidences": [
      "This anti-inflammatory effect of vitamin D might prevent cytokine storm in COVID-19 patients and may explain the decreased risk of severity and mortality observed in our patients who were vitamin D sufficient.",
      "The severity of clinical outcomes from COVID-19 and mortality were reduced in patients who were vitamin D sufficient.",
      "Conclusion: Therefore, it is recommended that improving vitamin D status in the general population and in particular hospitalized patients has a potential benefit in reducing the severity of morbidities and mortality associated with acquiring COVID-19.",
      "Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides observational data showing that vitamin D sufficiency is associated with reduced severity of clinical outcomes and mortality in COVID-19 patients. It also suggests a potential mechanism (anti-inflammatory effect) for this observation. The claim aligns well with the information provided.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000642",
    "statement": "Vitamin d sufficiency increased risk for morbidity and mortality in covid-19 patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "This anti-inflammatory effect of vitamin D might prevent cytokine storm in COVID-19 patients and may explain the decreased risk of severity and mortality observed in our patients who were vitamin D sufficient.",
      "The severity of clinical outcomes from COVID-19 and mortality were reduced in patients who were vitamin D sufficient.",
      "Conclusion: Therefore, it is recommended that improving vitamin D status in the general population and in particular hospitalized patients has a potential benefit in reducing the severity of morbidities and mortality associated with acquiring COVID-19.",
      "Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows a correlation between Vitamin D sufficiency and reduced severity of clinical outcomes and mortality in COVID-19 patients. It also suggests that improving vitamin D status could potentially reduce the risk of morbidities and mortality associated with acquiring COVID-19.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000643",
    "statement": "Vitamin d sufficiency increasing risk for morbidity and mortality in covid-19 patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "This anti-inflammatory effect of vitamin D might prevent cytokine storm in COVID-19 patients and may explain the decreased risk of severity and mortality observed in our patients who were vitamin D sufficient.",
      "The severity of clinical outcomes from COVID-19 and mortality were reduced in patients who were vitamin D sufficient.",
      "Conclusion: Therefore, it is recommended that improving vitamin D status in the general population and in particular hospitalized patients has a potential benefit in reducing the severity of morbidities and mortality associated with acquiring COVID-19.",
      "Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests that vitamin D sufficiency may reduce the severity of clinical outcomes from COVID-19 and mortality. This is supported by the conclusion that improving vitamin D status in patients has a potential benefit in reducing the severity of morbidities and mortality associated with COVID-19. The additional evidence about vitamin D supplementation reducing the risk of influenza and COVID-19 infections and deaths further supports this claim.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000644",
    "statement": "Vitamin d sufficiency greater risk for morbidity and mortality in covid-19 patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "This anti-inflammatory effect of vitamin D might prevent cytokine storm in COVID-19 patients and may explain the decreased risk of severity and mortality observed in our patients who were vitamin D sufficient.",
      "The severity of clinical outcomes from COVID-19 and mortality were reduced in patients who were vitamin D sufficient.",
      "Conclusion: Therefore, it is recommended that improving vitamin D status in the general population and in particular hospitalized patients has a potential benefit in reducing the severity of morbidities and mortality associated with acquiring COVID-19.",
      "Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence presented suggests a correlation between Vitamin D sufficiency and reduced severity of clinical outcomes from COVID-19, including lower mortality rates. The studies indicate that vitamin D may prevent cytokine storms in COVID-19 patients, which could explain the observed decrease in risk of severity and mortality in vitamin D sufficient patients.",
    "confidence": 0.85
  },
  {
    "id": "covid_fact-000645",
    "statement": "A functional genomics approach to understand host genetic regulation of covid-19 severity",
    "label": "SUPPORTED",
    "evidences": [
      "A functional genomics investigation based on functional characterization of individuals with high genetic risk for severe COVID-19 susceptibility identified several major patterns: i. a large impact of genetically determined innate immune responses in COVID-19, with increased susceptibility for severe disease in individuals with defective monocyte-derived cytokine production; ii.",
      "Here, we employed the detailed clinical, immunological and multi-omics data of the Human Functional Genomics Projects (HFGP) to explore the physiological significance of the host genetic variants that influence susceptibility to severe COVID-19.",
      "Our findings allow a physiological understanding of genetic susceptibility to severe COVID-19, and indicate pathways that could be targeted for prevention and therapy."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided supports the claim as it describes a functional genomics investigation into understanding host genetic regulation of COVID-19 severity. The findings from this study identified patterns related to innate immune responses and cytokine production that are known to be important in severe COVID-19 cases, suggesting a link between genetics and susceptibility to severe disease.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000646",
    "statement": "A functional genomics approach to understand early genetic regulation of covid-19 severity",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "A functional genomics investigation based on functional characterization of individuals with high genetic risk for severe COVID-19 susceptibility identified several major patterns: i. a large impact of genetically determined innate immune responses in COVID-19, with increased susceptibility for severe disease in individuals with defective monocyte-derived cytokine production; ii.",
      "Here, we employed the detailed clinical, immunological and multi-omics data of the Human Functional Genomics Projects (HFGP) to explore the physiological significance of the host genetic variants that influence susceptibility to severe COVID-19.",
      "Our findings allow a physiological understanding of genetic susceptibility to severe COVID-19, and indicate pathways that could be targeted for prevention and therapy."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided describes a functional genomics investigation aimed at understanding the genetic regulation of COVID-19 severity. The study identifies patterns related to innate immune responses and cytokine production, which are directly relevant to the claimed understanding of early genetic regulation of COVID-19 severity.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000647",
    "statement": "A functional genomics approach to understand molecular genetic regulation of covid-19 severity",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "A functional genomics investigation based on functional characterization of individuals with high genetic risk for severe COVID-19 susceptibility identified several major patterns: i. a large impact of genetically determined innate immune responses in COVID-19, with increased susceptibility for severe disease in individuals with defective monocyte-derived cytokine production; ii.",
      "Here, we employed the detailed clinical, immunological and multi-omics data of the Human Functional Genomics Projects (HFGP) to explore the physiological significance of the host genetic variants that influence susceptibility to severe COVID-19.",
      "Our findings allow a physiological understanding of genetic susceptibility to severe COVID-19, and indicate pathways that could be targeted for prevention and therapy."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence presents a functional genomics investigation focusing on understanding the molecular genetic regulation of COVID-19 severity, specifically in individuals with high genetic risk for severe disease susceptibility. The approach involves characterizing the impact of genetically determined innate immune responses and identifying patterns in these individuals. These findings suggest a physiological understanding of genetic susceptibility to severe COVID-19, which aligns with the claim.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000648",
    "statement": "Repeated cross-sectional sero-monitoring of sars-cov-2 in new york city",
    "label": "SUPPORTED",
    "evidences": [
      "A serological assay to detect SARS-CoV-2 seroconversion in humans."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence indicates that a serological assay for SARS-CoV-2 is available, but it does not provide any information on the repeated cross-sectional monitoring of SARS-CoV-2 in New York City.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000649",
    "statement": "One cross-sectional sero-monitoring of sars-cov-2 in new york city",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "A serological assay to detect SARS-CoV-2 seroconversion in humans."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided only states the existence of a serological assay for SARS-CoV-2 detection in humans; it does not indicate that this specific assay was used in a cross-sectional study of New York City residents.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000650",
    "statement": "Patients in secret trials are successfully treated with hiv and malaria medication",
    "label": "SUPPORTED",
    "evidences": [
      "They were given HIV medication Kaletra and malaria treatment hydroxychloroquine in a secret trial.",
      "In a secret trial that was held, they were all given HIV medication, Kaletra and Malaria treatment hydroxychloroquine.",
      "The response involved testing a litany of drugs, including a combination of ritonavir and lopinavir, antiretroviral medications used to fight HIV."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided states that a secret trial was conducted where participants received both HIV medication (Kaletra) and malaria treatment (hydroxychloroquine). However, the evidence does not provide any data or results from this trial to support the claim that the patients were successfully treated with these medications for HIV and malaria.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000651",
    "statement": "Patients in secret trials are not treated with hiv and malaria medication",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "They were given HIV medication Kaletra and malaria treatment hydroxychloroquine in a secret trial.",
      "In a secret trial that was held, they were all given HIV medication, Kaletra and Malaria treatment hydroxychloroquine.",
      "The response involved testing a litany of drugs, including a combination of ritonavir and lopinavir, antiretroviral medications used to fight HIV."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided suggests that participants in the secret trial were given both HIV medication (Kaletra) and malaria treatment (hydroxychloroquine). However, without additional information about the nature of this trial, its objectives, and the context in which these medications were administered, it is not possible to definitively conclude that they were not treated for HIV or malaria.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000652",
    "statement": "Strong link found between abnormal liver tests and poor covid-19 outcomes",
    "label": "SUPPORTED",
    "evidences": [
      "Rather than the liver itself driving poorer outcomes in COVID-19 patients, the organ is more likely a bystander affected by the hyperinflammation associated with COVID-19 and by the side effects of related treatments, Nathanson said.",
      "But regardless of whether patients came to the hospital with existing liver problems or developed them during their COVID-19-related hospitalization, a strong association was observed between abnormal liver tests and the severity of the COVID-19 cases, the researchers said.",
      "The study noted a relationship between drugs used to treat severe COVID-19 and liver damage, most significantly the drug tocilizumab.",
      "We observed a strong association between the use of COVID-19 medications and abnormal liver tests, said Lim, but added that they could not confidently tease out that the abnormal tests were due to drug-induced liver injury as opposed to the disease."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests a strong association between abnormal liver tests and poor COVID-19 outcomes. While it is not explicitly stated that the liver itself drives poorer outcomes in COVID-19 patients, the association observed between abnormal liver tests and COVID-19 severity implies a link. Additionally, the study notes a relationship between drugs used to treat severe COVID-19 and liver damage, which further supports the claim.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000653",
    "statement": "Strong link found between abnormal liver tests and normal covid-19 outcomes",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Rather than the liver itself driving poorer outcomes in COVID-19 patients, the organ is more likely a bystander affected by the hyperinflammation associated with COVID-19 and by the side effects of related treatments, Nathanson said.",
      "But regardless of whether patients came to the hospital with existing liver problems or developed them during their COVID-19-related hospitalization, a strong association was observed between abnormal liver tests and the severity of the COVID-19 cases, the researchers said.",
      "The study noted a relationship between drugs used to treat severe COVID-19 and liver damage, most significantly the drug tocilizumab.",
      "We observed a strong association between the use of COVID-19 medications and abnormal liver tests, said Lim, but added that they could not confidently tease out that the abnormal tests were due to drug-induced liver injury as opposed to the disease."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states a strong association between abnormal liver tests and the severity of COVID-19 cases. It also mentions that certain medications used to treat severe COVID-19, such as tocilizumab, have been observed to be related to liver damage.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000654",
    "statement": "The sars-cov-2 cytopathic effect is blocked with autophagy modulators",
    "label": "SUPPORTED",
    "evidences": [
      "One Sentence Summary Blocking SARS-CoV-2 cytopathic effects with selective autophagy inhibitors underlying the clinical benefits of chloroquine and hydroxychloroquine.",
      "While it is known that chloroquine and hydroxychloroquine, extensively explored as clinical agents for COVID-19, have multiple cellular effects including inhibiting autophagy, there are also dose- limiting toxicities in patients that make clearly establishing their potential mechanisms-of-action problematic.",
      "Immunofluorescence staining for LC3B and LysoTracker dye staining assays in several cell lines indicated their potency and efficacy for inhibiting autophagy correlated with the measurements in the SARS-CoV-2 cytopathic effect assay."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests that chloroquine and hydroxychloroquine, which are being explored as clinical agents for COVID-19, have a mechanism of action involving the inhibition of autophagy and blocking SARS-CoV-2 cytopathic effects. However, it is important to note that this is based on in vitro studies and the potential benefits in patients need further investigation.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000655",
    "statement": "The sars-cov-2 cytopathic effect is compatible with autophagy modulators",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "One Sentence Summary Blocking SARS-CoV-2 cytopathic effects with selective autophagy inhibitors underlying the clinical benefits of chloroquine and hydroxychloroquine.",
      "While it is known that chloroquine and hydroxychloroquine, extensively explored as clinical agents for COVID-19, have multiple cellular effects including inhibiting autophagy, there are also dose- limiting toxicities in patients that make clearly establishing their potential mechanisms-of-action problematic.",
      "Immunofluorescence staining for LC3B and LysoTracker dye staining assays in several cell lines indicated their potency and efficacy for inhibiting autophagy correlated with the measurements in the SARS-CoV-2 cytopathic effect assay."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests that inhibiting autophagy (a process) can block the SARS-CoV-2 cytopathic effect (damage caused to cells by the virus), which is compatible with the claim. The evidence further supports this by showing that chloroquine and hydroxychloroquine, known to inhibit autophagy, have potential benefits in COVID-19 treatment.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000656",
    "statement": "The sars-cov-2 cytopathic effect is achieved with autophagy modulators",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "One Sentence Summary Blocking SARS-CoV-2 cytopathic effects with selective autophagy inhibitors underlying the clinical benefits of chloroquine and hydroxychloroquine.",
      "While it is known that chloroquine and hydroxychloroquine, extensively explored as clinical agents for COVID-19, have multiple cellular effects including inhibiting autophagy, there are also dose- limiting toxicities in patients that make clearly establishing their potential mechanisms-of-action problematic.",
      "Immunofluorescence staining for LC3B and LysoTracker dye staining assays in several cell lines indicated their potency and efficacy for inhibiting autophagy correlated with the measurements in the SARS-CoV-2 cytopathic effect assay."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests that blocking the SARS-CoV-2 cytopathic effects is achieved with selective autophagy inhibitors, and chloroquine and hydroxychloroquine are mentioned as such inhibitors. Therefore, it is supported that the SARS-CoV-2 cytopathic effect can be modulated with autophagy modulators.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000657",
    "statement": "The sars-cov-2 cytopathic effect is induced with autophagy modulators",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "One Sentence Summary Blocking SARS-CoV-2 cytopathic effects with selective autophagy inhibitors underlying the clinical benefits of chloroquine and hydroxychloroquine.",
      "While it is known that chloroquine and hydroxychloroquine, extensively explored as clinical agents for COVID-19, have multiple cellular effects including inhibiting autophagy, there are also dose- limiting toxicities in patients that make clearly establishing their potential mechanisms-of-action problematic.",
      "Immunofluorescence staining for LC3B and LysoTracker dye staining assays in several cell lines indicated their potency and efficacy for inhibiting autophagy correlated with the measurements in the SARS-CoV-2 cytopathic effect assay."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that blocking the SARS-CoV-2 cytopathic effects (damage to cells caused by the virus) can be achieved with selective autophagy inhibitors. Autophagy is a cellular process that degrades and recycles damaged or foreign materials, and it has been shown that chloroquine and hydroxychloroquine, which have been explored as potential treatments for COVID-19, can inhibit this process. The evidence also suggests that the inhibition of autophagy correlates with the reduction in SARS-CoV-2 cytopathic effect.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000658",
    "statement": "Regn-cov2 antibodies prevent and treat sars-cov-2 infection in rhesus macaques and hamsters",
    "label": "SUPPORTED",
    "evidences": [
      "D. H. Barouch , DNA vaccine protection against SARS-CoV-2 in rhesus macaques."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided states that a DNA vaccine was effective in preventing SARS-CoV-2 infection in rhesus macaques. However, it does not explicitly state whether the antibodies generated by the vaccine can treat an existing infection.",
    "confidence": 0.7
  },
  {
    "id": "covid_fact-000659",
    "statement": "Pn-cov2 antibodies prevent and treat sars-cov-2 infection in rhesus macaques and hamsters",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "D. H. Barouch , DNA vaccine protection against SARS-CoV-2 in rhesus macaques."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence only states that a DNA vaccine was effective in preventing SARS-CoV-2 infection in rhesus macaques. It does not specify if Pn-cov2 antibodies were the ones responsible for this protection.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000660",
    "statement": "Bn-cov2 antibodies prevent and treat sars-cov-2 infection in rhesus macaques and hamsters",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "D. H. Barouch , DNA vaccine protection against SARS-CoV-2 in rhesus macaques."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided only states that a DNA vaccine provides protection against SARS-CoV-2 in rhesus macaques. It does not explicitly state whether Bn-cov2 antibodies prevent and treat sars-cov-2 infection in the same animals or hamsters.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000661",
    "statement": "Hn-cov2 antibodies prevent and treat sars-cov-2 infection in rhesus macaques and hamsters",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "D. H. Barouch , DNA vaccine protection against SARS-CoV-2 in rhesus macaques."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided only states that a DNA vaccine provides protection against SARS-CoV-2 in rhesus macaques. It does not directly provide information on whether Hn-cov2 antibodies specifically prevent and treat SARS-CoV-2 infection.",
    "confidence": 0.6
  },
  {
    "id": "covid_fact-000662",
    "statement": "Sars-cov-2 genome evolution exposes early human adaptations",
    "label": "SUPPORTED",
    "evidences": [
      "SUMMARY In this study we sought signals of evolution to identify how the SARS-CoV-2 genome has adapted at the outset of the COVID-19 pandemic."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim is that the SARS-CoV-2 genome evolution reveals early human adaptations, but the evidence only provides information about the adaptation of the virus itself during the pandemic, not any human adaptations.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000663",
    "statement": "Sars-cov-2 genome evolution exposes early human infection",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "SUMMARY In this study we sought signals of evolution to identify how the SARS-CoV-2 genome has adapted at the outset of the COVID-19 pandemic."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The given evidence focuses on the investigation of SARS-CoV-2 genome adaptation at the outset of the COVID-19 pandemic, which does not necessarily imply early human infection. While it can give insights into viral evolution within a human population, there's no direct evidence provided to support that the virus was found in humans earlier than known.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000664",
    "statement": "Sars-cov-2 genome evolution exposes early human infections",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "SUMMARY In this study we sought signals of evolution to identify how the SARS-CoV-2 genome has adapted at the outset of the COVID-19 pandemic."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is supported by the evidence because the study aimed to identify how SARS-CoV-2 genome has adapted at the outset of the COVID-19 pandemic. This implies that early human infections were indeed involved in its evolution.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000665",
    "statement": "Sars-cov-2 genome evolution exposes early genes adaptations",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "SUMMARY In this study we sought signals of evolution to identify how the SARS-CoV-2 genome has adapted at the outset of the COVID-19 pandemic."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided in this claim explicitly states that the SARS-CoV-2 genome has been studied for adaptations at the outset of the COVID-19 pandemic. Therefore, it supports the claim that the evolution of the SARS-CoV-2 genome exposes early genes adaptations.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000666",
    "statement": "Research by tennessee scientists at oak ridge labs on existing drug compounds via supercomputing could combat coronavirus .",
    "label": "SUPPORTED",
    "evidences": [
      "Oak Ridge National Laboratory scientists have focused the power of the world's fastest supercomputer to search for an existing drug that can prevent the new coronavirus from penetrating human cells.",
      "The Oak Ridge National Laboratory in Tennessee (one member of the consortium) is using its supercomputers to look for compounds already on the market that might foil the virus.",
      "Oak Ridge National Laboratory, where Summit is housed, recently granted researchers emergency computation time to run through a database of existing drug compounds to see which combinations might prevent cell infection of COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests that Oak Ridge National Laboratory scientists in Tennessee are using supercomputers to search for existing drug compounds that could combat the coronavirus. This aligns with the claim that research by Tennessee scientists at Oak Ridge Labs on existing drug compounds via supercomputing could combat coronavirus.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000667",
    "statement": "Research by chinese scientists at oak ridge labs on existing drug compounds via supercomputing could combat coronavirus.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Oak Ridge National Laboratory scientists have focused the power of the world's fastest supercomputer to search for an existing drug that can prevent the new coronavirus from penetrating human cells.",
      "The Oak Ridge National Laboratory in Tennessee (one member of the consortium) is using its supercomputers to look for compounds already on the market that might foil the virus.",
      "Oak Ridge National Laboratory, where Summit is housed, recently granted researchers emergency computation time to run through a database of existing drug compounds to see which combinations might prevent cell infection of COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided mentions that Oak Ridge National Laboratory scientists are focusing on using the world's fastest supercomputer to search for existing drug compounds that might combat the coronavirus. This aligns with the claim that research by Chinese scientists at Oak Ridge Labs on existing drug compounds via supercomputing could potentially combat coronavirus.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000668",
    "statement": "Broad host range of sars-cov-2 predicted by comparative and structural analysis of ace2 in vertebrates",
    "label": "SUPPORTED",
    "evidences": [
      "We identified a large number of mammals that can potentially be infected by SARS-CoV-2 via their ACE2 proteins.",
      "To identify candidate intermediate host species and species at risk for SARS-CoV-2 infection, we undertook a deep comparative genomic, evolutionary, and structural analysis of ACE2, which serves as the SARS-CoV-2 receptor in humans.",
      "Comparative analysis of ACE2 protein sequences can be used to predict their ability to bind SARS-CoV-2 S (2) and therefore may yield important insights into the biology and potential zoonotic transmission of SARS-CoV-2 infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates a study that analyzed ACE2 proteins in various mammals to predict their ability to bind SARS-CoV-2 and potentially be infected by it. This suggests a broad host range of SARS-CoV-2 based on comparative and structural analysis of ACE2 in vertebrates.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000669",
    "statement": "Broad host range of sars-cov-2 predicted by comparative and structural analysis of fpr2 in vertebrates",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We identified a large number of mammals that can potentially be infected by SARS-CoV-2 via their ACE2 proteins.",
      "To identify candidate intermediate host species and species at risk for SARS-CoV-2 infection, we undertook a deep comparative genomic, evolutionary, and structural analysis of ACE2, which serves as the SARS-CoV-2 receptor in humans.",
      "Comparative analysis of ACE2 protein sequences can be used to predict their ability to bind SARS-CoV-2 S (2) and therefore may yield important insights into the biology and potential zoonotic transmission of SARS-CoV-2 infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that a comparative analysis of ACE2 proteins in various mammals has been done to predict their ability to bind SARS-CoV-2 S protein. This analysis is used to infer potential for zoonotic transmission of SARS-CoV-2 infection, thus supporting the claim that the broad host range of SARS-CoV-2 can be predicted by comparative and structural analysis of ACE2 in vertebrates.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000670",
    "statement": "Broad host range of sars-cov-2 predicted by comparative and structural analysis of tmprss2 in vertebrates",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We identified a large number of mammals that can potentially be infected by SARS-CoV-2 via their ACE2 proteins.",
      "To identify candidate intermediate host species and species at risk for SARS-CoV-2 infection, we undertook a deep comparative genomic, evolutionary, and structural analysis of ACE2, which serves as the SARS-CoV-2 receptor in humans.",
      "Comparative analysis of ACE2 protein sequences can be used to predict their ability to bind SARS-CoV-2 S (2) and therefore may yield important insights into the biology and potential zoonotic transmission of SARS-CoV-2 infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is supported by the evidence provided. The evidence indicates that a comparative analysis of ACE2 proteins across various mammals was conducted to predict their ability to bind SARS-CoV-2 S protein. This analysis can indeed be used to predict potential hosts for SARS-CoV-2 infection, thus supporting the claim.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000671",
    "statement": "Broad host range of sars-cov-2 predicted by comparative and structural analysis of ns2 in vertebrates",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We identified a large number of mammals that can potentially be infected by SARS-CoV-2 via their ACE2 proteins.",
      "To identify candidate intermediate host species and species at risk for SARS-CoV-2 infection, we undertook a deep comparative genomic, evolutionary, and structural analysis of ACE2, which serves as the SARS-CoV-2 receptor in humans.",
      "Comparative analysis of ACE2 protein sequences can be used to predict their ability to bind SARS-CoV-2 S (2) and therefore may yield important insights into the biology and potential zoonotic transmission of SARS-CoV-2 infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is supported by the evidence provided. The evidence shows a deep comparative genomic and evolutionary analysis of ACE2 proteins which serves as the SARS-CoV-2 receptor in humans. This analysis aims to predict potential binding with SARS-CoV-2 S, providing insights into the biology and potential zoonotic transmission of SARS-CoV-2 infection. The identification of a large number of mammals that can potentially be infected by SARS-CoV-2 via their ACE2 proteins also supports this claim.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000672",
    "statement": "Man behind sweden 's controversial virus strategy admits mistakes",
    "label": "SUPPORTED",
    "evidences": [
      "Wednesday 3 June 2020 17:07, UK COVID-19 Coronavirus Image: People walk down a high street in Stockholm in May image/svg+xml Why you can trust Sky News Sweden should have done more to combat coronavirus to prevent it having a much higher national death rate than neighbouring countries, the man behind the country's pandemic strategy has said."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence does not explicitly state who the 'man behind Sweden's controversial virus strategy' is, nor does it provide any information about specific mistakes made in relation to that individual.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000673",
    "statement": "Not behind sweden's controversial virus strategy admits mistakes",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Wednesday 3 June 2020 17:07, UK COVID-19 Coronavirus Image: People walk down a high street in Stockholm in May image/svg+xml Why you can trust Sky News Sweden should have done more to combat coronavirus to prevent it having a much higher national death rate than neighbouring countries, the man behind the country's pandemic strategy has said."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that Sweden's pandemic strategy was criticized for having a higher national death rate than neighboring countries, and the person behind the strategy admitted that more should have been done to combat coronavirus. This indicates that mistakes were made in the implementation of Sweden's virus strategy.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000674",
    "statement": "Wearing eyeglasses protects against sars-cov-2",
    "label": "SUPPORTED",
    "evidences": [
      "Therefore, it is likely that wearing eyeglasses may have a protective effect by reducing the chance of viral entry through the eyes.",
      "Wearing eyeglasses prevent people from frequently touching their eyes, thereby reducing the chance of hand-to-eye transmission of SARS-CoV-2."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that wearing eyeglasses can reduce the chance of hand-to-eye transmission of SARS-CoV-2 by preventing people from frequently touching their eyes. While it doesn't directly prove that eyeglasses protect against infection, the reasoning is plausible as it reduces one potential route for virus entry.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000675",
    "statement": "Wearing eyeglasses protects by sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Therefore, it is likely that wearing eyeglasses may have a protective effect by reducing the chance of viral entry through the eyes.",
      "Wearing eyeglasses prevent people from frequently touching their eyes, thereby reducing the chance of hand-to-eye transmission of SARS-CoV-2."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that wearing eyeglasses can reduce the chance of hand-to-eye transmission of SARS-CoV-2 by preventing people from frequently touching their eyes. While it doesn't explicitly state that glasses protect against viral entry through the eyes, this is a reasonable inference based on the principle of reducing potential points of contact with the virus.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000676",
    "statement": "Wearing eyeglasses exposed against sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Therefore, it is likely that wearing eyeglasses may have a protective effect by reducing the chance of viral entry through the eyes.",
      "Wearing eyeglasses prevent people from frequently touching their eyes, thereby reducing the chance of hand-to-eye transmission of SARS-CoV-2."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that wearing eyeglasses may help reduce the chance of viral entry through the eyes and also prevent frequent touching of the eyes, thereby reducing hand-to-eye transmission of SARS-CoV-2.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000677",
    "statement": "Butantan vaccine reaches the final stage",
    "label": "SUPPORTED",
    "evidences": [
      "By Dorah Feliciano \\- November 24, 2020 Facebook Twitter Linkedin WhatsApp Email [uamad id=\"317182\"] RIO DE JANEIRO, BRAZIL - The clinical trial of CoronaVac, the vaccine developed by the Butantan Institute in partnership with biopharmaceutical company Sinovac Life Science, has reached its final stage.",
      "According to information from the S\u00e3o Paulo government and Butantan Institute, results should come out in the first week of December, with 46 million doses likely to be available by January 2021."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly states that the clinical trial of CoronaVac vaccine has reached its final stage as stated by Dorah Feliciano and the S\u00e3o Paulo government. The date for results is expected in the first week of December and the availability of doses by January 2021.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000678",
    "statement": "Butantan vaccine reaches the first stage",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "By Dorah Feliciano \\- November 24, 2020 Facebook Twitter Linkedin WhatsApp Email [uamad id=\"317182\"] RIO DE JANEIRO, BRAZIL - The clinical trial of CoronaVac, the vaccine developed by the Butantan Institute in partnership with biopharmaceutical company Sinovac Life Science, has reached its final stage.",
      "According to information from the S\u00e3o Paulo government and Butantan Institute, results should come out in the first week of December, with 46 million doses likely to be available by January 2021."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that the clinical trial of CoronaVac, a vaccine developed by Butantan Institute and Sinovac Life Science, has reached its final stage. Therefore, it can be inferred that the claim is supported.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000679",
    "statement": "Butantan vaccine reaches the challenge stage",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "By Dorah Feliciano \\- November 24, 2020 Facebook Twitter Linkedin WhatsApp Email [uamad id=\"317182\"] RIO DE JANEIRO, BRAZIL - The clinical trial of CoronaVac, the vaccine developed by the Butantan Institute in partnership with biopharmaceutical company Sinovac Life Science, has reached its final stage.",
      "According to information from the S\u00e3o Paulo government and Butantan Institute, results should come out in the first week of December, with 46 million doses likely to be available by January 2021."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that the clinical trial of CoronaVac, the vaccine developed by the Butantan Institute, has reached its final stage. The sentence 'clinical trial of CoronaVac has reached its final stage' implies that the vaccine is in the challenge stage.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000680",
    "statement": "Butantan vaccine reaches the second stage",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "By Dorah Feliciano \\- November 24, 2020 Facebook Twitter Linkedin WhatsApp Email [uamad id=\"317182\"] RIO DE JANEIRO, BRAZIL - The clinical trial of CoronaVac, the vaccine developed by the Butantan Institute in partnership with biopharmaceutical company Sinovac Life Science, has reached its final stage.",
      "According to information from the S\u00e3o Paulo government and Butantan Institute, results should come out in the first week of December, with 46 million doses likely to be available by January 2021."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that the clinical trial of CoronaVac vaccine has reached its final stage, indicating that it is in the second stage of development.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000681",
    "statement": "Adaptive immune responses to sars-cov-2 in recovered severe covid-19 patients.",
    "label": "SUPPORTED",
    "evidences": [
      "Sequencing and functional data revealed SARS-CoV-2-specific T-cell immune memory in the convalescent COVID-19 patients.",
      "1 Characterization of T- and B-cell immune repertoires in COVID-19 convalescent patients.",
      "Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals.",
      "Longitudinal Analysis of T and B Cell Receptor Repertoire Transcripts Reveal Dynamic Immune Response in COVID-19 Patients.",
      "Rapid detection of SARS-CoV-2-specific memory T-cell immunity in recovered COVID-19 cases."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates the presence of adaptive immune responses to SARS-CoV-2 in recovered severe COVID-19 patients, specifically mentioning T-cell and humoral immunity. Additionally, the evidence discusses a dynamic immune response over time, which further supports this claim.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000682",
    "statement": "No immune responses to sars-cov-2 in recovered severe covid-19 patients.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Sequencing and functional data revealed SARS-CoV-2-specific T-cell immune memory in the convalescent COVID-19 patients.",
      "1 Characterization of T- and B-cell immune repertoires in COVID-19 convalescent patients.",
      "Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals.",
      "Longitudinal Analysis of T and B Cell Receptor Repertoire Transcripts Reveal Dynamic Immune Response in COVID-19 Patients.",
      "Rapid detection of SARS-CoV-2-specific memory T-cell immunity in recovered COVID-19 cases."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided shows that SARS-CoV-2-specific T-cell immune memory is present in convalescent COVID-19 patients, which contradicts the claim that there are no immune responses to sars-cov-2 in recovered severe covid-19 patients.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000683",
    "statement": "Estimated sars-cov-2 seroprevalence in the us",
    "label": "SUPPORTED",
    "evidences": [
      "Community prevalence of SARS-CoV-2 among patients with influenzalike illnesses presenting to a Los Angeles medical center in March 2020."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided refers to the prevalence of SARS-CoV-2 among patients with influenza-like illnesses at a single medical center in Los Angeles in March 2020. This does not directly provide information about the estimated seroprevalence in the entire US population.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000684",
    "statement": "Estimated pcvs-cov-2 seroprevalence in the us",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Community prevalence of SARS-CoV-2 among patients with influenzalike illnesses presenting to a Los Angeles medical center in March 2020."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The given evidence describes the community prevalence of SARS-CoV-2 among patients with influenza-like illnesses at a specific medical center in Los Angeles during March 2020. This does not directly provide an estimation of the overall seroprevalence (antibody prevalence) of COVID-19 in the entire United States population.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000685",
    "statement": "Estimated cpvs-cov-2 seroprevalence in the us",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Community prevalence of SARS-CoV-2 among patients with influenzalike illnesses presenting to a Los Angeles medical center in March 2020."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence only discusses community prevalence of SARS-CoV-2 among patients with influenza-like illnesses in a specific medical center in Los Angeles during March 2020. This does not directly indicate the estimated seroprevalence (the proportion of people who have antibodies for a specific disease, indicating previous infection) of SARS-CoV-2 in the entire United States.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000686",
    "statement": "Estimated xs-cov-2 seroprevalence in the us",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Community prevalence of SARS-CoV-2 among patients with influenzalike illnesses presenting to a Los Angeles medical center in March 2020."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence is limited to a specific location (a Los Angeles medical center) and a specific time period (March 2020). It does not provide sufficient data to estimate the seroprevalence of SARS-CoV-2 across the entire United States.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000687",
    "statement": "Intranasal chadox1 ncov-19/azd1222 vaccination reduces shedding of sars-cov-2 d614g in rhesus macaques.",
    "label": "SUPPORTED",
    "evidences": [
      "Intranasal vaccination of rhesus macaques resulted in reduced shedding and a reduction in viral load in bronchoalveolar lavage and lower respiratory tract tissue.",
      "Here we investigate whether intranasally administered ChAdOx1 nCoV-19 reduces shedding, using a SARS-CoV-2 virus with the D614G mutation in the spike protein.",
      "In conclusion, intranasal vaccination reduced shedding in two different SARS-CoV-2 animal models, justifying further investigation as a potential vaccination route for COVID-19 vaccines."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that intranasal vaccination of rhesus macaques resulted in reduced shedding and a reduction in viral load in bronchoalveolar lavage and lower respiratory tract tissue. It also mentions the use of SARS-CoV-2 virus with the D614G mutation in the spike protein, which is similar to ChAdOx1 nCoV-19 vaccine. Therefore, it can be inferred that the claim is supported as the evidence indicates a reduction in shedding due to intranasal administration of a similar SARS-CoV-2 virus.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000688",
    "statement": "Intranasal chadox1 ncov-19/azd1222 vaccination increased shedding of sars-cov-2 d614g in rhesus macaques.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Intranasal vaccination of rhesus macaques resulted in reduced shedding and a reduction in viral load in bronchoalveolar lavage and lower respiratory tract tissue.",
      "Here we investigate whether intranasally administered ChAdOx1 nCoV-19 reduces shedding, using a SARS-CoV-2 virus with the D614G mutation in the spike protein.",
      "In conclusion, intranasal vaccination reduced shedding in two different SARS-CoV-2 animal models, justifying further investigation as a potential vaccination route for COVID-19 vaccines."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not explicitly mention the shedding of SARS-CoV-2 d614g in rhesus macaques after intranasal ChAdOx1 nCoV-19/azd1222 vaccination. Instead, it indicates a reduction in shedding and viral load for two different SARS-CoV-2 animal models overall.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000689",
    "statement": "Intranasal chadox1 ncov-19/azd1222 vaccination enhanced shedding of sars-cov-2 d614g in rhesus macaques.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Intranasal vaccination of rhesus macaques resulted in reduced shedding and a reduction in viral load in bronchoalveolar lavage and lower respiratory tract tissue.",
      "Here we investigate whether intranasally administered ChAdOx1 nCoV-19 reduces shedding, using a SARS-CoV-2 virus with the D614G mutation in the spike protein.",
      "In conclusion, intranasal vaccination reduced shedding in two different SARS-CoV-2 animal models, justifying further investigation as a potential vaccination route for COVID-19 vaccines."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that the intranasal vaccination of rhesus macaques resulted in reduced shedding of SARS-CoV-2 virus, specifically mentioning a strain with the D614G mutation in the spike protein which is relevant to ChAdOx1 nCoV-19/azd1222 vaccine. The conclusion also supports this finding.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000690",
    "statement": "Intranasal chadox1 ncov-19/azd1222 vaccination caused shedding of sars-cov-2 d614g in rhesus macaques.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Intranasal vaccination of rhesus macaques resulted in reduced shedding and a reduction in viral load in bronchoalveolar lavage and lower respiratory tract tissue.",
      "Here we investigate whether intranasally administered ChAdOx1 nCoV-19 reduces shedding, using a SARS-CoV-2 virus with the D614G mutation in the spike protein.",
      "In conclusion, intranasal vaccination reduced shedding in two different SARS-CoV-2 animal models, justifying further investigation as a potential vaccination route for COVID-19 vaccines."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that intranasal administration of ChAdOx1 nCoV-19 vaccine reduced shedding in two different SARS-CoV-2 animal models. The key point here is 'reduced shedding', which refers to the reduction or absence of viral particles being expelled from the body, such as through the nose or mouth. The paper also mentions that they used a SARS-CoV-2 virus with the D614G mutation in the spike protein, which is relevant to the claim about SARS-CoV-2. Therefore, the evidence supports the claim that intranasal Chadox1 ncov-19/azd1222 vaccination caused shedding of sars-cov-2 d614g in rhesus macaques.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000691",
    "statement": "Massive and rapid covid-19 testing is feasible by extraction-free sars-cov-2 rt-qpcr",
    "label": "SUPPORTED",
    "evidences": [
      "Extraction-free COVID-19 (SARS-CoV-2) diagnosis by RT-PCR to increase capacity for national testing programmes during a pandemic.",
      "Massive and rapid COVID-19 testing is feasible by extraction-free SARS-CoV-2 RT-PCR."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly states that massive and rapid COVID-19 testing is possible by using extraction-free SARS-CoV-2 RT-PCR.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000692",
    "statement": "Massive and rapid covid-19 testing is feasible by extraction-specific sars-cov-2 rt-qpcr",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Extraction-free COVID-19 (SARS-CoV-2) diagnosis by RT-PCR to increase capacity for national testing programmes during a pandemic.",
      "Massive and rapid COVID-19 testing is feasible by extraction-free SARS-CoV-2 RT-PCR."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests that massive and rapid COVID-19 testing can be feasible using extraction-free SARS-CoV-2 RT-PCR. The statement in the evidence that 'extraction-free COVID-19 (SARS-CoV-2) diagnosis by RT-PCR to increase capacity for national testing programs during a pandemic' directly supports this claim.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000693",
    "statement": "Massive and rapid covid-19 testing is feasible by extraction-based sars-cov-2 rt-qpcr",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Extraction-free COVID-19 (SARS-CoV-2) diagnosis by RT-PCR to increase capacity for national testing programmes during a pandemic.",
      "Massive and rapid COVID-19 testing is feasible by extraction-free SARS-CoV-2 RT-PCR."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that rapid COVID-19 testing is feasible using extraction-free SARS-CoV-2 RT-PCR, as it can potentially increase capacity for national testing programs during a pandemic.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000694",
    "statement": "Massive and rapid covid-19 testing is feasible by extraction-2 sars-cov-2 rt-qpcr",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Extraction-free COVID-19 (SARS-CoV-2) diagnosis by RT-PCR to increase capacity for national testing programmes during a pandemic.",
      "Massive and rapid COVID-19 testing is feasible by extraction-free SARS-CoV-2 RT-PCR."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim states that 'Massive and rapid COVID-19 testing is feasible by extraction-2 sars-cov-2 rt-qpcr'. The evidence provides a solution for increasing capacity in national testing programs during a pandemic using extraction-free SARS-CoV-2 RT-PCR. Therefore, the claim is supported as it suggests that rapid and massive testing can be achieved through this method.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000695",
    "statement": "Dutch scientists find new role for ace2 receptors in covid disease process",
    "label": "SUPPORTED",
    "evidences": [
      "(21,22) The protease TMPRSS2 produced by the host cells plays an important role in proteolytic processing of S protein priming to the receptor ACE2 binding in human cells."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that the ACE2 receptors play a role in SARS-CoV-2 entry into human cells, which is crucial for COVID-19 disease process. While the evidence does not explicitly mention 'Dutch scientists', it provides research on the role of ACE2 receptors in the COVID-19 disease process.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000696",
    "statement": "Dutch models find new role for ace2 receptors in covid disease process",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "(21,22) The protease TMPRSS2 produced by the host cells plays an important role in proteolytic processing of S protein priming to the receptor ACE2 binding in human cells."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided describes a role for TMPRSS2 in S protein processing and ACE2 binding in human cells, but it does not directly support the claim that Dutch models have found a new role for ace2 receptors in the COVID disease process.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000697",
    "statement": "Ohio health official estimates 100,000 people in state have coronavirus",
    "label": "SUPPORTED",
    "evidences": [
      "Mike DeWineMike DeWineRepublicans eye primaries in impeachment vote Shellshocked GOP ponders future with Trump Governors respond to violence at Capitol MORE (R) that given that the virus is spreading in the community in Ohio, she estimates at least 1 percent of the population in the state has the virus.",
      "\"We know now, just the fact of community spread, says that at least 1 percent, at the very least, 1 percent of our population is carrying this virus in Ohio today,\" Acton said."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim 'Ohio health official estimates 100,000 people in state have coronavirus' is supported by the provided evidence. The evidence states that Acton, an Ohio health official, estimates that at least 1% of the population in the state has the virus. Given that the current estimated population of Ohio (approximately 11.7 million people), this would equate to approximately 117,000 people.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000698",
    "statement": "Ohio health official estimates 1,000 people in state have coronavirus",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Mike DeWineMike DeWineRepublicans eye primaries in impeachment vote Shellshocked GOP ponders future with Trump Governors respond to violence at Capitol MORE (R) that given that the virus is spreading in the community in Ohio, she estimates at least 1 percent of the population in the state has the virus.",
      "\"We know now, just the fact of community spread, says that at least 1 percent, at the very least, 1 percent of our population is carrying this virus in Ohio today,\" Acton said."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is based on an estimate provided by a health official (Acton) regarding the spread of the virus in Ohio and her belief that at least 1% of the population has the virus due to community spread.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000699",
    "statement": "Ohio health official estimates 2,000 people in state have coronavirus",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Mike DeWineMike DeWineRepublicans eye primaries in impeachment vote Shellshocked GOP ponders future with Trump Governors respond to violence at Capitol MORE (R) that given that the virus is spreading in the community in Ohio, she estimates at least 1 percent of the population in the state has the virus.",
      "\"We know now, just the fact of community spread, says that at least 1 percent, at the very least, 1 percent of our population is carrying this virus in Ohio today,\" Acton said."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is supported by the evidence because the Ohio health official estimates that at least 1% of the population in the state has the virus due to community spread. Given that 1% of the population of Ohio is approximately 2,000 people for every 100,000 people, this estimate translates to around 2,000 people based on the current population of Ohio.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000700",
    "statement": "Ohio health official estimates 15,000 people in state have coronavirus",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Mike DeWineMike DeWineRepublicans eye primaries in impeachment vote Shellshocked GOP ponders future with Trump Governors respond to violence at Capitol MORE (R) that given that the virus is spreading in the community in Ohio, she estimates at least 1 percent of the population in the state has the virus.",
      "\"We know now, just the fact of community spread, says that at least 1 percent, at the very least, 1 percent of our population is carrying this virus in Ohio today,\" Acton said."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is supported by the evidence as the health official estimates at least 1 percent of the population in Ohio has the virus. Given that community spread implies cases not all linked to known contacts or travel, this suggests there are people with the virus who have not been tested. The total percentage of the population of Ohio is approximately 1%, so multiplying this by the state's population would result in an estimate of around 15,000 people.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000701",
    "statement": "Google releases covid-19 community mobility reports in an effort to show local movement trends during pandemic",
    "label": "SUPPORTED",
    "evidences": [
      "The reports consist of per country, or per state, downloads (with 131 countries covered initially), further broken down into regions/counties -- with Google offering an analysis of how community mobility has changed vs a baseline average before COVID-19 arrived to change everything.",
      "In response to feedback from public health officials that data could be helpful for making critical decisions to combat COVID-19, Google has published an early release of COVID-19 Community Mobility Reports.",
      "The COVID-19 Community Mobility Reports web site will show population data trends of six categories: Retail and recreation, grocery and pharmacy, parks, transit stations, workplaces, and residential."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly states that Google has released COVID-19 Community Mobility Reports to show local movement trends during the pandemic. The reports cover regions and countries, and they provide data on six categories: Retail and recreation, grocery and pharmacy, parks, transit stations, workplaces, and residential.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000702",
    "statement": "Who releases covid-19 community mobility reports in an effort to show local movement trends during pandemic",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The reports consist of per country, or per state, downloads (with 131 countries covered initially), further broken down into regions/counties -- with Google offering an analysis of how community mobility has changed vs a baseline average before COVID-19 arrived to change everything.",
      "In response to feedback from public health officials that data could be helpful for making critical decisions to combat COVID-19, Google has published an early release of COVID-19 Community Mobility Reports.",
      "The COVID-19 Community Mobility Reports web site will show population data trends of six categories: Retail and recreation, grocery and pharmacy, parks, transit stations, workplaces, and residential."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that Google has published COVID-19 Community Mobility Reports. These reports are designed to show trends in community mobility during the pandemic, and they cover per country or state data. This supports the claim that Google releases these reports.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000703",
    "statement": "China releases covid-19 community mobility reports in an effort to show local movement trends during pandemic",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The reports consist of per country, or per state, downloads (with 131 countries covered initially), further broken down into regions/counties -- with Google offering an analysis of how community mobility has changed vs a baseline average before COVID-19 arrived to change everything.",
      "In response to feedback from public health officials that data could be helpful for making critical decisions to combat COVID-19, Google has published an early release of COVID-19 Community Mobility Reports.",
      "The COVID-19 Community Mobility Reports web site will show population data trends of six categories: Retail and recreation, grocery and pharmacy, parks, transit stations, workplaces, and residential."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence directly states that Google has published an early release of COVID-19 Community Mobility Reports, which aim to show local movement trends during the pandemic. This aligns with the claim that China (or any country) might release such reports.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000704",
    "statement": "Exhaled aerosol increases with covid-19 infection , and risk factors of disease symptom severity",
    "label": "SUPPORTED",
    "evidences": [
      "In our observational cohort study of the exhaled breath particles of 74 healthy human subjects, and in our experimental infection study of eight nonhuman primates infected by aerosol with SARS- CoV-2, we found that exhaled aerosol particles increase one to three orders of magnitude with aging, high BMI, and COVID-19 infection.",
      "We studied respiratory droplet generation and exhalation in human and nonhuman primate subjects with and without COVID-19 infection to explore whether SARS- CoV-2 infection, and other changes in physiological state, translates into observable evolution of numbers and sizes of exhaled respiratory droplets in healthy and diseased subjects."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence presented shows a direct correlation between COVID-19 infection and an increase in exhaled aerosol particles according to the studies on human subjects and nonhuman primates infected with SARS-CoV-2.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000705",
    "statement": "Acute aerosol increases with covid-19 infection, and risk factors of disease symptom severity",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In our observational cohort study of the exhaled breath particles of 74 healthy human subjects, and in our experimental infection study of eight nonhuman primates infected by aerosol with SARS- CoV-2, we found that exhaled aerosol particles increase one to three orders of magnitude with aging, high BMI, and COVID-19 infection.",
      "We studied respiratory droplet generation and exhalation in human and nonhuman primate subjects with and without COVID-19 infection to explore whether SARS- CoV-2 infection, and other changes in physiological state, translates into observable evolution of numbers and sizes of exhaled respiratory droplets in healthy and diseased subjects."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided supports the claim that acute aerosol increases with COVID-19 infection, and risk factors of disease symptom severity. The study shows an increase in exhaled aerosol particles with aging, high BMI, and COVID-19 infection.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000706",
    "statement": "Chronic aerosol increases with covid-19 infection, and risk factors of disease symptom severity",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In our observational cohort study of the exhaled breath particles of 74 healthy human subjects, and in our experimental infection study of eight nonhuman primates infected by aerosol with SARS- CoV-2, we found that exhaled aerosol particles increase one to three orders of magnitude with aging, high BMI, and COVID-19 infection.",
      "We studied respiratory droplet generation and exhalation in human and nonhuman primate subjects with and without COVID-19 infection to explore whether SARS- CoV-2 infection, and other changes in physiological state, translates into observable evolution of numbers and sizes of exhaled respiratory droplets in healthy and diseased subjects."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows a direct correlation between COVID-19 infection and an increase in exhaled aerosol particles in both human and nonhuman primate subjects. The study also indicates that factors such as aging and high BMI further contribute to this increase.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000707",
    "statement": "U.s. manufacturers sent millions of dollars of face masks to china early this year , ignoring pandemic warning signs",
    "label": "SUPPORTED",
    "evidences": [
      "Still, Doggett was incredulous that masks desperately sought today by U.S. medical providers were provided to China by U.S. companies in large numbers through February.",
      "Washington Post: U.S. sent millions of face masks to China early this year, ignoring pandemic warning signs \"U.S. manufacturers shipped millions of dollars' worth of face masks and other protective medical equipment to China in January and February with encouragement from the federal government, a Washington Post review of economic data and internal government documents has found.",
      "Today, Chinas imports of masks and other PPE from around the world is seen by some White House officials as part of a deliberate attempt by China to corner the market as it concealed and downplayed the danger posed by the outbreak.",
      "AD While China was silent on the seriousness of the crisis, they were quietly buying up a large portion of the worlds global supply for masks and other PPE, Navarro said.",
      "Sent Millions Of Masks To China, Ignoring Warning Signs Of Pandemic By News & Guts Still life of a face mask and blue protective gloves on turquoise background Share on Facebook Share on Twitter Share on Email Manufacturers in the U.S. shipped millions of dollars worth of face masks and other equipment to China in January and February, according to an investigation by The Washington Post."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided by the Washington Post states that U.S. manufacturers shipped millions of dollars worth of face masks and other equipment to China in January and February. This is consistent with the claim that U.S. manufacturers sent millions of dollars of face masks to China.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000708",
    "statement": "U.s. manufacturers sent millions of dollars of face masks to china early this year, for pandemic warning signs",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Still, Doggett was incredulous that masks desperately sought today by U.S. medical providers were provided to China by U.S. companies in large numbers through February.",
      "Washington Post: U.S. sent millions of face masks to China early this year, ignoring pandemic warning signs \"U.S. manufacturers shipped millions of dollars' worth of face masks and other protective medical equipment to China in January and February with encouragement from the federal government, a Washington Post review of economic data and internal government documents has found.",
      "Today, Chinas imports of masks and other PPE from around the world is seen by some White House officials as part of a deliberate attempt by China to corner the market as it concealed and downplayed the danger posed by the outbreak.",
      "AD While China was silent on the seriousness of the crisis, they were quietly buying up a large portion of the worlds global supply for masks and other PPE, Navarro said.",
      "Sent Millions Of Masks To China, Ignoring Warning Signs Of Pandemic By News & Guts Still life of a face mask and blue protective gloves on turquoise background Share on Facebook Share on Twitter Share on Email Manufacturers in the U.S. shipped millions of dollars worth of face masks and other equipment to China in January and February, according to an investigation by The Washington Post."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided by the Washington Post states that U.S. manufacturers shipped millions of dollars worth of face masks and other protective medical equipment to China in January and February. This directly supports the claim that U.S. manufacturers sent millions of dollars of face masks to China early this year.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000709",
    "statement": "U.s. manufacturers sent millions of dollars of face masks to china early this year, following pandemic warning signs",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Still, Doggett was incredulous that masks desperately sought today by U.S. medical providers were provided to China by U.S. companies in large numbers through February.",
      "Washington Post: U.S. sent millions of face masks to China early this year, ignoring pandemic warning signs \"U.S. manufacturers shipped millions of dollars' worth of face masks and other protective medical equipment to China in January and February with encouragement from the federal government, a Washington Post review of economic data and internal government documents has found.",
      "Today, Chinas imports of masks and other PPE from around the world is seen by some White House officials as part of a deliberate attempt by China to corner the market as it concealed and downplayed the danger posed by the outbreak.",
      "AD While China was silent on the seriousness of the crisis, they were quietly buying up a large portion of the worlds global supply for masks and other PPE, Navarro said.",
      "Sent Millions Of Masks To China, Ignoring Warning Signs Of Pandemic By News & Guts Still life of a face mask and blue protective gloves on turquoise background Share on Facebook Share on Twitter Share on Email Manufacturers in the U.S. shipped millions of dollars worth of face masks and other equipment to China in January and February, according to an investigation by The Washington Post."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided from The Washington Post states that U.S. manufacturers shipped millions of dollars worth of face masks and other equipment to China in January and February. This directly supports the claim that U.S. manufacturers sent millions of dollars of face masks to China.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000710",
    "statement": "U.s. manufacturers sent millions of dollars of face masks to china early this year, under pandemic warning signs",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Still, Doggett was incredulous that masks desperately sought today by U.S. medical providers were provided to China by U.S. companies in large numbers through February.",
      "Washington Post: U.S. sent millions of face masks to China early this year, ignoring pandemic warning signs \"U.S. manufacturers shipped millions of dollars' worth of face masks and other protective medical equipment to China in January and February with encouragement from the federal government, a Washington Post review of economic data and internal government documents has found.",
      "Today, Chinas imports of masks and other PPE from around the world is seen by some White House officials as part of a deliberate attempt by China to corner the market as it concealed and downplayed the danger posed by the outbreak.",
      "AD While China was silent on the seriousness of the crisis, they were quietly buying up a large portion of the worlds global supply for masks and other PPE, Navarro said.",
      "Sent Millions Of Masks To China, Ignoring Warning Signs Of Pandemic By News & Guts Still life of a face mask and blue protective gloves on turquoise background Share on Facebook Share on Twitter Share on Email Manufacturers in the U.S. shipped millions of dollars worth of face masks and other equipment to China in January and February, according to an investigation by The Washington Post."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is supported by the evidence provided by The Washington Post article, which states that 'U.S. manufacturers shipped millions of dollars' worth of face masks and other protective medical equipment to China in January and February.' This directly contradicts the current situation where U.S. medical providers are desperately seeking these items.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000711",
    "statement": "Fox news falls out of love with hydroxychloroquine",
    "label": "SUPPORTED",
    "evidences": [
      "Fox News has fallen out of love with hydroxychloroquine."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim directly matches the evidence provided.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000712",
    "statement": "Fox news falls out of patients with hydroxychloroquine",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Fox News has fallen out of love with hydroxychloroquine."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not clearly indicate a cause for the purported falling-out between Fox News and hydroxychloroquine. The statement implies a relationship between the two before, which is not supported by the given information.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000713",
    "statement": "Fox news falls out of contacts with hydroxychloroquine",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Fox News has fallen out of love with hydroxychloroquine."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The given evidence does not provide direct or clear information about whether Fox News has officially 'fallen out of contacts' with hydroxychloroquine. The statement is a metaphorical claim, and the given evidence doesn't provide concrete details to support this assertion.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000714",
    "statement": "Autopsies show varied forms of heart damage in covid-19 patients",
    "label": "SUPPORTED",
    "evidences": [
      "Researchers had found, for example, that 8-12 percent of hospitalized COVID-19 patients had elevated levels of muscle contraction-regulating proteins called troponins--a sign of heart damage--and that these patients had an increased risk of mortality compared with those who didn't have excess troponins.",
      "Early in the pandemic, other clinicians noted that even some patients who didn't have preexisting heart conditions experienced cardiovascular damage while fighting COVID-19 infections, pointing to a possible causative link.",
      "But Stone says he was surprised to see just how common these were--18 out of 21 COVID-19 patients' hearts harbored macrophages that exhibited this type of inflammation."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows that researchers found elevated levels of troponins in 8-12% of hospitalized COVID-19 patients, which is a sign of heart damage and is associated with an increased risk of mortality. Additionally, the study by Stone found that 18 out of 21 COVID-19 patients' hearts harbored inflammation exhibited by macrophages, supporting the claim.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000715",
    "statement": "Autopsies show common forms of heart damage in covid-19 patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Researchers had found, for example, that 8-12 percent of hospitalized COVID-19 patients had elevated levels of muscle contraction-regulating proteins called troponins--a sign of heart damage--and that these patients had an increased risk of mortality compared with those who didn't have excess troponins.",
      "Early in the pandemic, other clinicians noted that even some patients who didn't have preexisting heart conditions experienced cardiovascular damage while fighting COVID-19 infections, pointing to a possible causative link.",
      "But Stone says he was surprised to see just how common these were--18 out of 21 COVID-19 patients' hearts harbored macrophages that exhibited this type of inflammation."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that researchers found elevated levels of troponins (a sign of heart damage) in 8-12% of hospitalized COVID-19 patients, and these patients had an increased risk of mortality compared with those who didn't have excess troponins. Additionally, the text mentions that even some patients without preexisting heart conditions experienced cardiovascular damage during their fight against COVID-19 infections, suggesting a possible causative link. Furthermore, it is stated that 18 out of 21 COVID-19 patients' hearts had inflammation associated with macrophages, which further supports the claim.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000716",
    "statement": "Autopsies show typical forms of heart damage in covid-19 patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Researchers had found, for example, that 8-12 percent of hospitalized COVID-19 patients had elevated levels of muscle contraction-regulating proteins called troponins--a sign of heart damage--and that these patients had an increased risk of mortality compared with those who didn't have excess troponins.",
      "Early in the pandemic, other clinicians noted that even some patients who didn't have preexisting heart conditions experienced cardiovascular damage while fighting COVID-19 infections, pointing to a possible causative link.",
      "But Stone says he was surprised to see just how common these were--18 out of 21 COVID-19 patients' hearts harbored macrophages that exhibited this type of inflammation."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that the autopsies of COVID-19 patients often show signs of heart damage, specifically elevated levels of troponins and cardiovascular inflammation in macrophages. This supports the claim.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000717",
    "statement": "Genomic study points to natural origin of covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "The genomic data of the new coronavirus responsible for COVID-19 show that its spike protein contains some unique adaptations.",
      "This provides additional evidence that the coronavirus that causes COVID-19 almost certainly originated in nature.",
      "Their analysis showed that the backbone of the new coronaviruss genome most closely resembles that of a bat coronavirus discovered after the COVID-19 pandemic began."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that the genetic data of the new coronavirus causing COVID-19 is most closely related to a bat coronavirus discovered after the pandemic started. This supports the claim that the virus likely originated in nature.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000718",
    "statement": "Genomic study points to human origin of covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The genomic data of the new coronavirus responsible for COVID-19 show that its spike protein contains some unique adaptations.",
      "This provides additional evidence that the coronavirus that causes COVID-19 almost certainly originated in nature.",
      "Their analysis showed that the backbone of the new coronaviruss genome most closely resembles that of a bat coronavirus discovered after the COVID-19 pandemic began."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence points to a natural origin for the coronavirus causing COVID-19, as the genomic data shows similarities with bat coronaviruses. The unique adaptations in the spike protein of the new coronavirus suggest it likely evolved in nature, not in a lab.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000719",
    "statement": "Genomic study points to recent origin of covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The genomic data of the new coronavirus responsible for COVID-19 show that its spike protein contains some unique adaptations.",
      "This provides additional evidence that the coronavirus that causes COVID-19 almost certainly originated in nature.",
      "Their analysis showed that the backbone of the new coronaviruss genome most closely resembles that of a bat coronavirus discovered after the COVID-19 pandemic began."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests that the genomic data of the new coronavirus responsible for COVID-19 shows unique adaptations and its backbone most closely resembles a bat coronavirus discovered after the COVID-19 pandemic began. This points to a recent origin of covid-19 in nature.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000720",
    "statement": "Genomic study points to geographic origin of covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The genomic data of the new coronavirus responsible for COVID-19 show that its spike protein contains some unique adaptations.",
      "This provides additional evidence that the coronavirus that causes COVID-19 almost certainly originated in nature.",
      "Their analysis showed that the backbone of the new coronaviruss genome most closely resembles that of a bat coronavirus discovered after the COVID-19 pandemic began."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that the genomic data of SARS-CoV-2 (the virus causing COVID-19) shows similarities to a bat coronavirus, indicating its possible origin in nature. The statement implies geographic origin and this inference can be reasonably made given the known habitats of bats.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000721",
    "statement": "Colchicine to be investigated as a possible treatment for covid-19 in the recovery trial",
    "label": "SUPPORTED",
    "evidences": [
      "By including colchicine in the RECOVERY trial, we will be able to establish whether it helps tackle the worst consequences of COVID-19. It is anticipated that at least 2500 patients recruited to the RECOVERY trial will be randomly allocated to receive colchicine plus usual standard-of-care, and results will be compared with at least 2500 patients who receive the usual standard-of-care on its own."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that colchicine is being investigated as a possible treatment for COVID-19 in the RECOVERY trial.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000722",
    "statement": "Colchicine to be investigated as a possible treatment for covid-19 in the icu trial",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "By including colchicine in the RECOVERY trial, we will be able to establish whether it helps tackle the worst consequences of COVID-19. It is anticipated that at least 2500 patients recruited to the RECOVERY trial will be randomly allocated to receive colchicine plus usual standard-of-care, and results will be compared with at least 2500 patients who receive the usual standard-of-care on its own."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that colchicine will be investigated as a possible treatment for COVID-19 in the RECOVERY trial. This is supported by the statement that patients recruited to the trial will receive colchicine plus usual standard-of-care and their outcomes will be compared with those who only receive the usual standard-of-care.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000723",
    "statement": "Colchicine to be investigated as a possible treatment for covid-19 in the present trial",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "By including colchicine in the RECOVERY trial, we will be able to establish whether it helps tackle the worst consequences of COVID-19. It is anticipated that at least 2500 patients recruited to the RECOVERY trial will be randomly allocated to receive colchicine plus usual standard-of-care, and results will be compared with at least 2500 patients who receive the usual standard-of-care on its own."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that colchicine is being investigated as a possible treatment for COVID-19 in the RECOVERY trial. This claim is supported by the fact that patients in the trial will be randomly allocated to receive colchicine plus usual standard-of-care, and results will be compared with those who receive only the usual standard-of-care.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000724",
    "statement": "Colchicine to be investigated as a possible treatment for covid-19 in the patient trial",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "By including colchicine in the RECOVERY trial, we will be able to establish whether it helps tackle the worst consequences of COVID-19. It is anticipated that at least 2500 patients recruited to the RECOVERY trial will be randomly allocated to receive colchicine plus usual standard-of-care, and results will be compared with at least 2500 patients who receive the usual standard-of-care on its own."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that colchicine will be investigated as a possible treatment for COVID-19 in the RECOVERY trial, which means it is being studied to see if it helps tackle the worst consequences of the disease.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000725",
    "statement": "An alphavirus-derived replicon rna vaccine induces sars-cov-2 neutralizing antibody and t cell responses in mice and nonhuman primates",
    "label": "SUPPORTED",
    "evidences": [
      "These data suggest that a 250-\u03bcg prime-only dose or a 50-\u03bcg prime/boost immunization with the LION/repRNA-CoV2S vaccine induced concentrations of neutralizing antibodies that would be sufficient to protect nonhuman primates from infection and disease."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence indicates that the LION/repRNA-CoV2S vaccine induces sars-cov-2 neutralizing antibody responses in nonhuman primates. The presence of a t cell response is not explicitly mentioned but can be reasonably inferred since immunization often stimulates both humoral (antibody) and cellular (T cell) responses.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000726",
    "statement": "An alphavirus-derived replicon rna vaccine induces sars-cov-2 neutralizing antibody and t cell responses in humans and nonhuman primates",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These data suggest that a 250-\u03bcg prime-only dose or a 50-\u03bcg prime/boost immunization with the LION/repRNA-CoV2S vaccine induced concentrations of neutralizing antibodies that would be sufficient to protect nonhuman primates from infection and disease."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence presents data showing that a specific vaccine (LION/repRNA-CoV2S) induces neutralizing antibody and T cell responses in nonhuman primates, which is consistent with the claim that an alphavirus-derived replicon RNA vaccine can induce SARS-CoV-2 neutralizing antibody and T cell responses.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000727",
    "statement": "An alphavirus-derived replicon rna vaccine induces sars-cov-2 neutralizing antibody and t cell responses in human and nonhuman primates",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These data suggest that a 250-\u03bcg prime-only dose or a 50-\u03bcg prime/boost immunization with the LION/repRNA-CoV2S vaccine induced concentrations of neutralizing antibodies that would be sufficient to protect nonhuman primates from infection and disease."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests that the LION/repRNA-CoV2S vaccine induces neutralizing antibody responses in nonhuman primates, which could potentially protect them from SARS-CoV-2 infection and disease. The study does not directly state whether the same is true for humans, but the use of both human and nonhuman primates as test subjects implies that similar effects are expected in humans.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000728",
    "statement": "Coronavirus antibodies fall dramatically in first 3 months after mild cases of covid-19 according to new ucla study .",
    "label": "SUPPORTED",
    "evidences": [
      "FINDINGS A study by UCLA researchers shows that in people with mild cases of COVID-19, antibodies against SARS-CoV-2 -- the virus that causes the disease -- drop sharply over the first three months after infection, decreasing by roughly half every 36 days."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence directly states that antibodies against SARS-CoV-2 decrease by roughly half every 36 days in people with mild cases of COVID-19 according to a UCLA study. This supports the claim that coronavirus antibodies fall dramatically in the first 3 months after mild cases of COVID-19.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000729",
    "statement": "Coronavirus antibodies increased dramatically in first 3 months after mild cases of covid-19 according to new ucla study.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "FINDINGS A study by UCLA researchers shows that in people with mild cases of COVID-19, antibodies against SARS-CoV-2 -- the virus that causes the disease -- drop sharply over the first three months after infection, decreasing by roughly half every 36 days."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that antibodies against SARS-CoV-2 decrease by roughly half every 36 days in people with mild cases of COVID-19 according to a study by UCLA researchers. This implies that the antibody levels increased dramatically during the first three months after infection.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000730",
    "statement": "Coronavirus antibodies increase dramatically in first 3 months after mild cases of covid-19 according to new ucla study.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "FINDINGS A study by UCLA researchers shows that in people with mild cases of COVID-19, antibodies against SARS-CoV-2 -- the virus that causes the disease -- drop sharply over the first three months after infection, decreasing by roughly half every 36 days."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that UCLA researchers found that antibodies against SARS-CoV-2 decrease by roughly half every 36 days in the first three months after infection in people with mild cases of COVID-19. This implies an increase in antibodies during this period.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000731",
    "statement": "Coronavirus antibodies peaked dramatically in first 3 months after mild cases of covid-19 according to new ucla study.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "FINDINGS A study by UCLA researchers shows that in people with mild cases of COVID-19, antibodies against SARS-CoV-2 -- the virus that causes the disease -- drop sharply over the first three months after infection, decreasing by roughly half every 36 days."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The study conducted by UCLA researchers indicates that antibodies against SARS-CoV-2 (the virus causing COVID-19) decrease dramatically over the first three months after infection in people with mild cases of the disease. The findings suggest that peak antibody levels occur within this time frame.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000732",
    "statement": "Coronavirus fears have led to a golden age of hand-washing psas",
    "label": "SUPPORTED",
    "evidences": [
      "His Chaplinesque performance infuses high art and physical comedy into the subject of hygiene.",
      "Some are extremely winning, like the hand-washing dance created by Vietnamese choreographer Quang \u0110\u0103ng.",
      "Because the coronavirus is a global concern, video PSAs are emerging from all corners of the globe, all at once."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests that there has been an increase in the creation and dissemination of hand-washing PSAs due to coronavirus fears (as indicated by the global concern mentioned). The examples given further support this claim by illustrating various creative attempts at encouraging hand-washing, such as the hand-washing dance. While the specific term 'golden age' is not explicitly mentioned in the evidence, the frequency and diversity of these PSAs imply a surge in their production.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000733",
    "statement": "Coronavirus fears have led to a golden loss of hand-washing psas",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "His Chaplinesque performance infuses high art and physical comedy into the subject of hygiene.",
      "Some are extremely winning, like the hand-washing dance created by Vietnamese choreographer Quang \u0110\u0103ng.",
      "Because the coronavirus is a global concern, video PSAs are emerging from all corners of the globe, all at once."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The given evidence mentions the creation of hand-washing PSAs due to coronavirus fears and the example of a hand-washing dance. However, it does not provide any specific data or statistics on a 'golden loss' of hand-washing PSAs.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000734",
    "statement": "A human neutralizing antibody targets the receptor binding site of sars-cov-2",
    "label": "SUPPORTED",
    "evidences": [
      ", A human monoclonal antibody blocking SARS-CoV-2 infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided states that a human monoclonal antibody blocks SARS-CoV-2 infection. This suggests that the antibody targets a site on the virus (presumably the receptor binding site), as it prevents the virus from infecting its host.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000735",
    "statement": "A rabbit neutralizing antibody targets the receptor binding site of sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      ", A human monoclonal antibody blocking SARS-CoV-2 infection."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided refers to a human monoclonal antibody that blocks SARS-CoV-2 infection, but it does not explicitly state whether the antibody is derived from a rabbit or not.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000736",
    "statement": "A mouse neutralizing antibody targets the receptor binding site of sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      ", A human monoclonal antibody blocking SARS-CoV-2 infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided states that a human monoclonal antibody blocks SARS-CoV-2 infection. Since the receptor binding site of SARS-CoV-2 is what the virus uses to attach and enter cells in the body, a neutralizing antibody that blocks this process would target the receptor binding site.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000737",
    "statement": "A human neutralizing antibody targets the peptide binding site of sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      ", A human monoclonal antibody blocking SARS-CoV-2 infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that a human monoclonal antibody blocks SARS-CoV-2 infection. Monoclonal antibodies are produced by the immune system in response to an antigen and function by binding to specific epitopes on the antigen. In this case, the antibody targets the peptide binding site of SARS-CoV-2 (the antigen) to block infection.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000738",
    "statement": "Neuroinvasive potential of sars-cov-2 revealed in a human brain organoid model",
    "label": "SUPPORTED",
    "evidences": [
      "Following SARS-CoV-2 infection of human brain organoids, clear evidence of infection was observed, with accompanying metabolic changes in the infected and neighboring neurons."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence shows that SARS-CoV-2 infection was observed in human brain organoids and there were metabolic changes in the infected neurons, which suggests neuroinvasive potential.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000739",
    "statement": "Neuroinvasive potential of sars-cov-2 revealed in a canine brain organoid model",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Following SARS-CoV-2 infection of human brain organoids, clear evidence of infection was observed, with accompanying metabolic changes in the infected and neighboring neurons."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "While the evidence shows that SARS-CoV-2 can infect human brain organoids (artificial mini-brains derived from stem cells), it does not provide enough information to confirm or refute whether the virus has neuroinvasive potential in canine brains. Additional research specifically focused on SARS-CoV-2 infection in canine brain organoids is required.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000740",
    "statement": "Neuroinvasive potential of sars-cov-2 revealed in a rat brain organoid model",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Following SARS-CoV-2 infection of human brain organoids, clear evidence of infection was observed, with accompanying metabolic changes in the infected and neighboring neurons."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that SARS-CoV-2 has been observed to infect human brain organoids, providing clear evidence of its neuroinvasive potential.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000741",
    "statement": "Neuroinvasive potential of sars-cov-2 revealed in a mouse brain organoid model",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Following SARS-CoV-2 infection of human brain organoids, clear evidence of infection was observed, with accompanying metabolic changes in the infected and neighboring neurons."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows that SARS-CoV-2 was observed to infect human brain organoids, which suggests a neuroinvasive potential. This inference is supported by the fact that infection was accompanied by metabolic changes in the infected neurons.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000742",
    "statement": "Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms",
    "label": "SUPPORTED",
    "evidences": [
      "These data were integrated with genetic data where the interactions uncovered with SARS-CoV-2 were perturbed using RNA interference (RNAi) and CRISPR in different cellular systems and viral assaysan effort that functionally connected many host factors to infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that the interactions between SARS-CoV-2 and host proteins have been studied using functional assays such as RNA interference (RNAi) and CRISPR. This suggests that comparative analysis of these protein interactions could reveal common mechanisms across different coronaviruses, which aligns with the claim.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000743",
    "statement": "Comparative anti-coronavirus protein interaction networks reveal pan-viral disease mechanisms",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These data were integrated with genetic data where the interactions uncovered with SARS-CoV-2 were perturbed using RNA interference (RNAi) and CRISPR in different cellular systems and viral assaysan effort that functionally connected many host factors to infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that the interactions between SARS-CoV-2 and host factors have been studied using RNA interference (RNAi) and CRISPR in different cellular systems and viral assays. This implies that researchers are comparing these interactions to other virus-host interactions, thus supporting the claim that they are revealing pan-viral disease mechanisms.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000744",
    "statement": "Comparative non-coronavirus protein interaction networks reveal pan-viral disease mechanisms",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These data were integrated with genetic data where the interactions uncovered with SARS-CoV-2 were perturbed using RNA interference (RNAi) and CRISPR in different cellular systems and viral assaysan effort that functionally connected many host factors to infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows that the interactions of proteins with SARS-CoV-2 were perturbed using RNAi and CRISPR in different cellular systems and viral assays. This implies that comparative non-coronavirus protein interaction networks are being used to understand disease mechanisms, as the findings from SARS-CoV-2 can be compared with those of other viruses. Therefore, it is reasonable to conclude that the claim is supported.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000745",
    "statement": "Comparative beta-coronavirus protein interaction networks reveal pan-viral disease mechanisms",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These data were integrated with genetic data where the interactions uncovered with SARS-CoV-2 were perturbed using RNA interference (RNAi) and CRISPR in different cellular systems and viral assaysan effort that functionally connected many host factors to infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows an integration of genetic data with interactions uncovered from SARS-CoV-2 that were functionally connected to infection through RNAi and CRISPR experiments in cellular systems. This suggests the establishment of protein interaction networks for this coronavirus and their effects on host factors, indicating a comparison with other beta-coronaviruses could indeed reveal shared disease mechanisms.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000746",
    "statement": "Covid vaccine needs horseshoe crab blood but the ecosystem may suffer",
    "label": "SUPPORTED",
    "evidences": [
      "He said horseshoe crabs are vital in the process to find a coronavirus vaccine because their immune system is the most sensitive in the world.",
      "But she and other conservationists fear that without rFC or other alternatives available, the ongoing burden on horseshoe crab blood for COVID-19 vaccines and related therapeutics may imperil the crabs and the marine ecosystems that depend on them."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is supported because the evidence states that horseshoe crab blood is vital in finding a COVID-19 vaccine and using it may have an impact on the ecosystems that depend on them.",
    "confidence": 0.85
  },
  {
    "id": "covid_fact-000747",
    "statement": "Covid vaccine needs horseshoe crab blood but the ecosystem may benefit",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "He said horseshoe crabs are vital in the process to find a coronavirus vaccine because their immune system is the most sensitive in the world.",
      "But she and other conservationists fear that without rFC or other alternatives available, the ongoing burden on horseshoe crab blood for COVID-19 vaccines and related therapeutics may imperil the crabs and the marine ecosystems that depend on them."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided suggests that horseshoe crab's immune system is crucial in the process of finding a Covid-19 vaccine and there are concerns about the impact on their population due to increased demand for their blood. However, it does not explicitly state or prove that the Covid-19 vaccine actually needs horseshoe crab blood.",
    "confidence": 0.6
  },
  {
    "id": "covid_fact-000748",
    "statement": "Breakthrough needle-less vaccine could help in mass distribution",
    "label": "SUPPORTED",
    "evidences": [
      "Since the ingredients to make the film are inexpensive and the process is relatively simple, it could make vaccine campaigns much more affordable."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence does not directly support or refute the claim about a breakthrough needle-less vaccine. The discussion is centered around the inexpensive and simple process of making a film, which is irrelevant to the creation and distribution of vaccines.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000749",
    "statement": "Breakthrough needle-specific vaccine could help in mass distribution",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Since the ingredients to make the film are inexpensive and the process is relatively simple, it could make vaccine campaigns much more affordable."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The given claim and evidence do not have a clear connection. The provided evidence discusses the inexpensive ingredients and simplicity of producing a film, which does not directly support the claim about an affordable vaccine.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000750",
    "statement": "Breakthrough needle-driven vaccine could help in mass distribution",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Since the ingredients to make the film are inexpensive and the process is relatively simple, it could make vaccine campaigns much more affordable."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided discusses the affordability of a film-making process, not a needle-driven vaccine or its distribution.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000751",
    "statement": "Breakthrough needle-coated vaccine could help in mass distribution",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Since the ingredients to make the film are inexpensive and the process is relatively simple, it could make vaccine campaigns much more affordable."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim is about vaccines while the evidence provided discusses a simpler and cheaper process for making films, which does not provide enough information to support or refute the claim regarding vaccine distribution.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000752",
    "statement": "Recovery of monocyte exhaustion is associated with resolution of lung injury in covid-19 convalescence .",
    "label": "SUPPORTED",
    "evidences": [
      "These data suggest persistent changes in innate immune function following recovery from COVID-19 and indicate that immune modulating therapies targeting monocytes and leucocyte migration may be useful in recovering COVID-19 patients with persistent symptoms.",
      "Recovery of monocyte exhaustion is associated with resolution of lung injury in COVID-19 c",
      "Expression of migration molecules on monocytes was also consistently higher in convalescent patients with a normal chest X-ray.",
      "We recently demonstrated profound alterations of monocytes in hospitalised COVID-19 patients."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that there are persistent changes in innate immune function following recovery from COVID-19, particularly with regard to monocytes. The data also indicates an association between the recovery of monocyte exhaustion and resolution of lung injury. Furthermore, it is stated that expression of migration molecules on monocytes was higher in convalescent patients with a normal chest X-ray, which implies their role in resolving lung injury.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000753",
    "statement": "Recovery of monocyte exhaustion is associated without resolution of lung injury in covid-19 convalescence.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These data suggest persistent changes in innate immune function following recovery from COVID-19 and indicate that immune modulating therapies targeting monocytes and leucocyte migration may be useful in recovering COVID-19 patients with persistent symptoms.",
      "Recovery of monocyte exhaustion is associated with resolution of lung injury in COVID-19 c",
      "Expression of migration molecules on monocytes was also consistently higher in convalescent patients with a normal chest X-ray.",
      "We recently demonstrated profound alterations of monocytes in hospitalised COVID-19 patients."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided suggests that there are persistent changes in innate immune function following recovery from COVID-19 and that expression of migration molecules on monocytes is higher in convalescent patients with a normal chest X-ray. However, it does not directly state or imply a relationship between the recovery of monocyte exhaustion and resolution of lung injury in COVID-19 convalescence.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000754",
    "statement": "Recovery of monocyte proliferation is associated with resolution of lung injury in covid-19 convalescence.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These data suggest persistent changes in innate immune function following recovery from COVID-19 and indicate that immune modulating therapies targeting monocytes and leucocyte migration may be useful in recovering COVID-19 patients with persistent symptoms.",
      "Recovery of monocyte exhaustion is associated with resolution of lung injury in COVID-19 c",
      "Expression of migration molecules on monocytes was also consistently higher in convalescent patients with a normal chest X-ray.",
      "We recently demonstrated profound alterations of monocytes in hospitalised COVID-19 patients."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that changes in innate immune function, specifically recovery of monocyte exhaustion and increased expression of migration molecules on monocytes, are associated with resolution of lung injury in COVID-19 convalescence. This supports the claim that recovery of monocyte proliferation is associated with resolution of lung injury in covid-19 convalescence.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000755",
    "statement": "Recovery of monocyte activation is associated with resolution of lung injury in covid-19 convalescence.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These data suggest persistent changes in innate immune function following recovery from COVID-19 and indicate that immune modulating therapies targeting monocytes and leucocyte migration may be useful in recovering COVID-19 patients with persistent symptoms.",
      "Recovery of monocyte exhaustion is associated with resolution of lung injury in COVID-19 c",
      "Expression of migration molecules on monocytes was also consistently higher in convalescent patients with a normal chest X-ray.",
      "We recently demonstrated profound alterations of monocytes in hospitalised COVID-19 patients."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that there are persistent changes in innate immune function following recovery from COVID-19, which includes alterations of monocytes. The text also suggests a link between the recovery of monocyte exhaustion and resolution of lung injury. However, it does not explicitly state 'recovery of monocyte activation', but the context implies that this is part of the recovery process.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000756",
    "statement": "Imperial college mrna vaccine technology could protect against future pandemics",
    "label": "SUPPORTED",
    "evidences": [
      "If our approach works and the vaccine provides effective protection against disease, it could revolutionise how we respond to disease outbreaks in future.\"",
      "If these trials are successful a vaccine will not only help us tackle coronavirus but also emerging diseases now and into the future.\"",
      "Now scientists say the technology, a slow-motion revolution in the making since the discovery of mRNA nearly 60 years ago, could speed up the development of new vaccines.",
      "It will be the first test of a new self-amplifying RNA technology, which has the potential to revolutionise vaccine development and enable scientists to respond more quickly to emerging diseases."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that the Imperial College mRNA vaccine technology is being developed with the goal of providing protection against not just the current pandemic (coronavirus), but also future diseases. The quote 'It will be the first test of a new self-amplifying RNA technology, which has the potential to revolutionise vaccine development and enable scientists to respond more quickly to emerging diseases' indicates that this technology could speed up the response to future pandemics.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000757",
    "statement": "Imperial college mrna vaccine technology cannot protect against future pandemics",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "If our approach works and the vaccine provides effective protection against disease, it could revolutionise how we respond to disease outbreaks in future.\"",
      "If these trials are successful a vaccine will not only help us tackle coronavirus but also emerging diseases now and into the future.\"",
      "Now scientists say the technology, a slow-motion revolution in the making since the discovery of mRNA nearly 60 years ago, could speed up the development of new vaccines.",
      "It will be the first test of a new self-amplifying RNA technology, which has the potential to revolutionise vaccine development and enable scientists to respond more quickly to emerging diseases."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not explicitly state or imply that the Imperial College mRNA vaccine technology cannot protect against future pandemics. Instead, it suggests that the technology could speed up the development of new vaccines for emerging diseases in the future.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000758",
    "statement": "Dr. fauci predicts drugmakers will likely produce 1 billion covid-19 vaccines by the end of 2021",
    "label": "SUPPORTED",
    "evidences": [
      "But as we get into 2021, the manufacturers tell us that they will have hundreds of millions and likely a billion doses by the end of 2021,\" Fauci said in an interview with Reuters.",
      "Drugmakers will likely have produced a billion doses of a COVID-19 vaccine by the end of next year, Dr. Anthony Fauci, the United States' top infectious disease official, said Wednesday."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is directly stated in the evidence provided by Dr. Anthony Fauci himself.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000759",
    "statement": "Dr. fauci predicts drugmakers will not produce 1 billion covid-19 vaccines by the end of 2021",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "But as we get into 2021, the manufacturers tell us that they will have hundreds of millions and likely a billion doses by the end of 2021,\" Fauci said in an interview with Reuters.",
      "Drugmakers will likely have produced a billion doses of a COVID-19 vaccine by the end of next year, Dr. Anthony Fauci, the United States' top infectious disease official, said Wednesday."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence indicates that Dr. Fauci expects drugmakers to produce 'hundreds of millions and likely a billion doses' by the end of 2021, not that they will not produce one billion doses.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000760",
    "statement": "White house 's opening up america again guidelines",
    "label": "SUPPORTED",
    "evidences": [
      "According to the White House, once these criteria are met, states and regions can begin returning to normal economic activity in three phases.",
      "Titled \"Opening Up America Again,\" the document lays out recommendations for easing stay-at-home restrictions for individuals, employers and organizations once a series of \"gating criteria\" are met.",
      "Learn more about the guidelines at WhiteHouse.gov/OpeningAmerica.",
      "This evening, President Trump continued his unprecedented level of access to the American people at a press conference where he presented his guidelines on the three phases of Opening Up America Again.",
      "During a virtual leadership roundtable hosted by Meeting Professionals International, held during Virtual Global Meetings Industry Day  two days before the White House released the \"Opening Up America Again\" guidelines  U.S. Travel Association CEO Roger Dow described how he and other industry leaders have started discussing specific guidelines for events once gatherings are again allowed to take place."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that the White House has released guidelines titled 'Opening Up America Again', which provide recommendations for easing stay-at-home restrictions in three phases. This aligns with the claim that the White House has opened up America again guidelines.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000761",
    "statement": "Each house's opening up america again guidelines",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "According to the White House, once these criteria are met, states and regions can begin returning to normal economic activity in three phases.",
      "Titled \"Opening Up America Again,\" the document lays out recommendations for easing stay-at-home restrictions for individuals, employers and organizations once a series of \"gating criteria\" are met.",
      "Learn more about the guidelines at WhiteHouse.gov/OpeningAmerica.",
      "This evening, President Trump continued his unprecedented level of access to the American people at a press conference where he presented his guidelines on the three phases of Opening Up America Again.",
      "During a virtual leadership roundtable hosted by Meeting Professionals International, held during Virtual Global Meetings Industry Day  two days before the White House released the \"Opening Up America Again\" guidelines  U.S. Travel Association CEO Roger Dow described how he and other industry leaders have started discussing specific guidelines for events once gatherings are again allowed to take place."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that there is a set of guidelines titled 'Opening Up America Again' that were presented by the White House for easing stay-at-home restrictions. The document lays out recommendations for returning to normal economic activity in three phases.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000762",
    "statement": "Any house's opening up america again guidelines",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "According to the White House, once these criteria are met, states and regions can begin returning to normal economic activity in three phases.",
      "Titled \"Opening Up America Again,\" the document lays out recommendations for easing stay-at-home restrictions for individuals, employers and organizations once a series of \"gating criteria\" are met.",
      "Learn more about the guidelines at WhiteHouse.gov/OpeningAmerica.",
      "This evening, President Trump continued his unprecedented level of access to the American people at a press conference where he presented his guidelines on the three phases of Opening Up America Again.",
      "During a virtual leadership roundtable hosted by Meeting Professionals International, held during Virtual Global Meetings Industry Day  two days before the White House released the \"Opening Up America Again\" guidelines  U.S. Travel Association CEO Roger Dow described how he and other industry leaders have started discussing specific guidelines for events once gatherings are again allowed to take place."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided clearly indicates that the White House has presented guidelines titled 'Opening Up America Again' for easing stay-at-home restrictions in three phases. The guidelines are intended for individuals, employers, and organizations, suggesting they can be considered as a house's opening up America again guidelines.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000763",
    "statement": "Scientists are turning to existing drugs to combat covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "To expediate the development and approval process, many are looking at repurposing drugs to combat COVID-19.",
      "This means that it could potentially be tested sooner rather than later for patients with COVID-19.9 Other protease inhibitors that are currently being tested include the combination of ritonavir and lopinavir, drugs that were originally used for patients with HIV."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence indicates that some existing drugs are being considered for the treatment of COVID-19 by repurposing them (i.e., using them for a different purpose). This process is being pursued to expedite the development and approval process.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000764",
    "statement": "Scientists are turning to new drugs to combat covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "To expediate the development and approval process, many are looking at repurposing drugs to combat COVID-19.",
      "This means that it could potentially be tested sooner rather than later for patients with COVID-19.9 Other protease inhibitors that are currently being tested include the combination of ritonavir and lopinavir, drugs that were originally used for patients with HIV."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that scientists are looking to repurpose existing drugs (such as ritonavir and lopinavir originally used for patients with HIV) to combat COVID-19. This means that they are turning to new drugs in a sense.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000765",
    "statement": "Scientists are turning to developing drugs to combat covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "To expediate the development and approval process, many are looking at repurposing drugs to combat COVID-19.",
      "This means that it could potentially be tested sooner rather than later for patients with COVID-19.9 Other protease inhibitors that are currently being tested include the combination of ritonavir and lopinavir, drugs that were originally used for patients with HIV."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that scientists are indeed considering the use of existing drugs to combat COVID-19. The mention of repurposing drugs and the specific example of ritonavir and lopinavir (originally used for patients with HIV) supports this claim.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000766",
    "statement": "Scientists are turning to develop drugs to combat covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "To expediate the development and approval process, many are looking at repurposing drugs to combat COVID-19.",
      "This means that it could potentially be tested sooner rather than later for patients with COVID-19.9 Other protease inhibitors that are currently being tested include the combination of ritonavir and lopinavir, drugs that were originally used for patients with HIV."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that scientists are considering repurposing existing drugs, such as ritonavir and lopinavir (originally used for patients with HIV), to combat COVID-19. This implies that they are indeed developing or investigating the use of drugs to combat the virus.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000767",
    "statement": "Indomethacin has a potent antiviral activity against sars coronavirus",
    "label": "SUPPORTED",
    "evidences": [
      "Conclusions: The results identify INDO as a potent inhibitor of coronavirus replication and suggest that, having both anti-inflammatory and antiviral activity, INDO could be beneficial in SARS therapy.",
      "Results: Unexpectedly, we found that INDO has a potent direct antiviral activity against the coronaviruses SARS-CoV and CCoV."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided directly states that Indomethacin has a potent direct antiviral activity against the coronaviruses SARS-CoV and CCoV. Therefore, it is supported that Indomethacin has a potent antiviral activity against SARS coronavirus.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000768",
    "statement": "Indomethacin has a weak antiviral activity against sars coronavirus",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusions: The results identify INDO as a potent inhibitor of coronavirus replication and suggest that, having both anti-inflammatory and antiviral activity, INDO could be beneficial in SARS therapy.",
      "Results: Unexpectedly, we found that INDO has a potent direct antiviral activity against the coronaviruses SARS-CoV and CCoV."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that Indomethacin has a potent direct antiviral activity against the coronaviruses SARS-CoV and CCoV. Therefore, it can be inferred that Indomethacin has a weak antiviral activity against SARS coronavirus.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000769",
    "statement": "Coronavirus inflicts a short , sharp recession on global economy - cre herald",
    "label": "SUPPORTED",
    "evidences": [
      "\"In the current (first) quarter of 2020, we expect the global economy to have contracted at a faster pace than during the global financial crisis, with a fall of some 2% in world GDP, and our baseline forecasts then projecting a further quarterly fall of 0.4% in Q2,\" said in the analysis.",
      "The zero growth - Oxford Economics forecasts for 2020 - will mark the second- weakest year for the global economy in almost 50 years of comparable data, with only 2009, in the depths of the financial crisis, worse."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that a fall of some 2% in world GDP is expected in Q1 of 2020 and a further quarterly fall of 0.4% in Q2. This suggests a significant contraction in the global economy over a short period, which aligns with the description of a 'short, sharp recession'.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000770",
    "statement": "Coronavirus inflicts a world, sharp recession on global economy - cre herald",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "\"In the current (first) quarter of 2020, we expect the global economy to have contracted at a faster pace than during the global financial crisis, with a fall of some 2% in world GDP, and our baseline forecasts then projecting a further quarterly fall of 0.4% in Q2,\" said in the analysis.",
      "The zero growth - Oxford Economics forecasts for 2020 - will mark the second- weakest year for the global economy in almost 50 years of comparable data, with only 2009, in the depths of the financial crisis, worse."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence states that the global economy is expected to contract by a significant margin (2% in Q1 and 0.4% in Q2) according to Oxford Economics forecasts, which aligns with the definition of a sharp recession. Furthermore, the statement indicates that this contraction will make 2020 one of the weakest years for the global economy in nearly 50 years, supporting the claim of a world-wide impact.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000771",
    "statement": "Coronavirus inflicts a pandemic, sharp recession on global economy - cre herald",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "\"In the current (first) quarter of 2020, we expect the global economy to have contracted at a faster pace than during the global financial crisis, with a fall of some 2% in world GDP, and our baseline forecasts then projecting a further quarterly fall of 0.4% in Q2,\" said in the analysis.",
      "The zero growth - Oxford Economics forecasts for 2020 - will mark the second- weakest year for the global economy in almost 50 years of comparable data, with only 2009, in the depths of the financial crisis, worse."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided clearly indicates a global economic contraction due to the pandemic (as suggested by the falling GDP), and this contraction is compared to both the current quarter and the financial crisis of 2009. Additionally, it is stated that the zero growth forecasted for 2020 will be one of the weakest years in almost 50 years of comparable data.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000772",
    "statement": "Coronavirus inflicts a short, sharp recession on global health - cre herald",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "\"In the current (first) quarter of 2020, we expect the global economy to have contracted at a faster pace than during the global financial crisis, with a fall of some 2% in world GDP, and our baseline forecasts then projecting a further quarterly fall of 0.4% in Q2,\" said in the analysis.",
      "The zero growth - Oxford Economics forecasts for 2020 - will mark the second- weakest year for the global economy in almost 50 years of comparable data, with only 2009, in the depths of the financial crisis, worse."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that there is a forecasted contraction in global GDP for the first and second quarters of 2020, which fits the definition of a short, sharp recession (usually defined as two consecutive quarters of negative GDP growth).",
    "confidence": 1
  },
  {
    "id": "covid_fact-000773",
    "statement": "Onerace , the sydney research team is launching its crowdfunding campaign to help the world with the current pandemic covid19 .",
    "label": "SUPPORTED",
    "evidences": [
      "^ \"Private group says it's started building border wall using millions donated in GoFundMe campaign\".",
      "ABC Home Open Sites menu ABC Home News iview TV Radio Kids Shop More Search AustraliaWeather Just In Politics World Business Analysis Sport Science Health Arts Fact Check Other Cyclone warning For latest updates on Cyclone Kimi in Far North Queensland , search on ABC Emergency or find your local ABC radio station Live blog Follow our live coverage for the latest news on the coronavirus pandemic USA Votes Follow our live coverage ahead of the inauguration of Joe Biden as the next US president Email "
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence does not provide any information about 'Onerace' or their planned crowdfunding campaign regarding the COVID-19 pandemic. The given quote is about a private group building a border wall, which is unrelated to the claim.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000774",
    "statement": "Onerace, the sydney training team is launching its crowdfunding campaign to help the world with the current pandemic covid19.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "^ \"Private group says it's started building border wall using millions donated in GoFundMe campaign\".",
      "ABC Home Open Sites menu ABC Home News iview TV Radio Kids Shop More Search AustraliaWeather Just In Politics World Business Analysis Sport Science Health Arts Fact Check Other Cyclone warning For latest updates on Cyclone Kimi in Far North Queensland , search on ABC Emergency or find your local ABC radio station Live blog Follow our live coverage for the latest news on the coronavirus pandemic USA Votes Follow our live coverage ahead of the inauguration of Joe Biden as the next US president Email "
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The given evidence does not provide information about the crowdfunding campaign of Onerace Sydney Training Team to help with the COVID-19 pandemic. The cited news article is about a different group starting a crowdfunding campaign for building a border wall.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000775",
    "statement": "Irace, the sydney research team is launching its crowdfunding campaign to help the world with the current pandemic covid19.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "^ \"Private group says it's started building border wall using millions donated in GoFundMe campaign\".",
      "ABC Home Open Sites menu ABC Home News iview TV Radio Kids Shop More Search AustraliaWeather Just In Politics World Business Analysis Sport Science Health Arts Fact Check Other Cyclone warning For latest updates on Cyclone Kimi in Far North Queensland , search on ABC Emergency or find your local ABC radio station Live blog Follow our live coverage for the latest news on the coronavirus pandemic USA Votes Follow our live coverage ahead of the inauguration of Joe Biden as the next US president Email "
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence does not directly support or refute the claim about Irace, the Sydney research team launching a crowdfunding campaign to help with the COVID-19 pandemic. The given evidence is about a different group (implicitly) starting a border wall using donations from a GoFundMe campaign.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000776",
    "statement": "Rerace, the sydney research team is launching its crowdfunding campaign to help the world with the current pandemic covid19.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "^ \"Private group says it's started building border wall using millions donated in GoFundMe campaign\".",
      "ABC Home Open Sites menu ABC Home News iview TV Radio Kids Shop More Search AustraliaWeather Just In Politics World Business Analysis Sport Science Health Arts Fact Check Other Cyclone warning For latest updates on Cyclone Kimi in Far North Queensland , search on ABC Emergency or find your local ABC radio station Live blog Follow our live coverage for the latest news on the coronavirus pandemic USA Votes Follow our live coverage ahead of the inauguration of Joe Biden as the next US president Email "
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence does not clearly indicate that Rerace, the Sydney research team is launching a crowdfunding campaign for COVID-19. The evidence only mentions a private group starting a building project and donations made via GoFundMe, which is unrelated to the pandemic.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000777",
    "statement": "Mva vector vaccines inhibit sars cov-2 replication in upper and lower respiratory tracts of transgenic mice and prevent lethal disease.",
    "label": "SUPPORTED",
    "evidences": [
      "In a transgenic mouse model, one or two injections of recombinant MVAs that express modified forms of S inhibited CoV-2 replication in the upper and lower respiratory tracts and prevented severe disease.",
      "A recent paper, that appeared as a preprint on the bioRxiv server in January 2021, shows the effectiveness of a novel recombinant vaccinia virus that expresses modified SARS-CoV-2 spike antigen, in preventing the replication of the virus in the respiratory tract of transgenic mice, and to prevent lethal disease.",
      "The researchers found that serum from mice vaccinated with MVA that expressed wildtype S could be given intraperitoneally to transgenic hACE2-expressing mice, producing a high neutralizing titer.",
      "Weight loss and lethality following intranasal infection of transgenic hACE2 mice with CoV-2 was prevented by one or two immunizations with rMVAs or by passive transfer of serum from vaccinated mice."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided in the statement directly supports the claim that MVA vector vaccines inhibit SARS-CoV-2 replication in upper and lower respiratory tracts of transgenic mice and prevent lethal disease. The study demonstrates this by showing the effectiveness of a novel recombinant vaccinia virus (MVA) expressing modified SARS-CoV-2 spike antigen in preventing the replication of the virus in the respiratory tract of transgenic mice and preventing lethal disease.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000778",
    "statement": "Mva vector vaccines promote sars cov-2 replication in upper and lower respiratory tracts of transgenic mice and prevent lethal disease.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In a transgenic mouse model, one or two injections of recombinant MVAs that express modified forms of S inhibited CoV-2 replication in the upper and lower respiratory tracts and prevented severe disease.",
      "A recent paper, that appeared as a preprint on the bioRxiv server in January 2021, shows the effectiveness of a novel recombinant vaccinia virus that expresses modified SARS-CoV-2 spike antigen, in preventing the replication of the virus in the respiratory tract of transgenic mice, and to prevent lethal disease.",
      "The researchers found that serum from mice vaccinated with MVA that expressed wildtype S could be given intraperitoneally to transgenic hACE2-expressing mice, producing a high neutralizing titer.",
      "Weight loss and lethality following intranasal infection of transgenic hACE2 mice with CoV-2 was prevented by one or two immunizations with rMVAs or by passive transfer of serum from vaccinated mice."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided in the claim directly supports that Mva vector vaccines promote SARS-CoV-2 replication inhibition in upper and lower respiratory tracts of transgenic mice and prevent lethal disease.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000779",
    "statement": "Mva vector vaccines enhance sars cov-2 replication in upper and lower respiratory tracts of transgenic mice and prevent lethal disease.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In a transgenic mouse model, one or two injections of recombinant MVAs that express modified forms of S inhibited CoV-2 replication in the upper and lower respiratory tracts and prevented severe disease.",
      "A recent paper, that appeared as a preprint on the bioRxiv server in January 2021, shows the effectiveness of a novel recombinant vaccinia virus that expresses modified SARS-CoV-2 spike antigen, in preventing the replication of the virus in the respiratory tract of transgenic mice, and to prevent lethal disease.",
      "The researchers found that serum from mice vaccinated with MVA that expressed wildtype S could be given intraperitoneally to transgenic hACE2-expressing mice, producing a high neutralizing titer.",
      "Weight loss and lethality following intranasal infection of transgenic hACE2 mice with CoV-2 was prevented by one or two immunizations with rMVAs or by passive transfer of serum from vaccinated mice."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows that the recombinant MVA (Modified Vaccinia Ankara) vaccines expressing modified forms of S inhibited SARS-CoV-2 replication in the upper and lower respiratory tracts of transgenic mice, and prevented severe disease. This aligns with the claim that Mva vector vaccines enhance SARS-CoV-2 replication in the respiratory tracts of these mice and prevent lethal disease.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000780",
    "statement": "Mva vector vaccines induce sars cov-2 replication in upper and lower respiratory tracts of transgenic mice and prevent lethal disease.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In a transgenic mouse model, one or two injections of recombinant MVAs that express modified forms of S inhibited CoV-2 replication in the upper and lower respiratory tracts and prevented severe disease.",
      "A recent paper, that appeared as a preprint on the bioRxiv server in January 2021, shows the effectiveness of a novel recombinant vaccinia virus that expresses modified SARS-CoV-2 spike antigen, in preventing the replication of the virus in the respiratory tract of transgenic mice, and to prevent lethal disease.",
      "The researchers found that serum from mice vaccinated with MVA that expressed wildtype S could be given intraperitoneally to transgenic hACE2-expressing mice, producing a high neutralizing titer.",
      "Weight loss and lethality following intranasal infection of transgenic hACE2 mice with CoV-2 was prevented by one or two immunizations with rMVAs or by passive transfer of serum from vaccinated mice."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows that the recombinant MVA vaccines expressing modified forms of S inhibited SARS-CoV-2 replication in the upper and lower respiratory tracts of transgenic mice and prevented lethal disease. This supports the claim.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000781",
    "statement": "Sars-cov-2 orf6 hijacks nup98 to block stat nuclear import and antagonize interferon signaling",
    "label": "SUPPORTED",
    "evidences": [
      "The Orf6-Nup98 interaction is critical to block STAT nuclear translocation and IFN signaling.",
      "The Orf6-Nup98 interaction is critical to block STAT nuclear translocation and IFN signaling. Fig.",
      "In this study, we show that SARS-CoV-2 is able to efficiently block STAT1 and STAT2 nuclear translocation in order to impair transcriptional induction of IFN-stimulated genes (ISGs).",
      "We found that SARS-CoV-2 Orf6 localizes at the nuclear pore complex (NPC) and directly interacts with Nup98-Rae1 via its C-terminal domain to impair docking of cargo-receptor (karyopherin/importin) complex and disrupt nuclear import."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence directly states that the interaction between Orf6 from SARS-CoV-2 and Nup98 is critical for blocking STAT nuclear translocation and interferon signaling. Additionally, it describes how this interaction disrupts the docking of cargo-receptor complexes at the nuclear pore complex, which is a key mechanism for nuclear import.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000782",
    "statement": "Sars-cov-2 orf6 hijacks nup98 to promote stat nuclear import and antagonize interferon signaling",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The Orf6-Nup98 interaction is critical to block STAT nuclear translocation and IFN signaling.",
      "The Orf6-Nup98 interaction is critical to block STAT nuclear translocation and IFN signaling. Fig.",
      "In this study, we show that SARS-CoV-2 is able to efficiently block STAT1 and STAT2 nuclear translocation in order to impair transcriptional induction of IFN-stimulated genes (ISGs).",
      "We found that SARS-CoV-2 Orf6 localizes at the nuclear pore complex (NPC) and directly interacts with Nup98-Rae1 via its C-terminal domain to impair docking of cargo-receptor (karyopherin/importin) complex and disrupt nuclear import."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly states that the Orf6 protein of SARS-CoV-2 interacts with Nup98-Rae1 and this interaction is critical to block STAT nuclear translocation and IFN signaling. The figure and the statements in the study support this claim.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000783",
    "statement": "Sars-cov-2 orf6 hijacks nup98 to facilitate stat nuclear import and antagonize interferon signaling",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The Orf6-Nup98 interaction is critical to block STAT nuclear translocation and IFN signaling.",
      "The Orf6-Nup98 interaction is critical to block STAT nuclear translocation and IFN signaling. Fig.",
      "In this study, we show that SARS-CoV-2 is able to efficiently block STAT1 and STAT2 nuclear translocation in order to impair transcriptional induction of IFN-stimulated genes (ISGs).",
      "We found that SARS-CoV-2 Orf6 localizes at the nuclear pore complex (NPC) and directly interacts with Nup98-Rae1 via its C-terminal domain to impair docking of cargo-receptor (karyopherin/importin) complex and disrupt nuclear import."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided in the statement directly supports the claim that SARS-CoV-2 Orf6 hijacks Nup98 to facilitate nuclear import and antagonize interferon signaling. The statement explains that the Orf6-Nup98 interaction is critical for blocking STAT nuclear translocation and IFN signaling, which are key components of the immune response against viral infections. Additionally, it is shown that SARS-CoV-2 Orf6 localizes at the nuclear pore complex (NPC) and directly interacts with Nup98-Rae1 to disrupt nuclear import, further supporting the claim.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000784",
    "statement": "Sars-cov-2 orf6 hijacks nup98 to induce stat nuclear import and antagonize interferon signaling",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The Orf6-Nup98 interaction is critical to block STAT nuclear translocation and IFN signaling.",
      "The Orf6-Nup98 interaction is critical to block STAT nuclear translocation and IFN signaling. Fig.",
      "In this study, we show that SARS-CoV-2 is able to efficiently block STAT1 and STAT2 nuclear translocation in order to impair transcriptional induction of IFN-stimulated genes (ISGs).",
      "We found that SARS-CoV-2 Orf6 localizes at the nuclear pore complex (NPC) and directly interacts with Nup98-Rae1 via its C-terminal domain to impair docking of cargo-receptor (karyopherin/importin) complex and disrupt nuclear import."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided in the study demonstrates that the Orf6 protein of SARS-CoV-2 interacts with Nup98-Rae1, which is critical for blocking STAT nuclear translocation and IFN signaling. Additionally, the study shows that this interaction impairs the docking of cargo-receptor complexes at the nuclear pore complex and disrupts nuclear import. These findings suggest that SARS-CoV-2 Orf6 hijacks nup98 to induce STAT nuclear import and antagonize interferon signaling.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000785",
    "statement": "Patients are coming in too late for treatment .",
    "label": "SUPPORTED",
    "evidences": [
      "Late diagnosis can occur when a patient delays going to see a doctor about symptoms they have developed, or a doctor wrongly judges those signs to be of no concern or believes they indicate another illness, such as irritable bowel syndrome."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence discusses the possibility of late diagnosis but does not directly support the claim that 'patients are coming in too late for treatment'. To determine if this is indeed a common occurrence, data or statistics about the percentage or number of patients seeking treatment after an appropriate time frame would be required.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000786",
    "statement": "Patients are coming in too short for treatment.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Late diagnosis can occur when a patient delays going to see a doctor about symptoms they have developed, or a doctor wrongly judges those signs to be of no concern or believes they indicate another illness, such as irritable bowel syndrome."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided discusses the issue of late diagnosis, not the problem of patients coming in too short for treatment. While late diagnosis can potentially lead to improper or delayed treatment, the evidence does not directly support the claim that patients are physically coming in too short.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000787",
    "statement": "Patients are coming in too time for treatment.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Late diagnosis can occur when a patient delays going to see a doctor about symptoms they have developed, or a doctor wrongly judges those signs to be of no concern or believes they indicate another illness, such as irritable bowel syndrome."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence describes scenarios where late diagnosis can occur but does not provide any data or information about patients coming in 'too late' for treatment specifically.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000788",
    "statement": "Irish-developed kit that confirms covid-19 infection in 15 minutes could be released in seven days",
    "label": "SUPPORTED",
    "evidences": [
      "Photo: PA Laura Lynott March 16 2020 02:30 AM Facebook Twitter Email An Irish company is preparing to release rapid Covid-19 testing kits, which can provide results in 15 minutes and potentially act as a \"clinical weapon\" against coronavirus."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided suggests that an Irish company is preparing to release rapid Covid-19 testing kits capable of providing results in 15 minutes. However, the claim states that the kit could be released in seven days. The article does not provide any information or evidence to support this timeframe.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000789",
    "statement": "Irish-developed kit that confirms covid-19 infection in 15 minutes could be released in seven hours",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Photo: PA Laura Lynott March 16 2020 02:30 AM Facebook Twitter Email An Irish company is preparing to release rapid Covid-19 testing kits, which can provide results in 15 minutes and potentially act as a \"clinical weapon\" against coronavirus."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not give a definitive timeline for the release of the rapid Covid-19 testing kits. While it states that the company is preparing to release them, it does not specify when this will happen within seven hours.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000790",
    "statement": "Normally invisible saliva droplets can linger in the air , visualized by researchers using laser technology .",
    "label": "SUPPORTED",
    "evidences": [
      "He runs a laser lab normally used to study protein structural dynamics, but was able to use that technology to investigate the hunch that normal speaking produces small droplets that can spread disease.",
      "Whereas large droplets fall quickly to the ground, small droplets can dehydrate and linger as droplet nuclei in the air, where they behave like an aerosol and thereby expand the spatial extent of emitted infectious particles.2 We report the results of a laser light-scattering experiment in which speech-generated droplets and their trajectories were visualized.",
      "Laser light is a common technique to visualize and count droplets in the air, says Alex Huffman, an associate professor who studies aerosols in the department of chemistry and biochemistry at the University of Denver.",
      "Image Laser light scattering observations of droplets in the experimental setup.Credit...Valentyn Stadnytskyi; Philip Anfinrud; Christina E. Bax; Adriaan Bax The scientists also found that while droplets start shrinking from dehydration as soon as they leave a persons mouth, they can still float in the air for eight to 14 minutes."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided describes an experiment conducted using laser technology to visualize and study the droplets produced during speaking. The results of this experiment indicate that these small droplets can dehydrate and linger as droplet nuclei in the air, behaving like an aerosol and potentially spreading disease. Therefore, it is supported that normally invisible saliva droplets can linger in the air as per the claim.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000791",
    "statement": "Normally invisible saliva droplets can spread in the air, visualized by researchers using laser technology.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "He runs a laser lab normally used to study protein structural dynamics, but was able to use that technology to investigate the hunch that normal speaking produces small droplets that can spread disease.",
      "Whereas large droplets fall quickly to the ground, small droplets can dehydrate and linger as droplet nuclei in the air, where they behave like an aerosol and thereby expand the spatial extent of emitted infectious particles.2 We report the results of a laser light-scattering experiment in which speech-generated droplets and their trajectories were visualized.",
      "Laser light is a common technique to visualize and count droplets in the air, says Alex Huffman, an associate professor who studies aerosols in the department of chemistry and biochemistry at the University of Denver.",
      "Image Laser light scattering observations of droplets in the experimental setup.Credit...Valentyn Stadnytskyi; Philip Anfinrud; Christina E. Bax; Adriaan Bax The scientists also found that while droplets start shrinking from dehydration as soon as they leave a persons mouth, they can still float in the air for eight to 14 minutes."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence describes an experiment using laser technology to visualize and study speech-generated droplets in the air. This supports the claim that normally invisible saliva droplets can spread in the air, as they are being observed and studied.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000792",
    "statement": "Normally invisible saliva droplets can increase in the air, visualized by researchers using laser technology.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "He runs a laser lab normally used to study protein structural dynamics, but was able to use that technology to investigate the hunch that normal speaking produces small droplets that can spread disease.",
      "Whereas large droplets fall quickly to the ground, small droplets can dehydrate and linger as droplet nuclei in the air, where they behave like an aerosol and thereby expand the spatial extent of emitted infectious particles.2 We report the results of a laser light-scattering experiment in which speech-generated droplets and their trajectories were visualized.",
      "Laser light is a common technique to visualize and count droplets in the air, says Alex Huffman, an associate professor who studies aerosols in the department of chemistry and biochemistry at the University of Denver.",
      "Image Laser light scattering observations of droplets in the experimental setup.Credit...Valentyn Stadnytskyi; Philip Anfinrud; Christina E. Bax; Adriaan Bax The scientists also found that while droplets start shrinking from dehydration as soon as they leave a persons mouth, they can still float in the air for eight to 14 minutes."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence describes an experiment using laser technology to visualize and measure speech-generated droplets in the air, demonstrating that they can increase in the air and linger for a certain period. This supports the claim that normally invisible saliva droplets can increase in the air, as visualized by researchers using laser technology.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000793",
    "statement": "Sex differences in immune responses to sars-cov-2 that underlie disease outcomes",
    "label": "SUPPORTED",
    "evidences": [
      "In this study, we examined sex differences in viral loads, SARS-CoV-2-specific antibody titers, plasma cytokines, as well as blood cell phenotyping in COVID-19 patients.",
      "Conversely, higher innate immune cytokines in female patients associated with worse disease progression, but not in male patients.",
      "In contrast, female patients mounted significantly more robust T cell activation than male patients during SARS-CoV-2 infection, which was sustained in old age."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence presents a study examining sex differences in immune responses to SARS-CoV-2 in COVID-19 patients. The study finds that higher innate immune cytokines in female patients are associated with worse disease progression, and female patients mount more robust T cell activation during SARS-CoV-2 infection compared to male patients. These findings support the claim of sex differences in immune responses to SARS-CoV-2 that underlie disease outcomes.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000794",
    "statement": "Sex differences in immune responses to sars-cov-2 that underlie protection outcomes",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In this study, we examined sex differences in viral loads, SARS-CoV-2-specific antibody titers, plasma cytokines, as well as blood cell phenotyping in COVID-19 patients.",
      "Conversely, higher innate immune cytokines in female patients associated with worse disease progression, but not in male patients.",
      "In contrast, female patients mounted significantly more robust T cell activation than male patients during SARS-CoV-2 infection, which was sustained in old age."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence presented in the study shows differences in immune responses to SARS-CoV-2 between males and females, specifically regarding viral loads, antibody titers, cytokines, and T cell activation. These differences may underlie protection outcomes.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000795",
    "statement": "Adjuvant-free nanofiber vaccine induces in situ lung dendritic cell activation and th17 responses",
    "label": "SUPPORTED",
    "evidences": [
      "These observations are congruent with the conclusion of independent priming by intranasal E\u03b1Q11 nanofibers of CD4+ T cells in the lung.",
      "Thus, in the absence of exogenous adjuvants, intranasally administered nanofiber vaccines preferentially elicit robust antigen-specific TH17 responses that accumulated in both the LN and lung.",
      "During primary immune responses elicited by pathogens such as Gram-negative bacteria, IL-17 at the lung mucosal surface is produced by natural killer (NK) cells, \u03b3\u03b4 T cells, and group 3 innate lymphoid cells (ILCs) [reviewed in ( 35)]."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that the intranasal administration of E\u03b1Q11 nanofibers induces robust antigen-specific TH17 responses in the absence of exogenous adjuvants. This implies that the claim that the Adjuvant-free nanofiber vaccine induces in situ lung dendritic cell activation and Th17 responses is supported by the provided evidence.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000796",
    "statement": "Adjuvant-free nanofiber vaccine knocks in situ lung dendritic cell activation and th17 responses",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These observations are congruent with the conclusion of independent priming by intranasal E\u03b1Q11 nanofibers of CD4+ T cells in the lung.",
      "Thus, in the absence of exogenous adjuvants, intranasally administered nanofiber vaccines preferentially elicit robust antigen-specific TH17 responses that accumulated in both the LN and lung.",
      "During primary immune responses elicited by pathogens such as Gram-negative bacteria, IL-17 at the lung mucosal surface is produced by natural killer (NK) cells, \u03b3\u03b4 T cells, and group 3 innate lymphoid cells (ILCs) [reviewed in ( 35)]."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that the intranasal administration of E\u03b1Q11 nanofibers without exogenous adjuvants can induce antigen-specific TH17 responses in the lung and LN. This is consistent with the claim that an adjuvant-free nanofiber vaccine can knock in situ lung dendritic cell activation and TH17 responses.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000797",
    "statement": "Adjuvant-free nanofiber vaccine induces in situ memory dendritic cell activation and th17 responses",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These observations are congruent with the conclusion of independent priming by intranasal E\u03b1Q11 nanofibers of CD4+ T cells in the lung.",
      "Thus, in the absence of exogenous adjuvants, intranasally administered nanofiber vaccines preferentially elicit robust antigen-specific TH17 responses that accumulated in both the LN and lung.",
      "During primary immune responses elicited by pathogens such as Gram-negative bacteria, IL-17 at the lung mucosal surface is produced by natural killer (NK) cells, \u03b3\u03b4 T cells, and group 3 innate lymphoid cells (ILCs) [reviewed in ( 35)]."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests that the intranasal administration of E\u03b1Q11 nanofibers without adjuvants can elicit robust antigen-specific TH17 responses in the LN and lung. This is indicated by the observations of CD4+ T cell priming, accumulation of these cells in both the LN and lung, and the production of IL-17 at the mucosal surface. The evidence mentions that during primary immune responses elicited by pathogens such as Gram-negative bacteria, IL-17 is produced by various cell types including NK cells, \u03b3\u03b4 T cells, and group 3 ILCs.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000798",
    "statement": "The fda has canceled emergency use of hydroxychloroquine for covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "In addition, the FDA warned June 15 that hydroxychloroquine and chloroquine shouldnt be given in combination with remdesivir, an antiviral drug that has been shown to shorten recovery time from COVID-19 ( SN: 4/29/20 ).",
      "After reviewing evidence, its no longer reasonable to believe that [hydroxychloroquine] and [chloroquine] may be effective in treating COVID-19, Hinton wrote.",
      "Coronavirus (COVID-19) update: FDA revokes emergency use authorization for chloroquine and hydroxychloroquine."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that the FDA has revoked the emergency use authorization for both chloroquine and hydroxychloroquine in treating COVID-19. Therefore, it can be concluded that the FDA has canceled the emergency use of hydroxychloroquine for COVID-19.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000799",
    "statement": "The fda has increased emergency use of hydroxychloroquine for covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In addition, the FDA warned June 15 that hydroxychloroquine and chloroquine shouldnt be given in combination with remdesivir, an antiviral drug that has been shown to shorten recovery time from COVID-19 ( SN: 4/29/20 ).",
      "After reviewing evidence, its no longer reasonable to believe that [hydroxychloroquine] and [chloroquine] may be effective in treating COVID-19, Hinton wrote.",
      "Coronavirus (COVID-19) update: FDA revokes emergency use authorization for chloroquine and hydroxychloroquine."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence does not explicitly state that the FDA has increased the emergency use of hydroxychloroquine for COVID-19. Instead, it states that the FDA revoked the emergency use authorization (EUA) for chloroquine and hydroxychloroquine in treating COVID-19.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000800",
    "statement": "The fda has potential emergency use of hydroxychloroquine for covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In addition, the FDA warned June 15 that hydroxychloroquine and chloroquine shouldnt be given in combination with remdesivir, an antiviral drug that has been shown to shorten recovery time from COVID-19 ( SN: 4/29/20 ).",
      "After reviewing evidence, its no longer reasonable to believe that [hydroxychloroquine] and [chloroquine] may be effective in treating COVID-19, Hinton wrote.",
      "Coronavirus (COVID-19) update: FDA revokes emergency use authorization for chloroquine and hydroxychloroquine."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided indicates that the FDA has revoked the emergency use authorization for chloroquine and hydroxychloroquine in treating COVID-19. This suggests that there is no longer a reasonable belief that these drugs may be effective in treating the disease.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000801",
    "statement": "The fda has good emergency use of hydroxychloroquine for covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In addition, the FDA warned June 15 that hydroxychloroquine and chloroquine shouldnt be given in combination with remdesivir, an antiviral drug that has been shown to shorten recovery time from COVID-19 ( SN: 4/29/20 ).",
      "After reviewing evidence, its no longer reasonable to believe that [hydroxychloroquine] and [chloroquine] may be effective in treating COVID-19, Hinton wrote.",
      "Coronavirus (COVID-19) update: FDA revokes emergency use authorization for chloroquine and hydroxychloroquine."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided suggests that the FDA has revoked the emergency use authorization for hydroxychloroquine and chloroquine in treating COVID-19. This implies that there is currently insufficient evidence to support the claim that these drugs have good emergency use for COVID-19.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000802",
    "statement": "Antibody testing will enhance the power and accuracy of covid-19-prevention trials",
    "label": "SUPPORTED",
    "evidences": [
      "Knowing that someone seroconverts and becomes immune during the trial despite having no symptoms could, for instance, prove to be a more optimal outcome than simply preventing infection and the development of immunity altogether, as has been observed in some patients receiving chemoprophylaxis for influenza8.",
      "Here we argue that serological testing of trial participants at the start and end of the trial (and perhaps at intermediate points) will enhance the value and interpretability of these studies."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests that seroconversion (the process where a person develops antibodies in response to an infection) can provide valuable information about the effectiveness of covid-19 prevention trials. This is because it indicates that a person has developed immunity despite having no symptoms, which could be a more optimal outcome as observed in some patients receiving chemoprophylaxis for influenza. Therefore, antibody testing can potentially enhance the power and accuracy of covid-19 prevention trials by providing insights into this aspect.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000803",
    "statement": "Antibody testing will reduce the power and accuracy of covid-19-prevention trials",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Knowing that someone seroconverts and becomes immune during the trial despite having no symptoms could, for instance, prove to be a more optimal outcome than simply preventing infection and the development of immunity altogether, as has been observed in some patients receiving chemoprophylaxis for influenza8.",
      "Here we argue that serological testing of trial participants at the start and end of the trial (and perhaps at intermediate points) will enhance the value and interpretability of these studies."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence discusses the potential benefits of serological testing in COVID-19 trials, rather than suggesting that it will reduce the power and accuracy of such trials. The claim is not supported by the given evidence.",
    "confidence": 0.7
  },
  {
    "id": "covid_fact-000804",
    "statement": "Antibody testing will limit the power and accuracy of covid-19-prevention trials",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Knowing that someone seroconverts and becomes immune during the trial despite having no symptoms could, for instance, prove to be a more optimal outcome than simply preventing infection and the development of immunity altogether, as has been observed in some patients receiving chemoprophylaxis for influenza8.",
      "Here we argue that serological testing of trial participants at the start and end of the trial (and perhaps at intermediate points) will enhance the value and interpretability of these studies."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided suggests that antibody testing could potentially improve the interpretation and value of COVID-19 prevention trials by providing insight into immunity development. However, it does not directly support the claim that antibody testing will limit the power and accuracy of these trials. The focus seems to be on enhancing the understanding rather than undermining the trial's accuracy.",
    "confidence": 0.6
  },
  {
    "id": "covid_fact-000805",
    "statement": "Antibody testing will decrease the power and accuracy of covid-19-prevention trials",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Knowing that someone seroconverts and becomes immune during the trial despite having no symptoms could, for instance, prove to be a more optimal outcome than simply preventing infection and the development of immunity altogether, as has been observed in some patients receiving chemoprophylaxis for influenza8.",
      "Here we argue that serological testing of trial participants at the start and end of the trial (and perhaps at intermediate points) will enhance the value and interpretability of these studies."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided discusses the potential benefits of antibody testing in covid-19 trials, not its negative impact on their power and accuracy. The argument that serological testing could enhance the value and interpretability of studies suggests that it may have a positive effect.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000806",
    "statement": "Cytodyn reports strong results from eind covid-19 patients treated with leronlimab ; majority of patients have demonstrated remarkable recoveries",
    "label": "SUPPORTED",
    "evidences": [
      "Bruce Patterson, M.D., Chief Executive Officer and founder of IncellDx, a diagnostics company and an advisor to CytoDyn, expanded on these findings by stating, We are excited that patients are responding extremely well to leronlimab as expected from the novel mechanism of COVID-19 pathogenesis we discovered and will be reporting in the coming days. Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn said, We believe these results, although anecdotal, are very impressive and the number of patients treated under eIND is rapidly increasing.",
      "All patient blood samples were evaluated and important powerful results from the effect of leronlimab were demonstrated in almost all of these patients."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence consists of statements by individuals associated with CytoDyn, a company developing leronlimab for COVID-19 treatment. However, these are anecdotal claims and do not provide concrete, empirical data or results from a controlled study to support the statement that the majority of patients have demonstrated remarkable recoveries when treated with leronlimab.",
    "confidence": 0.7
  },
  {
    "id": "covid_fact-000807",
    "statement": "Cytodyn reports strong results from eind covid-19 patients treated with leronlimab ; none of patients have demonstrated remarkable recoveries",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Bruce Patterson, M.D., Chief Executive Officer and founder of IncellDx, a diagnostics company and an advisor to CytoDyn, expanded on these findings by stating, We are excited that patients are responding extremely well to leronlimab as expected from the novel mechanism of COVID-19 pathogenesis we discovered and will be reporting in the coming days. Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn said, We believe these results, although anecdotal, are very impressive and the number of patients treated under eIND is rapidly increasing.",
      "All patient blood samples were evaluated and important powerful results from the effect of leronlimab were demonstrated in almost all of these patients."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not directly support or refute the claim that 'none of patients have demonstrated remarkable recoveries'. The evidence only states that 'important powerful results from the effect of leronlimab were demonstrated in almost all of these patients', but it does not provide concrete information on whether these results translate to 'remarkable recoveries'.",
    "confidence": 0.6
  },
  {
    "id": "covid_fact-000808",
    "statement": "Cytodyn reports strong results from eind covid-19 patients treated with leronlimab ; few of patients have demonstrated remarkable recoveries",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Bruce Patterson, M.D., Chief Executive Officer and founder of IncellDx, a diagnostics company and an advisor to CytoDyn, expanded on these findings by stating, We are excited that patients are responding extremely well to leronlimab as expected from the novel mechanism of COVID-19 pathogenesis we discovered and will be reporting in the coming days. Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn said, We believe these results, although anecdotal, are very impressive and the number of patients treated under eIND is rapidly increasing.",
      "All patient blood samples were evaluated and important powerful results from the effect of leronlimab were demonstrated in almost all of these patients."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim mentions 'strong results' and 'remarkable recoveries' from COVID-19 patients treated with leronlimab, however, the evidence only states that the results are 'impressive' (according to Nader Pourhassan) and the blood samples were evaluated demonstrating powerful effects. The data does not provide specific numbers or details about the number of patients who have recovered remarkably.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000809",
    "statement": "Cytodyn reports strong results from eind covid-19 patients treated with leronlimab ; two of patients have demonstrated remarkable recoveries",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Bruce Patterson, M.D., Chief Executive Officer and founder of IncellDx, a diagnostics company and an advisor to CytoDyn, expanded on these findings by stating, We are excited that patients are responding extremely well to leronlimab as expected from the novel mechanism of COVID-19 pathogenesis we discovered and will be reporting in the coming days. Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn said, We believe these results, although anecdotal, are very impressive and the number of patients treated under eIND is rapidly increasing.",
      "All patient blood samples were evaluated and important powerful results from the effect of leronlimab were demonstrated in almost all of these patients."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided consists mainly of statements by two individuals involved with CytoDyn, a company developing leronlimab for treatment of COVID-19. While the statement suggests 'strong results' and 'remarkable recoveries', no concrete or quantifiable data has been presented to support these claims. The number and specifics of these patients, their recovery status, and the comparison against a control group are not mentioned.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000810",
    "statement": "Sars-cov-2 infects brain choroid plexus and disrupts the blood-csf-barrier",
    "label": "SUPPORTED",
    "evidences": [
      "We find that infected cells of the choroid plexus are an apolipoprotein and ACE2 expressing subset of epithelial barrier cells.",
      "These findings suggest that neurological complications may result from effects on the choroid plexus, an important barrier that normally prevents entry of immune cells and cytokines into the cerebrospinal fluid (CSF) and brain.",
      "We then challenge organoids with both SARS-CoV-2 spike protein pseudovirus and live virus to demonstrate high viral tropism for choroid plexus epithelial cells but not stromal cells, and little to no infection of neurons or glia.",
      "Here, we use brain organoids to examine SARS-CoV-2 neurotropism.",
      "Finally, we show that infection with live SARS-CoV-2 leads to barrier breakdown of the choroid plexus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that infected cells of the choroid plexus express ACE2, a receptor used by SARS-CoV-2 to enter cells. The findings suggest that neurological complications may result from effects on the choroid plexus, which is an important barrier preventing entry of immune cells and cytokines into the cerebrospinal fluid (CSF) and brain. Furthermore, the evidence shows that infection with live SARS-CoV-2 leads to barrier breakdown of the choroid plexus.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000811",
    "statement": "Sars-cov-2 infects intestinal choroid plexus and disrupts the blood-csf-barrier",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We find that infected cells of the choroid plexus are an apolipoprotein and ACE2 expressing subset of epithelial barrier cells.",
      "These findings suggest that neurological complications may result from effects on the choroid plexus, an important barrier that normally prevents entry of immune cells and cytokines into the cerebrospinal fluid (CSF) and brain.",
      "We then challenge organoids with both SARS-CoV-2 spike protein pseudovirus and live virus to demonstrate high viral tropism for choroid plexus epithelial cells but not stromal cells, and little to no infection of neurons or glia.",
      "Here, we use brain organoids to examine SARS-CoV-2 neurotropism.",
      "Finally, we show that infection with live SARS-CoV-2 leads to barrier breakdown of the choroid plexus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence presented shows that infected cells of the choroid plexus express ACE2, a protein known to be a receptor for SARS-CoV-2. The findings suggest neurological complications may result from effects on the choroid plexus, and they demonstrate high viral tropism for choroid plexus epithelial cells but not stromal cells, and little to no infection of neurons or glia. Furthermore, the evidence shows that infection with live SARS-CoV-2 leads to barrier breakdown of the choroid plexus.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000812",
    "statement": "Sars-cov-2 infects brain choroid plexus and backs the blood-csf-barrier",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We find that infected cells of the choroid plexus are an apolipoprotein and ACE2 expressing subset of epithelial barrier cells.",
      "These findings suggest that neurological complications may result from effects on the choroid plexus, an important barrier that normally prevents entry of immune cells and cytokines into the cerebrospinal fluid (CSF) and brain.",
      "We then challenge organoids with both SARS-CoV-2 spike protein pseudovirus and live virus to demonstrate high viral tropism for choroid plexus epithelial cells but not stromal cells, and little to no infection of neurons or glia.",
      "Here, we use brain organoids to examine SARS-CoV-2 neurotropism.",
      "Finally, we show that infection with live SARS-CoV-2 leads to barrier breakdown of the choroid plexus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides direct findings that infected cells of the choroid plexus express ACE2 (a receptor for SARS-CoV-2), suggesting potential infection by SARS-CoV-2. The evidence also shows that infection with live SARS-CoV-2 leads to barrier breakdown of the choroid plexus, further supporting the claim. The findings suggest neurological complications may result from effects on the choroid plexus, another indication that SARS-CoV-2 infects this part of the brain.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000813",
    "statement": "Coronial autopsies identify the indirect effects of covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "Deaths from drug and alcohol misuse significantly increased during the lockdown period in comparison to the same period in 2018 (appendix), but it was not possible to identify whether individual cases were influenced by COVID-19 movement restrictions.",
      "Review of autopsy reports enabled the determination of the relative contributions of undiagnosed COVID-19 and lockdown restrictions on deaths."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided discusses an increase in deaths from drug and alcohol misuse during the lockdown period compared to the same period in 2018, but it does not provide any information or autopsy reports that directly link these deaths to COVID-19 indirect effects. The review of autopsy reports suggests determining relative contributions, but this is different from identifying specific cases influenced by COVID-19.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000814",
    "statement": "Coronial autopsies identify the therapeutic effects of covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Deaths from drug and alcohol misuse significantly increased during the lockdown period in comparison to the same period in 2018 (appendix), but it was not possible to identify whether individual cases were influenced by COVID-19 movement restrictions.",
      "Review of autopsy reports enabled the determination of the relative contributions of undiagnosed COVID-19 and lockdown restrictions on deaths."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence does not directly support the claim that coronial autopsies identify the therapeutic effects of COVID-19. The evidence discusses an increase in deaths from drug and alcohol misuse during the lockdown period, and autopsy reports being used to determine the relative contributions of undiagnosed COVID-19 and lockdown restrictions on deaths, but it does not mention anything about therapeutic effects.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000815",
    "statement": "Coronial autopsies identify the biological effects of covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Deaths from drug and alcohol misuse significantly increased during the lockdown period in comparison to the same period in 2018 (appendix), but it was not possible to identify whether individual cases were influenced by COVID-19 movement restrictions.",
      "Review of autopsy reports enabled the determination of the relative contributions of undiagnosed COVID-19 and lockdown restrictions on deaths."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not directly support the claim that coronial autopsies identify the biological effects of COVID-19. While it mentions the review of autopsy reports to determine the relative contributions of undiagnosed COVID-19 and lockdown restrictions on deaths, it does not provide any information about the identification of the biological effects of COVID-19.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000816",
    "statement": "Coronial autopsies identify the cytotoxic effects of covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Deaths from drug and alcohol misuse significantly increased during the lockdown period in comparison to the same period in 2018 (appendix), but it was not possible to identify whether individual cases were influenced by COVID-19 movement restrictions.",
      "Review of autopsy reports enabled the determination of the relative contributions of undiagnosed COVID-19 and lockdown restrictions on deaths."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim states that coronial autopsies can identify the cytotoxic effects of Covid-19. The evidence supports this by stating that a review of autopsy reports enables the determination of the relative contributions of undiagnosed COVID-19 and lockdown restrictions on deaths, implying that the autopsy results can provide information about the presence and effects of Covid-19.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000817",
    "statement": "3blue1brown provided detailed simulations of an epidemic",
    "label": "SUPPORTED",
    "evidences": [
      "Epidemic Simulation An interactive inspired by 3Blue1Brown's \"Simulating an Epidemic\" video."
    ],
    "model_verdict": "ERROR",
    "explanation": "Failed to parse model response",
    "confidence": 0.0
  },
  {
    "id": "covid_fact-000818",
    "statement": "3blue1brown provided detailed simulations of an algorithm",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Epidemic Simulation An interactive inspired by 3Blue1Brown's \"Simulating an Epidemic\" video."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides a clear link between the 'Epidemic Simulation' interactive and a video titled 'Simulating an Epidemic', which was created by 3blue1brown. This implies that 3blue1brown provided detailed simulations of an algorithm in this video.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000819",
    "statement": "3blue1brown provided detailed simulations of an equation",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Epidemic Simulation An interactive inspired by 3Blue1Brown's \"Simulating an Epidemic\" video."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that the simulation is 'inspired by' 3blue1brown's 'Simulating an Epidemic' video, indicating that they provided detailed simulations of an equation in their video.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000820",
    "statement": "3blue1brown provided detailed simulations of an alignment",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Epidemic Simulation An interactive inspired by 3Blue1Brown's \"Simulating an Epidemic\" video."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence shows that a simulation inspired by a video created by '3Blue1Brown' was made for an epidemic, but it does not directly support the claim that they provided detailed simulations of an alignment.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000821",
    "statement": "Delaware medical supplier says fema seized 400,000 n95 masks , now he 's out millions of dollars",
    "label": "SUPPORTED",
    "evidences": [
      "Citing Defense Production Act authority, the FEMA document further ordered Indutex to \"set aside\" all N95 or surgical masks it may come to possess during the federal emergency for a potential sale to FEMA.",
      "George Gianforcaro, owner of the small, Newark, Delaware-based Indutex USA, said the Federal Emergency Management Agency did not pay him when it took possession of two imported shipments of masks bound for customers across the United States."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided shows that FEMA seized the N95 masks from Indutex USA, but it does not specify the number of masks seized (400,000). Additionally, the evidence does not confirm or deny whether Indutex is out millions of dollars as a result of this action.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000822",
    "statement": "Delaware medical supplier and fema seized 400,000 n95 masks, now he's out millions of dollars",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Citing Defense Production Act authority, the FEMA document further ordered Indutex to \"set aside\" all N95 or surgical masks it may come to possess during the federal emergency for a potential sale to FEMA.",
      "George Gianforcaro, owner of the small, Newark, Delaware-based Indutex USA, said the Federal Emergency Management Agency did not pay him when it took possession of two imported shipments of masks bound for customers across the United States."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not state that the Delaware medical supplier (Indutex) is out millions of dollars as a result of seizing 400,000 N95 masks by FEMA. It only mentions that Indutex owner George Gianforcaro claimed that FEMA did not pay him when they took possession of two shipments destined for other customers.",
    "confidence": 0.5
  },
  {
    "id": "covid_fact-000823",
    "statement": "Delaware medical supplier with fema seized 400,000 n95 masks, now he's out millions of dollars",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Citing Defense Production Act authority, the FEMA document further ordered Indutex to \"set aside\" all N95 or surgical masks it may come to possess during the federal emergency for a potential sale to FEMA.",
      "George Gianforcaro, owner of the small, Newark, Delaware-based Indutex USA, said the Federal Emergency Management Agency did not pay him when it took possession of two imported shipments of masks bound for customers across the United States."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not directly state that the Delaware medical supplier is now out millions of dollars due to the seizure of masks by FEMA. It only mentions that they did not receive payment from FEMA when their shipments were seized.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000824",
    "statement": "Fauci predicts us deaths from coronavirus",
    "label": "SUPPORTED",
    "evidences": [
      "Dr. Anthony Fauci said based on modeling of the current pace of the coronavirus' spread in the U.S., \"between 100,000 and 200,000\" people may die from COVID-19, the disease caused by the novel coronavirus.",
      "> Dr. Anthony Fauci says there could potentially be between 100,000 to 200,000 > deaths related to the coronavirus and millions of cases."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided directly supports the claim that Dr. Anthony Fauci predicted between 100,000 and 200,000 deaths from the coronavirus in the U.S.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000825",
    "statement": "Fauci predicts us deaths globally coronavirus",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Dr. Anthony Fauci said based on modeling of the current pace of the coronavirus' spread in the U.S., \"between 100,000 and 200,000\" people may die from COVID-19, the disease caused by the novel coronavirus.",
      "> Dr. Anthony Fauci says there could potentially be between 100,000 to 200,000 > deaths related to the coronavirus and millions of cases."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "Dr. Anthony Fauci's statement about potential deaths from COVID-19 due to its current pace in the U.S. is directly related to the claim made. The evidence supports this claim.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000826",
    "statement": "Fauci predicts us deaths worldwide coronavirus",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Dr. Anthony Fauci said based on modeling of the current pace of the coronavirus' spread in the U.S., \"between 100,000 and 200,000\" people may die from COVID-19, the disease caused by the novel coronavirus.",
      "> Dr. Anthony Fauci says there could potentially be between 100,000 to 200,000 > deaths related to the coronavirus and millions of cases."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The statement 'Fauci predicts us deaths worldwide coronavirus' is supported by the evidence provided which directly quotes Dr. Anthony Fauci as saying that 'between 100,000 and 200,000' people may die from COVID-19 in the U.S., implying he has made a prediction about deaths related to the coronavirus.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000827",
    "statement": "Leronlimab used in seven patients in nyc with severe covid-19 demonstrated promise with two intubated patients in icu , removed from icu and extubated with reduced pulmonary inflammation",
    "label": "SUPPORTED",
    "evidences": [
      "Our companion diagnostics showed that after three days of therapy, the immune profile in these patients approached normal levels and the levels of cytokines involved in the cytokine storm were much improved. Jacob Lalezari, M.D., Interim Chief Medical Officer of CytoDyn, commented, These preliminary results give hope that leronlimab may help hospitalized patients with COVID-19 recover from the pulmonary inflammation that drives mortality and the need for ventilators.",
      "The treatment with leronlimab is targeted as a therapy for patients who experience respiratory complications as a result of contracting SARS-CoV-2 causing the Coronavirus Disease 2019 (COVID-19).",
      "Moreover, a Phase 2b clinical trial demonstrated that leronlimab monotherapy can prevent viral escape in HIV-infected patients; some patients on leronlimab monotherapy have remained virally suppressed for more than five years.",
      "Clinical results to date from multiple trials have shown that leronlimab can significantly reduce viral burden in people infected with HIV with no reported drug-related serious adverse events (SAEs)."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided describes the potential beneficial effect of leronlimab on reducing pulmonary inflammation in patients with severe COVID-19, as well as its mechanism of action and previous clinical results in HIV treatment. However, it does not directly support the claim that two specific intubated patients were removed from the ICU and extubated after being treated with leronlimab.",
    "confidence": 0.7
  },
  {
    "id": "covid_fact-000828",
    "statement": "Leronlimab used in two patients in nyc with severe covid-19 demonstrated promise with two intubated patients in icu, removed from icu and extubated with reduced pulmonary inflammation",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our companion diagnostics showed that after three days of therapy, the immune profile in these patients approached normal levels and the levels of cytokines involved in the cytokine storm were much improved. Jacob Lalezari, M.D., Interim Chief Medical Officer of CytoDyn, commented, These preliminary results give hope that leronlimab may help hospitalized patients with COVID-19 recover from the pulmonary inflammation that drives mortality and the need for ventilators.",
      "The treatment with leronlimab is targeted as a therapy for patients who experience respiratory complications as a result of contracting SARS-CoV-2 causing the Coronavirus Disease 2019 (COVID-19).",
      "Moreover, a Phase 2b clinical trial demonstrated that leronlimab monotherapy can prevent viral escape in HIV-infected patients; some patients on leronlimab monotherapy have remained virally suppressed for more than five years.",
      "Clinical results to date from multiple trials have shown that leronlimab can significantly reduce viral burden in people infected with HIV with no reported drug-related serious adverse events (SAEs)."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not directly demonstrate that the specific patients in NYC experienced recovery and removal from ICU due to leronlimab treatment. It indicates improvement in immune profile and reduced pulmonary inflammation, but it is not clear if these improvements led to the patients being extubated or discharged from the ICU.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000829",
    "statement": "Leronlimab used in three patients in nyc with severe covid-19 demonstrated promise with two intubated patients in icu, removed from icu and extubated with reduced pulmonary inflammation",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our companion diagnostics showed that after three days of therapy, the immune profile in these patients approached normal levels and the levels of cytokines involved in the cytokine storm were much improved. Jacob Lalezari, M.D., Interim Chief Medical Officer of CytoDyn, commented, These preliminary results give hope that leronlimab may help hospitalized patients with COVID-19 recover from the pulmonary inflammation that drives mortality and the need for ventilators.",
      "The treatment with leronlimab is targeted as a therapy for patients who experience respiratory complications as a result of contracting SARS-CoV-2 causing the Coronavirus Disease 2019 (COVID-19).",
      "Moreover, a Phase 2b clinical trial demonstrated that leronlimab monotherapy can prevent viral escape in HIV-infected patients; some patients on leronlimab monotherapy have remained virally suppressed for more than five years.",
      "Clinical results to date from multiple trials have shown that leronlimab can significantly reduce viral burden in people infected with HIV with no reported drug-related serious adverse events (SAEs)."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not directly show that leronlimab has demonstrated promise in treating three patients with severe COVID-19, specifically showing improvement for two intubated patients and their subsequent removal from the ICU and extubation. The information given primarily discusses the potential positive effects of the treatment on immune profiles and cytokine levels but does not detail specific patient outcomes.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000830",
    "statement": "Leronlimab used in four patients in nyc with severe covid-19 demonstrated promise with two intubated patients in icu, removed from icu and extubated with reduced pulmonary inflammation",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our companion diagnostics showed that after three days of therapy, the immune profile in these patients approached normal levels and the levels of cytokines involved in the cytokine storm were much improved. Jacob Lalezari, M.D., Interim Chief Medical Officer of CytoDyn, commented, These preliminary results give hope that leronlimab may help hospitalized patients with COVID-19 recover from the pulmonary inflammation that drives mortality and the need for ventilators.",
      "The treatment with leronlimab is targeted as a therapy for patients who experience respiratory complications as a result of contracting SARS-CoV-2 causing the Coronavirus Disease 2019 (COVID-19).",
      "Moreover, a Phase 2b clinical trial demonstrated that leronlimab monotherapy can prevent viral escape in HIV-infected patients; some patients on leronlimab monotherapy have remained virally suppressed for more than five years.",
      "Clinical results to date from multiple trials have shown that leronlimab can significantly reduce viral burden in people infected with HIV with no reported drug-related serious adverse events (SAEs)."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that leronlimab therapy showed improvement in immune profile and reduction of cytokines involved in the cytokine storm, which is associated with severe COVID-19. The treatment is targeted towards patients experiencing respiratory complications from SARS-CoV-2 infection, and it was mentioned that two intubated patients in ICU were removed and extubated after therapy. Although specific numbers or cases aren't provided, the text implies that these improvements were observed in at least four patients in NYC.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000831",
    "statement": "Home testing for coronavirus to track levels of infection in the community",
    "label": "SUPPORTED",
    "evidences": [
      "The samples will be collected by courier and tested in the laboratory using the gold standard PCR (polymerase chain reaction) test, which detects the presence of genetic material from the virus.",
      "Home testing kits are widely used in health care, for example in the management of diabetes and the diagnosis of HIV."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided describes a method of using home testing kits for coronavirus, which involves collecting samples and sending them to a lab for PCR testing. The use of similar methods for other diseases (e.g., diabetes and HIV) supports the claim that home testing can be used for tracking levels of coronavirus infection in the community.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000832",
    "statement": "Laboratory testing for coronavirus to track levels of infection in the community",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The samples will be collected by courier and tested in the laboratory using the gold standard PCR (polymerase chain reaction) test, which detects the presence of genetic material from the virus.",
      "Home testing kits are widely used in health care, for example in the management of diabetes and the diagnosis of HIV."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests that laboratory testing for coronavirus is being conducted using PCR tests, which are used to detect the presence of genetic material from the virus. This indicates that such tests can be used to track levels of infection in a community. The use of home testing kits in healthcare also supports this claim as it shows that similar diagnostic methods are already utilized for other diseases.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000833",
    "statement": "Studies testing for coronavirus to track levels of infection in the community",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The samples will be collected by courier and tested in the laboratory using the gold standard PCR (polymerase chain reaction) test, which detects the presence of genetic material from the virus.",
      "Home testing kits are widely used in health care, for example in the management of diabetes and the diagnosis of HIV."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence supports the claim that studies testing for coronavirus to track levels of infection in the community are possible as they use a widely recognized and established test (PCR) to detect the presence of the virus's genetic material. Additionally, it is known that home testing kits are used in healthcare settings.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000834",
    "statement": "The sars-cov-2-like virus found in captive pangolins from guangdong should be better sequenced .",
    "label": "SUPPORTED",
    "evidences": [
      "bioRxiv - Bioinformatics Pub Date : 2020-05-07 , DOI: 10.1101/2020.05.07.077016 Alexandre Hassanin Viruses closely related to SARS-CoV-2, which is the virus responsible of the Covid-19 pandemic, were sequenced in several Sunda pangolins ( Manis javanica ) seized in the Guangdong and Guangxi provinces of China between 2017 and 20191-3.",
      "The GD/P2S dataset2 contains reads that are identical to SARS-CoV-2, suggesting either the coexistence of two SARS-CoV-2-like viruses in the same pangolin or contamination by the human virus.",
      "To overcome this absence, I assembled these genomes from the Sequence Read Archive (SRA) data available for SARS- CoV-2-like viruses detected in five captive pangolins from Guangdong."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides sequencing data for SARS-CoV-2-like viruses found in captive pangolins from Guangdong. The text suggests that the sequences are identical to SARS-CoV-2 but may represent contamination or coexistence of two similar viruses. To overcome this issue, the sequencing data is being improved by assembling genomes from the Sequence Read Archive (SRA) data available for these viruses. This suggests that better sequencing of the SARS-CoV-2-like virus found in captive pangolins from Guangdong is indeed necessary.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000835",
    "statement": "The sars-cov-2-like virus found in captive pangolins from guangdong cannot be better sequenced.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "bioRxiv - Bioinformatics Pub Date : 2020-05-07 , DOI: 10.1101/2020.05.07.077016 Alexandre Hassanin Viruses closely related to SARS-CoV-2, which is the virus responsible of the Covid-19 pandemic, were sequenced in several Sunda pangolins ( Manis javanica ) seized in the Guangdong and Guangxi provinces of China between 2017 and 20191-3.",
      "The GD/P2S dataset2 contains reads that are identical to SARS-CoV-2, suggesting either the coexistence of two SARS-CoV-2-like viruses in the same pangolin or contamination by the human virus.",
      "To overcome this absence, I assembled these genomes from the Sequence Read Archive (SRA) data available for SARS- CoV-2-like viruses detected in five captive pangolins from Guangdong."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided mentions the sequencing of SARS-CoV-2-like viruses in pangolins, but it does not explicitly state that these sequences are the best possible or cannot be improved further. To definitively answer whether the claim is supported or not, more information would be needed about what constitutes 'better sequencing' in this context.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000836",
    "statement": "High dose vitamin d improves total serum antioxidant capacity and icu outcome in critically ill patients.",
    "label": "SUPPORTED",
    "evidences": [
      "Perron RM, Lee P. Efficacy of high-dose vitamin D supplementation in the critically ill patients.",
      "Therefore, vitamin D has the ability to act synergistically on the immune response to acute systemic inflammation and infection (19, 34), lung epithelial function (35), muscle function and metabolism (36) and cardiac function (37), to name a few (Fig.",
      "Vitamin D status in critically ill patients: the evidence is now bioavailable!"
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided article references the potential benefits of high-dose vitamin D supplementation on various physiological functions in critically ill patients, but does not provide specific evidence for improvement in total serum antioxidant capacity or ICU outcomes.",
    "confidence": 0.4
  },
  {
    "id": "covid_fact-000837",
    "statement": "High dose vitamin d reduces total serum antioxidant capacity and icu outcome in critically ill patients.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Perron RM, Lee P. Efficacy of high-dose vitamin D supplementation in the critically ill patients.",
      "Therefore, vitamin D has the ability to act synergistically on the immune response to acute systemic inflammation and infection (19, 34), lung epithelial function (35), muscle function and metabolism (36) and cardiac function (37), to name a few (Fig.",
      "Vitamin D status in critically ill patients: the evidence is now bioavailable!"
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence only states that vitamin D has potential effects on immune response, lung epithelial function, muscle function and metabolism, cardiac function, among other things (19, 34-37). It does not directly support or contradict the claim that high dose vitamin D reduces total serum antioxidant capacity and ICU outcome in critically ill patients.",
    "confidence": 0.5
  },
  {
    "id": "covid_fact-000838",
    "statement": "High dose vitamin d decreased total serum antioxidant capacity and icu outcome in critically ill patients.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Perron RM, Lee P. Efficacy of high-dose vitamin D supplementation in the critically ill patients.",
      "Therefore, vitamin D has the ability to act synergistically on the immune response to acute systemic inflammation and infection (19, 34), lung epithelial function (35), muscle function and metabolism (36) and cardiac function (37), to name a few (Fig.",
      "Vitamin D status in critically ill patients: the evidence is now bioavailable!"
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not directly support the claim that high dose vitamin D decreased total serum antioxidant capacity and ICU outcome in critically ill patients. The evidence mentions the potential beneficial effects of vitamin D on immune response, lung epithelial function, muscle function, cardiac function, etc., but it does not demonstrate a causal link between high dose vitamin D and improved ICU outcomes or antioxidant capacity in critically ill patients.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000839",
    "statement": "High dose vitamin d reduced total serum antioxidant capacity and icu outcome in critically ill patients.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Perron RM, Lee P. Efficacy of high-dose vitamin D supplementation in the critically ill patients.",
      "Therefore, vitamin D has the ability to act synergistically on the immune response to acute systemic inflammation and infection (19, 34), lung epithelial function (35), muscle function and metabolism (36) and cardiac function (37), to name a few (Fig.",
      "Vitamin D status in critically ill patients: the evidence is now bioavailable!"
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence does not directly support or refute the claim that high dose vitamin D reduces total serum antioxidant capacity and ICU outcome in critically ill patients. The evidence only states that vitamin D has potential benefits on the immune response, lung epithelial function, muscle function, and cardiac function, but it does not specifically address the claim about total serum antioxidant capacity or ICU outcomes.",
    "confidence": 0.5
  },
  {
    "id": "covid_fact-000840",
    "statement": "Epidemiologic features and clinical course of 1st 18 patients infected with sars-cov-2 in singapore",
    "label": "SUPPORTED",
    "evidences": [
      "Conclusions and relevance: Among the first 18 patients diagnosed with SARS-CoV-2 infection in Singapore, clinical presentation was frequently a mild respiratory tract infection."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence only indicates the clinical presentation of the first 18 patients diagnosed with SARS-CoV-2 in Singapore was frequently a mild respiratory tract infection. However, it does not provide enough details about the epidemiologic features (such as age, gender distribution, geographical origin, exposure history) or the full course of the disease for each patient to support such a claim.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000841",
    "statement": "Epidemiologic features and clinical course of 10 18 patients infected with sars-cov-2 in singapore",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusions and relevance: Among the first 18 patients diagnosed with SARS-CoV-2 infection in Singapore, clinical presentation was frequently a mild respiratory tract infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly supports the claim that among the first 18 patients diagnosed with SARS-CoV-2 infection in Singapore, their clinical presentation was frequently a mild respiratory tract infection.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000842",
    "statement": "Epidemiologic features and clinical course of all 18 patients infected with sars-cov-2 in singapore",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusions and relevance: Among the first 18 patients diagnosed with SARS-CoV-2 infection in Singapore, clinical presentation was frequently a mild respiratory tract infection."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided only mentions that the first 18 patients diagnosed with SARS-CoV-2 infection in Singapore had a frequently mild respiratory tract infection. It does not provide enough information about the epidemiologic features or the clinical course of all 18 patients to definitively support this claim.",
    "confidence": 0.4
  },
  {
    "id": "covid_fact-000843",
    "statement": "Epidemiologic features and clinical course of over 18 patients infected with sars-cov-2 in singapore",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusions and relevance: Among the first 18 patients diagnosed with SARS-CoV-2 infection in Singapore, clinical presentation was frequently a mild respiratory tract infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides conclusions based on the clinical course of the first 18 patients infected with SARS-CoV-2 in Singapore, stating that the clinical presentation was frequently a mild respiratory tract infection.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000844",
    "statement": "A bifidobacterial protein that can reduce inflammation in covid-19 found by a rudn geneticist",
    "label": "SUPPORTED",
    "evidences": [
      "The fact that bifidobacterial surface proteins were able to recognize specific classes of cytokines supported the team's theory: these bacteria are also capable of regulating our immune response.",
      "A fragment of this protein can be used as an anti-inflammatory medication when treating coronavirus and other diseases."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence mentions that a bifidobacterial protein can recognize specific classes of cytokines (influential substances in the immune response) and that a fragment of this protein can be used as an anti-inflammatory medication when treating coronavirus. This suggests that the researcher (a rudn geneticist, according to the claim) may have discovered a bifidobacterial protein capable of reducing inflammation in covid-19.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000845",
    "statement": "A bifidobacterial protein that cannot reduce inflammation in covid-19 found by a rudn geneticist",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The fact that bifidobacterial surface proteins were able to recognize specific classes of cytokines supported the team's theory: these bacteria are also capable of regulating our immune response.",
      "A fragment of this protein can be used as an anti-inflammatory medication when treating coronavirus and other diseases."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided only indicates that bifidobacterial surface proteins can recognize specific classes of cytokines and potentially regulate immune response. It does not directly support the claim that a specific protein from this bacterium has been found to reduce inflammation specifically in COVID-19 or that it is being used as an anti-inflammatory medication for treating coronavirus.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000846",
    "statement": "A bifidobacterial virus that can reduce inflammation in covid-19 found by a rudn geneticist",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The fact that bifidobacterial surface proteins were able to recognize specific classes of cytokines supported the team's theory: these bacteria are also capable of regulating our immune response.",
      "A fragment of this protein can be used as an anti-inflammatory medication when treating coronavirus and other diseases."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not support the claim that a bifidobacterial virus has been found by a rudn geneticist to reduce inflammation in COVID-19. While the evidence suggests that certain bifidobacterial proteins can help regulate the immune response, it does not mention a virus or a discovery of a virus by a rudn geneticist specifically for reducing inflammation in COVID-19.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000847",
    "statement": "Swissmedic begins rolling review of moderna 's mrna vaccine against covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "This rolling review process allows Swissmedic to review data from ongoing clinical trials as soon as it is available."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The given evidence does not provide any specific information about a COVID-19 vaccine by Moderna being reviewed by Swissmedic. While the rolling review process allows Swissmedic to review data from ongoing clinical trials, it doesn't guarantee that any particular vaccine is under review.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000848",
    "statement": "Swissmedic begins rolling production of moderna's mrna vaccine against covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "This rolling review process allows Swissmedic to review data from ongoing clinical trials as soon as it is available."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence indicates that Swissmedic performs a rolling review process on data from Moderna's mRNA vaccine against COVID-19 clinical trials. However, it does not necessarily imply that production of the vaccine has begun at Swissmedic.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000849",
    "statement": "Sars-cov-2 spike protein promotes hyper-inflammatory response that can be ameliorated by spike-antagonistic peptide and fda-approved er stress and map kinase inhibitors in vitro",
    "label": "SUPPORTED",
    "evidences": [
      "We developed an antagonistic peptide that inhibits S1-ACE2 interaction and CoV2-S1-induced productions of pro-inflammatory cytokines.",
      "Here we demonstrate that 2019 SARS-CoV-2 spike protein subunit 1 (CoV2-S1) induces high levels of NF-\u03baB activations, production of pro- inflammatory cytokines and mild epithelial damage, in human bronchial epithelial cells."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that the spike protein of SARS-CoV-2 induces high levels of NF-\u03baB activations, production of pro-inflammatory cytokines and mild epithelial damage in human bronchial epithelial cells. The claim suggests that hyper-inflammatory response can be ameliorated by spike-antagonistic peptide (which is demonstrated in the evidence by its inhibition of S1-ACE2 interaction and CoV2-S1-induced productions of pro-inflammatory cytokines) and fda-approved er stress and map kinase inhibitors. Therefore, the evidence supports the claim.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000850",
    "statement": "Sars-cov-2 spike protein promotes hyper-inflammatory response that cannot be ameliorated by spike-antagonistic peptide and fda-approved er stress and map kinase inhibitors in vitro",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We developed an antagonistic peptide that inhibits S1-ACE2 interaction and CoV2-S1-induced productions of pro-inflammatory cytokines.",
      "Here we demonstrate that 2019 SARS-CoV-2 spike protein subunit 1 (CoV2-S1) induces high levels of NF-\u03baB activations, production of pro- inflammatory cytokines and mild epithelial damage, in human bronchial epithelial cells."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided shows that the spike protein of SARS-CoV-2 induces NF-\u03baB activation, production of pro-inflammatory cytokines, and mild epithelial damage in human bronchial epithelial cells. However, it does not provide clear evidence to support or refute the claim that this hyper-inflammatory response cannot be ameliorated by a spike-antagonistic peptide, FDA-approved ER stress and MAP kinase inhibitors. The development of an antagonistic peptide that inhibits S1-ACE2 interaction and CoV2-S1-induced production of pro-inflammatory cytokines is mentioned, but it's not clear whether this peptide can effectively ameliorate the hyper-inflammatory response in vivo.",
    "confidence": 0.75
  },
  {
    "id": "covid_fact-000851",
    "statement": "Finding suggests technology can be installed in air conditioning , vacuum , and water systems",
    "label": "SUPPORTED",
    "evidences": [
      "Eventually, as the science develops, the industry will be able to make the necessary adjustments and install the bulbs in robotic systems or air conditioning, vacuum, and water systems, and thereby be able to efficiently disinfect large surfaces and spaces.",
      "Disinfection systems based on LED bulbs, however, can be installed in the ventilation system and air conditioner, for example, and sterilize the air sucked in and then emitted into the room.",
      "In the future, the researchers will test their unique combination of integrated damage mechanisms and more ideas they recently developed on combined efficient direct and indirect damage to bacteria and viruses on different surfaces, air, and water."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that technology can be developed to install disinfection systems in robotic systems, air conditioning, vacuum, and water systems. The text mentions the possibility of installing such systems in ventilation systems and air conditioners, indicating that these specific systems are examples where this technology could potentially be applied.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000852",
    "statement": "Finding suggests technology cannot be installed in air conditioning, vacuum, and water systems",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Eventually, as the science develops, the industry will be able to make the necessary adjustments and install the bulbs in robotic systems or air conditioning, vacuum, and water systems, and thereby be able to efficiently disinfect large surfaces and spaces.",
      "Disinfection systems based on LED bulbs, however, can be installed in the ventilation system and air conditioner, for example, and sterilize the air sucked in and then emitted into the room.",
      "In the future, the researchers will test their unique combination of integrated damage mechanisms and more ideas they recently developed on combined efficient direct and indirect damage to bacteria and viruses on different surfaces, air, and water."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence suggests that technology can be installed in specific systems like ventilation and air conditioning for disinfection purposes. However, it does not clearly indicate that the same technology cannot be installed in air conditioning, vacuum, and water systems. The claim that no such technology can be installed is not supported by the provided evidence.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000853",
    "statement": "Oxford university vaccine shows 70 % protection - bbc news",
    "label": "SUPPORTED",
    "evidences": [
      "The researchers said it worked out at 70% protection, which is better than the seasonal flu jab."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly states that the Oxford University vaccine shows 70% protection, as per the researchers' statement.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000854",
    "statement": "Oxford university vaccine shows 70 % protection -19 news",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The researchers said it worked out at 70% protection, which is better than the seasonal flu jab."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided states that the Oxford University vaccine offers 70% protection, as reported by the researchers. This supports the claim made in the statement.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000855",
    "statement": "Mast cells activated by sars-cov-2 release histamine which increases il-1 levels causing cytokine storm and inflammatory reaction in covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "In this pathologic environment, the activation of mast cells (MCs) causes the release of histamine, proteases, cytokines, chemokines and arachidonic acid compounds, such as prostaglandin D2 and leukotrienes, all of which are involved in the inflammatory network.",
      "IL-1 induces throboxane-A2 (TxA2) in COVID-19 causing inflammation and micro-thrombi: inhibitory effect of the IL-1 receptor antagonist (IL-1Ra)."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided describes the activation of mast cells by sars-cov-2 leading to the release of histamine and cytokines such as IL-1. The text also states that IL-1 induces TxA2 which causes inflammation in COVID-19, suggesting a cytokine storm and inflammatory reaction.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000856",
    "statement": "Mast cells activated by sars-cov-2 release histamine which reduces il-1 levels causing cytokine storm and inflammatory reaction in covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In this pathologic environment, the activation of mast cells (MCs) causes the release of histamine, proteases, cytokines, chemokines and arachidonic acid compounds, such as prostaglandin D2 and leukotrienes, all of which are involved in the inflammatory network.",
      "IL-1 induces throboxane-A2 (TxA2) in COVID-19 causing inflammation and micro-thrombi: inhibitory effect of the IL-1 receptor antagonist (IL-1Ra)."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides a link between the activation of mast cells by SARS-CoV-2, the release of histamine and other inflammatory molecules, and the subsequent inflammation and potential cytokine storm observed in COVID-19. The reference to IL-1 inducing TxA2, which causes inflammation and micro-thrombi, also supports the claim by showing that IL-1 plays a role in inflammatory reactions in COVID-19.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000857",
    "statement": "Mast cells activated by sars-cov-2 release histamine which decreases il-1 levels causing cytokine storm and inflammatory reaction in covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In this pathologic environment, the activation of mast cells (MCs) causes the release of histamine, proteases, cytokines, chemokines and arachidonic acid compounds, such as prostaglandin D2 and leukotrienes, all of which are involved in the inflammatory network.",
      "IL-1 induces throboxane-A2 (TxA2) in COVID-19 causing inflammation and micro-thrombi: inhibitory effect of the IL-1 receptor antagonist (IL-1Ra)."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence suggests that mast cells activated by SARS-CoV-2 release various compounds, including histamine, cytokines, and chemokines, which are all involved in the inflammatory network. Additionally, another piece of evidence indicates that IL-1 induces Thromboxane-A2 (TxA2) in COVID-19, causing inflammation and micro-thrombi. This could be interpreted as a decrease in IL-1 levels leading to a cytokine storm and inflammatory reaction in COVID-19, as stated in the claim.",
    "confidence": 0.85
  },
  {
    "id": "covid_fact-000858",
    "statement": "Mast cells activated by sars-cov-2 release histamine which inhibits il-1 levels causing cytokine storm and inflammatory reaction in covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In this pathologic environment, the activation of mast cells (MCs) causes the release of histamine, proteases, cytokines, chemokines and arachidonic acid compounds, such as prostaglandin D2 and leukotrienes, all of which are involved in the inflammatory network.",
      "IL-1 induces throboxane-A2 (TxA2) in COVID-19 causing inflammation and micro-thrombi: inhibitory effect of the IL-1 receptor antagonist (IL-1Ra)."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence describes the activation of mast cells in a pathological environment leading to the release of histamine and cytokines (including IL-1). While it does not explicitly state that this results in inhibition of IL-1 levels causing a cytokine storm and inflammatory reaction specifically in COVID-19, it suggests a causal relationship between mast cell activation, cytokine release, and inflammation. The second part of the evidence also indicates the role of IL-1 in causing inflammation and micro-thrombi in COVID-19, which supports the claim indirectly.",
    "confidence": 0.85
  },
  {
    "id": "covid_fact-000859",
    "statement": "The furin cleavage site of sars-cov-2 spike protein is a key determinant for transmission due to enhanced replication in airway cells .",
    "label": "SUPPORTED",
    "evidences": [
      "Using lentiviral pseudotypes and a cell- culture adapted SARS-CoV-2 virus with a S1/S2 deletion, we show that the polybasic insertion is selected for in lung cells and primary human airway epithelial cultures but selected against in Vero E6, a cell line used for passaging SARS-CoV-2.",
      "The furin cleavage site of SARS-CoV-2 spike protein is a key determinant for transmission",
      "We find this selective advantage depends on expression of the cell surface protease, TMPRSS2, that allows virus entry independent of endosomes thus avoiding antiviral IFITM proteins.",
      "SARS-CoV-2 has a unique polybasic insertion at the S1/S2 CS, which we demonstrate can be cleaved by furin."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that the SARS-CoV-2 virus has a unique polybasic insertion at its spike protein's furin cleavage site, which can be cleaved by furin. This selective advantage depends on expression of the cell surface protease TMPRSS2, allowing virus entry independent of endosomes and avoiding antiviral IFITM proteins. Furthermore, the study demonstrates that this polybasic insertion is selected for in lung cells and primary human airway epithelial cultures, suggesting a key role in transmission.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000860",
    "statement": "The furin cleavage site of sars-cov-2 spike protein is a key determinant for transmission due to enhanced infection in airway cells.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Using lentiviral pseudotypes and a cell- culture adapted SARS-CoV-2 virus with a S1/S2 deletion, we show that the polybasic insertion is selected for in lung cells and primary human airway epithelial cultures but selected against in Vero E6, a cell line used for passaging SARS-CoV-2.",
      "The furin cleavage site of SARS-CoV-2 spike protein is a key determinant for transmission",
      "We find this selective advantage depends on expression of the cell surface protease, TMPRSS2, that allows virus entry independent of endosomes thus avoiding antiviral IFITM proteins.",
      "SARS-CoV-2 has a unique polybasic insertion at the S1/S2 CS, which we demonstrate can be cleaved by furin."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides experimental data that demonstrates a selective advantage of the polybasic insertion in lung cells and primary human airway epithelial cultures for SARS-CoV-2 virus replication, which requires furin cleavage site in the spike protein. This suggests that the furin cleavage site of SARS-CoV-2 spike protein plays a significant role in its transmission due to enhanced infection in airway cells.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000861",
    "statement": "Is there an airborne component to the transmission of covid-19 ?",
    "label": "SUPPORTED",
    "evidences": [
      "Conclusions Given that live SARS-CoV-2 virions are known to be shed in high concentrations from the nasal cavity of both symptomatic and asymptomatic COVID-19 patients, the results suggest that those sharing enclosed spaces with infectors for long periods may be at risk of contracting COVID-19 by the aerosol route, even when practicing social distancing.",
      "In order to quantify the risk posed by COVID-19 infectors exhaling respiratory aerosols in enclosed spaces, we undertook a computer modelling study to simulate transmission in an office building.",
      "]: dot [@]: at [MHRA]: Medicines and Healthcare products Regulatory Agency [JCVI]: Joint Committee for Vaccination and Immunisation [PMC]: Penske Media Corporation [ COVID-19]: coronavirus disease 2019 [COVID-19]: coronavirus disease 2019 [v]: View this template [t]: telephone [e]: email []: You need to accept this checkbox."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides information about the presence of SARS-CoV-2 virions in high concentrations from the nasal cavity of COVID-19 patients, which suggests aerosol transmission risk. Additionally, it mentions computer modeling studies to simulate transmission in enclosed spaces, supporting the idea that airborne spread can occur.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000862",
    "statement": "Is there an airborne component to the entry of covid-19?",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusions Given that live SARS-CoV-2 virions are known to be shed in high concentrations from the nasal cavity of both symptomatic and asymptomatic COVID-19 patients, the results suggest that those sharing enclosed spaces with infectors for long periods may be at risk of contracting COVID-19 by the aerosol route, even when practicing social distancing.",
      "In order to quantify the risk posed by COVID-19 infectors exhaling respiratory aerosols in enclosed spaces, we undertook a computer modelling study to simulate transmission in an office building.",
      "]: dot [@]: at [MHRA]: Medicines and Healthcare products Regulatory Agency [JCVI]: Joint Committee for Vaccination and Immunisation [PMC]: Penske Media Corporation [ COVID-19]: coronavirus disease 2019 [COVID-19]: coronavirus disease 2019 [v]: View this template [t]: telephone [e]: email []: You need to accept this checkbox."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests that COVID-19 can be transmitted through the aerosol route in enclosed spaces, indicating a potential for airborne spread. This supports the claim that there is an airborne component to the entry of COVID-19.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000863",
    "statement": "Is there an airborne component to the development of covid-19?",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusions Given that live SARS-CoV-2 virions are known to be shed in high concentrations from the nasal cavity of both symptomatic and asymptomatic COVID-19 patients, the results suggest that those sharing enclosed spaces with infectors for long periods may be at risk of contracting COVID-19 by the aerosol route, even when practicing social distancing.",
      "In order to quantify the risk posed by COVID-19 infectors exhaling respiratory aerosols in enclosed spaces, we undertook a computer modelling study to simulate transmission in an office building.",
      "]: dot [@]: at [MHRA]: Medicines and Healthcare products Regulatory Agency [JCVI]: Joint Committee for Vaccination and Immunisation [PMC]: Penske Media Corporation [ COVID-19]: coronavirus disease 2019 [COVID-19]: coronavirus disease 2019 [v]: View this template [t]: telephone [e]: email []: You need to accept this checkbox."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that COVID-19 can be transmitted through the aerosol route in enclosed spaces, which implies an airborne component to the disease transmission.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000864",
    "statement": "Is there an airborne component to the use of covid-19?",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusions Given that live SARS-CoV-2 virions are known to be shed in high concentrations from the nasal cavity of both symptomatic and asymptomatic COVID-19 patients, the results suggest that those sharing enclosed spaces with infectors for long periods may be at risk of contracting COVID-19 by the aerosol route, even when practicing social distancing.",
      "In order to quantify the risk posed by COVID-19 infectors exhaling respiratory aerosols in enclosed spaces, we undertook a computer modelling study to simulate transmission in an office building.",
      "]: dot [@]: at [MHRA]: Medicines and Healthcare products Regulatory Agency [JCVI]: Joint Committee for Vaccination and Immunisation [PMC]: Penske Media Corporation [ COVID-19]: coronavirus disease 2019 [COVID-19]: coronavirus disease 2019 [v]: View this template [t]: telephone [e]: email []: You need to accept this checkbox."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence discusses the aerosol route of transmission for SARS-CoV-2 virions (the virus that causes COVID-19), which are expelled from infected individuals through respiratory aerosols. This suggests that airborne spread of the virus is possible, particularly in enclosed spaces.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000865",
    "statement": "Saliva-based antigen testing is better than the pcr swab",
    "label": "SUPPORTED",
    "evidences": [
      "And, just as importantly, antigen-based testing is highly specific: unlike its PCR counterpart, the antigen test isnt fooled by faint signals of lingering viral matter outside the period of infectiousness.",
      "Fortunately, other attributes of saliva-based antigen testing make this feasible: unlike PCR, it doesnt require trained personnel, specific chemical supplies, or centralized, expensive laboratory instrument; it is less vulnerable to the supply chain bottlenecks that plague PCR-based labs; it returns results in a matter of hours; it costs as little as $1 per test; and it could be as convenient as sucking on a piece of paper.",
      "Rapid, saliva-based antigen testing is an essential weapon in the fight to resume many of the activities and reopen many of the venues that comprise what we used to call normal life. It is practical, convenient, cost-effective, and easily scaled."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests that antigen-based testing has several advantages over PCR swab tests, including convenience, cost-effectiveness, speed, and reduced need for specialized personnel and equipment. Additionally, it is mentioned that the antigen test is highly specific, which implies higher accuracy compared to its counterpart in detecting active infections.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000866",
    "statement": "Saliva-based antigen testing is lower than the pcr swab",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "And, just as importantly, antigen-based testing is highly specific: unlike its PCR counterpart, the antigen test isnt fooled by faint signals of lingering viral matter outside the period of infectiousness.",
      "Fortunately, other attributes of saliva-based antigen testing make this feasible: unlike PCR, it doesnt require trained personnel, specific chemical supplies, or centralized, expensive laboratory instrument; it is less vulnerable to the supply chain bottlenecks that plague PCR-based labs; it returns results in a matter of hours; it costs as little as $1 per test; and it could be as convenient as sucking on a piece of paper.",
      "Rapid, saliva-based antigen testing is an essential weapon in the fight to resume many of the activities and reopen many of the venues that comprise what we used to call normal life. It is practical, convenient, cost-effective, and easily scaled."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that saliva-based antigen testing is less expensive, less technically demanding, and returns results faster than PCR swab tests. Furthermore, the text emphasizes that it is an essential weapon in the fight against COVID-19 and that it can help resume many activities, supporting the claim.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000867",
    "statement": "Saliva-based antigen testing is less than the pcr swab",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "And, just as importantly, antigen-based testing is highly specific: unlike its PCR counterpart, the antigen test isnt fooled by faint signals of lingering viral matter outside the period of infectiousness.",
      "Fortunately, other attributes of saliva-based antigen testing make this feasible: unlike PCR, it doesnt require trained personnel, specific chemical supplies, or centralized, expensive laboratory instrument; it is less vulnerable to the supply chain bottlenecks that plague PCR-based labs; it returns results in a matter of hours; it costs as little as $1 per test; and it could be as convenient as sucking on a piece of paper.",
      "Rapid, saliva-based antigen testing is an essential weapon in the fight to resume many of the activities and reopen many of the venues that comprise what we used to call normal life. It is practical, convenient, cost-effective, and easily scaled."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that antigen-based testing is less vulnerable to supply chain bottlenecks, faster, cheaper, and more convenient than PCR swab tests. The text also mentions that it is highly specific, meaning it is not fooled by faint signals of viral matter outside the period of infectiousness.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000868",
    "statement": "10 % of stockholmers infected",
    "label": "SUPPORTED",
    "evidences": [
      "That is a horrible number. With cases having crossed the 30,000 mark, Swedens death toll in the pandemic has reached 3,831, more than three times the combined total of Denmark, Norway, Finland and Iceland, all nations with similar welfare systems and demographics.",
      "Published May 05, 2020 By the first weeks of April, 10 percent of Stockholms population had been infected with the coronavirus and developed antibodies, according to sampling collected via post from 1,000 of the citys residents."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is supported by the evidence provided in the text. The text states that 'by the first weeks of April, 10 percent of Stockholms population had been infected with the coronavirus and developed antibodies.'",
    "confidence": 1
  },
  {
    "id": "covid_fact-000869",
    "statement": "10 % of authorers infected",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "That is a horrible number. With cases having crossed the 30,000 mark, Swedens death toll in the pandemic has reached 3,831, more than three times the combined total of Denmark, Norway, Finland and Iceland, all nations with similar welfare systems and demographics.",
      "Published May 05, 2020 By the first weeks of April, 10 percent of Stockholms population had been infected with the coronavirus and developed antibodies, according to sampling collected via post from 1,000 of the citys residents."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly states that 10% of Stockholms population had been infected with the coronavirus and developed antibodies.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000870",
    "statement": "10 % of readers infected",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "That is a horrible number. With cases having crossed the 30,000 mark, Swedens death toll in the pandemic has reached 3,831, more than three times the combined total of Denmark, Norway, Finland and Iceland, all nations with similar welfare systems and demographics.",
      "Published May 05, 2020 By the first weeks of April, 10 percent of Stockholms population had been infected with the coronavirus and developed antibodies, according to sampling collected via post from 1,000 of the citys residents."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly states that 10 percent of Stockhom's population had been infected with the coronavirus and developed antibodies according to a sampling collected via post from 1,000 of the city's residents.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000871",
    "statement": "10 % of allers infected",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "That is a horrible number. With cases having crossed the 30,000 mark, Swedens death toll in the pandemic has reached 3,831, more than three times the combined total of Denmark, Norway, Finland and Iceland, all nations with similar welfare systems and demographics.",
      "Published May 05, 2020 By the first weeks of April, 10 percent of Stockholms population had been infected with the coronavirus and developed antibodies, according to sampling collected via post from 1,000 of the citys residents."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly states that 'by the first weeks of April, 10 percent of Stockholm's population had been infected with the coronavirus and developed antibodies.' This supports the claim that 10% of allers (presumably referring to Stockholm residents) were infected.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000872",
    "statement": "Sars-cov-2 d614g variant exhibits enhanced replication ex vivo and earlier transmission in vivo",
    "label": "SUPPORTED",
    "evidences": [
      "Our study demonstrated the SARS-CoV2 D614G substitution enhances infectivity, replication fitness, and early transmission.",
      "This article has been published \"SARS-CoV-2 D614G Variant Exhibits Efficient Replication ex vivo and Transmission in vivo\" in Science."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence directly supports the claim that the SARS-CoV2 d614g variant exhibits enhanced replication ex vivo and earlier transmission in vivo, as stated in the article title.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000873",
    "statement": "Sars-cov-2 d614g variant inhibited enhanced replication ex vivo and earlier transmission in vivo",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our study demonstrated the SARS-CoV2 D614G substitution enhances infectivity, replication fitness, and early transmission.",
      "This article has been published \"SARS-CoV-2 D614G Variant Exhibits Efficient Replication ex vivo and Transmission in vivo\" in Science."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided states that the SARS-CoV2 D614G variant enhances infectivity, replication fitness, and early transmission, but it does not explicitly confirm or refute the claim that it inhibited enhanced replication ex vivo and earlier transmission in vivo. The article title suggests a different conclusion.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000874",
    "statement": "Orf8 and orf3b antibodies are accurate serological markers of early and late sars-cov-2 infection",
    "label": "SUPPORTED",
    "evidences": [
      "We identified new targets of the immune response to SARS-CoV-2 and show that nucleocapsid, open reading frame (ORF)8 and ORF3b elicit the strongest specific antibody responses.",
      "We have identified ORF8 antibodies as a major marker of acute, convalescent and long-term antibody response to SARS-CoV-2 infection because of its immunodominance and specificity, in addition to N protein."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided states that ORF8 and ORF3b antibodies are identified as new targets of the immune response to SARS-CoV-2 and show strong specific antibody responses. Furthermore, it is stated that ORF8 antibodies are a major marker of acute, convalescent, and long-term antibody response to SARS-CoV-2 infection. This suggests that these antibodies can be accurate serological markers of early and late SARS-CoV-2 infection.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000875",
    "statement": "Orf8 and orf3b antibodies are accurate serological markers of early and acute sars-cov-2 infection",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We identified new targets of the immune response to SARS-CoV-2 and show that nucleocapsid, open reading frame (ORF)8 and ORF3b elicit the strongest specific antibody responses.",
      "We have identified ORF8 antibodies as a major marker of acute, convalescent and long-term antibody response to SARS-CoV-2 infection because of its immunodominance and specificity, in addition to N protein."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that ORF8 and ORF3b are identified as new targets of the immune response to SARS-CoV-2 and show strong specific antibody responses. Additionally, it is mentioned that ORF8 is a major marker of acute, convalescent and long-term antibody response to SARS-CoV-2 infection. Therefore, based on this information, it can be inferred that ORF8 and orf3b antibodies are accurate serological markers of early and acute SARS-CoV-2 infection.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000876",
    "statement": "Plasma from recovered covid19 subjects inhibits spike protein binding to ace2 in a microsphere-based inhibition assay",
    "label": "SUPPORTED",
    "evidences": [
      "Next, we find that plasma from all 22/24 subjects with anti-trimer IgGs inhibited ACE2-trimer binding to a greater degree than controls, and that the degree of inhibition correlated with anti-trimer IgG levels.",
      "This inhibition assay may be broadly useful to quantify the functional antibody response of recovered COVID19 patients or vaccine recipients in a cell-free assay system.",
      "Here we present microsphere-based Flow Cytometry assays that quantify both anti-spike IgGs in plasma, and the ability of plasma to inhibit the binding of spike protein to angiotensin converting enzyme 2 (ACE2)."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows that plasma from subjects recovered from COVID-19 inhibits spike protein binding to ACE2 in a microsphere-based inhibition assay, as indicated by the statement 'Next, we find that plasma from all 22/24 subjects with anti-trimer IgGs inhibited ACE2-trimer binding to a greater degree than controls'.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000877",
    "statement": "Blood from recovered covid19 subjects inhibits spike protein binding to ace2 in a microsphere-based inhibition assay",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Next, we find that plasma from all 22/24 subjects with anti-trimer IgGs inhibited ACE2-trimer binding to a greater degree than controls, and that the degree of inhibition correlated with anti-trimer IgG levels.",
      "This inhibition assay may be broadly useful to quantify the functional antibody response of recovered COVID19 patients or vaccine recipients in a cell-free assay system.",
      "Here we present microsphere-based Flow Cytometry assays that quantify both anti-spike IgGs in plasma, and the ability of plasma to inhibit the binding of spike protein to angiotensin converting enzyme 2 (ACE2)."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides results from an inhibition assay that shows plasma from recovered COVID-19 subjects (22/24) with anti-trimer IgGs inhibited ACE2-trimer binding to a greater degree than controls. This suggests that blood from these patients contains components that can inhibit the spike protein binding to ACE2, which is characteristic of SARS-CoV-2.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000878",
    "statement": "Rna from recovered covid19 subjects inhibits spike protein binding to ace2 in a microsphere-based inhibition assay",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Next, we find that plasma from all 22/24 subjects with anti-trimer IgGs inhibited ACE2-trimer binding to a greater degree than controls, and that the degree of inhibition correlated with anti-trimer IgG levels.",
      "This inhibition assay may be broadly useful to quantify the functional antibody response of recovered COVID19 patients or vaccine recipients in a cell-free assay system.",
      "Here we present microsphere-based Flow Cytometry assays that quantify both anti-spike IgGs in plasma, and the ability of plasma to inhibit the binding of spike protein to angiotensin converting enzyme 2 (ACE2)."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that plasma from recovered COVID-19 subjects with anti-trimer IgGs inhibited ACE2-trimer binding to a greater degree than controls, indicating that RNA from recovered COVID-19 subjects may indeed inhibit spike protein binding to ACE2 in the microsphere-based inhibition assay.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000879",
    "statement": "Cdna from recovered covid19 subjects inhibits spike protein binding to ace2 in a microsphere-based inhibition assay",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Next, we find that plasma from all 22/24 subjects with anti-trimer IgGs inhibited ACE2-trimer binding to a greater degree than controls, and that the degree of inhibition correlated with anti-trimer IgG levels.",
      "This inhibition assay may be broadly useful to quantify the functional antibody response of recovered COVID19 patients or vaccine recipients in a cell-free assay system.",
      "Here we present microsphere-based Flow Cytometry assays that quantify both anti-spike IgGs in plasma, and the ability of plasma to inhibit the binding of spike protein to angiotensin converting enzyme 2 (ACE2)."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that plasma from COVID-19 recovered subjects inhibited the binding of spike protein to ACE2 in a microsphere-based inhibition assay, and the degree of inhibition correlated with anti-trimer IgG levels. This implies that CDNA from recovered COVID-19 subjects could inhibit spike protein binding to ACE2.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000880",
    "statement": "Dana-farber to test blood cancer drug in covid-19 patients",
    "label": "SUPPORTED",
    "evidences": [
      "Dana-Farber will collaborate with the study sponsor to carry out corollary studies to understand how the immune system functions in COVID-19 patients and how the addition of BTK-inhibitors can stop immune over-activity in response to the virus."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not directly indicate that Dana-Farber is testing a blood cancer drug specifically in COVID-19 patients. Instead, it mentions a collaboration to study the immune system's response to COVID-19 and how adding BTK-inhibitors can affect this response. The claim needs further evidence to support it.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000881",
    "statement": "Dana-farber to test breast cancer drug in covid-19 patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Dana-Farber will collaborate with the study sponsor to carry out corollary studies to understand how the immune system functions in COVID-19 patients and how the addition of BTK-inhibitors can stop immune over-activity in response to the virus."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided suggests that Dana-Farber Cancer Institute is collaborating on a study involving BTK-inhibitors and COVID-19 patients to understand immune system functioning and potential over-activity in response to the virus. However, it does not directly support or refute the claim about testing a breast cancer drug specifically.",
    "confidence": 0.5
  },
  {
    "id": "covid_fact-000882",
    "statement": "Dana-farber to test human cancer drug in covid-19 patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Dana-Farber will collaborate with the study sponsor to carry out corollary studies to understand how the immune system functions in COVID-19 patients and how the addition of BTK-inhibitors can stop immune over-activity in response to the virus."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not explicitly state that Dana-Farber will test a human cancer drug on COVID-19 patients. It mentions collaboration to study how the immune system functions and the use of BTK-inhibitors in response to the virus, but there's no clear indication that a specific cancer drug is being tested.",
    "confidence": 0.5
  },
  {
    "id": "covid_fact-000883",
    "statement": "Hydroxychloroquine improves airflow and lowers circulating ige levels in subjects with moderate symptomatic asthma",
    "label": "SUPPORTED",
    "evidences": [
      "Hydroxychloroquine (HCQ) is a well-tolerated, safe immunomodulating drug, with proven efficacy in rheumatic diseases and known actions that suggest potential utility in the treatment of asthma."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence suggests that hydroxychloroquine is a well-tolerated, safe immunomodulating drug with potential utility in the treatment of asthma due to its known actions. However, this does not directly support the claim that it improves airflow and lowers circulating IGE levels in subjects with moderate symptomatic asthma.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000884",
    "statement": "Hydroxychloroquine improves airflow and increases circulating ige levels in subjects with moderate symptomatic asthma",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Hydroxychloroquine (HCQ) is a well-tolerated, safe immunomodulating drug, with proven efficacy in rheumatic diseases and known actions that suggest potential utility in the treatment of asthma."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided suggests that Hydroxychloroquine is a well-tolerated, safe drug with potential utility in the treatment of asthma due to its immunomodulating properties and known actions. However, it does not directly support or refute the claim that HCQ improves airflow and increases circulating IGE levels in subjects with moderate symptomatic asthma.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000885",
    "statement": "Hydroxychloroquine decreases airflow and lowers circulating ige levels in subjects with moderate symptomatic asthma",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Hydroxychloroquine (HCQ) is a well-tolerated, safe immunomodulating drug, with proven efficacy in rheumatic diseases and known actions that suggest potential utility in the treatment of asthma."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence suggests that hydroxychloroquine is a well-tolerated, safe drug with potential utility in the treatment of asthma due to its immunomodulating properties. However, it does not directly show or provide data to support the claim that HCQ decreases airflow and lowers circulating IGE levels specifically in subjects with moderate symptomatic asthma.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000886",
    "statement": "Hydroxychloroquine improves airflow and increased circulating ige levels in subjects with moderate symptomatic asthma",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Hydroxychloroquine (HCQ) is a well-tolerated, safe immunomodulating drug, with proven efficacy in rheumatic diseases and known actions that suggest potential utility in the treatment of asthma."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence suggests that Hydroxychloroquine (HCQ) has been proven effective in rheumatic diseases and may have potential utility in the treatment of asthma due to its immunomodulating properties. However, it does not provide direct or concrete evidence that HCQ improves airflow or increases circulating IgE levels in subjects with moderate symptomatic asthma.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000887",
    "statement": "Moderna has completed case accrual for first planned interim analysis of its mrna vaccine against covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "About mRNA-1273 mRNA-1273 is an mRNA vaccine against COVID-19 encoding for a prefusion stabilized form of the Spike (S) protein, which was co-developed by Moderna and investigators from NIAIDs Vaccine Research Center.",
      "The first clinical batch, which was funded by the Coalition for Epidemic Preparedness Innovations, was completed on February 7, 2020 and underwent analytical testing; it was shipped to the NIH on February 24, 42 days from sequence selection."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not explicitly state that Moderna has completed case accrual for the first planned interim analysis of its mRNA vaccine against COVID-19. However, it does mention the completion of the first clinical batch and shipping to NIH, which are important milestones in a vaccine trial but do not directly relate to case accrual.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000888",
    "statement": "Moderna has no case accrual for first planned interim analysis of its mrna vaccine against covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "About mRNA-1273 mRNA-1273 is an mRNA vaccine against COVID-19 encoding for a prefusion stabilized form of the Spike (S) protein, which was co-developed by Moderna and investigators from NIAIDs Vaccine Research Center.",
      "The first clinical batch, which was funded by the Coalition for Epidemic Preparedness Innovations, was completed on February 7, 2020 and underwent analytical testing; it was shipped to the NIH on February 24, 42 days from sequence selection."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence does not directly mention case accrual or the timing of a first planned interim analysis for Moderna's mRNA vaccine against COVID-19. While it is known that the first clinical batch was completed on February 7, 2020, there is no information about when or how data from this trial might be analyzed.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000889",
    "statement": "Moderna has completed case accrual for first planned interim analysis of its dna vaccine against covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "About mRNA-1273 mRNA-1273 is an mRNA vaccine against COVID-19 encoding for a prefusion stabilized form of the Spike (S) protein, which was co-developed by Moderna and investigators from NIAIDs Vaccine Research Center.",
      "The first clinical batch, which was funded by the Coalition for Epidemic Preparedness Innovations, was completed on February 7, 2020 and underwent analytical testing; it was shipped to the NIH on February 24, 42 days from sequence selection."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not explicitly state that Moderna has completed case accrual for the first planned interim analysis of its COVID-19 vaccine. While the timeline for producing and shipping the initial batch of the vaccine is mentioned, there's no information about whether the trial has progressed to the point of case accrual or interim analysis.",
    "confidence": 0.5
  },
  {
    "id": "covid_fact-000890",
    "statement": "Amplicon contamination in labs masquerades as covid19 in surveillance tests",
    "label": "SUPPORTED",
    "evidences": [
      "Minimizing instances of amplicon contamination and developing protocols for handling suspected cases are critical to propel research efforts and to avoid diverting university and healthcare resources from patients with COVID-19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided only mentions the importance of minimizing instances of amplicon contamination and developing protocols for handling suspected cases to avoid diverting resources from patients with COVID-19. It does not explicitly state or imply that amplicon contamination masquerades as COVID-19 in surveillance tests.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000891",
    "statement": "Amplicon contamination in human masquerades as covid19 in surveillance tests",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Minimizing instances of amplicon contamination and developing protocols for handling suspected cases are critical to propel research efforts and to avoid diverting university and healthcare resources from patients with COVID-19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided discusses the importance of minimizing instances of amplicon contamination in research and avoiding diverting resources from COVID-19 patients. However, it does not directly support or refute the claim about amplicon contamination in human samples masquerading as COVID-19 in surveillance tests.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000892",
    "statement": "Amplicon contamination in labs masquerades as covid19 in preparation tests",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Minimizing instances of amplicon contamination and developing protocols for handling suspected cases are critical to propel research efforts and to avoid diverting university and healthcare resources from patients with COVID-19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided discusses the importance of minimizing amplicon contamination in lab work and developing protocols to handle suspected cases. However, it does not provide any direct or indirect evidence that amplicon contamination masquerades as COVID-19 in preparation tests.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000893",
    "statement": "Amplicon contamination in labs masquerades as covid19 in children tests",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Minimizing instances of amplicon contamination and developing protocols for handling suspected cases are critical to propel research efforts and to avoid diverting university and healthcare resources from patients with COVID-19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not directly support the claim that amplicon contamination in labs masquerades as Covid-19 in children's tests. The statement about minimizing instances of amplicon contamination and developing protocols for handling suspected cases is generally true for all lab work, including but not limited to Covid-19 testing, and does not necessarily imply contaminated results are being misidentified as Covid-19.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000894",
    "statement": "Male sex hormones appear to help the coronavirus infiltrate human cells",
    "label": "SUPPORTED",
    "evidences": [
      "Her studies at the UCSF stem cell laboratory found that androgens -- male hormones, including testosterone -- actually help SARS-CoV-2, the specific coronavirus that causes COVID-19, infiltrate human cells."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that studies at UCSF stem cell laboratory found a connection between androgens (male hormones) and the ability of SARS-CoV-2 to infiltrate human cells.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000895",
    "statement": "Male sex hormones fail to help the coronavirus infiltrate human cells",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Her studies at the UCSF stem cell laboratory found that androgens -- male hormones, including testosterone -- actually help SARS-CoV-2, the specific coronavirus that causes COVID-19, infiltrate human cells."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly states that androgens, which are male hormones including testosterone, help SARS-CoV-2 infiltrate human cells. Therefore, the claim that male sex hormones fail to help the coronavirus infiltrate human cells is not supported by this information.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000896",
    "statement": "Il-6 : a novel signature associated with covid-19 disease progression and development of anti-sars-cov-2 antibodies",
    "label": "SUPPORTED",
    "evidences": [
      "Findings IL-6 and sMAdCAM expressed as a novel integrative marker (sMIL index) are associated both with disease-states (early infection and convalescence) as well as development of antiviral humoral responses.",
      "Share sMAdCAM:IL-6 (sMIL Index): A novel signature associated with COVID-19 disease progression and development of anti-SARS-CoV-2 antibodies Dhanashree Jagtap, Vikrant M Bhor, Shilpa Bhowmick, Nandini Kasarpalkar, Pooja Sagvekar, Bhalchandra Kulkarni, Manish Pathak, Nirjhar Chatterjee, Pranam Dolas, Harsha Palav, Snehal Kaginkar, Sharad Bhagat, Itti Munshi, Swapneil Parikh, Sachee Agrawal, Chandrakant Pawar, Mala Kaneria, Smita D Mahale, Jayanthi Shastri, Vainav Patel medRxiv 2020.10.13.20182949; doi: https://doi.org/10.1101/2020.10.13.20182949 Share This Article: Copy Citation Tools sMAdCAM:IL-6 (sMIL Index): A novel signature associated with COVID-19 disease progression and development of anti-SARS-CoV-2 antibodies Dhanashree Jagtap, Vikrant M Bhor, Shilpa Bhowmick, Nandini Kasarpalkar, Pooja Sagvekar, Bhalchandra Kulkarni, Manish Pathak, Nirjhar Chatterjee, Pranam Dolas, Harsha Palav, Snehal Kaginkar, Sharad Bhagat, Itti Munshi, Swapneil Parikh, Sachee Agrawal, Chandrakant Pawar, Mala Kaneria, Smita D Mahale, Jayanthi Shastri, Vainav Patel medRxiv 2020.10.13.20182949; doi: https://doi.org/10.1101/2020.10.13.20182949 "
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that sMAdCAM:IL-6 (sMIL Index) is associated with COVID-19 disease progression and development of anti-SARS-CoV-2 antibodies. This implies that the Il-6 is indeed a novel signature associated with covid-19 disease progression.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000897",
    "statement": "Il-6 : a common signature associated with covid-19 disease progression and development of anti-sars-cov-2 antibodies",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Findings IL-6 and sMAdCAM expressed as a novel integrative marker (sMIL index) are associated both with disease-states (early infection and convalescence) as well as development of antiviral humoral responses.",
      "Share sMAdCAM:IL-6 (sMIL Index): A novel signature associated with COVID-19 disease progression and development of anti-SARS-CoV-2 antibodies Dhanashree Jagtap, Vikrant M Bhor, Shilpa Bhowmick, Nandini Kasarpalkar, Pooja Sagvekar, Bhalchandra Kulkarni, Manish Pathak, Nirjhar Chatterjee, Pranam Dolas, Harsha Palav, Snehal Kaginkar, Sharad Bhagat, Itti Munshi, Swapneil Parikh, Sachee Agrawal, Chandrakant Pawar, Mala Kaneria, Smita D Mahale, Jayanthi Shastri, Vainav Patel medRxiv 2020.10.13.20182949; doi: https://doi.org/10.1101/2020.10.13.20182949 Share This Article: Copy Citation Tools sMAdCAM:IL-6 (sMIL Index): A novel signature associated with COVID-19 disease progression and development of anti-SARS-CoV-2 antibodies Dhanashree Jagtap, Vikrant M Bhor, Shilpa Bhowmick, Nandini Kasarpalkar, Pooja Sagvekar, Bhalchandra Kulkarni, Manish Pathak, Nirjhar Chatterjee, Pranam Dolas, Harsha Palav, Snehal Kaginkar, Sharad Bhagat, Itti Munshi, Swapneil Parikh, Sachee Agrawal, Chandrakant Pawar, Mala Kaneria, Smita D Mahale, Jayanthi Shastri, Vainav Patel medRxiv 2020.10.13.20182949; doi: https://doi.org/10.1101/2020.10.13.20182949 "
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that IL-6 is associated with COVID-19 disease progression and development of anti-SARS-CoV-2 antibodies according to the study 'sMAdCAM:IL-6 (sMIL Index): A novel signature associated with COVID-19 disease progression and development of anti-SARS-CoV-2 antibodies'. The evidence also mentions that this association is found both during early infection and convalescence.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000898",
    "statement": "Slovakia to test all adults for sars-cov-2",
    "label": "SUPPORTED",
    "evidences": [
      "Slovakia has begun a massive operation to test its entire adult population for SARS-CoV-2 in a bid to halt what its government has said is an alarming acceleration of the spread of the virus in the country."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that Slovakia has started a massive operation to test its entire adult population for SARS-CoV-2. This directly supports the claim that Slovakia is testing all adults for SARS-CoV-2.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000899",
    "statement": "He to test all adults for sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Slovakia has begun a massive operation to test its entire adult population for SARS-CoV-2 in a bid to halt what its government has said is an alarming acceleration of the spread of the virus in the country."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that Slovakia is indeed conducting a mass operation to test its entire adult population for SARS-CoV-2, which supports the claim.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000900",
    "statement": "Slovakia to represent all adults for sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Slovakia has begun a massive operation to test its entire adult population for SARS-CoV-2 in a bid to halt what its government has said is an alarming acceleration of the spread of the virus in the country."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided only indicates that Slovakia is testing its entire adult population for SARS-CoV-2, which does not necessarily mean they will represent all adults for the virus.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000901",
    "statement": "failed to test all adults for sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Slovakia has begun a massive operation to test its entire adult population for SARS-CoV-2 in a bid to halt what its government has said is an alarming acceleration of the spread of the virus in the country."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence states that Slovakia started a massive operation to test its entire adult population for SARS-CoV-2, not that it has failed to do so in the past.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000902",
    "statement": "Extra doses found in pfizer 's coronavirus vaccine.",
    "label": "SUPPORTED",
    "evidences": [
      "Owermohle S. FDA says Pfizer vaccine vials hold extra doses, expanding supply.",
      "Author: TEGNA Published: 6:03 PM PST December 16, 2020 Updated: 9:45 PM PST December 16, 2020 Pharmacists have discovered that many of the vials which are supposed to hold five doses of Pfizer's coronavirus vaccine have extra doses, multiple outlets are reporting.",
      "FDA says extra doses from vials of Pfizer's COVID-19 vaccine can be used.",
      "Reuters ; December 16, 2020. https://www.reuters.com/article/health-coronavirus-usa-pfizer/fda-says-extra-doses-from-vials-of-pfizers-covid-19-vaccine-can-be-used-idUSKBN28R050."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that pharmacists have discovered extra doses in the vials of Pfizer's coronavirus vaccine and the FDA has approved their use. This suggests that it is indeed the case that extra doses are found in Pfizer's coronavirus vaccine.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000903",
    "statement": "No doses found in pfizer's coronavirus vaccine.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Owermohle S. FDA says Pfizer vaccine vials hold extra doses, expanding supply.",
      "Author: TEGNA Published: 6:03 PM PST December 16, 2020 Updated: 9:45 PM PST December 16, 2020 Pharmacists have discovered that many of the vials which are supposed to hold five doses of Pfizer's coronavirus vaccine have extra doses, multiple outlets are reporting.",
      "FDA says extra doses from vials of Pfizer's COVID-19 vaccine can be used.",
      "Reuters ; December 16, 2020. https://www.reuters.com/article/health-coronavirus-usa-pfizer/fda-says-extra-doses-from-vials-of-pfizers-covid-19-vaccine-can-be-used-idUSKBN28R050."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that extra doses can be found in Pfizer's coronavirus vaccine vials, as reported by multiple outlets and confirmed by the FDA.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000904",
    "statement": "One doses found in pfizer's coronavirus vaccine.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Owermohle S. FDA says Pfizer vaccine vials hold extra doses, expanding supply.",
      "Author: TEGNA Published: 6:03 PM PST December 16, 2020 Updated: 9:45 PM PST December 16, 2020 Pharmacists have discovered that many of the vials which are supposed to hold five doses of Pfizer's coronavirus vaccine have extra doses, multiple outlets are reporting.",
      "FDA says extra doses from vials of Pfizer's COVID-19 vaccine can be used.",
      "Reuters ; December 16, 2020. https://www.reuters.com/article/health-coronavirus-usa-pfizer/fda-says-extra-doses-from-vials-of-pfizers-covid-19-vaccine-can-be-used-idUSKBN28R050."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that pharmacists have discovered extra doses in Pfizer's coronavirus vaccine vials and the FDA has approved the use of these extra doses. This indicates that there are indeed extra doses found in Pfizer's coronavirus vaccine.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000905",
    "statement": "Low doses found in pfizer's coronavirus vaccine.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Owermohle S. FDA says Pfizer vaccine vials hold extra doses, expanding supply.",
      "Author: TEGNA Published: 6:03 PM PST December 16, 2020 Updated: 9:45 PM PST December 16, 2020 Pharmacists have discovered that many of the vials which are supposed to hold five doses of Pfizer's coronavirus vaccine have extra doses, multiple outlets are reporting.",
      "FDA says extra doses from vials of Pfizer's COVID-19 vaccine can be used.",
      "Reuters ; December 16, 2020. https://www.reuters.com/article/health-coronavirus-usa-pfizer/fda-says-extra-doses-from-vials-of-pfizers-covid-19-vaccine-can-be-used-idUSKBN28R050."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that extra doses can be found in Pfizer's coronavirus vaccine vials, according to the FDA. Therefore, it is supported that low doses are found in the Pfizer's coronavirus vaccine.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000906",
    "statement": "Bradykinin initiates cytokine-mediated inflammatory hyperalgesia",
    "label": "SUPPORTED",
    "evidences": [
      "These data show that bradykinin can initiate the cascade of cytokine release that mediates hyperalgesic responses to carrageenin and endotoxin (1 microgram).",
      "Bradykinin release of TNF-alpha plays a key role in the development of inflammatory hyperalgesia."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows that bradykinin triggers the release of TNF-alpha (Tumor Necrosis Factor alpha), a cytokine known to mediate inflammatory responses. Hyperalgesia is an increase in pain sensitivity, often associated with inflammation. Therefore, it can be inferred that bradykinin initiates cytokine-mediated inflammatory hyperalgesia based on the evidence.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000907",
    "statement": "Bradykinin initiates cytokine-independent inflammatory hyperalgesia",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These data show that bradykinin can initiate the cascade of cytokine release that mediates hyperalgesic responses to carrageenin and endotoxin (1 microgram).",
      "Bradykinin release of TNF-alpha plays a key role in the development of inflammatory hyperalgesia."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided shows that bradykinin can initiate the release of TNF-alpha and contributes to the development of inflammatory hyperalgesia. However, it does not show whether bradykinin can initiate cytokine-independent inflammatory hyperalgesia as stated in the claim.",
    "confidence": 0.6
  },
  {
    "id": "covid_fact-000908",
    "statement": "Bradykinin cans cytokine-mediated inflammatory hyperalgesia",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These data show that bradykinin can initiate the cascade of cytokine release that mediates hyperalgesic responses to carrageenin and endotoxin (1 microgram).",
      "Bradykinin release of TNF-alpha plays a key role in the development of inflammatory hyperalgesia."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence indicates that bradykinin is involved in the release of TNF-alpha (a cytokine) which plays a key role in the development of inflammatory hyperalgesia (hypersensitivity to pain).",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000909",
    "statement": "Potently neutralizing human antibodies that block sars-cov-2 receptor binding and protect animals",
    "label": "SUPPORTED",
    "evidences": [
      "From a panel of monoclonal antibodies (mAbs) targeting the spike (S) glycoprotein isolated from the B cells of infected subjects, we identified several mAbs that exhibited potent neutralizing activity with IC50 values as low as 0.9 or 15 ng/mL in pseudovirus or wild-type ( wt ) SARS-CoV-2 neutralization tests, respectively."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides data on the identification of monoclonal antibodies (mAbs) that exhibit potent neutralizing activity against SARS-CoV-2. The low IC50 values in the neutralization tests (0.9 ng/mL and 15 ng/mL) support this claim.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000910",
    "statement": "Potently neutralizing mouse antibodies that block sars-cov-2 receptor binding and protect animals",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "From a panel of monoclonal antibodies (mAbs) targeting the spike (S) glycoprotein isolated from the B cells of infected subjects, we identified several mAbs that exhibited potent neutralizing activity with IC50 values as low as 0.9 or 15 ng/mL in pseudovirus or wild-type ( wt ) SARS-CoV-2 neutralization tests, respectively."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence demonstrates the identification of several monoclonal antibodies (mAbs) that exhibit potent neutralizing activity against SARS-CoV-2. This implies that these mAbs can potentially protect animals from SARS-CoV-2 infection.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000911",
    "statement": "Potently neutralizing human antibodies that block sars-cov-2 receptor binding and neutralization animals",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "From a panel of monoclonal antibodies (mAbs) targeting the spike (S) glycoprotein isolated from the B cells of infected subjects, we identified several mAbs that exhibited potent neutralizing activity with IC50 values as low as 0.9 or 15 ng/mL in pseudovirus or wild-type ( wt ) SARS-CoV-2 neutralization tests, respectively."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows the identification of monoclonal antibodies (mAbs) that exhibit potent neutralizing activity against SARS-CoV-2. This directly supports the claim that the mAbs can potently neutralize human antibodies that block sars-cov-2 receptor binding and neutralization.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000912",
    "statement": "Persistence of viral rna , pneumocyte syncytia and thrombosis are hallmarks of advanced covid-19 pathology",
    "label": "SUPPORTED",
    "evidences": [
      "Viral presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study.",
      "COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided in the form of two separate studies suggest that viral presence (persistent RNA), pneumocyte syncytia (damage to type II alveolar cells), and thrombosis (blood clots) are observed in patients with severe or lethal COVID-19, thus supporting the claim.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000913",
    "statement": "Persistence of viral dna, pneumocyte syncytia and thrombosis are hallmarks of advanced covid-19 pathology",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Viral presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study.",
      "COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence consists of two studies that focus on COVID-19 pathology in patients with lethal cases of the disease. One study specifically mentions viral presence (persistence of viral DNA), and the other study discusses thrombosis as a complication associated with COVID-19. The concept of pneumocyte syncytia is also widely recognized as a hallmark pathology in severe cases of COVID-19, as these multinucleated giant cells are formed due to alveolar epithelial cell fusion, which is a response to the SARS-CoV-2 virus. Therefore, all three hallmarks (persistent viral DNA, pneumocyte syncytia, and thrombosis) can be found in advanced COVID-19 pathology based on the available evidence.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000914",
    "statement": "Persistence of viral replication, pneumocyte syncytia and thrombosis are hallmarks of advanced covid-19 pathology",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Viral presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study.",
      "COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence consists of two studies focusing on autopsy findings in patients with severe COVID-19 and the relationship between COVID-19 and thrombosis. The persistence of viral replication, pneumocyte syncytia (a hallmark of SARS-CoV-2 infection), and thrombosis are key findings reported in both studies.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000915",
    "statement": "The novel severe acute respiratory syndrome coronavirus 2 directly decimates human spleens and lymph nodes",
    "label": "SUPPORTED",
    "evidences": [
      "The Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Directly Decimates Human Spleens and Lymph Nodes",
      "SARS-CoV-2 infection induces severe tissue damage including lymph follicle depletion, splenic nodule atrophy, histiocyte hyperplasia and lymphocyte reductions.",
      "The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) directly decimates human spleens and lymph nodes."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided directly states that SARS-CoV-2 infection induces severe tissue damage in the spleen and lymph nodes.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000916",
    "statement": "The primary severe acute respiratory syndrome coronavirus 2 directly decimates human spleens and lymph nodes",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Directly Decimates Human Spleens and Lymph Nodes",
      "SARS-CoV-2 infection induces severe tissue damage including lymph follicle depletion, splenic nodule atrophy, histiocyte hyperplasia and lymphocyte reductions.",
      "The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) directly decimates human spleens and lymph nodes."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided states that SARS-CoV-2 infection induces severe tissue damage including lymph follicle depletion (lymph nodes) and splenic nodule atrophy (spleen). These changes are considered as decimation of the mentioned organs.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000917",
    "statement": "The first severe acute respiratory syndrome coronavirus 2 directly decimates human spleens and lymph nodes",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Directly Decimates Human Spleens and Lymph Nodes",
      "SARS-CoV-2 infection induces severe tissue damage including lymph follicle depletion, splenic nodule atrophy, histiocyte hyperplasia and lymphocyte reductions.",
      "The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) directly decimates human spleens and lymph nodes."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence directly states that SARS-CoV-2 infection induces severe tissue damage including 'lymph follicle depletion' and 'splenic nodule atrophy', which implies the decimation of human spleens and lymph nodes.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000918",
    "statement": "Researchers discover new variant of covid-19 virus in columbus , ohio.",
    "label": "SUPPORTED",
    "evidences": [
      "The Ohio State Wexner Medical Center has been sequencing the genome of SARS- Cov-2 viruses in patients with COVID-19 since March 2020 in order to monitor the evolution of the virus.",
      "Doctors at Ohio State talked about the COVID-19 vaccine and the new variant of the coronavirus in the briefing below.",
      "Scientists at The Ohio State University Wexner Medical Center and College of Medicine have discovered a new strain of COVID-19.",
      "> OSU COVID variant > > Researchers at Ohio State discuss COVID-19 vaccinations and a new variant of > the virus discovered in Columbus.",
      "The Ohio State Wexner Medical Center has been sequencing the genome of SARS- CoV-2 viruses in patients with COVID-19 since March 2020 in order to monitor the evolution of the virus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is supported by the evidence provided because it is explicitly stated that scientists at The Ohio State University Wexner Medical Center and College of Medicine have discovered a new strain of COVID-19.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000919",
    "statement": "Researchers no new variant of covid-19 virus in columbus, ohio.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The Ohio State Wexner Medical Center has been sequencing the genome of SARS- Cov-2 viruses in patients with COVID-19 since March 2020 in order to monitor the evolution of the virus.",
      "Doctors at Ohio State talked about the COVID-19 vaccine and the new variant of the coronavirus in the briefing below.",
      "Scientists at The Ohio State University Wexner Medical Center and College of Medicine have discovered a new strain of COVID-19.",
      "> OSU COVID variant > > Researchers at Ohio State discuss COVID-19 vaccinations and a new variant of > the virus discovered in Columbus.",
      "The Ohio State Wexner Medical Center has been sequencing the genome of SARS- CoV-2 viruses in patients with COVID-19 since March 2020 in order to monitor the evolution of the virus."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided mentions that scientists at The Ohio State University Wexner Medical Center and College of Medicine have discovered a new strain of COVID-19, but it does not specify that the discovery was made in Columbus, Ohio.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000920",
    "statement": "Coronavirus vaccine shows promising early results in china",
    "label": "SUPPORTED",
    "evidences": [
      "Lab research at CanSino Biologics in Tianjin, China, in 2018.Credit...China Stringer Network/Reuters By Apoorva Mandavilli Published May 22, 2020Updated July 16, 2020 A vaccine developed in China appears to be safe and may protect people from the new coronavirus, researchers reported on Friday.",
      "A vaccine for the new coronavirus is considered to be the best long-term solution for allowing countries to reopen their economies and return to normalcy.",
      "That vaccine has now entered mid-stage human trials, the manufacturer, Sinovac Biotech Ltd., said on Friday."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided describes lab research conducted in 2018 at CanSino Biologics in Tianjin, China on a vaccine for the new coronavirus. This research is preliminary and does not necessarily mean that the vaccine shows promising early results in China as of the time the claim was made.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000921",
    "statement": "Coronavirus vaccine shows no early results in china",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Lab research at CanSino Biologics in Tianjin, China, in 2018.Credit...China Stringer Network/Reuters By Apoorva Mandavilli Published May 22, 2020Updated July 16, 2020 A vaccine developed in China appears to be safe and may protect people from the new coronavirus, researchers reported on Friday.",
      "A vaccine for the new coronavirus is considered to be the best long-term solution for allowing countries to reopen their economies and return to normalcy.",
      "That vaccine has now entered mid-stage human trials, the manufacturer, Sinovac Biotech Ltd., said on Friday."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided only states that a vaccine developed in China has entered mid-stage human trials and appears to be safe and may protect people from the new coronavirus. It does not provide any information about early results of the vaccine in China.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000922",
    "statement": "Sars-cov-2 triggers inflammatory responses and cell death through caspase-8 activation",
    "label": "SUPPORTED",
    "evidences": [
      "4 SARS-CoV-2 infection triggers apoptosis through caspase-8 activation.",
      "2 SARS-CoV-2 infection induces caspase-8 activation to mediate pro-IL-1\u03b2 processing.",
      "2 SARS-CoV-2 infection induces caspase-8 activation Fig.",
      "SARS-CoV-2 infection induces the cell death through the activation of caspase-8.",
      "Here we report that SARS-CoV-2 infection activates caspase-8 to trigger cell apoptosis and inflammatory cytokine processing in the lung epithelial cells."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided directly states that SARS-CoV-2 infection activates caspase-8 which triggers cell apoptosis and inflammatory cytokine processing in lung epithelial cells. This supports the claim that SARS-CoV-2 triggers inflammatory responses and cell death through caspase-8 activation.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000923",
    "statement": "Sars-cov-2 suppress inflammatory responses and cell death through caspase-8 activation",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "4 SARS-CoV-2 infection triggers apoptosis through caspase-8 activation.",
      "2 SARS-CoV-2 infection induces caspase-8 activation to mediate pro-IL-1\u03b2 processing.",
      "2 SARS-CoV-2 infection induces caspase-8 activation Fig.",
      "SARS-CoV-2 infection induces the cell death through the activation of caspase-8.",
      "Here we report that SARS-CoV-2 infection activates caspase-8 to trigger cell apoptosis and inflammatory cytokine processing in the lung epithelial cells."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is supported by the provided evidence. The evidence indicates that SARS-CoV-2 infection triggers apoptosis (cell death) through caspase-8 activation and induces caspase-8 activation to mediate pro-IL-1\u03b2 processing, which are markers of inflammatory responses. Furthermore, it is reported that SARS-CoV-2 infection activates caspase-8 to trigger cell apoptosis and inflammatory cytokine processing in the lung epithelial cells.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000924",
    "statement": "Sars-cov-2 inhibits inflammatory responses and cell death through caspase-8 activation",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "4 SARS-CoV-2 infection triggers apoptosis through caspase-8 activation.",
      "2 SARS-CoV-2 infection induces caspase-8 activation to mediate pro-IL-1\u03b2 processing.",
      "2 SARS-CoV-2 infection induces caspase-8 activation Fig.",
      "SARS-CoV-2 infection induces the cell death through the activation of caspase-8.",
      "Here we report that SARS-CoV-2 infection activates caspase-8 to trigger cell apoptosis and inflammatory cytokine processing in the lung epithelial cells."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that SARS-CoV-2 infection triggers apoptosis (cell death) through caspase-8 activation and also induces caspase-8 activation to mediate pro-IL-1\u03b2 processing, which is associated with inflammatory responses. Furthermore, it is reported that SARS-CoV-2 infection activates caspase-8 to trigger cell apoptosis and inflammatory cytokine processing in lung epithelial cells.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000925",
    "statement": "Sars-cov-2 inhibited inflammatory responses and cell death through caspase-8 activation",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "4 SARS-CoV-2 infection triggers apoptosis through caspase-8 activation.",
      "2 SARS-CoV-2 infection induces caspase-8 activation to mediate pro-IL-1\u03b2 processing.",
      "2 SARS-CoV-2 infection induces caspase-8 activation Fig.",
      "SARS-CoV-2 infection induces the cell death through the activation of caspase-8.",
      "Here we report that SARS-CoV-2 infection activates caspase-8 to trigger cell apoptosis and inflammatory cytokine processing in the lung epithelial cells."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that SARS-CoV-2 infection triggers caspase-8 activation, which in turn induces apoptosis and inflammatory responses. The four studies referenced support this claim.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000926",
    "statement": "Sars-cov-2 reinfection in a cohort of 43,000 antibody-positive individuals followed for up to 35 weeks.",
    "label": "SUPPORTED",
    "evidences": [
      "Results Among 43,044 anti-SARS-CoV-2 positive persons who were followed for a median of 16.3 weeks (range: 0-34.6), 314 individuals (0.7%) had at least one PCR positive swab 14 days after the first-positive antibody test.",
      "Results: Among 43,044 anti-SARS-CoV-2 positive persons who were followed for a median of 16.3 weeks (range: 0-34.6), 314 individuals (0.7%) had at least one PCR positive swab 14 days after the first-positive antibody test."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that a small percentage (0.7%) of individuals who were previously positive for SARS-CoV-2 antibodies had at least one PCR-positive swab 14 days after the first positive antibody test, suggesting possible reinfections or false negatives/positives in some cases.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000927",
    "statement": "Sars-cov-2 reinfection in a cohort of 43,000 antibody-positive individuals followed for up to 35 years.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Results Among 43,044 anti-SARS-CoV-2 positive persons who were followed for a median of 16.3 weeks (range: 0-34.6), 314 individuals (0.7%) had at least one PCR positive swab 14 days after the first-positive antibody test.",
      "Results: Among 43,044 anti-SARS-CoV-2 positive persons who were followed for a median of 16.3 weeks (range: 0-34.6), 314 individuals (0.7%) had at least one PCR positive swab 14 days after the first-positive antibody test."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that 314 individuals (0.7%) out of a cohort of 43,044 antibody-positive individuals had at least one PCR positive swab 14 days after the first-positive antibody test, indicating potential reinfection with SARS-CoV-2.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000928",
    "statement": "Sars-cov-2 reinfection in a cohort of 43,000 antibody-positive individuals followed for up to 35 days.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Results Among 43,044 anti-SARS-CoV-2 positive persons who were followed for a median of 16.3 weeks (range: 0-34.6), 314 individuals (0.7%) had at least one PCR positive swab 14 days after the first-positive antibody test.",
      "Results: Among 43,044 anti-SARS-CoV-2 positive persons who were followed for a median of 16.3 weeks (range: 0-34.6), 314 individuals (0.7%) had at least one PCR positive swab 14 days after the first-positive antibody test."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that a small percentage (0.7%) of individuals who had initially tested positive for SARS-CoV-2 antibodies later tested positive for the virus by PCR swab after a median of 16.3 weeks (range: 0-34.6). This suggests possible reinfection or false-positive/negative results.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000929",
    "statement": "Sars-cov-2 reinfection in a cohort of 43,000 antibody-positive individuals followed for up to 35 hours.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Results Among 43,044 anti-SARS-CoV-2 positive persons who were followed for a median of 16.3 weeks (range: 0-34.6), 314 individuals (0.7%) had at least one PCR positive swab 14 days after the first-positive antibody test.",
      "Results: Among 43,044 anti-SARS-CoV-2 positive persons who were followed for a median of 16.3 weeks (range: 0-34.6), 314 individuals (0.7%) had at least one PCR positive swab 14 days after the first-positive antibody test."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows that among a cohort of 43,044 individuals who were previously positive for SARS-CoV-2 antibodies and followed up for a period ranging from 0 to 34.6 weeks, 314 individuals (0.7%) had at least one PCR positive swab 14 days after the first-positive antibody test. This suggests a possibility of SARS-CoV-2 reinfection in this group.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000930",
    "statement": "Anakinra to prevent respiratory failure in covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "Conclusions Early suPAR-guided anakinra treatment is associated with decrease of the risk for SRF and restoration of the pro- /anti-inflammatory balance.",
      "We investigated if early suPAR (soluble urokinase plasminogen activator receptor)-guided anakinra treatment could prevent COVID-19-assocated SRF.",
      "Anakinra treatment was associated with decrease in SOFA score and in circulating interleukin (IL)-6, sCD163 and sIL2-R; the serum IL-10/IL-6 ratio on day 7 was inversely associated with the change in SOFA score."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not directly demonstrate that Anakinra prevents respiratory failure specifically in COVID-19 patients. It shows an association between Anakinra treatment and a decrease in SOFA score, IL-6, sCD163, sIL2-R, and an improvement in the pro-/anti-inflammatory balance. However, this is not conclusive proof that Anakinra prevents respiratory failure in COVID-19.",
    "confidence": 0.5
  },
  {
    "id": "covid_fact-000931",
    "statement": "Anakinra to prevent neurological failure in covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusions Early suPAR-guided anakinra treatment is associated with decrease of the risk for SRF and restoration of the pro- /anti-inflammatory balance.",
      "We investigated if early suPAR (soluble urokinase plasminogen activator receptor)-guided anakinra treatment could prevent COVID-19-assocated SRF.",
      "Anakinra treatment was associated with decrease in SOFA score and in circulating interleukin (IL)-6, sCD163 and sIL2-R; the serum IL-10/IL-6 ratio on day 7 was inversely associated with the change in SOFA score."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence discusses a study investigating the effects of Anakinra treatment on SRF (sequential organ failure assessment) and inflammatory markers in COVID-19 patients. However, it does not directly prove that Anakinra can prevent neurological failure specifically in COVID-19. More studies would be needed to establish a definitive link between the two.",
    "confidence": 0.4
  },
  {
    "id": "covid_fact-000932",
    "statement": "Anakinra to cause respiratory failure in covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusions Early suPAR-guided anakinra treatment is associated with decrease of the risk for SRF and restoration of the pro- /anti-inflammatory balance.",
      "We investigated if early suPAR (soluble urokinase plasminogen activator receptor)-guided anakinra treatment could prevent COVID-19-assocated SRF.",
      "Anakinra treatment was associated with decrease in SOFA score and in circulating interleukin (IL)-6, sCD163 and sIL2-R; the serum IL-10/IL-6 ratio on day 7 was inversely associated with the change in SOFA score."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not directly indicate or prove that Anakinra causes respiratory failure in COVID-19 patients. Instead, it suggests that early treatment with Anakinra might be associated with a decrease in the risk for SRF (respiratory failure) and restoration of the pro-/anti-inflammatory balance.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000933",
    "statement": "Anakinra to causes respiratory failure in covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusions Early suPAR-guided anakinra treatment is associated with decrease of the risk for SRF and restoration of the pro- /anti-inflammatory balance.",
      "We investigated if early suPAR (soluble urokinase plasminogen activator receptor)-guided anakinra treatment could prevent COVID-19-assocated SRF.",
      "Anakinra treatment was associated with decrease in SOFA score and in circulating interleukin (IL)-6, sCD163 and sIL2-R; the serum IL-10/IL-6 ratio on day 7 was inversely associated with the change in SOFA score."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided discusses the association between Anakinra treatment and a decrease in the risk for SRF (acute respiratory failure) and restoration of pro-/anti-inflammatory balance in COVID-19 patients. However, it does not explicitly state that Anakinra causes respiratory failure in COVID-19. The claim requires additional evidence or studies directly linking the use of Anakinra to the onset of respiratory failure.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000934",
    "statement": "Hadassah doctors crack the cause of fatal corona blood clots",
    "label": "SUPPORTED",
    "evidences": [
      "Hadassah researchers discovered that the patients who form these fatal clots have an increased level of alpha defensin protein in their blood, explained Dr. Abd Alrauf Higavi, who directs a lab at Hadassah and has been studying blood clots for 30 years.",
      "The results show that alpha defensin speeds up blood clot formation, which can cause pulmonary embolism, heart attacks and stroke."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates a correlation between the presence of alpha defensin protein in the blood and the formation of fatal clots such as pulmonary embolism, heart attacks, and stroke. While it does not prove that Hadassah doctors have definitively 'cracked' the cause of these clots, it does support the claim that they have discovered a factor (alpha defensin) associated with their formation.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000935",
    "statement": "Hadassah virus crack the cause of fatal corona blood clots",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Hadassah researchers discovered that the patients who form these fatal clots have an increased level of alpha defensin protein in their blood, explained Dr. Abd Alrauf Higavi, who directs a lab at Hadassah and has been studying blood clots for 30 years.",
      "The results show that alpha defensin speeds up blood clot formation, which can cause pulmonary embolism, heart attacks and stroke."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided shows that a correlation has been found between an increased level of alpha defensin protein in the blood and the formation of fatal clots in patients, but it does not directly prove that the Hadassah virus (if it exists) is the cause of this condition.",
    "confidence": 0.4
  },
  {
    "id": "covid_fact-000936",
    "statement": "Hadassah doctors remain the cause of fatal corona blood clots",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Hadassah researchers discovered that the patients who form these fatal clots have an increased level of alpha defensin protein in their blood, explained Dr. Abd Alrauf Higavi, who directs a lab at Hadassah and has been studying blood clots for 30 years.",
      "The results show that alpha defensin speeds up blood clot formation, which can cause pulmonary embolism, heart attacks and stroke."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided indicates that Hadassah researchers discovered a protein (alpha defensin) in the blood of patients who form fatal clots and this protein speeds up blood clot formation. However, it does not establish that Hadassah doctors cause these fatal corona blood clots. More evidence is needed to support such a claim.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000937",
    "statement": "Virus can infect heart cells in lab dish",
    "label": "SUPPORTED",
    "evidences": [
      "The study also demonstrated that human stem cell-derived heart cells infected by SARS-CoV-2 change their gene expression profile, further confirming that the cells can be actively infected by the virus and activate innate cellular \"defense mechanisms\" in an effort to help clear out the virus.",
      "A new study shows that SARS-CoV-2, the virus that causes COVID-19 (coronavirus), can infect heart cells in a lab dish, indicating it may be possible for heart cells in COVID-19 patients to be directly infected by the virus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that SARS-CoV-2 can infect human stem cell-derived heart cells in a lab dish, which implies it may be possible for heart cells in COVID-19 patients to be directly infected by the virus.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000938",
    "statement": "Virus cannot infect heart cells in lab dish",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The study also demonstrated that human stem cell-derived heart cells infected by SARS-CoV-2 change their gene expression profile, further confirming that the cells can be actively infected by the virus and activate innate cellular \"defense mechanisms\" in an effort to help clear out the virus.",
      "A new study shows that SARS-CoV-2, the virus that causes COVID-19 (coronavirus), can infect heart cells in a lab dish, indicating it may be possible for heart cells in COVID-19 patients to be directly infected by the virus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that SARS-CoV-2 can change the gene expression profile of heart cells in a lab dish, which suggests active infection. Additionally, the statement contradicts the claim, indicating that the virus can indeed infect heart cells.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000939",
    "statement": "Alpha-1 antitrypsin inhibits sars-cov-2 infection",
    "label": "SUPPORTED",
    "evidences": [
      "Our findings show that endogenous \u03b11-AT restricts SARS-CoV-2 and repurposes \u03b11-AT-based drugs for COVID-19 therapy.",
      "To identify factors of the respiratory tract that suppress SARS-CoV-2, we screened a peptide/protein library derived from bronchoalveolar lavage, and identified \u03b11-antitrypsin (\u03b11-AT) as specific inhibitor of SARS-CoV-2.",
      "\u03b11-AT targets the viral spike protein and blocks SARS-CoV-2 infection of human airway epithelium at physiological concentrations."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly states that endogenous \u03b11-AT restricts SARS-CoV-2, and specifically identifies \u03b11-AT as a specific inhibitor of SARS-CoV-2. Furthermore, it explains that \u03b11-AT targets the viral spike protein and blocks SARS-CoV-2 infection at physiological concentrations.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000940",
    "statement": "Cox-1 antitrypsin inhibits sars-cov-2 infection",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our findings show that endogenous \u03b11-AT restricts SARS-CoV-2 and repurposes \u03b11-AT-based drugs for COVID-19 therapy.",
      "To identify factors of the respiratory tract that suppress SARS-CoV-2, we screened a peptide/protein library derived from bronchoalveolar lavage, and identified \u03b11-antitrypsin (\u03b11-AT) as specific inhibitor of SARS-CoV-2.",
      "\u03b11-AT targets the viral spike protein and blocks SARS-CoV-2 infection of human airway epithelium at physiological concentrations."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows that the study found \u03b11-antitrypsin (\u03b11-AT) to be a specific inhibitor of SARS-CoV-2 and demonstrated that it targets the viral spike protein and blocks infection at physiological concentrations. Therefore, it is reasonable to conclude that Cox-1 antitrypsin inhibits SARS-CoV-2 infection.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000941",
    "statement": "Mcp-1 antitrypsin inhibits sars-cov-2 infection",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our findings show that endogenous \u03b11-AT restricts SARS-CoV-2 and repurposes \u03b11-AT-based drugs for COVID-19 therapy.",
      "To identify factors of the respiratory tract that suppress SARS-CoV-2, we screened a peptide/protein library derived from bronchoalveolar lavage, and identified \u03b11-antitrypsin (\u03b11-AT) as specific inhibitor of SARS-CoV-2.",
      "\u03b11-AT targets the viral spike protein and blocks SARS-CoV-2 infection of human airway epithelium at physiological concentrations."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows that the study found \u03b11-antitrypsin (\u03b11-AT) to be a specific inhibitor of SARS-CoV-2 infection, targeting the viral spike protein and blocking infection at physiological concentrations. Therefore, it supports the claim that Mcp-1 antitrypsin inhibits SARS-CoV-2 infection.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000942",
    "statement": "Il-1 antitrypsin inhibits sars-cov-2 infection",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our findings show that endogenous \u03b11-AT restricts SARS-CoV-2 and repurposes \u03b11-AT-based drugs for COVID-19 therapy.",
      "To identify factors of the respiratory tract that suppress SARS-CoV-2, we screened a peptide/protein library derived from bronchoalveolar lavage, and identified \u03b11-antitrypsin (\u03b11-AT) as specific inhibitor of SARS-CoV-2.",
      "\u03b11-AT targets the viral spike protein and blocks SARS-CoV-2 infection of human airway epithelium at physiological concentrations."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided directly states that endogenous \u03b11-AT restricts SARS-CoV-2 and targets the viral spike protein to block infection. This supports the claim that Il-1 antitrypsin inhibits sars-cov-2 infection.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000943",
    "statement": "New study suggests children may carry covid-19 at high levels",
    "label": "SUPPORTED",
    "evidences": [
      "\"Young children can potentially be important drivers of SARS-CoV-2 spread in the general population,\" the authors wrote.",
      "A much larger South Korean study recently found that children younger than 10 transmit to others much less often than adults do, while those between the ages of 10 and 19 can spread the virus at least as well as adults do."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that children, particularly those aged 10 and above, may transmit SARS-CoV-2 (the virus causing COVID-19) at least as well as adults do. This suggests that children can potentially carry the virus at high levels.",
    "confidence": 0.85
  },
  {
    "id": "covid_fact-000944",
    "statement": "New study suggests cats may carry covid-19 at high levels",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "\"Young children can potentially be important drivers of SARS-CoV-2 spread in the general population,\" the authors wrote.",
      "A much larger South Korean study recently found that children younger than 10 transmit to others much less often than adults do, while those between the ages of 10 and 19 can spread the virus at least as well as adults do."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence does not directly support the claim about cats carrying covid-19 at high levels. The focus of the evidence is on children as potential transmitters of SARS-CoV-2 in general populations and mentions a South Korean study that found differences in transmission rates between children and adults, but no information regarding cats.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000945",
    "statement": "New study suggests bats may carry covid-19 at high levels",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "\"Young children can potentially be important drivers of SARS-CoV-2 spread in the general population,\" the authors wrote.",
      "A much larger South Korean study recently found that children younger than 10 transmit to others much less often than adults do, while those between the ages of 10 and 19 can spread the virus at least as well as adults do."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not directly support the claim that bats may carry covid-19 at high levels. The claim implies that bats are carriers of the virus in general, whereas the evidence only discusses children's role in SARS-CoV-2 spread within the human population.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000946",
    "statement": "New study suggests coronaviruses may carry covid-19 at high levels",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "\"Young children can potentially be important drivers of SARS-CoV-2 spread in the general population,\" the authors wrote.",
      "A much larger South Korean study recently found that children younger than 10 transmit to others much less often than adults do, while those between the ages of 10 and 19 can spread the virus at least as well as adults do."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not directly support the claim that coronaviruses may carry covid-19 at high levels. Instead, it indicates that children under 10 transmit SARS-CoV-2 less often than adults and those between ages 10 and 19 can potentially spread it as much as adults. This does not necessarily imply that the viral load in these age groups is higher or lower than in adults.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000947",
    "statement": "In the coronavirus pandemic , we 're making decisions without reliable data",
    "label": "SUPPORTED",
    "evidences": [
      "In the absence of data on the real course of the epidemic, we dont know whether this perspective was brilliant or catastrophic.",
      "As the coronavirus pandemic takes hold, we are making decisions without reliable data By John P.A."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence does not directly support or refute the claim that 'we are making decisions without reliable data during the coronavirus pandemic'. The statement made by John P.A. is his personal perspective, and it does not provide any empirical evidence about the existence of reliable data being used in decision-making processes related to the pandemic.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000948",
    "statement": "In the coronavirus pandemic, we're making decisions with reliable data",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In the absence of data on the real course of the epidemic, we dont know whether this perspective was brilliant or catastrophic.",
      "As the coronavirus pandemic takes hold, we are making decisions without reliable data By John P.A."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim is not directly supported by the provided evidence as it does not provide any specific data or examples of decision making during the coronavirus pandemic.",
    "confidence": 0.5
  },
  {
    "id": "covid_fact-000949",
    "statement": "In the coronavirus pandemic, we're making decisions and reliable data",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In the absence of data on the real course of the epidemic, we dont know whether this perspective was brilliant or catastrophic.",
      "As the coronavirus pandemic takes hold, we are making decisions without reliable data By John P.A."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim is not directly supported by the provided evidence as it does not present any specific data or examples of decisions made during the coronavirus pandemic, nor does it provide a comparison between the decisions and the reliability of the data available.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000950",
    "statement": "In the coronavirus pandemic, we're making decisions in reliable data",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In the absence of data on the real course of the epidemic, we dont know whether this perspective was brilliant or catastrophic.",
      "As the coronavirus pandemic takes hold, we are making decisions without reliable data By John P.A."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim is not directly supported by the provided evidence, as it does not present any specific decision-making processes made during the pandemic that are based on reliable data.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000951",
    "statement": "Early transfusion of a large cohort of covid-19 patients with high titer anti-sars-cov-2 spike protein igg convalescent plasma confirms a signal of significantly decreased mortality",
    "label": "SUPPORTED",
    "evidences": [
      "In the aggregate, the analysis confirms and extends our previous preliminary finding that transfusion of COVID-19 patients soon after hospitalization with high titer anti-spike protein RBD IgG present in convalescent plasma significantly reduces mortality.",
      "Transfusion of convalescent plasma collected from donors who have recovered from COVID-19 disease has emerged as a promising therapy and has been granted emergency use authorization by the U.S. Food and Drug Administration (FDA).",
      "With respect to altering mortality, our analysis identified an optimal window of 44 hours post-hospitalization for transfusing COVID-19 patients with high titer convalescent plasma.",
      "We recently reported results from interim analysis of a propensity-score matched study suggesting that early treatment of COVID-19 patients with convalescent plasma containing high titer anti-spike protein receptor binding domain (RBD) IgG significantly decreases mortality."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided states that early transfusion of a large cohort of COVID-19 patients with high titer anti-SARS-CoV-2 spike protein IgG convalescent plasma significantly reduces mortality. This is based on an analysis which confirms and extends a previous finding, and they refer to results from interim analysis of a propensity-score matched study suggesting the same.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000952",
    "statement": "Early transfusion of a large cohort of covid-19 patients with high titer anti-sars-cov-2 spike protein igg convalescent plasma confirms a signal of significantly increased mortality",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In the aggregate, the analysis confirms and extends our previous preliminary finding that transfusion of COVID-19 patients soon after hospitalization with high titer anti-spike protein RBD IgG present in convalescent plasma significantly reduces mortality.",
      "Transfusion of convalescent plasma collected from donors who have recovered from COVID-19 disease has emerged as a promising therapy and has been granted emergency use authorization by the U.S. Food and Drug Administration (FDA).",
      "With respect to altering mortality, our analysis identified an optimal window of 44 hours post-hospitalization for transfusing COVID-19 patients with high titer convalescent plasma.",
      "We recently reported results from interim analysis of a propensity-score matched study suggesting that early treatment of COVID-19 patients with convalescent plasma containing high titer anti-spike protein receptor binding domain (RBD) IgG significantly decreases mortality."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided discusses the benefits of transfusing convalescent plasma from COVID-19 recovered donors to patients, suggesting that it may reduce mortality. However, this study also found an 'optimal window' of 44 hours post-hospitalization for transfusion. The claim states that early transfusion leads to significantly increased mortality, which contradicts the findings from the provided evidence.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000953",
    "statement": "Early transfusion of a large cohort of covid-19 patients with high titer anti-sars-cov-2 spike protein igg convalescent plasma confirms a signal of significantly increase mortality",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In the aggregate, the analysis confirms and extends our previous preliminary finding that transfusion of COVID-19 patients soon after hospitalization with high titer anti-spike protein RBD IgG present in convalescent plasma significantly reduces mortality.",
      "Transfusion of convalescent plasma collected from donors who have recovered from COVID-19 disease has emerged as a promising therapy and has been granted emergency use authorization by the U.S. Food and Drug Administration (FDA).",
      "With respect to altering mortality, our analysis identified an optimal window of 44 hours post-hospitalization for transfusing COVID-19 patients with high titer convalescent plasma.",
      "We recently reported results from interim analysis of a propensity-score matched study suggesting that early treatment of COVID-19 patients with convalescent plasma containing high titer anti-spike protein receptor binding domain (RBD) IgG significantly decreases mortality."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided suggests that early transfusion of a large cohort of COVID-19 patients with high titer anti-SARS-CoV-2 spike protein IgG convalescent plasma significantly reduces mortality based on interim analysis. However, it does not provide sufficient information to confirm a signal of significantly increased mortality as stated in the claim.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000954",
    "statement": "Early transfusion of a large cohort of covid-19 patients with high titer anti-sars-cov-2 spike protein igg convalescent plasma confirms a signal of significantly higher mortality",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In the aggregate, the analysis confirms and extends our previous preliminary finding that transfusion of COVID-19 patients soon after hospitalization with high titer anti-spike protein RBD IgG present in convalescent plasma significantly reduces mortality.",
      "Transfusion of convalescent plasma collected from donors who have recovered from COVID-19 disease has emerged as a promising therapy and has been granted emergency use authorization by the U.S. Food and Drug Administration (FDA).",
      "With respect to altering mortality, our analysis identified an optimal window of 44 hours post-hospitalization for transfusing COVID-19 patients with high titer convalescent plasma.",
      "We recently reported results from interim analysis of a propensity-score matched study suggesting that early treatment of COVID-19 patients with convalescent plasma containing high titer anti-spike protein receptor binding domain (RBD) IgG significantly decreases mortality."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not directly support the claim that early transfusion of a large cohort of COVID-19 patients with high titer anti-SARS-CoV-2 spike protein IgG convalescent plasma confirms a signal of significantly higher mortality. Instead, it suggests that such treatment reduces mortality when administered within an optimal window (44 hours post-hospitalization) and contains high titer anti-spike protein receptor binding domain (RBD) IgG.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000955",
    "statement": "Egyptian doctors are speaking out against health authorities over increasing coronavirus infections and deaths among medical staff across the country .",
    "label": "SUPPORTED",
    "evidences": [
      "Another Egyptian doctor told Amnesty International that doctors who speak out are subjected to threats, interrogations by the National Security Agency (NSA), administrative questioning, and penalties.",
      "A correspondent in Egypt Topics covered health care, medical supplies, covid-19, coronavirus, egyptian doctors, doctors Jun 8, 2020 Egyptian doctors have expressed anger in recent days, accusing the authorities of neglecting them and failing to protect and provide them with the protective equipment they need.",
      "Egypts arrests of medical professionals who criticized its Covid-19 policies warrant unambiguous opposition from the World Bank, in line with its commitment not to tolerate reprisals, said Amr Magdi, Middle East and North Africa researcher at Human Rights Watch."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides several indications that Egyptian doctors are expressing concern and criticism about the authorities' handling of COVID-19 infections among medical staff. The doctors have expressed anger at what they perceive as neglect by the authorities (second sentence). Amnesty International has interviewed another Egyptian doctor who reported being subjected to threats, interrogations, administrative questioning, and penalties for speaking out (first sentence). Furthermore, a researcher at Human Rights Watch has called for opposition to Egypt's arrests of medical professionals who criticize its COVID-19 policies (fourth sentence). Therefore, it is supported that Egyptian doctors are speaking out against health authorities over increasing coronavirus infections and deaths among medical staff across the country.",
    "confidence": 0.85
  },
  {
    "id": "covid_fact-000956",
    "statement": "Egyptian doctors are ruled out against health authorities over increasing coronavirus infections and deaths among medical staff across the country.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Another Egyptian doctor told Amnesty International that doctors who speak out are subjected to threats, interrogations by the National Security Agency (NSA), administrative questioning, and penalties.",
      "A correspondent in Egypt Topics covered health care, medical supplies, covid-19, coronavirus, egyptian doctors, doctors Jun 8, 2020 Egyptian doctors have expressed anger in recent days, accusing the authorities of neglecting them and failing to protect and provide them with the protective equipment they need.",
      "Egypts arrests of medical professionals who criticized its Covid-19 policies warrant unambiguous opposition from the World Bank, in line with its commitment not to tolerate reprisals, said Amr Magdi, Middle East and North Africa researcher at Human Rights Watch."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not directly support the claim that Egyptian doctors are ruled out against health authorities over increasing coronavirus infections and deaths among medical staff across the country. While it is stated that doctors have expressed anger and accused the authorities of neglecting them, there is no clear indication that this is a nationwide issue or that it involves a ruling against the health authorities.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000957",
    "statement": "High sars-cov-2 viral load is associated with a worse clinical outcome of covid-19 disease",
    "label": "SUPPORTED",
    "evidences": [
      "Here we report a statistically significant correlation between viral load and disease severity, being high viral load associated with worse clinical prognosis, independently of several previously identified risk factors such as age, sex, hypertension, cardiovascular disease, diabetes, obesity, and lung disease (asthma and chronic obstructive pulmonary disease).",
      "The data presented here reinforce the viral load as a potential biomarker for predicting disease severity in SARS-CoV-2-infected patients.",
      "It is also an important parameter in viral evolution since it relates to the numbers and types of variant genomes present in a viral population, a potential determinant of disease progression."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows a statistically significant correlation between viral load and disease severity of COVID-19. The text explicitly states that high viral load is associated with worse clinical prognosis, which supports the claim.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000958",
    "statement": "High sars-cov-2 viral load is associated with a greater clinical outcome of covid-19 disease",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Here we report a statistically significant correlation between viral load and disease severity, being high viral load associated with worse clinical prognosis, independently of several previously identified risk factors such as age, sex, hypertension, cardiovascular disease, diabetes, obesity, and lung disease (asthma and chronic obstructive pulmonary disease).",
      "The data presented here reinforce the viral load as a potential biomarker for predicting disease severity in SARS-CoV-2-infected patients.",
      "It is also an important parameter in viral evolution since it relates to the numbers and types of variant genomes present in a viral population, a potential determinant of disease progression."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence presented directly states that high viral load is associated with worse clinical prognosis in SARS-CoV-2 infected patients.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000959",
    "statement": "High sars-cov-2 viral load is associated with a better clinical outcome of covid-19 disease",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Here we report a statistically significant correlation between viral load and disease severity, being high viral load associated with worse clinical prognosis, independently of several previously identified risk factors such as age, sex, hypertension, cardiovascular disease, diabetes, obesity, and lung disease (asthma and chronic obstructive pulmonary disease).",
      "The data presented here reinforce the viral load as a potential biomarker for predicting disease severity in SARS-CoV-2-infected patients.",
      "It is also an important parameter in viral evolution since it relates to the numbers and types of variant genomes present in a viral population, a potential determinant of disease progression."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence shows that high viral load is associated with WORSE clinical prognosis, not a better one. The sentence 'being high viral load associated with worse clinical prognosis' directly contradicts the claim.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000960",
    "statement": "High sars-cov-2 viral load is associated with a higher clinical outcome of covid-19 disease",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Here we report a statistically significant correlation between viral load and disease severity, being high viral load associated with worse clinical prognosis, independently of several previously identified risk factors such as age, sex, hypertension, cardiovascular disease, diabetes, obesity, and lung disease (asthma and chronic obstructive pulmonary disease).",
      "The data presented here reinforce the viral load as a potential biomarker for predicting disease severity in SARS-CoV-2-infected patients.",
      "It is also an important parameter in viral evolution since it relates to the numbers and types of variant genomes present in a viral population, a potential determinant of disease progression."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides a statistically significant correlation between viral load and disease severity of COVID-19, showing that high viral load is associated with worse clinical prognosis.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000961",
    "statement": "In silico mutagenesis of human ace2 with s protein and translational efficiency explain sars-cov-2 infectivity in different species",
    "label": "SUPPORTED",
    "evidences": [
      "Genomic variability across species, including humans, results in ACE2 variants that destabilize its fold, modify ACE2/SARS- CoV-2 recognition, or both.",
      "SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.",
      "Two significant factors conditioning infection are ACE2-mediated SARS-CoV-2 cellular entry and viral proteome translation efficiency.",
      "We observed that humans are the species in which SARS- CoV-2 is both most efficiently translated as well as optimally interacting with ACE2.",
      "SARS-CoV-2 translational efficiency and ACE2 expression across species."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence presents a clear connection between SARS-CoV-2 infectivity in different species, translational efficiency of the virus, and ACE2 interaction. The claim is supported by the discussion of genomic variability across species leading to differences in ACE2 variants and their interactions with SARS-CoV-2, as well as the emphasis on both ACE2-mediated cellular entry and viral proteome translation efficiency as significant factors conditioning infection. The statement that humans have optimal conditions for both efficient translation of SARS-CoV-2 and interaction with ACE2 supports the claim.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000962",
    "statement": "In silico mutagenesis of bat ace2 with s protein and translational efficiency explain sars-cov-2 infectivity in different species",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Genomic variability across species, including humans, results in ACE2 variants that destabilize its fold, modify ACE2/SARS- CoV-2 recognition, or both.",
      "SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.",
      "Two significant factors conditioning infection are ACE2-mediated SARS-CoV-2 cellular entry and viral proteome translation efficiency.",
      "We observed that humans are the species in which SARS- CoV-2 is both most efficiently translated as well as optimally interacting with ACE2.",
      "SARS-CoV-2 translational efficiency and ACE2 expression across species."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests a relationship between SARS-CoV-2 infectivity in different species and the efficiency of its translation within those species as well as ACE2 expression levels. The claim that 'in silico mutagenesis of bat ace2 with s protein and translational efficiency explain SARS-CoV-2 infectivity in different species' is supported by the evidence that genomic variability across species results in ACE2 variants that destabilize its fold, modify ACE2/SARS-CoV-2 recognition, or both. Additionally, it is stated that humans are the species in which SARS-CoV-2 is both most efficiently translated and optimally interacting with ACE2, indicating a higher infectivity rate.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000963",
    "statement": "In silico mutagenesis of human ace2 with s protein and translational efficiency inhibited sars-cov-2 infectivity in different species",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Genomic variability across species, including humans, results in ACE2 variants that destabilize its fold, modify ACE2/SARS- CoV-2 recognition, or both.",
      "SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.",
      "Two significant factors conditioning infection are ACE2-mediated SARS-CoV-2 cellular entry and viral proteome translation efficiency.",
      "We observed that humans are the species in which SARS- CoV-2 is both most efficiently translated as well as optimally interacting with ACE2.",
      "SARS-CoV-2 translational efficiency and ACE2 expression across species."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that SARS-CoV-2 infectivity depends on ACE2 and TMPRSS2, and that humans have an optimal interaction with ACE2 regarding cellular entry. Additionally, the evidence mentions that human cells are most efficient in translating SARS-CoV-2. These points suggest that altering or mutating ACE2 through in silico mutagenesis could potentially inhibit SARS-CoV-2 infectivity.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000964",
    "statement": "Plasmin cascade mediates thrombolytic events in sars-cov-2 infection via complement and platelet-activating systems",
    "label": "SUPPORTED",
    "evidences": [
      "Our results indicate that plasmin is a crucial mediator which primes interactions between complement and platelet-activating systems in lung epithelia upon SARS-CoV-2 infection, with a potential for therapeutic intervention."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests that plasmin is involved in interactions between complement and platelet-activating systems in lung epithelia upon SARS-CoV-2 infection. This implies a role for the plasmin cascade in mediating thrombolytic events during the infection.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000965",
    "statement": "Plasmin cascade mediates thrombolytic events in sars-cov-2 production via complement and platelet-activating systems",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our results indicate that plasmin is a crucial mediator which primes interactions between complement and platelet-activating systems in lung epithelia upon SARS-CoV-2 infection, with a potential for therapeutic intervention."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence indicates that plasmin is shown to play a crucial role in mediating interactions between complement and platelet-activating systems in lung epithelia upon SARS-CoV-2 infection. This suggests it may be involved in thrombolytic events related to SARS-CoV-2 production.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000966",
    "statement": "Private firm running uk ppe stockpile was sold in middle of pandemic .",
    "label": "SUPPORTED",
    "evidences": [
      "Meanwhile, management of the stock has been passed from a Germanowned multinational to an American one.",
      "The distribution of that stockpiles PPE, it seems, may no longer solely be the responsibility of Movianto."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The given evidence does not clearly show that the private firm running the UK PPE stockpile was sold during the pandemic. While it is mentioned that management has been passed to an American multinational, there is no explicit statement indicating a sale or transfer of ownership.",
    "confidence": 0.4
  },
  {
    "id": "covid_fact-000967",
    "statement": "Private firm running uk ppe stockpile was established in middle of pandemic.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Meanwhile, management of the stock has been passed from a Germanowned multinational to an American one.",
      "The distribution of that stockpiles PPE, it seems, may no longer solely be the responsibility of Movianto."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not directly indicate when the private firm running the UK PPE stockpile was established. It only mentions a change in management from a German-owned multinational to an American one.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000968",
    "statement": "No firm running uk ppe stockpile was sold in middle of pandemic.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Meanwhile, management of the stock has been passed from a Germanowned multinational to an American one.",
      "The distribution of that stockpiles PPE, it seems, may no longer solely be the responsibility of Movianto."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not indicate whether or not a firm running UK PPE stockpile was sold during the pandemic. The information provided is about the transfer of management of the stock from a German-owned multinational to an American one and potential changes in distribution responsibilities, but it does not provide information on sales or the timing of these sales.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000969",
    "statement": "Private firm running uk ppe stockpile was developed in middle of pandemic.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Meanwhile, management of the stock has been passed from a Germanowned multinational to an American one.",
      "The distribution of that stockpiles PPE, it seems, may no longer solely be the responsibility of Movianto."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not clearly indicate that the private firm running the UK PPE stockpile was developed during the pandemic. It only mentions a change in management of the stock from a German-owned multinational to an American one.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000970",
    "statement": "A systematic review uncovers a wide-gap between covid-19 in humans and animal models",
    "label": "SUPPORTED",
    "evidences": [
      "No severe illness associated with mortality was observed, suggesting a wide gap between COVID-19 in humans and animal models.",
      "We used the search terms COVID-19 OR SARS-CoV-2 AND, animal models, hamsters, nonhuman primates, macaques, rodent, mice, rats, ferrets, rabbits, cats, and dogs."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided consists of a single observation that no severe illness associated with mortality was observed in animal models, which suggests a wide gap between COVID-19 in humans and animal models. However, the claim is not supported by this evidence because it does not provide any systematic review of data on this topic. A systemic review would involve examining multiple studies related to the research question to draw conclusions.",
    "confidence": 0.7
  },
  {
    "id": "covid_fact-000971",
    "statement": "A systematic review focuseds a wide-gap between covid-19 in humans and animal models",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "No severe illness associated with mortality was observed, suggesting a wide gap between COVID-19 in humans and animal models.",
      "We used the search terms COVID-19 OR SARS-CoV-2 AND, animal models, hamsters, nonhuman primates, macaques, rodent, mice, rats, ferrets, rabbits, cats, and dogs."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests a wide gap between COVID-19 in humans and animal models, as no severe illness associated with mortality was observed in the animal models studied (hamsters, nonhuman primates, macaques, rodents, ferrets, rabbits, cats, and dogs). This implies that there is a systematic review focusing on this gap.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000972",
    "statement": "A systematic review focusess a wide-gap between covid-19 in humans and animal models",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "No severe illness associated with mortality was observed, suggesting a wide gap between COVID-19 in humans and animal models.",
      "We used the search terms COVID-19 OR SARS-CoV-2 AND, animal models, hamsters, nonhuman primates, macaques, rodent, mice, rats, ferrets, rabbits, cats, and dogs."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence suggests that there is a lack of severe illness associated with mortality in animal models compared to humans, implying a wide gap between COVID-19 in humans and these specific animal models. However, it does not provide sufficient information to support or refute the claim that a systematic review focuses on this wide gap between COVID-19 in humans and animal models as a whole.",
    "confidence": 0.5
  },
  {
    "id": "covid_fact-000973",
    "statement": "A systematic review focuss a wide-gap between covid-19 in humans and animal models",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "No severe illness associated with mortality was observed, suggesting a wide gap between COVID-19 in humans and animal models.",
      "We used the search terms COVID-19 OR SARS-CoV-2 AND, animal models, hamsters, nonhuman primates, macaques, rodent, mice, rats, ferrets, rabbits, cats, and dogs."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided only shows that no severe illness or mortality associated with COVID-19 was observed in the animal models tested (hamsters, nonhuman primates, macaques, rodents, ferrets, rabbits, cats, and dogs). However, it does not necessarily prove a wide gap between COVID-19 in humans and these animal models as the study might not have investigated other animal species or aspects that could contribute to a 'wide gap'. To confirm this claim, more comprehensive studies evaluating a wider range of animal models are required.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000974",
    "statement": "Cardiac sars-cov-2 infection is associated with distinct transcriptomic changes within the heart.",
    "label": "SUPPORTED",
    "evidences": [
      "In this autopsy series, cardiac replication of SARS-CoV-2 was associated with early death.",
      "Understanding both direct and indirect damage caused to the heart and the vascular system by SARS-CoV-2 infection is necessary to identify optimal clinical care strategies.",
      "Accordingly, there are several studies reporting a direct effect on heart function of coronaviruses with a pathogenicity similar to that of SARS-CoV-2.",
      "Indeed, upon SARS-CoV-2 infection, cardiac insufficiency is more likely to occur in these patients where cardiac function is already compromised by myocardial ischemia [4,5,6, 83, 84]."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided shows that cardiac replication of SARS-CoV-2 is associated with early death and cardiac insufficiency in patients where cardiac function is already compromised by myocardial ischemia (heart-related issues). This suggests that SARS-CoV-2 infection can cause distinct transcriptomic changes within the heart, as transcriptional changes are a common response to infection or injury. Furthermore, the evidence mentions several studies reporting a direct effect on heart function of coronaviruses with a pathogenicity similar to SARS-CoV-2, further supporting the claim.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000975",
    "statement": "Cardiac sars-cov-2 infection is associated with distinct transcriptomic changes within the lung.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In this autopsy series, cardiac replication of SARS-CoV-2 was associated with early death.",
      "Understanding both direct and indirect damage caused to the heart and the vascular system by SARS-CoV-2 infection is necessary to identify optimal clinical care strategies.",
      "Accordingly, there are several studies reporting a direct effect on heart function of coronaviruses with a pathogenicity similar to that of SARS-CoV-2.",
      "Indeed, upon SARS-CoV-2 infection, cardiac insufficiency is more likely to occur in these patients where cardiac function is already compromised by myocardial ischemia [4,5,6, 83, 84]."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence suggests that SARS-CoV-2 infection can lead to cardiac replication and early death, which is indicative of damage to the heart. Additionally, there are studies reporting direct effects on heart function of coronaviruses with a pathogenicity similar to SARS-CoV-2. Therefore, it is supported that cardiac sars-cov-2 infection is associated with distinct transcriptomic changes within the lung.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000976",
    "statement": "Cardiac sars-cov-2 infection is associated with distinct transcriptomic changes within the lungs.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In this autopsy series, cardiac replication of SARS-CoV-2 was associated with early death.",
      "Understanding both direct and indirect damage caused to the heart and the vascular system by SARS-CoV-2 infection is necessary to identify optimal clinical care strategies.",
      "Accordingly, there are several studies reporting a direct effect on heart function of coronaviruses with a pathogenicity similar to that of SARS-CoV-2.",
      "Indeed, upon SARS-CoV-2 infection, cardiac insufficiency is more likely to occur in these patients where cardiac function is already compromised by myocardial ischemia [4,5,6, 83, 84]."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that SARS-CoV-2 infection can cause cardiac replication and may lead to early death. Additionally, there are studies reporting a direct effect on heart function by coronaviruses similar to SARS-CoV-2. Therefore, it is reasonable to infer that cardiac SARS-CoV-2 infection is associated with distinct transcriptomic changes within the lungs due to the potential damage caused to the heart.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000977",
    "statement": "Cardiac sars-cov-2 infection is associated with distinct transcriptomic changes within the liver.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In this autopsy series, cardiac replication of SARS-CoV-2 was associated with early death.",
      "Understanding both direct and indirect damage caused to the heart and the vascular system by SARS-CoV-2 infection is necessary to identify optimal clinical care strategies.",
      "Accordingly, there are several studies reporting a direct effect on heart function of coronaviruses with a pathogenicity similar to that of SARS-CoV-2.",
      "Indeed, upon SARS-CoV-2 infection, cardiac insufficiency is more likely to occur in these patients where cardiac function is already compromised by myocardial ischemia [4,5,6, 83, 84]."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that there are several studies reporting a direct effect on heart function of coronaviruses with a pathogenicity similar to SARS-CoV-2. The autopsy series indicates cardiac replication of SARS-CoV-2, which was associated with early death, and mentions cardiac insufficiency is more likely to occur in patients where cardiac function is already compromised by myocardial ischemia. While the evidence does not directly show distinct transcriptomic changes within the liver caused by cardiac sars-cov-2 infection, it does indicate that SARS-CoV-2 affects the heart and vascular system, which could in turn affect other organs such as the liver.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000978",
    "statement": "'in a few weeks , we will have coronavirus vaccine '",
    "label": "SUPPORTED",
    "evidences": [
      "The vaccine could \"achieve safety approval in 90 days,\" he said.",
      "\"Given the urgent global need for a human coronavirus vaccine, we are doing everything we can to accelerate development,\" MIGAL CEO David Zigdon said.",
      "Yes, in a few weeks, if it all works, we would have a vaccine to prevent coronavirus.\"",
      "\"We are in the middle of this process, and hopefully in a few weeks we will have the vaccine in our hands."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The given evidence indicates that the vaccine is being developed and could receive safety approval within 90 days. However, it does not guarantee that the vaccine will be available for distribution 'in a few weeks' following its approval.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000979",
    "statement": "'in a few years, we will have coronavirus vaccine '",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The vaccine could \"achieve safety approval in 90 days,\" he said.",
      "\"Given the urgent global need for a human coronavirus vaccine, we are doing everything we can to accelerate development,\" MIGAL CEO David Zigdon said.",
      "Yes, in a few weeks, if it all works, we would have a vaccine to prevent coronavirus.\"",
      "\"We are in the middle of this process, and hopefully in a few weeks we will have the vaccine in our hands."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided indicates that a vaccine for coronavirus is in development and may achieve safety approval in 90 days, according to the MIGAL CEO's statement. However, it does not specify when the vaccine will be distributed or available to the public as 'a few years'. The timeline remains uncertain.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000980",
    "statement": "'in a few hours, we will have coronavirus vaccine '",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The vaccine could \"achieve safety approval in 90 days,\" he said.",
      "\"Given the urgent global need for a human coronavirus vaccine, we are doing everything we can to accelerate development,\" MIGAL CEO David Zigdon said.",
      "Yes, in a few weeks, if it all works, we would have a vaccine to prevent coronavirus.\"",
      "\"We are in the middle of this process, and hopefully in a few weeks we will have the vaccine in our hands."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim is that 'in a few hours' we will have a coronavirus vaccine. The evidence mentions the vaccine could achieve safety approval in 90 days and that they are in the middle of the process, implying it will take a few weeks, not hours.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-000981",
    "statement": "'in a few decades, we will have coronavirus vaccine '",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The vaccine could \"achieve safety approval in 90 days,\" he said.",
      "\"Given the urgent global need for a human coronavirus vaccine, we are doing everything we can to accelerate development,\" MIGAL CEO David Zigdon said.",
      "Yes, in a few weeks, if it all works, we would have a vaccine to prevent coronavirus.\"",
      "\"We are in the middle of this process, and hopefully in a few weeks we will have the vaccine in our hands."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence states that the vaccine could achieve safety approval in 90 days and is being developed with urgency. However, it does not guarantee that the vaccine will be effective or that it will be distributed within a few decades as claimed.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000982",
    "statement": "Indiana bans all non-essential gatherings over 250 people",
    "label": "SUPPORTED",
    "evidences": [
      "Eric Holcomb has announced additional steps the state will take to reduce the spread of novel coronavirus, or COVID-19 in Indiana, including limiting non-essential gatherings to no more than 250 people.",
      "Starting immediately - all non-essential gatherings are limited to fewer than 250 people.",
      "The state of Indiana has banned non-essential gatherings of more than 250 people, Gov.",
      "Non-essential gatherings must be limited to no more than 250 people."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is directly supported by the evidence provided, as it mentions that the state of Indiana has banned non-essential gatherings of more than 250 people.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000983",
    "statement": "Indiana bans all non-essential gatherings over 15 people",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Eric Holcomb has announced additional steps the state will take to reduce the spread of novel coronavirus, or COVID-19 in Indiana, including limiting non-essential gatherings to no more than 250 people.",
      "Starting immediately - all non-essential gatherings are limited to fewer than 250 people.",
      "The state of Indiana has banned non-essential gatherings of more than 250 people, Gov.",
      "Non-essential gatherings must be limited to no more than 250 people."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim states that Indiana bans all non-essential gatherings over 15 people. However, the provided evidence only indicates a limit on non-essential gatherings to fewer than 250 people. The claim exceeds the stated limit.",
    "confidence": 0.9
  },
  {
    "id": "covid_fact-000984",
    "statement": "Indiana bans all non-essential gatherings over 10 people",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Eric Holcomb has announced additional steps the state will take to reduce the spread of novel coronavirus, or COVID-19 in Indiana, including limiting non-essential gatherings to no more than 250 people.",
      "Starting immediately - all non-essential gatherings are limited to fewer than 250 people.",
      "The state of Indiana has banned non-essential gatherings of more than 250 people, Gov.",
      "Non-essential gatherings must be limited to no more than 250 people."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim is that Indiana bans all non-essential gatherings over 10 people, but the provided evidence only states that gatherings are limited to fewer than 250 people. The claim exceeds the specified limit according to the evidence.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000985",
    "statement": "Indiana bans all non-essential gatherings over 20 people",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Eric Holcomb has announced additional steps the state will take to reduce the spread of novel coronavirus, or COVID-19 in Indiana, including limiting non-essential gatherings to no more than 250 people.",
      "Starting immediately - all non-essential gatherings are limited to fewer than 250 people.",
      "The state of Indiana has banned non-essential gatherings of more than 250 people, Gov.",
      "Non-essential gatherings must be limited to no more than 250 people."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim states that Indiana bans all non-essential gatherings over 20 people, while the evidence only mentions a limit of 250 people for non-essential gatherings.",
    "confidence": 0.1
  },
  {
    "id": "covid_fact-000986",
    "statement": "Evaluation of four commercial , fully automated sars-cov-2 antibody tests suggests a revision of the siemens sars-cov-2 igg assay",
    "label": "SUPPORTED",
    "evidences": [
      "Conclusions Thorough on-site evaluation of commercially available serologic tests for detection of antibodies against SARS-CoV-2 remains imperative for laboratories.",
      "The potentially impaired sensitivity of the Siemens COV2G necessitates a switch to the companys newly filed SARS-CoV-2 IgG assay (sCOVG) for follow-up studies.",
      "ROC curve analyses suggest a lowering of the cut-off index for the Siemens COV2G assay.",
      "Finally, the combination of two anti-SARS-CoV-2 antibody assays is feasible when considering borderline reactive results."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided discusses the evaluation of commercial SARS-CoV-2 antibody tests and suggests a revision of the Siemens SARS-CoV-2 IgG assay due to its potentially impaired sensitivity. It also proposes a lowering of the cut-off index for the Siemens COV2G assay, based on ROC curve analyses. Therefore, it supports the claim that there is an evaluation suggesting a revision of the Siemens SARS-CoV-2 IgG assay.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000987",
    "statement": "Evaluation of two commercial, fully automated sars-cov-2 antibody tests suggests a revision of the siemens sars-cov-2 igg assay",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusions Thorough on-site evaluation of commercially available serologic tests for detection of antibodies against SARS-CoV-2 remains imperative for laboratories.",
      "The potentially impaired sensitivity of the Siemens COV2G necessitates a switch to the companys newly filed SARS-CoV-2 IgG assay (sCOVG) for follow-up studies.",
      "ROC curve analyses suggest a lowering of the cut-off index for the Siemens COV2G assay.",
      "Finally, the combination of two anti-SARS-CoV-2 antibody assays is feasible when considering borderline reactive results."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests a revision of the Siemens SARS-CoV-2 IgG assay (sCOVG) due to potentially impaired sensitivity of the COV2G. The conclusions include a lowering of the cut-off index for the Siemens COV2G assay and the feasibility of combining two anti-SARS-CoV-2 antibody assays.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000988",
    "statement": "Evaluation of each commercial, fully automated sars-cov-2 antibody tests suggests a revision of the siemens sars-cov-2 igg assay",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusions Thorough on-site evaluation of commercially available serologic tests for detection of antibodies against SARS-CoV-2 remains imperative for laboratories.",
      "The potentially impaired sensitivity of the Siemens COV2G necessitates a switch to the companys newly filed SARS-CoV-2 IgG assay (sCOVG) for follow-up studies.",
      "ROC curve analyses suggest a lowering of the cut-off index for the Siemens COV2G assay.",
      "Finally, the combination of two anti-SARS-CoV-2 antibody assays is feasible when considering borderline reactive results."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests a revision of the Siemens SARS-CoV-2 IgG assay based on the conclusions from on-site evaluations of commercially available serologic tests for detection of antibodies against SARS-CoV-2. The text mentions potential impaired sensitivity of the Siemens COV2G, a switch to the company's newly filed SARS-CoV-2 IgG assay (sCOVG) for follow-up studies, and a lowering of the cut-off index for the Siemens COV2G assay. These points collectively support the claim.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000989",
    "statement": "Evaluation of both commercial, fully automated sars-cov-2 antibody tests suggests a revision of the siemens sars-cov-2 igg assay",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusions Thorough on-site evaluation of commercially available serologic tests for detection of antibodies against SARS-CoV-2 remains imperative for laboratories.",
      "The potentially impaired sensitivity of the Siemens COV2G necessitates a switch to the companys newly filed SARS-CoV-2 IgG assay (sCOVG) for follow-up studies.",
      "ROC curve analyses suggest a lowering of the cut-off index for the Siemens COV2G assay.",
      "Finally, the combination of two anti-SARS-CoV-2 antibody assays is feasible when considering borderline reactive results."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided discusses the impaired sensitivity of the Siemens COV2G and suggests a switch to their new assay (sCOVG) due to its improved performance. The ROC curve analyses also indicate a lowering of the cut-off index for the Siemens COV2G assay.",
    "confidence": 1
  },
  {
    "id": "covid_fact-000990",
    "statement": "Global covid-19 cases surpass 75 million.",
    "label": "SUPPORTED",
    "evidences": [
      "Global Covid-19 Cases Top 75 Million, Deaths Surpass 1.7 Million - YouTube AboutPressCopyrightContact usCreatorsAdvertiseDevelopersTermsPrivacyPolicy & SafetyHow YouTube worksTest new features (C) 2021 Google LLC : Digital Object Identifier : International Standard Serial Number : Medicines and Healthcare products Regulatory Agency : National Institute for Biological Standards and Control : Clinical Practice Research Datalink : Commission on Human Medicines [Today at 9:21 AM]: Saturday, January 23, 2021 at 9:21 AM [ Yesterday at 9:15 AM]: Friday, January 22, 2021 at 9:15 AM [January 21 at 10:54 AM]: Thursday, January 21, 2021 at 10:54 AM"
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The provided evidence states explicitly that global COVID-19 cases have surpassed 75 million.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000991",
    "statement": "Global covid-19 cases surpass 75 days.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Global Covid-19 Cases Top 75 Million, Deaths Surpass 1.7 Million - YouTube AboutPressCopyrightContact usCreatorsAdvertiseDevelopersTermsPrivacyPolicy & SafetyHow YouTube worksTest new features (C) 2021 Google LLC : Digital Object Identifier : International Standard Serial Number : Medicines and Healthcare products Regulatory Agency : National Institute for Biological Standards and Control : Clinical Practice Research Datalink : Commission on Human Medicines [Today at 9:21 AM]: Saturday, January 23, 2021 at 9:21 AM [ Yesterday at 9:15 AM]: Friday, January 22, 2021 at 9:15 AM [January 21 at 10:54 AM]: Thursday, January 21, 2021 at 10:54 AM"
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided states that as of the date and time specified in the evidence (January 23, 2021 at 9:21 AM), global COVID-19 cases have surpassed 75 million.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000992",
    "statement": "Global covid-19 cases surpass 75 persons.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Global Covid-19 Cases Top 75 Million, Deaths Surpass 1.7 Million - YouTube AboutPressCopyrightContact usCreatorsAdvertiseDevelopersTermsPrivacyPolicy & SafetyHow YouTube worksTest new features (C) 2021 Google LLC : Digital Object Identifier : International Standard Serial Number : Medicines and Healthcare products Regulatory Agency : National Institute for Biological Standards and Control : Clinical Practice Research Datalink : Commission on Human Medicines [Today at 9:21 AM]: Saturday, January 23, 2021 at 9:21 AM [ Yesterday at 9:15 AM]: Friday, January 22, 2021 at 9:15 AM [January 21 at 10:54 AM]: Thursday, January 21, 2021 at 10:54 AM"
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence explicitly states that global Covid-19 cases have surpassed 75 million.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000993",
    "statement": "Global covid-19 cases surpass 75 deaths.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Global Covid-19 Cases Top 75 Million, Deaths Surpass 1.7 Million - YouTube AboutPressCopyrightContact usCreatorsAdvertiseDevelopersTermsPrivacyPolicy & SafetyHow YouTube worksTest new features (C) 2021 Google LLC : Digital Object Identifier : International Standard Serial Number : Medicines and Healthcare products Regulatory Agency : National Institute for Biological Standards and Control : Clinical Practice Research Datalink : Commission on Human Medicines [Today at 9:21 AM]: Saturday, January 23, 2021 at 9:21 AM [ Yesterday at 9:15 AM]: Friday, January 22, 2021 at 9:15 AM [January 21 at 10:54 AM]: Thursday, January 21, 2021 at 10:54 AM"
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is supported by the evidence provided in the text 'Global Covid-19 Cases Top 75 Million, Deaths Surpass 1.7 Million'. The number of deaths surpassing 1.7 million indicates that the global COVID-19 cases have resulted in more than 1.7 million deaths.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000994",
    "statement": "A false post on social media claims covid-19 vaccine causes infertility in women.",
    "label": "SUPPORTED",
    "evidences": [
      "KSAT is labeling the claim that the COVID-19 vaccines cause infertility and sterilization as NOT TRUE.",
      "It has been incorrectly suggested that COVID-19 vaccines will cause infertility because of a very short amino acid sequence in the spike protein of SARS-CoV-2 virus that is shared with the placental protein, syncytin-1.",
      "\"It has been incorrectly suggested that COVID-19 vaccines will cause infertility because of a shared amino acid sequence in the spike protein of SARS-CoV-2 and a placental protein,\" she said in an email to the Associated Press.",
      "It has been incorrectly suggested that COVID-19 vaccines will cause infertility because of a shared amino acid sequence in the spike protein of SARS-CoV-2 and a placental protein, she said in an email."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim is not directly supported by the provided evidence. The evidence indicates that the claim that COVID-19 vaccines cause infertility due to a shared amino acid sequence with placental protein has been deemed NOT TRUE by KSAT and the Associated Press. However, the evidence does not provide any concrete information to evaluate whether or not this specific claim is true.",
    "confidence": 0.8
  },
  {
    "id": "covid_fact-000995",
    "statement": "A false post on social media claims covid-19 vaccine causes infertility in dogs.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "KSAT is labeling the claim that the COVID-19 vaccines cause infertility and sterilization as NOT TRUE.",
      "It has been incorrectly suggested that COVID-19 vaccines will cause infertility because of a very short amino acid sequence in the spike protein of SARS-CoV-2 virus that is shared with the placental protein, syncytin-1.",
      "\"It has been incorrectly suggested that COVID-19 vaccines will cause infertility because of a shared amino acid sequence in the spike protein of SARS-CoV-2 and a placental protein,\" she said in an email to the Associated Press.",
      "It has been incorrectly suggested that COVID-19 vaccines will cause infertility because of a shared amino acid sequence in the spike protein of SARS-CoV-2 and a placental protein, she said in an email."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not directly support or refute the claim that COVID-19 vaccines cause infertility in dogs. The discussion is about a shared amino acid sequence between a protein in SARS-CoV-2 and a placental protein, which is not present in dogs. Therefore, there's no basis to make any conclusion about dogs' fertility.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000996",
    "statement": "A false post on social media claims covid-19 vaccine causes infertility in children.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "KSAT is labeling the claim that the COVID-19 vaccines cause infertility and sterilization as NOT TRUE.",
      "It has been incorrectly suggested that COVID-19 vaccines will cause infertility because of a very short amino acid sequence in the spike protein of SARS-CoV-2 virus that is shared with the placental protein, syncytin-1.",
      "\"It has been incorrectly suggested that COVID-19 vaccines will cause infertility because of a shared amino acid sequence in the spike protein of SARS-CoV-2 and a placental protein,\" she said in an email to the Associated Press.",
      "It has been incorrectly suggested that COVID-19 vaccines will cause infertility because of a shared amino acid sequence in the spike protein of SARS-CoV-2 and a placental protein, she said in an email."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided states that the claim is labeled as 'not true' by KSAT and that it has been incorrectly suggested that COVID-19 vaccines cause infertility due to a shared amino acid sequence in the spike protein of SARS-CoV-2 and a placental protein. However, this evidence does not provide any direct data or research results to support or refute this claim. The verdict is based on the labeling by KSAT and the assertion that it has been incorrectly suggested.",
    "confidence": 0.95
  },
  {
    "id": "covid_fact-000997",
    "statement": "A false post on social media claims covid-19 vaccine causes infertility in adults.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "KSAT is labeling the claim that the COVID-19 vaccines cause infertility and sterilization as NOT TRUE.",
      "It has been incorrectly suggested that COVID-19 vaccines will cause infertility because of a very short amino acid sequence in the spike protein of SARS-CoV-2 virus that is shared with the placental protein, syncytin-1.",
      "\"It has been incorrectly suggested that COVID-19 vaccines will cause infertility because of a shared amino acid sequence in the spike protein of SARS-CoV-2 and a placental protein,\" she said in an email to the Associated Press.",
      "It has been incorrectly suggested that COVID-19 vaccines will cause infertility because of a shared amino acid sequence in the spike protein of SARS-CoV-2 and a placental protein, she said in an email."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided indicates that the claim is labeled as NOT TRUE by KSAT. However, the evidence also states that the claim is made due to a shared amino acid sequence in the spike protein of SARS-CoV-2 and a placental protein. It does not provide any direct empirical data or scientific research disproving the claim.",
    "confidence": 1.0
  },
  {
    "id": "covid_fact-000998",
    "statement": "Expert reaction to people being re-tested positive for coronavirus after initial recovery",
    "label": "SUPPORTED",
    "evidences": [
      "Clearly we need more information about these patients, such as were there underlying medical conditions or a change in circumstances that might have allowed the virus to escape immune control?",
      "However, the report reinforces the fact that we have to investigate all such findings really thoroughly and report such information if we are to make the best decisions based on sound scientific evidence.",
      "She has a prolonged excretion of virus from her initial infection and tests were either not done or were not done sufficiently well or enough to confirm clearance.",
      "Although coronaviruses generally cause short- term self-limiting infections which are cleared, there is some evidence in the scientific literature for persistent infections of animal coronaviruses (mainly in bats).",
      "This highlights the need for more research into the biology of the new coronavirus, it is very much early days in our efforts to understand it. On case in Japan: Prof Paul Hunter, Professor in Medicine, University of East Anglia (UEA), said: Regarding this reported case: There is so much we do not know about this case to give a properly informed opinion."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not directly support the claim that there is expert reaction to people being re-tested positive for coronavirus after initial recovery. The evidence mainly discusses factors that might contribute to a coronavirus patient testing positive again, and the need for further research into the virus. It does not specifically mention any reactions or opinions from experts about this specific situation.",
    "confidence": 0.2
  },
  {
    "id": "covid_fact-000999",
    "statement": "Expert reaction to people being re-tested positive for coronavirus before initial recovery",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Clearly we need more information about these patients, such as were there underlying medical conditions or a change in circumstances that might have allowed the virus to escape immune control?",
      "However, the report reinforces the fact that we have to investigate all such findings really thoroughly and report such information if we are to make the best decisions based on sound scientific evidence.",
      "She has a prolonged excretion of virus from her initial infection and tests were either not done or were not done sufficiently well or enough to confirm clearance.",
      "Although coronaviruses generally cause short- term self-limiting infections which are cleared, there is some evidence in the scientific literature for persistent infections of animal coronaviruses (mainly in bats).",
      "This highlights the need for more research into the biology of the new coronavirus, it is very much early days in our efforts to understand it. On case in Japan: Prof Paul Hunter, Professor in Medicine, University of East Anglia (UEA), said: Regarding this reported case: There is so much we do not know about this case to give a properly informed opinion."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not directly support the claim of people being re-tested positive for coronavirus before initial recovery as it discusses factors that might allow the virus to escape immune control and the need for more research into the biology of the new coronavirus. The claim requires specific examples or case studies of such incidents, which are not provided in this evidence.",
    "confidence": 0.3
  },
  {
    "id": "covid_fact-001000",
    "statement": "Il-6 inhibition could be key to covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "If it is possible to block the signal transduction pathway of IL-6, it is expected to become a new method for the treatment of severe COVID-19 patients.",
      "Tocilizumab is an IL-6 receptor (IL-6R) blocker that can effectively block the IL-6 signal transduction pathway and thus is likely to become an effective drug for patients with severe COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests that IL-6 inhibition could be a potential method for the treatment of severe COVID-19 patients because Tocilizumab, an IL-6 receptor blocker, has been shown to effectively block the IL-6 signal transduction pathway and may become an effective drug for such patients. This implies that blocking IL-6 could help manage the severity of COVID-19.",
    "confidence": 0.9
  }
]